{
    "nodes":2347,
    "edges":8655,
    "density":0.0031438076796084023,
    "triadic_closure":0.050460292145380975,
    "avg_clustering_coeff":0.83493965305032,
    "avg_node_similarity":0.06961761152126604,
    "leiden_modularity":0.6195394880656903,
    "leiden_num_communities":31,
    "louvain_modularity":0.6157166576390495,
    "louvain_num_communities":26,
    "girvan_newman_modularity":0.5876393198282849,
    "girvan_newman_num_communities":74,
    "degree":{
       "adhd":1130,
       "$77.5 to $115.9 billion":3,
       "adolescents and young adults with adhd":80,
       "substantial impairments":8,
       "traffic accidents":8,
       "% of patients medicated for adhd ":14,
       "prescription refills are coordinated with other prescribers":3,
       "transition care coordinated for vacations and other times away":3,
       "% patients evaluated with parent vanderbilt rating scales":2,
       "% patients meeting dsm criteria for adhd":7,
       "% patients treated with psychostimulant medication":7,
       "% patients evaluated with teacher vanderbilt rating scales":2,
       "% patients on medication with at least 2 follow-up visits a year in record":2,
       "% patients seen within 30 days medication initiation":2,
       "% patients whose medical record contains documentation of dsm criteria":2,
       "confirmation of impairment in 2+ settings":2,
       "seen within one month of first prescription":3,
       "screening":21,
       "% patients stabilized on an adhd medication ":5,
       "seen at least once per year":5,
       "communication with other health care providers occurs at least annually":3,
       "external treatment resources":3,
       "prescription monitoring program consulted at least annually":3,
       "psychosocial and educational needs have been re-evaluated at least annually":3,
       "risks and benefits of stopping treatment discussed at least annually":3,
       "substance use evaluated at least annually":3,
       "vitals taken at least annually":4,
       "% patients with adhd with documentation of impairment":2,
       "1.4 million individuals":3,
       "amphetamine":97,
       "intentional, nontherapeutic use":14,
       "stimulants":296,
       "2000 people":3,
       "adhd medication":169,
       "medical literature":14,
       "studies":40,
       "28 adhd experts":3,
       "draft list of 46 qms":12,
       "quality measure":27,
       "2–4 hours":4,
       "adhd impairments":34,
       "long acting":31,
       "short acting":31,
       "4.4% of adults":3,
       "40-50 percent of participants met adhd criteria at any given follow-up":3,
       "recurrence":14,
       "remission":17,
       "48 cohorts":2,
       "structural grey matter volume reductions":5,
       "5 mg orally in the morning on the first day":2,
       "cardiovascular history":12,
       "5.9%":3,
       "thorough evaluation":11,
       "adolescence":249,
       "50":3,
       "adult":96,
       "daily report card":6,
       "5mg and 10mg":4,
       "concerta":7,
       "dose":32,
       "long-acting medications":6,
       "dexmethylphenidate":169,
       "79 authors":3,
       "authors from 27 countries and 6 continents":5,
       "empirically supported statements":20,
       "a death in the family":2,
       "rutter's indicators of adversity":18,
       "a father or brother or sister with epilepsy":2,
       "epilepsy":12,
       "a frequent complaint among users":7,
       "behavioral changes":28,
       "cardiovascular effects":32,
       "central nervous system effects":42,
       "gastrointestinal issues":32,
       "mental conditions":87,
       "sleep disturbances":43,
       "a person's mother with epilepsy":2,
       "abdominal pain":15,
       "abnormalities of chromosomes":4,
       "adhd and many other psychiatric disorders":10,
       "high polygenic risk for adhd":22,
       "polygenic risk":11,
       "abstinence is not an absolute precondition to start treatment":4,
       "drug treatment":214,
       "stabilize substance use":4,
       "abstract problem solving":8,
       "basal ganglia":42,
       "focused attention":6,
       "inhibitory control":21,
       "adhd individuals":49,
       "sustained attention":12,
       "verbal memory":6,
       "working memory":20,
       "abuse":14,
       "diversion":12,
       "misuse":39,
       "nmu":55,
       "nmu of stimulants":53,
       "abuse liability":2,
       "nortriptyline":17,
       "tricyclic antidepressant":17,
       "abuse of prescription drugs":3,
       "alcohol":20,
       "atomoxetine":94,
       "long -acting stimulants":6,
       "norepinephrine reuptake inhibitors":8,
       "short-acting stimulants":6,
       "treatment ending early as the result of adverse events":6,
       "abuse, misuse and diversion":8,
       "adh d medications":2,
       "asthma medications":5,
       "multiple prescribers":2,
       "prescriptions at multiple pharmacies":2,
       "shopping behavior":16,
       "academic activity":4,
       "stimulant use":21,
       "weekends":6,
       "academic difficulties":3,
       "academic dishonesty":2,
       "academic function":3,
       "academic integrity policies":5,
       "alcohol/drug use policies":3,
       "nmu (non-medical use)":33,
       "students who reported nmu":1,
       "academic outcomes":32,
       "adverse medical outcomes":16,
       "amp abuse":3,
       "clinically significant effects":4,
       "clinician":46,
       "co-occurring disorders":3,
       "college graduation":4,
       "exposures":3,
       "family or friends":6,
       "disorders":13,
       "intravenous abusers":3,
       "intravenous":5,
       "longitudinal study":4,
       "nasal abusers":3,
       "nmu behavior":15,
       "patient education":20,
       "poison control calls":4,
       "practitioner":13,
       "prevention strategies":17,
       "rating scales":20,
       "risk of dying":14,
       "adverse effects":83,
       "social interactions":4,
       "treatment plan":20,
       "academic performance enhancement":5,
       "educational attainment":15,
       "misuse and diversion of stimulant medications":9,
       "non-medical use of prescribed stimulants":11,
       "psychotic events":9,
       "academic skills":5,
       "accommodations":11,
       "symptoms":77,
       "inattention symptoms":13,
       "accidental injuries":11,
       "depression":52,
       "sleep issues":14,
       "substance abuse":66,
       "attempted suicide":79,
       "mortality":24,
       "motor tics":49,
       "accidental physical injuries":3,
       "bullying":3,
       "burn injuries":5,
       "accidental poisoning":4,
       "accidents":5,
       "further reduce qol":5,
       "americans with disabilities act":4,
       "classroom-based programs":3,
       "disability":3,
       "idea (pl-101-476)":3,
       "school-based interventions":12,
       "section 504 of the rehabilitation act of 1973":2,
       "accommodations for children with adhd":5,
       "brand medication":10,
       "generic medication":12,
       "medications for children with adhd":10,
       "accurate diagnosis":2,
       "activated emotions":3,
       "adhd child":11,
       "ei (emotional impulsivity)":22,
       "activation of mania or hypomania":15,
       "viloxazine":30,
       "active substance use disorder":8,
       "adhd patients with co-occurring sud":3,
       "cocaine use disorder":4,
       "dextroamphetamine-amphetamine":10,
       "nicotine dependence":4,
       "opioid dependence":2,
       "active substance use disorder (sud)":6,
       "tcas":18,
       "acupuncture, yoga, and ayurvedic therapies":2,
       "adhd symptoms or associated impairments":12,
       "acute co-administration of alcohol and stimulants":3,
       "health consequences":3,
       "acute mania":3,
       "psychosis":15,
       "stimulant adverse effects":15,
       "adderall":7,
       "form":6,
       "form and doses":3,
       "usage":7,
       "adderall xr":11,
       "bubblegum flavor":3,
       "children who have trouble swallowing pills":3,
       "evekeo":4,
       "morning":10,
       "procentra":10,
       "adhd symptoms":195,
       "symptoms throughout the day":4,
       "symptoms with just one dose":3,
       "vyvanse":13,
       "zenzedi":4,
       "addiction":3,
       "misuse of prescription drugs":6,
       "additional meals or snacks":2,
       "weight loss":30,
       "weight loss in people with adhd":11,
       "additional pharmacotherapy":10,
       "adhd patients":103,
       "aggression and emotionaldysregulation":3,
       "atomoxetine (atx)":10,
       "callous emotional traits":3,
       "child emotionality":3,
       "emotion dysregulation":58,
       "emotional dysregulation symptoms":10,
       "odd symptoms":3,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":3,
       "additional problems the patient may have":2,
       "adhd clinical diagnoses":33,
       "address this growing public health problem":10,
       "consistent nomenclature":3,
       "definition of nmu":3,
       "epidemic levels":3,
       "health care professionals":12,
       "patient advocacy groups":2,
       "prescription stimulant":20,
       "surveys and databases":2,
       "genomewide study":0,
       "adhd -iv rating scales":4,
       "adhd aetiology":2,
       "adhd biological pathways":2,
       "adhd children":69,
       "adhd controls":2,
       "adhd criteria":20,
       "adhd and emotional dysregulation":45,
       "adhd genetic liability":2,
       "adhd genetic risk":2,
       "adhd guideline ng87":2,
       "adhd guidelines":4,
       "adhd in females":8,
       "adhd in their children":2,
       "adhd investigator symptom rating scale (aisrs)":2,
       "adhd lifespan course":2,
       "adhd medication use":4,
       "adhd medications (primarily stimulants)":9,
       "adhd presentation":2,
       "adhd probands":7,
       "adhd prototype":3,
       "adhd research":15,
       "adhd severity fluctuations":2,
       "adhd symptoms (e.g., aggression, hyperactivity)":4,
       "adhd symptoms/b ehaviors":8,
       "adhd traits":19,
       "adhd treatment effectiveness":2,
       "adhd outcomes":11,
       "adhd treatment response":2,
       "adhd-associated iq deficits":5,
       "adhd-c":6,
       "adhd-like behaviors and their associated impairments":2,
       "adhd-like symptoms":24,
       "adhd-related brain structural differences":3,
       "adhd-related hospital admissions":2,
       "adherence":10,
       "adverse outcomes later in life":2,
       "age":20,
       "age 25":3,
       "age at diagnosis":3,
       "age at menopause":20,
       "age at onset":2,
       "age at onset variation":2,
       "age of first birth":20,
       "air pollution":2,
       "alexander crichton":4,
       "allergic reactions":26,
       "allergic rhinitis":4,
       "alpha agonists":9,
       "alpha-2 adrenergic agonists (clonidine)":3,
       "alpha-2 adrenergic agonists (guanfacine)":3,
       "amblyopia":2,
       "amygdala":10,
       "ankylosing spondylitis":2,
       "antidepressant":10,
       "antisocial behaviour":2,
       "antisocial personality disorder (aspd)":2,
       "anxiety":34,
       "anxiety disorder":31,
       "anxiety or depression":4,
       "anxiety or tics":3,
       "appetite suppression":5,
       "arbor pharmaceuticals, llc":3,
       "arithmetic":3,
       "arrested":2,
       "artificial food color exclusion":7,
       "artificial food dyes":3,
       "asd":17,
       "asd and adhd":5,
       "aspd":2,
       "assessment and treatment response":3,
       "assets and strengths":2,
       "asthma":12,
       "asthmatic mothers":2,
       "astigmatism":2,
       "at all ages":2,
       "atomoxetine dosing":14,
       "atopic dermatitis":4,
       "attention":20,
       "attention and cognitive control networks":2,
       "attention and somatoform networks":2,
       "attention and working memory tasks":3,
       "atx":26,
       "augusto vidal perera":17,
       "autism":52,
       "autoimmune disease":3,
       "autoimmune thyroid disease":2,
       "behavior":25,
       "behavior management":5,
       "behavior management training":3,
       "behavior modification":4,
       "behavior therapy":38,
       "behavior therapy principles":3,
       "behavioral and mental health assessment":33,
       "behavioral intervention":15,
       "behavior monitoring":8,
       "behavioral regulation index of the brief-a":12,
       "behavioral responses":3,
       "behavioral responses and emotional responses":3,
       "behavioural interventions":10,
       "benefits for adhd":3,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":2,
       "biologic vulnerability":2,
       "biological and psychological causal mechanisms":3,
       "biological pathways":3,
       "biological test":2,
       "bipolar disorder":28,
       "black and latin minority youth":2,
       "black individuals":5,
       "black patients with adhd":2,
       "blood lead levels":8,
       "blood pressure":14,
       "body mass index":22,
       "boys":5,
       "boys and girls":2,
       "boys born to women who lost a close relative during pregnancy":4,
       "boys with adhd":12,
       "brain":8,
       "brain areas involved in cognition":3,
       "brain differences":2,
       "brain functioning":2,
       "brain imaging":4,
       "brain imaging studies":3,
       "brain volumes":2,
       "brain-specific neuronal subtypes":2,
       "brains of people with adhd":9,
       "breastfeeding women":3,
       "brief behavioral sleep intervention":3,
       "bupropion":43,
       "bupropion extended-release":2,
       "cannabis abuse or dependence":3,
       "cannabis use disorder":21,
       "cardiometabolic disease":5,
       "cardiac events":62,
       "cardiovascular monitoring":32,
       "care":5,
       "caregiver":32,
       "cause of adhd":2,
       "cbt":26,
       "cbt methods for emotional dysregulation issues":2,
       "cbt and dbt program":3,
       "cd":7,
       "celiac disease":13,
       "central nervous system injury":2,
       "certain areas":2,
       "certain birth defects":2,
       "chadd":18,
       "changing antecedent behavior and reinforcement":3,
       "characterization of ei/desr in adhd":3,
       "child's developmental stage":5,
       "child's health":8,
       "childhood adhd":2,
       "children and adolescents who do not respond to stimulants":3,
       "children and adolescents who have adhd plus other mental health conditions":3,
       "children and adolescents with adhd":9,
       "children who experienced sexual abuse or physical neglect":4,
       "children who grow up in difficult family situations":3,
       "children who had a specific type of viral infection (enterovirus)":3,
       "children whose mothers were severely obese":5,
       "children with adhd and smd":3,
       "children with low lead levels":2,
       "children without adhd":12,
       "cholinesterase inhibitors":2,
       "chrna7":12,
       "cigarettes smoked per day":20,
       "cingulate region":7,
       "clinical assessment":2,
       "clinical experience":4,
       "clinical features":2,
       "clinical global impression ratings":2,
       "clinical research":11,
       "clinician interview":2,
       "clonidine":39,
       "clonidine extended-release":11,
       "close friends":5,
       "cnvs":2,
       "cnvs in the 1q21.1 region":3,
       "cnvs in the 6q26 region":4,
       "co-contraindication for stimulant prescription":4,
       "cocaine":8,
       "cocaine or methamphetamine use":7,
       "coexisting condition":5,
       "coexisting mental health disorders":15,
       "cognitive behavior therapy":56,
       "cognitive errors":3,
       "cognitive function":13,
       "cognitive training":23,
       "college completion":16,
       "combination therapies":3,
       "combinations of social disadvantages":2,
       "common adverse effects":2,
       "community controls":2,
       "comorbid anxiety or tics":4,
       "comorbid condition":52,
       "comorbidities aggravate these outcomes":4,
       "complete specificity":3,
       "completion of no more than compulsory education":2,
       "complex cases":7,
       "complex psychosocial circumstances":5,
       "computer-based training":7,
       "condition":7,
       "conduct disorder":8,
       "conduct disorder (cd)":3,
       "conduct problems":7,
       "confounders":4,
       "conners global index (cgi) emotional lability scale":16,
       "adhd index of the conners adult adhd rating scale":8,
       "consistent set of causes for the disorder":2,
       "consultation":12,
       "controls":6,
       "core disorder in adhd":3,
       "core symptoms of adhd":4,
       "coronary artery disease":20,
       "cortical surface area":7,
       "cortical thickness":3,
       "crash risk":2,
       "crashes":2,
       "criminal offenses":2,
       "criminal records":2,
       "curative treatments for adhd":2,
       "d-amphetamine sulfate":2,
       "daily functioning":8,
       "daily life":4,
       "danish national register longitudinal cohort study":2,
       "danish national registers":8,
       "danish population":2,
       "death by homicide":3,
       "death from natural causes":2,
       "decision-making":2,
       "decrease":2,
       "decreased appetite":27,
       "decreases in appetite":3,
       "default-mode network (dmn)":12,
       "delayed onset of sleep":3,
       "delayed reinforcement":3,
       "deliberate self-poisoning":3,
       "dementia":3,
       "deprivation":4,
       "desr":8,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":2,
       "developmental disability–children’s global assessment scale":5,
       "developmental history":5,
       "dex":14,
       "dexedrine":4,
       "dextro amphetamine":7,
       "deﬁcient emotional self-regulation (desr)":2,
       "diagnoses":41,
       "diagnosis of apparent adult-onset adhd":2,
       "diagnostic criteria":3,
       "diagnostic delays":3,
       "diets":7,
       "differ between children and adults":5,
       "differences between groups of people who are and are not diagnosed with adhd":9,
       "difficult life circumstances":2,
       "difficulty breathing":4,
       "difficulty sustaining attention":3,
       "digital health interventions (dhis)":9,
       "disability service options":4,
       "disinhibited emotionally expressive behavior":2,
       "disorder":4,
       "disruptive mood dysregulation disorder":9,
       "distress":3,
       "distress tolerance":11,
       "dlpfc":3,
       "dmn":8,
       "doctor":15,
       "does not seem to listen":3,
       "domains":3,
       "dopamine":4,
       "dopamine levels in synapses":3,
       "dopamine regulation":4,
       "double-blind, placebo-controlled trials":5,
       "driver license suspensions":2,
       "drug contract or conducting periodic drug screens":4,
       "dsm and icd criteria":2,
       "dsm-5":5,
       "dsm-5 diagnosis":3,
       "dsm-5 symptom criteria":3,
       "dsm-5’s dmdd":2,
       "duration":2,
       "duration of treatment":6,
       "dusp6":12,
       "dysfunctional cognitive beliefs":5,
       "dysphoria":10,
       "dysregulation":2,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":2,
       "earnings reduction":3,
       "anorexia":31,
       "editorial support":3,
       "education planning":4,
       "educational and occupational failure":5,
       "eeg neurofeedback":7,
       "efficacy":8,
       "efficacy in treating adhd":10,
       "ei":21,
       "ei and desr":15,
       "electrical stimulation":4,
       "electrophysiology":2,
       "elevations in the theta/beta on the electroencephalogram":2,
       "elimination diets":8,
       "embryogenesis":3,
       "emergent health conditions":2,
       "emerging problems":2,
       "emotion processing":19,
       "emotion regulation":60,
       "emotional and behavioral trajectories":3,
       "emotional control scores":4,
       "emotional control subscale":4,
       "emotional intensity (ei)":6,
       "emotional lability":17,
       "emotion":19,
       "emotional symptoms":53,
       "employed":2,
       "employment reduction":3,
       "enigma-adhd working group set of cohort from around the world":4,
       "enterovirus patients":3,
       "environment":3,
       "environmental correlates":4,
       "environmental correlates of adhd":18,
       "environmental factors":18,
       "environmental risks":4,
       "epidemiologic studies":5,
       "essential fatty acid supplementation":12,
       "europe":2,
       "european network for hyper kinetic disorders (eunethydis)":8,
       "euthymic baseline":2,
       "evaluate care-giver burden in children":5,
       "evaluate family-related qol and activities of daily living in children":5,
       "evaluate overall functioning in children":5,
       "evidence":9,
       "exaggerated delay discounting":2,
       "executive dysfunction":10,
       "executive function":20,
       "executive function control":6,
       "executive functioning":5,
       "exposure‐response trend":3,
       "externalizing behavior problems":5,
       "extreme deprivation early in life":4,
       "fails to give close attention":3,
       "false positive diagnoses":3,
       "familial co-aggregation":3,
       "familial or genetic factors":2,
       "family":6,
       "family conflict":4,
       "family function":3,
       "family history of adhd":4,
       "family history of mental health issues":4,
       "family problems":2,
       "family strain index":5,
       "fatty acid concentrations":4,
       "fda approval":4,
       "fda approved medication":3,
       "fda-approved treatment for adhd":4,
       "felony":2,
       "female":4,
       "fidgeting":2,
       "fidgets with hands or feet":3,
       "financial problems":2,
       "financial stability":4,
       "fmri neurofeedback":4,
       "fmri studies of cognitive control":16,
       "dietary interventions":9,
       "foster care":2,
       "foxp1 and foxp2":2,
       "foxp2":4,
       "franz kramer and hans pollnow":17,
       "free fatty acids":7,
       "free tools":2,
       "frontal region":7,
       "functional impairment":6,
       "functioning":6,
       "funding for manuscript development":3,
       "fusiform gyrus":5,
       "future patient outcomes":2,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":4,
       "general behavior":2,
       "general population":2,
       "general psychopathology and several psychiatric disorders":2,
       "generalized emotional under-control":3,
       "genes and environment":2,
       "genetic and environmental risk factors":4,
       "genetic correlation":16,
       "genetic factors":4,
       "genetic influence":6,
       "genetic or familial causes":2,
       "genetic risk":5,
       "genetic variants":18,
       "genetics":5,
       "genomic loci":2,
       "geographic region":4,
       "george still":6,
       "girls":2,
       "girls with adhd":4,
       "glaucoma":2,
       "glutamatergic neurotransmission":2,
       "gonzalo rodriguez-lafora":3,
       "grade point sum":2,
       "growth issues":9,
       "guanfacine":43,
       "extended release guanfacine":18,
       "gudjonsson et al.":6,
       "guidelines":13,
       "gwas":2,
       "hba1c":3,
       "headache":51,
       "health-care disparities":2,
       "health care provider":29,
       "healthcare systems":5,
       "heart rate":20,
       "heinrich hoffmann":4,
       "high blood pressure":23,
       "high iqs":2,
       "high lead levels":2,
       "high risk of substance abuse":4,
       "high school and collegiate athletes":2,
       "high ses":2,
       "higher adhd symptom severity and poorer outcomes":2,
       "hippocampus":10,
       "hippocampus volume":4,
       "history of illicit stimulant use":3,
       "hong kong database":2,
       "hyperactivity":21,
       "hyperactivity in children":2,
       "hyperkinetic disorder":5,
       "hyperthyroidism (overactive thyroid)":3,
       "hypospadias":2,
       "hypotension":13,
       "hypothyroidism (underactive thyroid)":3,
       "icd-11":3,
       "icd-11 criteria":2,
       "ifc":2,
       "ifc and insula":2,
       "illegally used drugs":4,
       "imaging studies":2,
       "immediate reinforcement":2,
       "immediate rewards":4,
       "impaired academic functioning":5,
       "impairment":27,
       "impairments in quality of life":3,
       "improved academic performance":2,
       "improved brain function, most prominently in inferior frontal and striatal regions":2,
       "improved parent-reported child behavior":3,
       "improved relationships with caregivers, teachers, siblings, or peers":2,
       "improved rule following":2,
       "improved sleep":3,
       "improvements":8,
       "improvements in living":3,
       "impulsive decision-making":4,
       "impulsivity":11,
       "high inattentive factor":31,
       "inattention and hyperactivity":4,
       "inattentive type":3,
       "adhd inattentive type":4,
       "incarceration":2,
       "increase the risks of suicidality":4,
       "increased rate of rare genetic mutations":5,
       "incredible years (iy)":6,
       "individual":6,
       "infection":4,
       "inferior frontal dysfunction":4,
       "inflammation":2,
       "health professionals, patients and families":21,
       "inhibition":2,
       "initial treatment":11,
       "injuries":6,
       "insomnia":56,
       "insula":3,
       "insulin resistance":2,
       "integrative treatment":10,
       "integrity of auditory sensory memory and involuntary attention switching":2,
       "intellectual disabilities":5,
       "intellectual functioning":2,
       "intelligence":17,
       "intelligent individuals":2,
       "intensity":2,
       "intensity of subjective states and behavior":3,
       "intentional exposures":4,
       "interdisciplinary collaborations":2,
       "international resources":2,
       "interventions":14,
       "intracranial brain volume":2,
       "iq":10,
       "iq differences":11,
       "iq scores":3,
       "iq tests":2,
       "irritability":88,
       "juvenile detention":2,
       "kidney failure":2,
       "kidscreen-10":5,
       "l-deprenyl":2,
       "large family size":2,
       "large population studies":4,
       "larger delayed ones":2,
       "lead burden":2,
       "learning disorder":5,
       "leaves seat in situations":3,
       "licensed clinician":2,
       "limbic volume":5,
       "lines of communication":2,
       "lisdexamfetamine":14,
       "long-range fronto-posterior association tracts":4,
       "long-term medication use":3,
       "low ses":2,
       "low social class":2,
       "low social class conditions":2,
       "lower achievement scores":3,
       "lower family income":3,
       "lower quality of life":2,
       "lung cancer":20,
       "major depression":25,
       "makes careless mistakes":3,
       "male":6,
       "male-to-female sex ratio of adhd":15,
       "maois":11,
       "map1a":2,
       "maternal alcohol use during pregnancy":3,
       "maternal mental disorder":2,
       "maternal pre-existing type 1 diabetes":4,
       "maternal prenatal use of acetaminophen":2,
       "maternal smoking":13,
       "maximimum tolerated dose":2,
       "measurement tools":2,
       "measurement-based care":2,
       "measures of neurocognitive functioning":2,
       "measures to evaluate qol or functional impairment":5,
       "mechanisms of disease onset":2,
       "mechanisms/pathophysiology":2,
       "medical history":4,
       "medical problem":3,
       "medication periods":3,
       "medication therapy":6,
       "medication-free weekends":3,
       "mef2c":13,
       "melchior adam weikard":4,
       "memory":2,
       "meta-analyses":27,
       "metabolic disorders":2,
       "methamphetamine":2,
       "method of diagnosing adhd":3,
       "methods to improve adherence":2,
       "methylphenidate treatment":10,
       "methylphenidate users":3,
       "methylphenidate users ages 46-65":3,
       "methylphenidate users with previous alcohol and drug misuse":3,
       "methyphenidate prescription":6,
       "migraine":4,
       "milder adhd":3,
       "mindfulness and positive aspects of adhd":2,
       "mindfulness meditation":2,
       "mindfulness-based treatments":2,
       "minimal brain dysfunction":6,
       "minor structural and functional brain differences":3,
       "misconceptions":16,
       "misdemeanors":2,
       "mismatch negativity":2,
       "misuse and diversion of these medications":3,
       "mixed amphetamine salts":5,
       "modafinil":14,
       "molecular genetic data":3,
       "mood":11,
       "mood disorder":13,
       "mortality rates":5,
       "most cases of adhd":2,
       "mothers":9,
       "mothers who were obese before pregnancy":3,
       "mothers with two or more prior miscarriages":3,
       "motor vehicle collision":6,
       "mtbi":2,
       "multidisciplinary efforts":3,
       "multiple settings":3,
       "narcolepsy":2,
       "national health and nutrition examination survey":2,
       "national health insurance data":2,
       "national institute for health and care excellence (nice)":2,
       "national institute of mental health":2,
       "nationwide population study":4,
       "nausea":34,
       "negative parenting":5,
       "negative reinforcement":2,
       "neglect":3,
       "network meta-analyses":6,
       "network of researchers with annual meeting":2,
       "neurobiological research":2,
       "neurobiology":2,
       "neurocognitive function":8,
       "neurocognitive impairment":3,
       "neurodevelopment":3,
       "neurodevelopmental condition":2,
       "neuroimaging scans":4,
       "neuroimaging studies":2,
       "neuronal and nicotinic signalling pathways":2,
       "neuronal development and migration":4,
       "neuropsychological tests":4,
       "new directions for diagnosis":13,
       "new medications currently in development":3,
       "nice guidelines":8,
       "nicotine":4,
       "nicotinic signalling":3,
       "no association with adhd":2,
       "no significant effect on adhd":2,
       "non-medical treatments":13,
       "non-responders":22,
       "non-stimulant medications":9,
       "non-stimulants":42,
       "nonstimulant medications":10,
       "noradrenaline":8,
       "normal cognitive fluctuations":2,
       "normed scales":2,
       "north america":2,
       "number of children":20,
       "number of sessions":2,
       "obesity":33,
       "occupational functioning":2,
       "ocd":18,
       "odd":20,
       "older adolescents and adults":2,
       "omni healthcare communications":3,
       "onset":13,
       "onset prior to the age 12 years cannot be documented":2,
       "oppositional defiant disorder":17,
       "organisation skills":3,
       "other approaches to emotion-regulatory processes disrupted in adhd":2,
       "other psychiatric and substance use disorder":2,
       "other psychiatric diagnosis":7,
       "other stimulant class":2,
       "out-of-home care":2,
       "outcomes":13,
       "outcomes over longer periods of time":3,
       "overused medication":12,
       "oxidative stress":2,
       "paid tools":2,
       "parent":28,
       "parent behavior management training (pbmt)":6,
       "parent management training":3,
       "parent referral for treatment":3,
       "parent training":16,
       "parent training in behavior management (ptbm)":2,
       "parent-child behavior therapy":7,
       "parental criminality":2,
       "parental educational attainment":2,
       "parental outcomes":2,
       "parental relative income poverty":2,
       "parental unemployment":2,
       "parenting skills":4,
       "parents having low educational levels":2,
       "pargyline":2,
       "parietal region":5,
       "paroxetine":2,
       "particulate matter":2,
       "pathophysiology":2,
       "patient":73,
       "patient’s level of ei":2,
       "pbmt":2,
       "peer conflicts and social exclusion":4,
       "peers":9,
       "people":5,
       "people all around the world":2,
       "people who have read this document and agree with its contents":3,
       "performance deficits in psychological processes":4,
       "perpetrators of physical dating violence":2,
       "person":4,
       "personalized approach":3,
       "personalized treatments":2,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":4,
       "pharmacotherapy":15,
       "physical conditions":3,
       "physical examination":5,
       "placebo":8,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":3,
       "poisoning in children":3,
       "police station interrogations":2,
       "polr3c":4,
       "polygenic cause":2,
       "polythetic criteria":3,
       "poor judgment":2,
       "poor work performance":2,
       "positive parenting":2,
       "positive reinforcement":2,
       "posterior corpus callosum":5,
       "posterior parieto-temporal attention regions":4,
       "poverty":5,
       "pre-existing type 1 diabetes":2,
       "prediction":3,
       "predictive modelling":2,
       "predictor of treatment response":3,
       "preeclampsia":3,
       "pregnancies":26,
       "pregnancy and adhd":2,
       "pregnant or breastfeeding women":3,
       "premature death":21,
       "prenatal exposure":5,
       "prenatal exposure to maternal smoking":2,
       "preschool or daycare":2,
       "preschoolers with symptoms of adhd":4,
       "prescriber":6,
       "prevalence":11,
       "prevalence of adhd":5,
       "prevalence of adhd among adolescents":2,
       "prevalence of adhd in prisons":2,
       "prevalence of false confessions":2,
       "prevalence of physical dating violence":2,
       "priapism":14,
       "prior miscarriage":3,
       "prisma diagram in supplemental figure 1":3,
       "prison inmates":2,
       "prkn":2,
       "proband":5,
       "problem behaviors (e.g., aggression, caregiver-child relations)":4,
       "problem solving":6,
       "problematic substance use":4,
       "problems with connections between the two hemispheres":4,
       "professional health care associations":2,
       "proteins":2,
       "proton pump inhibitors":4,
       "provocation":4,
       "psoriasis":2,
       "comorbid psychiatric conditions":17,
       "psychoeducation":16,
       "psychological tests":2,
       "psychological treatment":3,
       "psychosocial domains of qol":5,
       "psychosocial interventions":9,
       "psychosocial, school and emotional functioning":5,
       "psychotherapy":15,
       "psychotropic co-prescriptions":3,
       "ptbm":7,
       "ptbm (behavior therapy)":12,
       "qol domains":5,
       "quality of life":13,
       "racemic amphetamine sulfate":2,
       "racial and ethnic minority populations":2,
       "rage":2,
       "randomized controlled trials (rcts)":2,
       "rare genetic mutations":2,
       "rare single gene defects":4,
       "rct":5,
       "rcts of adhd medications":4,
       "re-evaluate goals and behavior":2,
       "reading":3,
       "reading, spelling and arithmetic":2,
       "rebound effect":9,
       "reduce self-esteem and wellbeing":4,
       "reducing inattention, hyperactivity, and impulsivity":2,
       "referral to a dietician":4,
       "regular check-ups":32,
       "reinforcer":3,
       "relationship quality":4,
       "reliability and validity":3,
       "reliable diagnostic measure for adhd":2,
       "research":22,
       "resilience":2,
       "resilience factors":2,
       "resources":4,
       "responders":22,
       "response cost":2,
       "response to treatment":2,
       "response-inhibition":2,
       "restlessness":2,
       "reward":7,
       "right inferior frontal cortex":6,
       "potential risks":5,
       "risky driving behaviors":4,
       "robins and guze criteria":3,
       "sagitatal striatum":5,
       "scaffolding":7,
       "scales for emotion regulation":2,
       "schizophrenia":24,
       "school":4,
       "school interventions":4,
       "school performance":2,
       "school-based accommodations":4,
       "screening measures":11,
       "selective amplification of certain emotional states":3,
       "selective noradrenaline reuptake inhibitors":11,
       "self-esteem":4,
       "self-injury":2,
       "self-perceptions of competence":2,
       "self-referential thoughts and mind-wandering":2,
       "self-referral":3,
       "self-regulatory skills":4,
       "self-regulatory strategies":3,
       "self-report measures":3,
       "self-report scale":3,
       "self-reported executive function ratings":4,
       "serious transport accidents":5,
       "serotonin syndrome":12,
       "settings":3,
       "severe adhd":3,
       "severe marital discord":4,
       "severe mood dys-regulation (smd)":2,
       "sex":4,
       "sexual crimes victims":6,
       "sexually transmitted infections":4,
       "shared components of etiology":3,
       "shared mechanisms among disorders":3,
       "short- and long-acting formulations of a-2 adrenergic agonists":5,
       "simulant":4,
       "simulant medications":4,
       "single genetic abnormality":4,
       "six symptoms of hyperactivity-impulsivity":2,
       "six symptoms of inattention":2,
       "skills training":7,
       "sleep":4,
       "sleep efficiency":3,
       "sleep onset":3,
       "sleep onset delay":4,
       "small differences in brain structure and function":2,
       "small for gestational age":3,
       "small particulate matter levels":2,
       "small to moderate difficulties":5,
       "small-to-moderate reductions in mismatch negativity amplitude":2,
       "smaller brain areas":3,
       "smaller brain volumes":2,
       "cigarette smoking":8,
       "smoking initiation":20,
       "social acceptance":2,
       "social anxiety disorder":4,
       "social cognitive programs":2,
       "social function":3,
       "social functioning":4,
       "social skills":6,
       "social skills training":7,
       "socially and clinically important outcomes":3,
       "society for developmental and behavioral pediatrics":2,
       "socioeconomic cost":2,
       "ses (socioeconomic status)":4,
       "solriamfetol":18,
       "somatic co-prescriptions":3,
       "somatic disorders that co-occur with adhd":3,
       "sorcs3":13,
       "sorcs3, ptprf, and mef2c":2,
       "specialist":5,
       "speech disorders":6,
       "spelling":3,
       "splenium of the corpus callosum":11,
       "spouses":11,
       "ssri/snri":8,
       "standard diagnostic criteria":3,
       "standard therapies":5,
       "stigma":19,
       "adhd stigma":9,
       "stimulant":33,
       "stimulant medication":105,
       "stimulant therapy":20,
       "stimulant-refractory":2,
       "stimulants are the first line of drug treatment for adhd":3,
       "stress":3,
       "stress-related strains on cognition":2,
       "stressed events during childhood":2,
       "subcortical regions":3,
       "subjective well-being":20,
       "subsequent substance use":2,
       "substance misuse":3,
       "substance use":9,
       "sud":2,
       "suicide related events":9,
       "support groups":5,
       "sustained release bupropion":2,
       "sweden":2,
       "swedish national registers":7,
       "swedish population-based study":4,
       "swedish registry study":2,
       "symptom change":5,
       "symptom checklists":2,
       "symptom expression":2,
       "symptom severity":2,
       "synapse formation and plasticity":7,
       "synaptic development":2,
       "taiwan health insurance research database":4,
       "taiwanese study":4,
       "taiwanese youths":4,
       "tca (nortriptyline)":8,
       "tdcs":17,
       "teacher-assessed social skills":2,
       "teachers of children with adhd":3,
       "techniques":3,
       "teenage pregnancy":5,
       "teenage pregnancy and sexually transmitted diseases":4,
       "temper outbursts":5,
       "temporal pole":5,
       "temporal region":7,
       "temporo-parieto-occipital regions":5,
       "test scores":3,
       "testicular dysfunction":2,
       "tetrahydrocannabinol (marijuana)":3,
       "therapeutic approaches":4,
       "therapies":3,
       "therapy":24,
       "those seeking treatment":2,
       "those with epilepsy":2,
       "thyroid problems in mothers during pregnancy":3,
       "time management":5,
       "time off medication":3,
       "time-out":2,
       "tms":7,
       "tns":9,
       "token economy":2,
       "tolerability":11,
       "total sleep time":3,
       "toxic substances":2,
       "tracking and remote measurement technologies":3,
       "trans-diagnostic phenomena":3,
       "transport accidents":11,
       "trauma":9,
       "trauma-related emergency room admission":6,
       "traumatic brain injuries":13,
       "traumatic brain injury early in life":4,
       "treating adhd and preventing adverse outcomes":2,
       "treatment efficacy":3,
       "drug treatment initiation":31,
       "treatment of coexisting conditions":10,
       "treatment planning":2,
       "treatment targets":3,
       "trial":5,
       "trigeminal nerve stimulation":9,
       "trigeminal nerve stimulation (tns)":4,
       "twins":3,
       "type 1 diabetes mellitus (t1dm)":5,
       "type 2 diabetes":25,
       "typically developing peers":8,
       "ulcerative colitis":2,
       "unemployment":5,
       "unintended injuries":14,
       "unmedicated adults":3,
       "upper secondary school":2,
       "urbanization level":4,
       "us":2,
       "us population":5,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":3,
       "validated measure of symptom change":2,
       "validity of adhd as a mental disorder":3,
       "valproate":5,
       "vehicular crashes":2,
       "ventromedial orbito-frontal cortical thickness":5,
       "viloxazine er":2,
       "viloxazine extended-release":7,
       "violent crimes":6,
       "violent crimes against youth":2,
       "viral pneumonia":2,
       "visual attention":19,
       "weak support systems":3,
       "weight":8,
       "well-trained professionals":2,
       "wender-reimherr adult attention deficit disorder scale":11,
       "wes study":2,
       "white blood cell disorders":2,
       "white matter":4,
       "white matter integrity":2,
       "white-majority countries":2,
       "work functioning":4,
       "work performance":3,
       "working memory impairments":4,
       "world":5,
       "worse social adjustment":2,
       "year of first adhd diagnosis":2,
       "years of schooling":16,
       "youth aged 14-20":2,
       "youth with adhd":19,
       "α2 agonists":7,
       "emotional factors":4,
       "intellectual factors":4,
       "mood stabilizing medication":5,
       "negative health behaviours":4,
       "oocyte leading to pregnancy":4,
       "psychosocial impairment":4,
       "resilience in those susceptible to adhd":10,
       "sero tonergic medication":3,
       "sero tonergic reuptake inhibitor":3,
       "serotonin activity":4,
       "serotonin-norepinephrine reuptake inhibitors (snri)":5,
       "social factors":4,
       "selective serotonin reuptake inhibitor (ssri)":9,
       "adhd and its mental and somatic comorbidities":2,
       "classroom":2,
       "covert smile":3,
       "desr (delayed emotional return)":3,
       "emotional experience and behavior dyssynchrony":2,
       "emotionally evocative situations":6,
       "explosive giggle":2,
       "provoke- ing stimuli":2,
       "rapid emotional responses":2,
       "height gains":6,
       "age at which adhd criteria were met":2,
       "children with high iq":8,
       "rates of learning disorders":2,
       "rates of psychiatric disorders":2,
       "rates of stimulant treatment":2,
       "rates of substance abuse":2,
       "nitric oxide":2,
       "nitrogen dioxide levels":2,
       "particulate matter levels":4,
       "sulphur dioxide levels":2,
       "genetic architecture of adhd":2,
       "affective reactivity":3,
       "education":8,
       "expression of emotions":3,
       "family life":3,
       "financial":3,
       "legal":3,
       "predicting emotional symptoms":3,
       "social relations":3,
       "adhd europe":2,
       "health professionals and researchers":17,
       "adhd evidence project":3,
       "international consensus statement on adhd":26,
       "adhd experts":7,
       "brainstorming session":3,
       "existing guidelines":3,
       "literature review":4,
       "qms (quality measures)":10,
       "qms for adhd in youth":4,
       "survey":3,
       "adhd follow-up care visit":2,
       "visit":7,
       "adhd guidelines group of the association of medical scientific societies in germany":12,
       "adhd network of european college of neuropsychopharmacology":12,
       "adhd section of the world psychiatric association":12,
       "australian adhd professionals association":12,
       "chinese society of child and adolescent psychiatry":12,
       "federation of adhd":13,
       "israeli society of adhd":12,
       "large medical database called pubmed":23,
       "latin american league of adhd":12,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":15,
       "pubmed":13,
       "saudi adhd society":12,
       "adhd in adults":5,
       "adhd in big groups of people":3,
       "adhd in offspring":7,
       "fetal growth restriction":3,
       "maternal hyperthyroidism during pregnancy":3,
       "maternal hypothyroidism during pregnancy":3,
       "maternal preeclampsia":6,
       "obesity in mothers":3,
       "adhd in older adults":2,
       "mild cognitive impairment and dementia":2,
       "adhd malingering":2,
       "danish study":2,
       "reproductive-aged women":3,
       "risk of a motor vehicle collision":7,
       "short-term effects":2,
       "adhd medication metabolism affect":3,
       "mph":32,
       "comorbid anxiety":5,
       "duration of action":15,
       "duration of response":4,
       "intervention":4,
       "level of function":5,
       "methylin®":5,
       "methylphenidate-based medications":5,
       "mood dysregulation":4,
       "nonstimulants":12,
       "pharmacokinetics":4,
       "pharmacotherapies":2,
       "second-line nonstimulants":10,
       "short-acting methylphenidate":5,
       "specifically learning disorders and low iq":3,
       "stakeholders":2,
       "supplements":10,
       "treatment alternatives":3,
       "working memory training":5,
       "ɑ2 agonists":4,
       "prof. faraone":2,
       "completed suicide":6,
       "crime rates":3,
       "criminality":4,
       "diversion could be fatal when diverted to a person who is medically at risk":3,
       "diversion of medications is a felony":3,
       "gateway to non-oral use of illicit drugs":4,
       "injecting":8,
       "intranasally":3,
       "legal consequences of diverting medication":3,
       "medical consequences of diverting medication":3,
       "men with adhd":6,
       "diversion or nmu":5,
       "non-oral nmu":4,
       "non-oral routes":3,
       "oral administration":3,
       "repeated suicide attempts":10,
       "suicide deaths":6,
       "swedish national registers study":2,
       "teenagers with adhd":4,
       "youth with adhd and other psychiatric diagnoses":9,
       "adhd patients with ed but without smd":3,
       "coping skills for managing anger":10,
       "adhd pharmacotherapy":12,
       "adolescents with adhd":6,
       "driver's license":2,
       "females with adhd -i or controls":3,
       "individuals (age 6 to 24 years) with adhd":3,
       "motor vehicle crashes":12,
       "natural causes":2,
       "st imulant medications":3,
       "two-year mortality risk from all-causes":2,
       "unnatural causes such as suicide, accidental poisoning or injury":2,
       "employment":2,
       "employment status jobs":2,
       "prescription stimulant misuse":2,
       "adhd prs":3,
       "irritability traits":3,
       "adhd quality of life":2,
       "primerthe columbia impairment scale":2,
       "adhd rating scales":4,
       "cultural context":2,
       "culture":2,
       "adhd severity":4,
       "intelligence quotient":3,
       "adhd symptom checklists":6,
       "barkley deficits in executive function scale":4,
       "improvement in psychosocial functioning":4,
       "adhd symptom control extension":3,
       "adult adhd symptoms":5,
       "aggression":15,
       "alpha-2-adrenergic agonists":9,
       "amphetamine derivatives":5,
       "becoming unnaturally quiet":2,
       "broad-spectrum micronutrient supplements":4,
       "cbt alone":3,
       "child behavior checklist":3,
       "clinical prescriber with training in adhd diagnosis and management":2,
       "clinical subgroups":2,
       "combined treatment with medication and cbt":3,
       "dietary approach to stop hypertension":4,
       "dietary interventions for adhd":2,
       "digital interventions":2,
       "digital therapies":2,
       "direct skills training":12,
       "disruptive behavior disorders":14,
       "drug treatment resistant patients":2,
       "effect":5,
       "exclusion of food colour additives and preservatives":4,
       "exercise":25,
       "extended-release preparations":4,
       "good sleep practice":3,
       "hallucinogens":4,
       "healthy diets":10,
       "heroin":4,
       "homicidality":2,
       "imipramine":2,
       "immediate-release stimulants":4,
       "inhalants":4,
       "jornay":4,
       "marijuana":5,
       "medication alone":6,
       "medication or psychosocial interventions":2,
       "mediterranean diet":4,
       "melatonin":8,
       "mirtazapine (remeron)":2,
       "negative mood symptoms":4,
       "nutrition":3,
       "omega-3 fatty acid supplementation":18,
       "pain relievers":4,
       "parent behavior management program":3,
       "parent-rated emotional lability symptoms":2,
       "parent-rated oppositional symptoms":2,
       "participants and their significant others":2,
       "poor dental hygiene":2,
       "prognosis":7,
       "remission of aggressive behavior":4,
       "restricting synthetic food colors":2,
       "ssri and stimulant combination":3,
       "ssri antidepressants":2,
       "stimulant-refractory adhd":10,
       "tca":2,
       "teacher-rated emotional lability symptoms":2,
       "teacher-rated oppositional symptoms":2,
       "tranquilizers/sedatives":4,
       "treatment selection":2,
       "treatment success":4,
       "venlafaxine":7,
       "youth adhd symptoms":4,
       "adhd trea tment":2,
       "administration of stimulants in conjunction with alcohol use":5,
       "cardiotoxicity":3,
       "ecg":2,
       "lower all-cause mortality":2,
       "males with adhd":2,
       "patients medicated for adhd":24,
       "plasma levels":2,
       "polysubstance use":3,
       "qtc prolongation":2,
       "tachycardia":2,
       "tca treatment":3,
       "unnatural causes of mortality":2,
       "adhd treatment first line":2,
       "impulsive cognition":2,
       "learning problems":2,
       "poorly regulated emotions":2,
       "adhd treatment plan":2,
       "behaviors that we now associate with adhd":3,
       "cam therapies":11,
       "chelation therapy":9,
       "consensus statement":4,
       "large effect":3,
       "medium effect":3,
       "megavitamins":10,
       "reviews":3,
       "small effect":3,
       "smaller studies":5,
       "strong effects":3,
       "treatment studies":6,
       "vitamins":9,
       "adhd types":2,
       "adhd-like symptoms in children":3,
       "adhd-related cost study":2,
       "adhd-related costs":4,
       "seven european studies":2,
       "annual national costs":2,
       "€1 billion":2,
       "adhd-specific problems in daily life":2,
       "adjunctive psychotherapy":4,
       "suboptimal response":9,
       "adjust the timing of the dose":6,
       "excessive tiredness":34,
       "stomachaches, nausea":15,
       "adjusted odds ratio":2,
       "cardiovascular disease diagnosis":8,
       "drowsiness":33,
       "trouble sleeping":11,
       "adjusting the dose or timing may help":4,
       "adjustment":1,
       "administer the stimulant with meals to lessen its impact on appetite":2,
       "helping the noncompliant child":3,
       "homework organization":3,
       "incredible years parenting program":3,
       "new forest parenting program":4,
       "nmu of amp":7,
       "parent-child interaction therapy":3,
       "positive parenting program (triple p)":3,
       "self-monitoring skills":3,
       "study skills":3,
       "teacher ratings":16,
       "young adults who do not attend college":7,
       "intuniv":7,
       "kapvay":7,
       "qelbree":6,
       "adult adhd quality measures initiative (aaqmi)":4,
       "ahrq":6,
       "candidate qms":4,
       "clinical and research experts":4,
       "delivery of quality health care to adults with adhd":4,
       "development of qms":4,
       "existing guidelines for adult adhd":4,
       "expert opinion":2,
       "extended-release":3,
       "healthcare delivery":2,
       "healthcare processes":4,
       "immediate-release":3,
       "limited access to treatment by skilled providers":4,
       "multidisciplinary panel":4,
       "clinical guidelines":9,
       "qms":16,
       "quality indicators":4,
       "us agency for healthcare research and quality (ahrq)":4,
       "adult adhd quality of life survey":2,
       "adult adhd self-report scale":4,
       "measure":2,
       "affective lability scale –short form (als-18) ":10,
       "affective reactivity index (ari)":10,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":10,
       "behavior rating inventory of executive function (brief or emotion control subscale)":10,
       "brown add rating scales for children, adolescents and adults (badds)":10,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":14,
       "difﬁculties in emotion regulation scale (ders)":18,
       "distress tolerance scale":9,
       "drug holidays":2,
       "emotion dysregulation scale, short version (eds-short)":14,
       "emotion regulation checklist (erc)":14,
       "emotion regulation index for adults and children (erica)":14,
       "emotion regulation questionnaire (erq)":20,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":6,
       "expression and emotion scale for children (eesc)":7,
       "frustration discomfort scale":6,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":9,
       "trials norms availability":14,
       "adults (11 studies, 2909 participants)":2,
       "adults (cortese et al., 2018a)":2,
       "adults treated with viloxazine":3,
       "adults unresponsive to mph trial":3,
       "advancing age":5,
       "adverse":2,
       "clinical response":7,
       "driving and work performance":5,
       "emergency room visits":11,
       "maximum daily dose":7,
       "discontinuation":4,
       "follow-up visit":20,
       "medication response":20,
       "health care facilities":9,
       "adverse outcomes":4,
       "prevalence of stimulant nmu":14,
       "adverse side effects of atomoxetine":3,
       "monitoring and management":14,
       "adverse side effects of guanfacine":3,
       "adzenys xr -odt":7,
       "dexedrine spansule":7,
       "dyanavel xr":4,
       "mydayis":7,
       "tips for using amphetamine-based medications":4,
       "aerobic activity":3,
       "improvement in the core symptoms of adhd":16,
       "aerobic exercise":4,
       "affective components of executive control":5,
       "dopaminergic system":22,
       "executive control":24,
       "mood regulation":22,
       "noradrenergic system":22,
       "affordable care act":2,
       "african-american students":2,
       "viloxazine dose":3,
       "liver problems":15,
       "nausea/vomiting":15,
       "viloxazine (qelbree)":22,
       "agitation":3,
       "expert clinicians":3,
       "ahrq, medicare and medicaid":2,
       "alcohol use disorder: treatment overview":9,
       "counseling":3,
       "limit their alcohol consumption":2,
       "low-risk and risky alcohol use":3,
       "opioid use disorder: treatment overview":2,
       "stimulant use disorder: treatment overview":2,
       "stimulants for adhd":9,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":3,
       "all-cause treatment discontinuation":3,
       "dizziness":38,
       "increased blood pressure and heart rate":4,
       "itching":3,
       "monitoring":4,
       "rash":3,
       "vomiting":12,
       "motor or vocal tics":3,
       "nonstimulants for adhd":3,
       "alpha agonists (clonidine and guanfacine)":7,
       "liver problems such as hepatitis":5,
       "american academy of child and adolescent psychiatry adhd resource center":8,
       "attention deficit disorder association (adda)":8,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":6,
       "centers for disease control and prevention (cdc) adhd":8,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":8,
       "national institute of mental health (nimh) adhd":6,
       "the american professional society of adhd and related disorders (apsard)":8,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":6,
       "american academy of pediatricians":3,
       "american professional society of adhd and related disorders":6,
       "canadian adhd resource alliance":5,
       "world federation of adhd":19,
       "american psychopathological association":2,
       "pau l hoch award":2,
       "state university o f new york":4,
       "reasonable accommodations":2,
       "amp":2,
       "attention and impulsivity":2,
       "cardiac arrest":3,
       "cerebrovascular disease":3,
       "daily timing":2,
       "heart failure":3,
       "ischemic heart disease":3,
       "misuse and diversion":4,
       "prescribing medications for adhd":4,
       "prescription refill requests":4,
       "risks of stimulant misuse and diversion":4,
       "schedule ii controlled substances":3,
       "short-acting amphetamines":2,
       "studies regarding nmu of mph or amp":9,
       "symptom control":2,
       "tachyarrhythmias":3,
       "venous thromboembolism":3,
       "amphetamine formulations":3,
       "lisdexamfetamine dimesylate (ldx)":5,
       "amphetamine medication":3,
       "amphetamine stimulants":2,
       "children (7 studies, 1930 participants)":3,
       "growth suppression":9,
       "pregnant woman":7,
       "youths (9 studies, 2677 participants)":2,
       "analysis":2,
       "discontinuation due to adverse event":10,
       "lisdexamphetamine":10,
       "worse anorexia":10,
       "antacids":2,
       "antecedents of behaviour":2,
       "reinforcement techniques":2,
       "anthony l. rostain":2,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":2,
       "anticipatory appraisal and valuation":5,
       "emotion generation":19,
       "emotional state":17,
       "regulation":5,
       "antipsychotics":3,
       "not recommended adhd treatment":3,
       "dry mouth":27,
       "anxiety and substance use disorders":2,
       "benzodiazepines":4,
       "childhood irritability":3,
       "opioid":5,
       "any interpretation should keep in mind that the ratings are of relative importance":15,
       "care coordination":16,
       "care coordination and the patient experience domains":2,
       "follow-up":9,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":13,
       "low rating only means that the item is not essential for documenting the basics of quality care":2,
       "patient experience":8,
       "patients and health care systems":3,
       "quality diagnosis":9,
       "quality in these domains may be viewed as less relevant":3,
       "results may reflect a systematic bias in our sample of raters":3,
       "should include other relevant stakeholders, including patients and health care systems":3,
       "systematic bias in our sample of raters":3,
       "apsard":2,
       "apten sio xr":9,
       "capsules":9,
       "daytrana":9,
       "focalin xr":4,
       "liquid":5,
       "patches":4,
       "quillivant xr":5,
       "ritalin la":4,
       "arterial disease":2,
       "asian federation of adhd":2,
       "asian resource":2,
       "assignments":2,
       "association for behavior and cognitive therapies":4,
       "behavioral therapist":17,
       "caregivers of children age 6 to 12 years":17,
       "centers for disease control and prevention (cdc)":17,
       "association for child and adolescent mental health":0,
       "atomox etine":2,
       "atomoxetine levels":3,
       "atypical antidepressants":5,
       "blood monitoring":3,
       "brain cells communication":3,
       "cardiac malformations":5,
       "chemical messengers (norepinephrine)":3,
       "constipation":10,
       "correct dose":2,
       "treatment discontinuation":3,
       "tricyclic antidepressants (tcas)":5,
       "atomoxetine treatment for adhd":3,
       "attention and arousal":4,
       "behavioral functioning":6,
       "chronic condition management":6,
       "information provision":6,
       "dizziness and lightheadedness":20,
       "fatigue":23,
       "sedation":19,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":9,
       "behavioral management techniques that are used for children with adhd":2,
       "coexisting conditions that are associated with adhd or mimic its symptoms":2,
       "nonadherence to the treatment plan":2,
       "repetition of the diagnostic evaluation":2,
       "evidence-based statements about adhd":3,
       "international consensus statement":2,
       "meta-analyses and very large studies":3,
       "parents' medication guide":2,
       "parents' medication guidedysregulation":3,
       "project steering committee":2,
       "research and clinical care of adhd":2,
       "scientific data":2,
       "attention-deﬁcit/hyperactivity disorder":2,
       "impulsive aggression":8,
       "liver damage":3,
       "psychotic symptoms":3,
       "self-harming behavior":3,
       "unusual changes in behavior":3,
       "atx or dex":3,
       "atx treatment":3,
       "liver disease evaluation":3,
       "augmentation strategies":2,
       "charles bradley":3,
       "child psychiatry":2,
       "minimal brain dysfunction-related behaviors":3,
       "morris et al. and o'neal and robins":3,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":3,
       "u.s. food and drug administration":5,
       "world health organization":2,
       "authors":2,
       "emotional problems":3,
       "seizures":8,
       "sleep disorder":3,
       "availability of treatment":3,
       "avoid caffeine":2,
       "evening":8,
       "good sleep habits":10,
       "avoid skipped doses":2,
       "maladaptive emotions":6,
       "bachelor's degree":5,
       "dorsal anterior cingulate cortex":7,
       "fmri meta-analyses":3,
       "inferior frontal cortex":12,
       "neutral fmri tasks":2,
       "supplementary motor area":2,
       "typically developing individuals":2,
       "ventral anterior cingulate cortex":7,
       "become unusually quiet or appear over-focused":2,
       "child development":2,
       "metacognitive executive function training":8,
       "pre-kindergarten academic curriculum (stp-pre-k)":8,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":8,
       "tools":2,
       "behavior modification system":4,
       "behavior problems":4,
       "blood pressure monitoring":6,
       "chest pain":6,
       "education on side effects":8,
       "growth monitoring":6,
       "heart rate assessment":6,
       "impulsiveness":6,
       "long-term use":7,
       "mood monitoring":6,
       "mood swings":20,
       "palpitations":6,
       "peripheral vasculopathy":7,
       "raynaud’s phenomenon":7,
       "severe allergic reactions":7,
       "severe psychiatric symptoms":6,
       "side effects information":7,
       "sudden cardiac death":9,
       "swelling of the face, lips, tongue, or throat":7,
       "weight monitoring":6,
       "blurred vision or other visual changes":7,
       "development or worsening of motor or vocal tics":7,
       "elevated blood pressure (hypertension)":6,
       "especially in children":6,
       "increased aggression or hostility":6,
       "increased heart rate (tachycardia)":6,
       "nervousness":6,
       "rash or hypersensitivity reactions":7,
       "skin reactions":7,
       "trouble falling and staying asleep":6,
       "visual disturbances":7,
       "behavioral disinhibition":2,
       "observed behavior":7,
       "behavioral expression":7,
       "behavioral indicators":9,
       "subjective emotionality":9,
       "high emotional thresholds":5,
       "recovery times":4,
       "quick return to baseline":6,
       "behavioral response system":2,
       "subjective/cognitive response system":2,
       "child’s behavior":2,
       "coping strategies":2,
       "negative behaviors":2,
       "negative thought patterns":3,
       "parent -child relationship":2,
       "positive behaviors":2,
       "problematic behaviors":2,
       "finding activities in which the child can be successful (eg, hobbies, sports)":4,
       "identifying unintentional reinforcement of negative behaviors":4,
       "keeping environmental distractions to a minimum":4,
       "limiting choices":4,
       "maintaining a daily schedule":4,
       "national institute for children's health quality toolkit":4,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":4,
       "rewarding positive behavior (eg, with a 'token economy')":4,
       "setting small, reachable goals":4,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":4,
       "using charts and checklists to help the child stay 'on task'":4,
       "parenting context":2,
       "pharmaco logical therapy":2,
       "benefits and risks of treatment":2,
       "best practices":2,
       "best studies":2,
       "pulse":2,
       "blood pressure and pulse quarterly":4,
       "blood tests":2,
       "bone fractures":2,
       "borderline personality disorder":2,
       "boundaries between adhd and other disorders":2,
       "long-term side effects":5,
       "broader scope of the review":2,
       "bupropion (wellbutrin, zyban)":3,
       "caddra":2,
       "caffeine levels":2,
       "calendar year":2,
       "chelation":2,
       "primary care practitioner":6,
       "risks and benefits":2,
       "nonmedical users":2,
       "cardiac history or cardiac symptoms":2,
       "cardiac review":5,
       "cardiologist consultation":2,
       "findings outside of normal limits":2,
       "sudden death or ventricular arrhythmia":3,
       "cardiovascular health":3,
       "clinical response, duration of the effect during the day, and side effects":2,
       "electrocardiogram (ecg)":2,
       "low dose stimulant treatment":2,
       "short-acting dextroamphetamine-amphetamine":2,
       "child's height":8,
       "child's weight":8,
       "regular measurement":8,
       "qm":5,
       "quality care":6,
       "treatment follow-up":7,
       "care management plan":2,
       "careful dose titration required":2,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":2,
       "child's practitioner":11,
       "caregiver decision":3,
       "catapres":2,
       "category":2,
       "causes":2,
       "cbcl-dysregulation profile":2,
       "emotional dysregulation scores":2,
       "cbt group and individual therapy programs":3,
       "cbt group treatment":2,
       "orthostatic hypotension":7,
       "slow heart rate (bradycardia)":7,
       "cereals":2,
       "certain children":4,
       "certain events":2,
       "certain foci in the literature may have been missed":2,
       "chadd website":2,
       "coalition to prevent adhd medication misuse":2,
       "college administrators":2,
       "collegiate student leaders":2,
       "cpamm":7,
       "information about misuse and diversion":5,
       "personnel":2,
       "pharmaceutical industry":2,
       "changing the drug":3,
       "heart symptoms":9,
       "height":3,
       "long-term studies (lower risk of later cigarette or illegal substance use)":3,
       "meal timing":2,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":2,
       "mental health challenges":2,
       "mirtazapine":2,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":3,
       "mood problem":4,
       "moodiness":5,
       "over-focused or repeated movements (tics or habits)":2,
       "preparation":3,
       "separate issue":4,
       "sleep habits":2,
       "worsened heart problems":3,
       "zombie effect":2,
       "child and adolescent psychiatrist":2,
       "child psychologist":2,
       "immediate action":5,
       "medication holidays":4,
       "childhood diagnosis of adhd":2,
       "children in intervention group":3,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":2,
       "loss of appetite (anorexia)":3,
       "monitor for changes in behavior and report to the healthcare provider":2,
       "monitor your child closely for new or worsening tics":2,
       "offer high-calorie snacks such as instant breakfast drinks":2,
       "regularly check your child's weight to ensure they are growing normally":2,
       "sleep intervention":2,
       "teacher-reported behavior":3,
       "cohort studies":2,
       "children and youth with special health care needs":2,
       "children who have not yet entered elementary school":4,
       "classroom modifications":4,
       "developmental behavioral pediatrician":2,
       "intentional and unintentional injury":4,
       "china adhd alliance":2,
       "classroom modifications and accommodations":11,
       "combined medication and behavior treatment":2,
       "combined treatment":2,
       "lower doses of medication":2,
       "non-adhd symptoms":2,
       "provision of tutoring or resource room support":2,
       "school-aged children":6,
       "stressors in family life":2,
       "suboptimal response to pharmacotherapy":2,
       "normative data":5,
       "parents and teacher reports":4,
       "preschool teachers and clinicians":4,
       "ratings from other individuals":3,
       "scales":4,
       "secondary school teachers":3,
       "self-report":6,
       "structured behavioural observations":4,
       "such as":4,
       "tools for screening":2,
       "longer acting than clonidine":2,
       "short-acting medication":2,
       "tenex":2,
       "tic problems":2,
       "close monitoring":8,
       "close monitoring by healthcare provider":3,
       "persistent adhd":3,
       "cognitive components of executive control":5,
       "cognitive flexibility":7,
       "cognitive strengths and weaknesses":3,
       "play-based interventions":5,
       "problems with peers":2,
       "psychotherapy interventions":2,
       "students with disabilities":2,
       "summer treatment camp":4,
       "deficits":4,
       "guided walks":3,
       "increases the effectiveness of":4,
       "organizational/planning skills":3,
       "psychosocial well-being":3,
       "yoga":3,
       "patient's family":3,
       "collateral report":2,
       "colleagues":2,
       "gpas":5,
       "college peers":2,
       "common misconceptions":5,
       "nmu of mph":4,
       "nmu population prevalence":7,
       "parents with suspected or diagnosed adhd":2,
       "peer behavior":4,
       "printed handouts":4,
       "repetition":4,
       "sanctions":4,
       "social situations":2,
       "us college populations":5,
       "young adult populations":4,
       "enforcement":2,
       "incoming students":2,
       "com-ponents of emotional symptoms":2,
       "different terms used to describe them":2,
       "community psychosocial care":3,
       "community support":2,
       "specific treatment approach":4,
       "medication adherence":3,
       "diagnostic challenges":3,
       "simplex adhd":2,
       "standard information gathering":3,
       "comprehensive approach to literature on nmu":2,
       "concerns being discussed":3,
       "extended-release tablets":4,
       "reduce the need to take multiple doses throughout the day":4,
       "consistent sleep schedule":2,
       "consult with healthcare provider":3,
       "consult with the healthcare provider for further advice":4,
       "contents":3,
       "contraindications to drug treatment":2,
       "cooperating":2,
       "ingroup therapy":3,
       "integrative treatment program":3,
       "parental satisfaction":3,
       "core symptoms":3,
       "corticocerebellar networks":2,
       "criteria":2,
       "critical care unit":2,
       "current adhd symptoms":2,
       "secular private schools":2,
       "decongestants":2,
       "food supplements":8,
       "hepatitis":8,
       "low dose medication":8,
       "medication adjustment":16,
       "medication with food":8,
       "executive control and corticocerebellar networks":2,
       "frontal and parietal cortical areas":2,
       "inferior parietal and medial temporal regions":2,
       "medial prefrontal and the posterior cingulate cortices":2,
       "orbitofrontal cortex":2,
       "reward system":3,
       "thalamus":6,
       "ventromedial prefrontal cortex":2,
       "denmark, finland, sweden, norway, and iceland":3,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":2,
       "those reporting nmu in a survey of 4,297 us adults":0,
       "detect nmu":2,
       "medical/neurological history":2,
       "stimulant misuse risk assessment":3,
       "deﬁcits in response inhibition to frustration":2,
       "documented dsm-5 diagnosis of adhd":2,
       "diagnostic guidelines":2,
       "diagnostic utility for adhd":2,
       "symptoms commonly occurring in other disorders":2,
       "dietary restrictions":3,
       "disability services":2,
       "discontinuing medication":2,
       "discussions":2,
       "discussions of transfer of care with new clinician made":2,
       "emotional upsets":2,
       "motivation":2,
       "social payoff":2,
       "diurnal variation in symptoms":4,
       "malingering":6,
       "pills per prescription":5,
       "extended-release form":2,
       "hydration":4,
       "loss of appetite":5,
       "medication form adjustment":6,
       "more irritability or moodiness when taking medication":6,
       "slowing of heart rate":9,
       "snacks":2,
       "supplemental medications":6,
       "timing of medication":5,
       "dmdd":2,
       "intensified negative mood":2,
       "document":2,
       "documentation":2,
       "frontal lobes":4,
       "learning and memory":4,
       "movement regulation":4,
       "novelty processing":4,
       "parietal cortex":5,
       "reward processing":4,
       "signal-to-noise processing":4,
       "stress response":4,
       "mood symptoms":6,
       "time":5,
       "dose reduction":5,
       "dosing":2,
       "driving licenses suspension/revocation":2,
       "driving performance improvement":2,
       "gradually increase dose":2,
       "monitor mood symptoms":3,
       "excessive weight loss":3,
       "dsm criteria":2,
       "us college-aged women":2,
       "eating foods high in added sugar":5,
       "hyperactivity/impulsivity subtypes":5,
       "inattention symptoms and unhealthy eating habits":5,
       "monozygotic twins":5,
       "unhealthy dietary habits":5,
       "stimulant misuse":2,
       "history of psychosis":3,
       "prescribed stimulants":5,
       "size":2,
       "effect size findings":2,
       "effective self-regulation":2,
       "effortful strategy":9,
       "emotional arousal":9,
       "high ei":5,
       "reappraisal":10,
       "self-monitoring":10,
       "valuation":5,
       "el":2,
       "emotionally intense provocation":2,
       "hyperactive-impulsive adhd presentations":2,
       "inadequate self-control and weak behavioral inhibition":2,
       "patients with no ei":2,
       "rapid changes in emotional states":2,
       "self-regulatory processes":2,
       "elevated mood":4,
       "elevation of blood pressure or heart rate":2,
       "feeling sad":2,
       "healthcare facility utilization":2,
       "poison control centers data":2,
       "sleep difficulties":2,
       "study of 15,629 adults and adolescents":2,
       "regulatory processes":4,
       "emotional experience":5,
       "emotional valence":2,
       "heterogeneity":4,
       "neural activation":3,
       "poorly controlled emotionally driven behavior":2,
       "self-regulatory deficits":2,
       "self-regulatory deﬁcits":2,
       "executive function control of emotional response":3,
       "extended-release methylphenidate":2,
       "intermittent explosive disorder":3,
       "methylphenidate preparations":2,
       "oppositional deﬁant disorder":2,
       "emotional functioning":2,
       "impaired":7,
       "emotional instability":2,
       "negative emotion":2,
       "emotional reactivity":2,
       "high emotional impulsivity":2,
       "response systems":2,
       "future development of adhd criteria":2,
       "measurement tool/assessment instrument":2,
       "mistake for emotional symptoms to be specific for adhd":2,
       "multidimensional nature of emotional symptoms":2,
       "stephen v. faraone":2,
       "evidence-based assertions":3,
       "findings":3,
       "manuscript":3,
       "participants":5,
       "waiting-list controls":3,
       "encourage good sleep habits":4,
       "eunethydis":3,
       "euphoria":4,
       "european network adult adhd":2,
       "evaluation":2,
       "frozen yogurt":2,
       "instant breakfast drinks":2,
       "limit naps to less than 45 minutes":2,
       "reduce screen time before bed":2,
       "evidenced based fda approved medication":2,
       "exacerbation":4,
       "give medication with food to minimize stomach discomfort":4,
       "irritability or aggression (infrequent)":5,
       "monitor headaches and consult with the healthcare provider":4,
       "monitor irritability and consult with the healthcare provider":5,
       "some children do better with the daily dose divided into two doses":4,
       "start with a low dose and gradually increase":4,
       "this side effect usually improves over time":4,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":3,
       "exclusion criteria":3,
       "extended time":2,
       "factors leading to favorable outcomes":2,
       "fear of exposing nmu or minor unwanted effects":2,
       "individuals who experience minor unwanted effects":2,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":3,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":3,
       "feigned":2,
       "genu ine":2,
       "ferritin":3,
       "serum":2,
       "serum iron":2,
       "findings of interest":3,
       "misusers":7,
       "first drug treatment try":2,
       "fluctuating periods of remission and recurrence":2,
       "patient's symptoms":5,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":2,
       "patients with neither one physician visit nor medication claim in 6 months":2,
       "use of outside provider for adhd diagnosis":2,
       "job/school performance":4,
       "medication side effects/toxicity or signs of abuse/diversion":4,
       "potential side effects of atx":5,
       "relationship issues":4,
       "sexual dysfunction and dysmenorrhea":5,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":4,
       "target symptoms":4,
       "vital signs":6,
       "food":3,
       "foxp1":3,
       "synapse formation":3,
       "friendships":2,
       "functional impairment related to adhd":2,
       "functional outcomes":2,
       "insights into key details of nmu":2,
       "general qol measures for adults":2,
       "generic medication preparations":2,
       "pharmacies":2,
       "united kingdom":2,
       "grade point average (gpa)":2,
       "greater family cohesion":2,
       "group of experts":3,
       "organizations that study and treat adhd":3,
       "severe hypotension":2,
       "guanfacine treatment for adhd":3,
       "individuals who abused":2,
       "minor toxicity":2,
       "poison control centers":2,
       "health effects":3,
       "icasa":2,
       "national health and medical research council (australia)":2,
       "ukaan":2,
       "heart rate monitoring":2,
       "high risk for nmu":3,
       "high risk patients":1,
       "high-calorie foods":2,
       "high-quality studies":2,
       "high-risk populations":4,
       "prisoners":2,
       "vulnerability to psychosis":5,
       "holidays":2,
       "household public assistance":2,
       "huybrechts et al., 2018":3,
       "hyperactive-impulsive symptoms":2,
       "id":2,
       "immediate-release preparations allowed":2,
       "physical functioning":2,
       "school functioning":2,
       "popularity":2,
       "reciprocity":2,
       "rejection/likability":2,
       "sharing":2,
       "socializing with peers":2,
       "turn-taking":2,
       "meditation-based therapy":2,
       "in insomnia":2,
       "inclusion criteria":2,
       "medications misuse":2,
       "individuals at greatest risk":2,
       "study routes of administration":2,
       "individuals who die from stimulant overdoses":2,
       "information about negative academic or health effects":3,
       "willingness to use stimulants":3,
       "patient preference":3,
       "insu fflation":4,
       "smok ing":5,
       "stimulant s":4,
       "us adults":5,
       "insurance companies":2,
       "large studies":6,
       "new scientific findings from the past 20 years":2,
       "specific search terms":2,
       "international society of psychiatric geneti cs":2,
       "lifetime ach ievement award":2,
       "internet":2,
       "intolerance":2,
       "intuniv (guanfacine)":3,
       "irritability in adhd":2,
       "irritability in odd":2,
       "vulnerability for emotional disorders (mood and anxiety)":2,
       "legal issue":2,
       "liver function tests":2,
       "long-acting preparations recommended":2,
       "long-term outcomes":2,
       "low initial doses recommended":2,
       "neuroenhancement":3,
       "mania":2,
       "randomized trial":3,
       "medial frontal reductions":2,
       "medical causes of adhd symptoms":2,
       "problems":3,
       "safe storage":2,
       "medication choice":2,
       "medication contract":2,
       "patient commitment":2,
       "patient values and preferences":3,
       "phone calls":2,
       "target outcomes":3,
       "stimulant therapy dose":2,
       "medication trial":2,
       "naturalistic studies":2,
       "quality of life enjoyment and satisfaction questionnaire":2,
       "weiss functional impairment rating scale":3,
       "neuronal development":2,
       "neuronal proliferation":2,
       "synapse development":2,
       "mental health assessment":2,
       "standardized mean difference":2,
       "pregnancies in denmark":2,
       "pregnancies in the united states":2,
       "time course for improvement":3,
       "united states":3,
       "new onset":4,
       "motiv ations":3,
       "outcomes associated with nmu":3,
       "risk factors":5,
       "risk reduction methods":5,
       "mon itoring body mass index":3,
       "severe mood swings":2,
       "sweating of the face, lips, tongue, or throat":3,
       "underlying heart conditions":3,
       "national survey on drug use and health (nsduh)":2,
       "neurotransmitters":4,
       "new clinician":2,
       "us data bases":2,
       "pediatricians":2,
       "performance enhancement":2,
       "research methods":2,
       "stimulant-naïve college students":2,
       "nmu crisis":2,
       "nmu of prescription stimulants is highly prevalent":2,
       "wide variations in the definition of nmu":2,
       "performance enhancing drugs":3,
       "performance validity tests":3,
       "societal pressures to seek high levels of achievement":3,
       "symptom validity tests":3,
       "none":2,
       "nonmedical use and diversion":2,
       "nonmedical use and diversion of prescription stimulants":2,
       "overdose":2,
       "therapeutic range":2,
       "numbers":2,
       "offspring of mothers with a single prior miscarriage":2,
       "organizational structure or systems":2,
       "pill counts":2,
       "symptoms and prescription refill requests":2,
       "patient perceptions":2,
       "patient supply":2,
       "patient-generated goals discussed":4,
       "patients leaving practice":2,
       "patients seen within a timely fashion":3,
       "seen within a timely fashion":3,
       "patients with documentation of concerns being discussed":3,
       "patients with documented satisfaction assessment":3,
       "satisfaction assessment at least annually":3,
       "psychosocial treatment":2,
       "transfer of care":2,
       "poison control centers and dawn data":2,
       "population":1,
       "preferential seating":2,
       "teacher":2,
       "safeguards":2,
       "prescription for adhd medication":3,
       "suds":3,
       "theft":2,
       "serious health outcomes":2,
       "trends in nmu":2,
       "stimulant treatment history":3,
       "subsequent substance use, abuse, or dependence":3,
       "surgical treatment":2,
       "primary inattentive adhd":2,
       "psychostimulant medications":2,
       "risk of psychosis":2,
       "qol benefits":2,
       "rating scales with adult norms":2,
       "sustained remission":2,
       "regional and national databases":2,
       "research participants":2,
       "signatories":2,
       "topic":2,
       "residential instability":2,
       "risk for adverse events":2,
       "risky behaviors":2,
       "treatment alternatives, benefits and risks have been discussed":2,
       "validated measure":2,
       "stimulant overdoses before contacting emergency services":2,
       "systematic literature review":2,
       "study selection":2,
       "structural magnetic resonance imaging (mri) data":2,
       "treatment discontinuity":2,
       "taking medication":3,
       "verbal working memory":2
    },
    "avg_degree":{
       "1130":10.591150442477876,
       "3":215.33184523809524,
       "80":43.475,
       "8":123.91810344827586,
       "14":82.62732919254658,
       "2":266.08218318695106,
       "7":101.46285714285715,
       "21":78.06547619047619,
       "5":162.91194968553458,
       "4":181.97212543554008,
       "97":43.01030927835052,
       "296":20.050675675675677,
       "169":29.331360946745562,
       "40":52.975,
       "12":72.25952380952381,
       "27":57.97037037037037,
       "34":65.71323529411765,
       "31":62.17204301075269,
       "17":71.63667820069205,
       "11":105.47878787878788,
       "249":23.244979919678716,
       "96":36.541666666666664,
       "6":131.2463768115942,
       "32":60.6015625,
       "20":81.04444444444445,
       "18":71.8989898989899,
       "28":60.80952380952381,
       "42":54.72222222222222,
       "87":39.94252873563219,
       "43":63.02325581395349,
       "15":79.63174603174603,
       "10":85.41136363636363,
       "22":55.654545454545456,
       "214":28.0,
       "49":54.07142857142857,
       "39":66.73076923076923,
       "55":52.10909090909091,
       "53":47.009433962264154,
       "94":44.06382978723404,
       "16":79.64166666666667,
       "33":62.58080808080808,
       "1":63.5,
       "46":52.0,
       "13":106.78021978021978,
       "83":54.036144578313255,
       "9":95.46666666666667,
       "77":44.62337662337662,
       "52":58.13461538461539,
       "66":54.34848484848485,
       "79":53.77215189873418,
       "24":52.604166666666664,
       "30":88.15,
       "195":28.53846153846154,
       "103":30.611650485436893,
       "58":54.94827586206897,
       "0":0,
       "69":46.57971014492754,
       "45":45.8,
       "19":73.93567251461988,
       "26":77.61538461538461,
       "25":73.83,
       "38":51.18421052631579,
       "62":52.16129032258065,
       "56":56.035714285714285,
       "23":72.46739130434783,
       "41":61.21951219512195,
       "60":38.4,
       "51":66.88235294117646,
       "29":84.41379310344827,
       "88":50.56818181818182,
       "73":45.61643835616438,
       "105":41.49523809523809
    },
    "degree_centrality":{
       "adhd":0.4816709292412617,
       "$77.5 to $115.9 billion":0.001278772378516624,
       "adolescents and young adults with adhd":0.03410059676044331,
       "substantial impairments":0.0034100596760443308,
       "traffic accidents":0.0034100596760443308,
       "% of patients medicated for adhd ":0.005967604433077579,
       "prescription refills are coordinated with other prescribers":0.001278772378516624,
       "transition care coordinated for vacations and other times away":0.001278772378516624,
       "% patients evaluated with parent vanderbilt rating scales":0.0008525149190110827,
       "% patients meeting dsm criteria for adhd":0.0029838022165387893,
       "% patients treated with psychostimulant medication":0.0029838022165387893,
       "% patients evaluated with teacher vanderbilt rating scales":0.0008525149190110827,
       "% patients on medication with at least 2 follow-up visits a year in record":0.0008525149190110827,
       "% patients seen within 30 days medication initiation":0.0008525149190110827,
       "% patients whose medical record contains documentation of dsm criteria":0.0008525149190110827,
       "confirmation of impairment in 2+ settings":0.0008525149190110827,
       "seen within one month of first prescription":0.001278772378516624,
       "screening":0.008951406649616368,
       "% patients stabilized on an adhd medication ":0.002131287297527707,
       "seen at least once per year":0.002131287297527707,
       "communication with other health care providers occurs at least annually":0.001278772378516624,
       "external treatment resources":0.001278772378516624,
       "prescription monitoring program consulted at least annually":0.001278772378516624,
       "psychosocial and educational needs have been re-evaluated at least annually":0.001278772378516624,
       "risks and benefits of stopping treatment discussed at least annually":0.001278772378516624,
       "substance use evaluated at least annually":0.001278772378516624,
       "vitals taken at least annually":0.0017050298380221654,
       "% patients with adhd with documentation of impairment":0.0008525149190110827,
       "1.4 million individuals":0.001278772378516624,
       "amphetamine":0.04134697357203751,
       "intentional, nontherapeutic use":0.005967604433077579,
       "stimulants":0.12617220801364024,
       "2000 people":0.001278772378516624,
       "adhd medication":0.07203751065643649,
       "medical literature":0.005967604433077579,
       "studies":0.017050298380221655,
       "28 adhd experts":0.001278772378516624,
       "draft list of 46 qms":0.005115089514066496,
       "quality measure":0.011508951406649617,
       "2–4 hours":0.0017050298380221654,
       "adhd impairments":0.014492753623188406,
       "long acting":0.013213981244671782,
       "short acting":0.013213981244671782,
       "4.4% of adults":0.001278772378516624,
       "40-50 percent of participants met adhd criteria at any given follow-up":0.001278772378516624,
       "recurrence":0.005967604433077579,
       "remission":0.007246376811594203,
       "48 cohorts":0.0008525149190110827,
       "structural grey matter volume reductions":0.002131287297527707,
       "5 mg orally in the morning on the first day":0.0008525149190110827,
       "cardiovascular history":0.005115089514066496,
       "5.9%":0.001278772378516624,
       "thorough evaluation":0.004688832054560955,
       "adolescence":0.10613810741687979,
       "50":0.001278772378516624,
       "adult":0.040920716112531966,
       "daily report card":0.002557544757033248,
       "5mg and 10mg":0.0017050298380221654,
       "concerta":0.0029838022165387893,
       "dose":0.013640238704177323,
       "long-acting medications":0.002557544757033248,
       "dexmethylphenidate":0.07203751065643649,
       "79 authors":0.001278772378516624,
       "authors from 27 countries and 6 continents":0.002131287297527707,
       "empirically supported statements":0.008525149190110827,
       "a death in the family":0.0008525149190110827,
       "rutter's indicators of adversity":0.0076726342710997444,
       "a father or brother or sister with epilepsy":0.0008525149190110827,
       "epilepsy":0.005115089514066496,
       "a frequent complaint among users":0.0029838022165387893,
       "behavioral changes":0.011935208866155157,
       "cardiovascular effects":0.013640238704177323,
       "central nervous system effects":0.017902813299232736,
       "gastrointestinal issues":0.013640238704177323,
       "mental conditions":0.0370843989769821,
       "sleep disturbances":0.018329070758738276,
       "a person's mother with epilepsy":0.0008525149190110827,
       "abdominal pain":0.00639386189258312,
       "abnormalities of chromosomes":0.0017050298380221654,
       "adhd and many other psychiatric disorders":0.004262574595055414,
       "high polygenic risk for adhd":0.00937766410912191,
       "polygenic risk":0.004688832054560955,
       "abstinence is not an absolute precondition to start treatment":0.0017050298380221654,
       "drug treatment":0.09121909633418585,
       "stabilize substance use":0.0017050298380221654,
       "abstract problem solving":0.0034100596760443308,
       "basal ganglia":0.017902813299232736,
       "focused attention":0.002557544757033248,
       "inhibitory control":0.008951406649616368,
       "adhd individuals":0.020886615515771527,
       "sustained attention":0.005115089514066496,
       "verbal memory":0.002557544757033248,
       "working memory":0.008525149190110827,
       "abuse":0.005967604433077579,
       "diversion":0.005115089514066496,
       "misuse":0.016624040920716114,
       "nmu":0.023444160272804774,
       "nmu of stimulants":0.022591645353793693,
       "abuse liability":0.0008525149190110827,
       "nortriptyline":0.007246376811594203,
       "tricyclic antidepressant":0.007246376811594203,
       "abuse of prescription drugs":0.001278772378516624,
       "alcohol":0.008525149190110827,
       "atomoxetine":0.040068201193520885,
       "long -acting stimulants":0.002557544757033248,
       "norepinephrine reuptake inhibitors":0.0034100596760443308,
       "short-acting stimulants":0.002557544757033248,
       "treatment ending early as the result of adverse events":0.002557544757033248,
       "abuse, misuse and diversion":0.0034100596760443308,
       "adh d medications":0.0008525149190110827,
       "asthma medications":0.002131287297527707,
       "multiple prescribers":0.0008525149190110827,
       "prescriptions at multiple pharmacies":0.0008525149190110827,
       "shopping behavior":0.0068201193520886615,
       "academic activity":0.0017050298380221654,
       "stimulant use":0.008951406649616368,
       "weekends":0.002557544757033248,
       "academic difficulties":0.001278772378516624,
       "academic dishonesty":0.0008525149190110827,
       "academic function":0.001278772378516624,
       "academic integrity policies":0.002131287297527707,
       "alcohol/drug use policies":0.001278772378516624,
       "nmu (non-medical use)":0.014066496163682864,
       "students who reported nmu":0.00042625745950554135,
       "academic outcomes":0.013640238704177323,
       "adverse medical outcomes":0.0068201193520886615,
       "amp abuse":0.001278772378516624,
       "clinically significant effects":0.0017050298380221654,
       "clinician":0.0196078431372549,
       "co-occurring disorders":0.001278772378516624,
       "college graduation":0.0017050298380221654,
       "exposures":0.001278772378516624,
       "family or friends":0.002557544757033248,
       "disorders":0.005541346973572037,
       "intravenous abusers":0.001278772378516624,
       "intravenous":0.002131287297527707,
       "longitudinal study":0.0017050298380221654,
       "nasal abusers":0.001278772378516624,
       "nmu behavior":0.00639386189258312,
       "patient education":0.008525149190110827,
       "poison control calls":0.0017050298380221654,
       "practitioner":0.005541346973572037,
       "prevention strategies":0.007246376811594203,
       "rating scales":0.008525149190110827,
       "risk of dying":0.005967604433077579,
       "adverse effects":0.035379369138959935,
       "social interactions":0.0017050298380221654,
       "treatment plan":0.008525149190110827,
       "academic performance enhancement":0.002131287297527707,
       "educational attainment":0.00639386189258312,
       "misuse and diversion of stimulant medications":0.0038363171355498722,
       "non-medical use of prescribed stimulants":0.004688832054560955,
       "psychotic events":0.0038363171355498722,
       "academic skills":0.002131287297527707,
       "accommodations":0.004688832054560955,
       "symptoms":0.032821824381926684,
       "inattention symptoms":0.005541346973572037,
       "accidental injuries":0.004688832054560955,
       "depression":0.02216538789428815,
       "sleep issues":0.005967604433077579,
       "substance abuse":0.028132992327365727,
       "attempted suicide":0.033674339300937765,
       "mortality":0.010230179028132991,
       "motor tics":0.020886615515771527,
       "accidental physical injuries":0.001278772378516624,
       "bullying":0.001278772378516624,
       "burn injuries":0.002131287297527707,
       "accidental poisoning":0.0017050298380221654,
       "accidents":0.002131287297527707,
       "further reduce qol":0.002131287297527707,
       "americans with disabilities act":0.0017050298380221654,
       "classroom-based programs":0.001278772378516624,
       "disability":0.001278772378516624,
       "idea (pl-101-476)":0.001278772378516624,
       "school-based interventions":0.005115089514066496,
       "section 504 of the rehabilitation act of 1973":0.0008525149190110827,
       "accommodations for children with adhd":0.002131287297527707,
       "brand medication":0.004262574595055414,
       "generic medication":0.005115089514066496,
       "medications for children with adhd":0.004262574595055414,
       "accurate diagnosis":0.0008525149190110827,
       "activated emotions":0.001278772378516624,
       "adhd child":0.004688832054560955,
       "ei (emotional impulsivity)":0.00937766410912191,
       "activation of mania or hypomania":0.00639386189258312,
       "viloxazine":0.01278772378516624,
       "active substance use disorder":0.0034100596760443308,
       "adhd patients with co-occurring sud":0.001278772378516624,
       "cocaine use disorder":0.0017050298380221654,
       "dextroamphetamine-amphetamine":0.004262574595055414,
       "nicotine dependence":0.0017050298380221654,
       "opioid dependence":0.0008525149190110827,
       "active substance use disorder (sud)":0.002557544757033248,
       "tcas":0.0076726342710997444,
       "acupuncture, yoga, and ayurvedic therapies":0.0008525149190110827,
       "adhd symptoms or associated impairments":0.005115089514066496,
       "acute co-administration of alcohol and stimulants":0.001278772378516624,
       "health consequences":0.001278772378516624,
       "acute mania":0.001278772378516624,
       "psychosis":0.00639386189258312,
       "stimulant adverse effects":0.00639386189258312,
       "adderall":0.0029838022165387893,
       "form":0.002557544757033248,
       "form and doses":0.001278772378516624,
       "usage":0.0029838022165387893,
       "adderall xr":0.004688832054560955,
       "bubblegum flavor":0.001278772378516624,
       "children who have trouble swallowing pills":0.001278772378516624,
       "evekeo":0.0017050298380221654,
       "morning":0.004262574595055414,
       "procentra":0.004262574595055414,
       "adhd symptoms":0.08312020460358056,
       "symptoms throughout the day":0.0017050298380221654,
       "symptoms with just one dose":0.001278772378516624,
       "vyvanse":0.005541346973572037,
       "zenzedi":0.0017050298380221654,
       "addiction":0.001278772378516624,
       "misuse of prescription drugs":0.002557544757033248,
       "additional meals or snacks":0.0008525149190110827,
       "weight loss":0.01278772378516624,
       "weight loss in people with adhd":0.004688832054560955,
       "additional pharmacotherapy":0.004262574595055414,
       "adhd patients":0.04390451832907076,
       "aggression and emotionaldysregulation":0.001278772378516624,
       "atomoxetine (atx)":0.004262574595055414,
       "callous emotional traits":0.001278772378516624,
       "child emotionality":0.001278772378516624,
       "emotion dysregulation":0.0247229326513214,
       "emotional dysregulation symptoms":0.004262574595055414,
       "odd symptoms":0.001278772378516624,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":0.001278772378516624,
       "additional problems the patient may have":0.0008525149190110827,
       "adhd clinical diagnoses":0.014066496163682864,
       "address this growing public health problem":0.004262574595055414,
       "consistent nomenclature":0.001278772378516624,
       "definition of nmu":0.001278772378516624,
       "epidemic levels":0.001278772378516624,
       "health care professionals":0.005115089514066496,
       "patient advocacy groups":0.0008525149190110827,
       "prescription stimulant":0.008525149190110827,
       "surveys and databases":0.0008525149190110827,
       "genomewide study":0.0,
       "adhd -iv rating scales":0.0017050298380221654,
       "adhd aetiology":0.0008525149190110827,
       "adhd biological pathways":0.0008525149190110827,
       "adhd children":0.029411764705882353,
       "adhd controls":0.0008525149190110827,
       "adhd criteria":0.008525149190110827,
       "adhd and emotional dysregulation":0.01918158567774936,
       "adhd genetic liability":0.0008525149190110827,
       "adhd genetic risk":0.0008525149190110827,
       "adhd guideline ng87":0.0008525149190110827,
       "adhd guidelines":0.0017050298380221654,
       "adhd in females":0.0034100596760443308,
       "adhd in their children":0.0008525149190110827,
       "adhd investigator symptom rating scale (aisrs)":0.0008525149190110827,
       "adhd lifespan course":0.0008525149190110827,
       "adhd medication use":0.0017050298380221654,
       "adhd medications (primarily stimulants)":0.0038363171355498722,
       "adhd presentation":0.0008525149190110827,
       "adhd probands":0.0029838022165387893,
       "adhd prototype":0.001278772378516624,
       "adhd research":0.00639386189258312,
       "adhd severity fluctuations":0.0008525149190110827,
       "adhd symptoms (e.g., aggression, hyperactivity)":0.0017050298380221654,
       "adhd symptoms/b ehaviors":0.0034100596760443308,
       "adhd traits":0.008098891730605285,
       "adhd treatment effectiveness":0.0008525149190110827,
       "adhd outcomes":0.004688832054560955,
       "adhd treatment response":0.0008525149190110827,
       "adhd-associated iq deficits":0.002131287297527707,
       "adhd-c":0.002557544757033248,
       "adhd-like behaviors and their associated impairments":0.0008525149190110827,
       "adhd-like symptoms":0.010230179028132991,
       "adhd-related brain structural differences":0.001278772378516624,
       "adhd-related hospital admissions":0.0008525149190110827,
       "adherence":0.004262574595055414,
       "adverse outcomes later in life":0.0008525149190110827,
       "age":0.008525149190110827,
       "age 25":0.001278772378516624,
       "age at diagnosis":0.001278772378516624,
       "age at menopause":0.008525149190110827,
       "age at onset":0.0008525149190110827,
       "age at onset variation":0.0008525149190110827,
       "age of first birth":0.008525149190110827,
       "air pollution":0.0008525149190110827,
       "alexander crichton":0.0017050298380221654,
       "allergic reactions":0.011082693947144074,
       "allergic rhinitis":0.0017050298380221654,
       "alpha agonists":0.0038363171355498722,
       "alpha-2 adrenergic agonists (clonidine)":0.001278772378516624,
       "alpha-2 adrenergic agonists (guanfacine)":0.001278772378516624,
       "amblyopia":0.0008525149190110827,
       "amygdala":0.004262574595055414,
       "ankylosing spondylitis":0.0008525149190110827,
       "antidepressant":0.004262574595055414,
       "antisocial behaviour":0.0008525149190110827,
       "antisocial personality disorder (aspd)":0.0008525149190110827,
       "anxiety":0.014492753623188406,
       "anxiety disorder":0.013213981244671782,
       "anxiety or depression":0.0017050298380221654,
       "anxiety or tics":0.001278772378516624,
       "appetite suppression":0.002131287297527707,
       "arbor pharmaceuticals, llc":0.001278772378516624,
       "arithmetic":0.001278772378516624,
       "arrested":0.0008525149190110827,
       "artificial food color exclusion":0.0029838022165387893,
       "artificial food dyes":0.001278772378516624,
       "asd":0.007246376811594203,
       "asd and adhd":0.002131287297527707,
       "aspd":0.0008525149190110827,
       "assessment and treatment response":0.001278772378516624,
       "assets and strengths":0.0008525149190110827,
       "asthma":0.005115089514066496,
       "asthmatic mothers":0.0008525149190110827,
       "astigmatism":0.0008525149190110827,
       "at all ages":0.0008525149190110827,
       "atomoxetine dosing":0.005967604433077579,
       "atopic dermatitis":0.0017050298380221654,
       "attention":0.008525149190110827,
       "attention and cognitive control networks":0.0008525149190110827,
       "attention and somatoform networks":0.0008525149190110827,
       "attention and working memory tasks":0.001278772378516624,
       "atx":0.011082693947144074,
       "augusto vidal perera":0.007246376811594203,
       "autism":0.02216538789428815,
       "autoimmune disease":0.001278772378516624,
       "autoimmune thyroid disease":0.0008525149190110827,
       "behavior":0.010656436487638534,
       "behavior management":0.002131287297527707,
       "behavior management training":0.001278772378516624,
       "behavior modification":0.0017050298380221654,
       "behavior therapy":0.01619778346121057,
       "behavior therapy principles":0.001278772378516624,
       "behavioral and mental health assessment":0.014066496163682864,
       "behavioral intervention":0.00639386189258312,
       "behavior monitoring":0.0034100596760443308,
       "behavioral regulation index of the brief-a":0.005115089514066496,
       "behavioral responses":0.001278772378516624,
       "behavioral responses and emotional responses":0.001278772378516624,
       "behavioural interventions":0.004262574595055414,
       "benefits for adhd":0.001278772378516624,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":0.0008525149190110827,
       "biologic vulnerability":0.0008525149190110827,
       "biological and psychological causal mechanisms":0.001278772378516624,
       "biological pathways":0.001278772378516624,
       "biological test":0.0008525149190110827,
       "bipolar disorder":0.011935208866155157,
       "black and latin minority youth":0.0008525149190110827,
       "black individuals":0.002131287297527707,
       "black patients with adhd":0.0008525149190110827,
       "blood lead levels":0.0034100596760443308,
       "blood pressure":0.005967604433077579,
       "body mass index":0.00937766410912191,
       "boys":0.002131287297527707,
       "boys and girls":0.0008525149190110827,
       "boys born to women who lost a close relative during pregnancy":0.0017050298380221654,
       "boys with adhd":0.005115089514066496,
       "brain":0.0034100596760443308,
       "brain areas involved in cognition":0.001278772378516624,
       "brain differences":0.0008525149190110827,
       "brain functioning":0.0008525149190110827,
       "brain imaging":0.0017050298380221654,
       "brain imaging studies":0.001278772378516624,
       "brain volumes":0.0008525149190110827,
       "brain-specific neuronal subtypes":0.0008525149190110827,
       "brains of people with adhd":0.0038363171355498722,
       "breastfeeding women":0.001278772378516624,
       "brief behavioral sleep intervention":0.001278772378516624,
       "bupropion":0.018329070758738276,
       "bupropion extended-release":0.0008525149190110827,
       "cannabis abuse or dependence":0.001278772378516624,
       "cannabis use disorder":0.008951406649616368,
       "cardiometabolic disease":0.002131287297527707,
       "cardiac events":0.026427962489343565,
       "cardiovascular monitoring":0.013640238704177323,
       "care":0.002131287297527707,
       "caregiver":0.013640238704177323,
       "cause of adhd":0.0008525149190110827,
       "cbt":0.011082693947144074,
       "cbt methods for emotional dysregulation issues":0.0008525149190110827,
       "cbt and dbt program":0.001278772378516624,
       "cd":0.0029838022165387893,
       "celiac disease":0.005541346973572037,
       "central nervous system injury":0.0008525149190110827,
       "certain areas":0.0008525149190110827,
       "certain birth defects":0.0008525149190110827,
       "chadd":0.0076726342710997444,
       "changing antecedent behavior and reinforcement":0.001278772378516624,
       "characterization of ei/desr in adhd":0.001278772378516624,
       "child's developmental stage":0.002131287297527707,
       "child's health":0.0034100596760443308,
       "childhood adhd":0.0008525149190110827,
       "children and adolescents who do not respond to stimulants":0.001278772378516624,
       "children and adolescents who have adhd plus other mental health conditions":0.001278772378516624,
       "children and adolescents with adhd":0.0038363171355498722,
       "children who experienced sexual abuse or physical neglect":0.0017050298380221654,
       "children who grow up in difficult family situations":0.001278772378516624,
       "children who had a specific type of viral infection (enterovirus)":0.001278772378516624,
       "children whose mothers were severely obese":0.002131287297527707,
       "children with adhd and smd":0.001278772378516624,
       "children with low lead levels":0.0008525149190110827,
       "children without adhd":0.005115089514066496,
       "cholinesterase inhibitors":0.0008525149190110827,
       "chrna7":0.005115089514066496,
       "cigarettes smoked per day":0.008525149190110827,
       "cingulate region":0.0029838022165387893,
       "clinical assessment":0.0008525149190110827,
       "clinical experience":0.0017050298380221654,
       "clinical features":0.0008525149190110827,
       "clinical global impression ratings":0.0008525149190110827,
       "clinical research":0.004688832054560955,
       "clinician interview":0.0008525149190110827,
       "clonidine":0.016624040920716114,
       "clonidine extended-release":0.004688832054560955,
       "close friends":0.002131287297527707,
       "cnvs":0.0008525149190110827,
       "cnvs in the 1q21.1 region":0.001278772378516624,
       "cnvs in the 6q26 region":0.0017050298380221654,
       "co-contraindication for stimulant prescription":0.0017050298380221654,
       "cocaine":0.0034100596760443308,
       "cocaine or methamphetamine use":0.0029838022165387893,
       "coexisting condition":0.002131287297527707,
       "coexisting mental health disorders":0.00639386189258312,
       "cognitive behavior therapy":0.023870417732310314,
       "cognitive errors":0.001278772378516624,
       "cognitive function":0.005541346973572037,
       "cognitive training":0.00980392156862745,
       "college completion":0.0068201193520886615,
       "combination therapies":0.001278772378516624,
       "combinations of social disadvantages":0.0008525149190110827,
       "common adverse effects":0.0008525149190110827,
       "community controls":0.0008525149190110827,
       "comorbid anxiety or tics":0.0017050298380221654,
       "comorbid condition":0.02216538789428815,
       "comorbidities aggravate these outcomes":0.0017050298380221654,
       "complete specificity":0.001278772378516624,
       "completion of no more than compulsory education":0.0008525149190110827,
       "complex cases":0.0029838022165387893,
       "complex psychosocial circumstances":0.002131287297527707,
       "computer-based training":0.0029838022165387893,
       "condition":0.0029838022165387893,
       "conduct disorder":0.0034100596760443308,
       "conduct disorder (cd)":0.001278772378516624,
       "conduct problems":0.0029838022165387893,
       "confounders":0.0017050298380221654,
       "conners global index (cgi) emotional lability scale":0.0068201193520886615,
       "adhd index of the conners adult adhd rating scale":0.0034100596760443308,
       "consistent set of causes for the disorder":0.0008525149190110827,
       "consultation":0.005115089514066496,
       "controls":0.002557544757033248,
       "core disorder in adhd":0.001278772378516624,
       "core symptoms of adhd":0.0017050298380221654,
       "coronary artery disease":0.008525149190110827,
       "cortical surface area":0.0029838022165387893,
       "cortical thickness":0.001278772378516624,
       "crash risk":0.0008525149190110827,
       "crashes":0.0008525149190110827,
       "criminal offenses":0.0008525149190110827,
       "criminal records":0.0008525149190110827,
       "curative treatments for adhd":0.0008525149190110827,
       "d-amphetamine sulfate":0.0008525149190110827,
       "daily functioning":0.0034100596760443308,
       "daily life":0.0017050298380221654,
       "danish national register longitudinal cohort study":0.0008525149190110827,
       "danish national registers":0.0034100596760443308,
       "danish population":0.0008525149190110827,
       "death by homicide":0.001278772378516624,
       "death from natural causes":0.0008525149190110827,
       "decision-making":0.0008525149190110827,
       "decrease":0.0008525149190110827,
       "decreased appetite":0.011508951406649617,
       "decreases in appetite":0.001278772378516624,
       "default-mode network (dmn)":0.005115089514066496,
       "delayed onset of sleep":0.001278772378516624,
       "delayed reinforcement":0.001278772378516624,
       "deliberate self-poisoning":0.001278772378516624,
       "dementia":0.001278772378516624,
       "deprivation":0.0017050298380221654,
       "desr":0.0034100596760443308,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":0.0008525149190110827,
       "developmental disability–children’s global assessment scale":0.002131287297527707,
       "developmental history":0.002131287297527707,
       "dex":0.005967604433077579,
       "dexedrine":0.0017050298380221654,
       "dextro amphetamine":0.0029838022165387893,
       "deﬁcient emotional self-regulation (desr)":0.0008525149190110827,
       "diagnoses":0.017476555839727195,
       "diagnosis of apparent adult-onset adhd":0.0008525149190110827,
       "diagnostic criteria":0.001278772378516624,
       "diagnostic delays":0.001278772378516624,
       "diets":0.0029838022165387893,
       "differ between children and adults":0.002131287297527707,
       "differences between groups of people who are and are not diagnosed with adhd":0.0038363171355498722,
       "difficult life circumstances":0.0008525149190110827,
       "difficulty breathing":0.0017050298380221654,
       "difficulty sustaining attention":0.001278772378516624,
       "digital health interventions (dhis)":0.0038363171355498722,
       "disability service options":0.0017050298380221654,
       "disinhibited emotionally expressive behavior":0.0008525149190110827,
       "disorder":0.0017050298380221654,
       "disruptive mood dysregulation disorder":0.0038363171355498722,
       "distress":0.001278772378516624,
       "distress tolerance":0.004688832054560955,
       "dlpfc":0.001278772378516624,
       "dmn":0.0034100596760443308,
       "doctor":0.00639386189258312,
       "does not seem to listen":0.001278772378516624,
       "domains":0.001278772378516624,
       "dopamine":0.0017050298380221654,
       "dopamine levels in synapses":0.001278772378516624,
       "dopamine regulation":0.0017050298380221654,
       "double-blind, placebo-controlled trials":0.002131287297527707,
       "driver license suspensions":0.0008525149190110827,
       "drug contract or conducting periodic drug screens":0.0017050298380221654,
       "dsm and icd criteria":0.0008525149190110827,
       "dsm-5":0.002131287297527707,
       "dsm-5 diagnosis":0.001278772378516624,
       "dsm-5 symptom criteria":0.001278772378516624,
       "dsm-5’s dmdd":0.0008525149190110827,
       "duration":0.0008525149190110827,
       "duration of treatment":0.002557544757033248,
       "dusp6":0.005115089514066496,
       "dysfunctional cognitive beliefs":0.002131287297527707,
       "dysphoria":0.004262574595055414,
       "dysregulation":0.0008525149190110827,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":0.0008525149190110827,
       "earnings reduction":0.001278772378516624,
       "anorexia":0.013213981244671782,
       "editorial support":0.001278772378516624,
       "education planning":0.0017050298380221654,
       "educational and occupational failure":0.002131287297527707,
       "eeg neurofeedback":0.0029838022165387893,
       "efficacy":0.0034100596760443308,
       "efficacy in treating adhd":0.004262574595055414,
       "ei":0.008951406649616368,
       "ei and desr":0.00639386189258312,
       "electrical stimulation":0.0017050298380221654,
       "electrophysiology":0.0008525149190110827,
       "elevations in the theta/beta on the electroencephalogram":0.0008525149190110827,
       "elimination diets":0.0034100596760443308,
       "embryogenesis":0.001278772378516624,
       "emergent health conditions":0.0008525149190110827,
       "emerging problems":0.0008525149190110827,
       "emotion processing":0.008098891730605285,
       "emotion regulation":0.02557544757033248,
       "emotional and behavioral trajectories":0.001278772378516624,
       "emotional control scores":0.0017050298380221654,
       "emotional control subscale":0.0017050298380221654,
       "emotional intensity (ei)":0.002557544757033248,
       "emotional lability":0.007246376811594203,
       "emotion":0.008098891730605285,
       "emotional symptoms":0.022591645353793693,
       "employed":0.0008525149190110827,
       "employment reduction":0.001278772378516624,
       "enigma-adhd working group set of cohort from around the world":0.0017050298380221654,
       "enterovirus patients":0.001278772378516624,
       "environment":0.001278772378516624,
       "environmental correlates":0.0017050298380221654,
       "environmental correlates of adhd":0.0076726342710997444,
       "environmental factors":0.0076726342710997444,
       "environmental risks":0.0017050298380221654,
       "epidemiologic studies":0.002131287297527707,
       "essential fatty acid supplementation":0.005115089514066496,
       "europe":0.0008525149190110827,
       "european network for hyper kinetic disorders (eunethydis)":0.0034100596760443308,
       "euthymic baseline":0.0008525149190110827,
       "evaluate care-giver burden in children":0.002131287297527707,
       "evaluate family-related qol and activities of daily living in children":0.002131287297527707,
       "evaluate overall functioning in children":0.002131287297527707,
       "evidence":0.0038363171355498722,
       "exaggerated delay discounting":0.0008525149190110827,
       "executive dysfunction":0.004262574595055414,
       "executive function":0.008525149190110827,
       "executive function control":0.002557544757033248,
       "executive functioning":0.002131287297527707,
       "exposure‐response trend":0.001278772378516624,
       "externalizing behavior problems":0.002131287297527707,
       "extreme deprivation early in life":0.0017050298380221654,
       "fails to give close attention":0.001278772378516624,
       "false positive diagnoses":0.001278772378516624,
       "familial co-aggregation":0.001278772378516624,
       "familial or genetic factors":0.0008525149190110827,
       "family":0.002557544757033248,
       "family conflict":0.0017050298380221654,
       "family function":0.001278772378516624,
       "family history of adhd":0.0017050298380221654,
       "family history of mental health issues":0.0017050298380221654,
       "family problems":0.0008525149190110827,
       "family strain index":0.002131287297527707,
       "fatty acid concentrations":0.0017050298380221654,
       "fda approval":0.0017050298380221654,
       "fda approved medication":0.001278772378516624,
       "fda-approved treatment for adhd":0.0017050298380221654,
       "felony":0.0008525149190110827,
       "female":0.0017050298380221654,
       "fidgeting":0.0008525149190110827,
       "fidgets with hands or feet":0.001278772378516624,
       "financial problems":0.0008525149190110827,
       "financial stability":0.0017050298380221654,
       "fmri neurofeedback":0.0017050298380221654,
       "fmri studies of cognitive control":0.0068201193520886615,
       "dietary interventions":0.0038363171355498722,
       "foster care":0.0008525149190110827,
       "foxp1 and foxp2":0.0008525149190110827,
       "foxp2":0.0017050298380221654,
       "franz kramer and hans pollnow":0.007246376811594203,
       "free fatty acids":0.0029838022165387893,
       "free tools":0.0008525149190110827,
       "frontal region":0.0029838022165387893,
       "functional impairment":0.002557544757033248,
       "functioning":0.002557544757033248,
       "funding for manuscript development":0.001278772378516624,
       "fusiform gyrus":0.002131287297527707,
       "future patient outcomes":0.0008525149190110827,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":0.0017050298380221654,
       "general behavior":0.0008525149190110827,
       "general population":0.0008525149190110827,
       "general psychopathology and several psychiatric disorders":0.0008525149190110827,
       "generalized emotional under-control":0.001278772378516624,
       "genes and environment":0.0008525149190110827,
       "genetic and environmental risk factors":0.0017050298380221654,
       "genetic correlation":0.0068201193520886615,
       "genetic factors":0.0017050298380221654,
       "genetic influence":0.002557544757033248,
       "genetic or familial causes":0.0008525149190110827,
       "genetic risk":0.002131287297527707,
       "genetic variants":0.0076726342710997444,
       "genetics":0.002131287297527707,
       "genomic loci":0.0008525149190110827,
       "geographic region":0.0017050298380221654,
       "george still":0.002557544757033248,
       "girls":0.0008525149190110827,
       "girls with adhd":0.0017050298380221654,
       "glaucoma":0.0008525149190110827,
       "glutamatergic neurotransmission":0.0008525149190110827,
       "gonzalo rodriguez-lafora":0.001278772378516624,
       "grade point sum":0.0008525149190110827,
       "growth issues":0.0038363171355498722,
       "guanfacine":0.018329070758738276,
       "extended release guanfacine":0.0076726342710997444,
       "gudjonsson et al.":0.002557544757033248,
       "guidelines":0.005541346973572037,
       "gwas":0.0008525149190110827,
       "hba1c":0.001278772378516624,
       "headache":0.021739130434782608,
       "health-care disparities":0.0008525149190110827,
       "health care provider":0.0123614663256607,
       "healthcare systems":0.002131287297527707,
       "heart rate":0.008525149190110827,
       "heinrich hoffmann":0.0017050298380221654,
       "high blood pressure":0.00980392156862745,
       "high iqs":0.0008525149190110827,
       "high lead levels":0.0008525149190110827,
       "high risk of substance abuse":0.0017050298380221654,
       "high school and collegiate athletes":0.0008525149190110827,
       "high ses":0.0008525149190110827,
       "higher adhd symptom severity and poorer outcomes":0.0008525149190110827,
       "hippocampus":0.004262574595055414,
       "hippocampus volume":0.0017050298380221654,
       "history of illicit stimulant use":0.001278772378516624,
       "hong kong database":0.0008525149190110827,
       "hyperactivity":0.008951406649616368,
       "hyperactivity in children":0.0008525149190110827,
       "hyperkinetic disorder":0.002131287297527707,
       "hyperthyroidism (overactive thyroid)":0.001278772378516624,
       "hypospadias":0.0008525149190110827,
       "hypotension":0.005541346973572037,
       "hypothyroidism (underactive thyroid)":0.001278772378516624,
       "icd-11":0.001278772378516624,
       "icd-11 criteria":0.0008525149190110827,
       "ifc":0.0008525149190110827,
       "ifc and insula":0.0008525149190110827,
       "illegally used drugs":0.0017050298380221654,
       "imaging studies":0.0008525149190110827,
       "immediate reinforcement":0.0008525149190110827,
       "immediate rewards":0.0017050298380221654,
       "impaired academic functioning":0.002131287297527707,
       "impairment":0.011508951406649617,
       "impairments in quality of life":0.001278772378516624,
       "improved academic performance":0.0008525149190110827,
       "improved brain function, most prominently in inferior frontal and striatal regions":0.0008525149190110827,
       "improved parent-reported child behavior":0.001278772378516624,
       "improved relationships with caregivers, teachers, siblings, or peers":0.0008525149190110827,
       "improved rule following":0.0008525149190110827,
       "improved sleep":0.001278772378516624,
       "improvements":0.0034100596760443308,
       "improvements in living":0.001278772378516624,
       "impulsive decision-making":0.0017050298380221654,
       "impulsivity":0.004688832054560955,
       "high inattentive factor":0.013213981244671782,
       "inattention and hyperactivity":0.0017050298380221654,
       "inattentive type":0.001278772378516624,
       "adhd inattentive type":0.0017050298380221654,
       "incarceration":0.0008525149190110827,
       "increase the risks of suicidality":0.0017050298380221654,
       "increased rate of rare genetic mutations":0.002131287297527707,
       "incredible years (iy)":0.002557544757033248,
       "individual":0.002557544757033248,
       "infection":0.0017050298380221654,
       "inferior frontal dysfunction":0.0017050298380221654,
       "inflammation":0.0008525149190110827,
       "health professionals, patients and families":0.008951406649616368,
       "inhibition":0.0008525149190110827,
       "initial treatment":0.004688832054560955,
       "injuries":0.002557544757033248,
       "insomnia":0.023870417732310314,
       "insula":0.001278772378516624,
       "insulin resistance":0.0008525149190110827,
       "integrative treatment":0.004262574595055414,
       "integrity of auditory sensory memory and involuntary attention switching":0.0008525149190110827,
       "intellectual disabilities":0.002131287297527707,
       "intellectual functioning":0.0008525149190110827,
       "intelligence":0.007246376811594203,
       "intelligent individuals":0.0008525149190110827,
       "intensity":0.0008525149190110827,
       "intensity of subjective states and behavior":0.001278772378516624,
       "intentional exposures":0.0017050298380221654,
       "interdisciplinary collaborations":0.0008525149190110827,
       "international resources":0.0008525149190110827,
       "interventions":0.005967604433077579,
       "intracranial brain volume":0.0008525149190110827,
       "iq":0.004262574595055414,
       "iq differences":0.004688832054560955,
       "iq scores":0.001278772378516624,
       "iq tests":0.0008525149190110827,
       "irritability":0.03751065643648764,
       "juvenile detention":0.0008525149190110827,
       "kidney failure":0.0008525149190110827,
       "kidscreen-10":0.002131287297527707,
       "l-deprenyl":0.0008525149190110827,
       "large family size":0.0008525149190110827,
       "large population studies":0.0017050298380221654,
       "larger delayed ones":0.0008525149190110827,
       "lead burden":0.0008525149190110827,
       "learning disorder":0.002131287297527707,
       "leaves seat in situations":0.001278772378516624,
       "licensed clinician":0.0008525149190110827,
       "limbic volume":0.002131287297527707,
       "lines of communication":0.0008525149190110827,
       "lisdexamfetamine":0.005967604433077579,
       "long-range fronto-posterior association tracts":0.0017050298380221654,
       "long-term medication use":0.001278772378516624,
       "low ses":0.0008525149190110827,
       "low social class":0.0008525149190110827,
       "low social class conditions":0.0008525149190110827,
       "lower achievement scores":0.001278772378516624,
       "lower family income":0.001278772378516624,
       "lower quality of life":0.0008525149190110827,
       "lung cancer":0.008525149190110827,
       "major depression":0.010656436487638534,
       "makes careless mistakes":0.001278772378516624,
       "male":0.002557544757033248,
       "male-to-female sex ratio of adhd":0.00639386189258312,
       "maois":0.004688832054560955,
       "map1a":0.0008525149190110827,
       "maternal alcohol use during pregnancy":0.001278772378516624,
       "maternal mental disorder":0.0008525149190110827,
       "maternal pre-existing type 1 diabetes":0.0017050298380221654,
       "maternal prenatal use of acetaminophen":0.0008525149190110827,
       "maternal smoking":0.005541346973572037,
       "maximimum tolerated dose":0.0008525149190110827,
       "measurement tools":0.0008525149190110827,
       "measurement-based care":0.0008525149190110827,
       "measures of neurocognitive functioning":0.0008525149190110827,
       "measures to evaluate qol or functional impairment":0.002131287297527707,
       "mechanisms of disease onset":0.0008525149190110827,
       "mechanisms/pathophysiology":0.0008525149190110827,
       "medical history":0.0017050298380221654,
       "medical problem":0.001278772378516624,
       "medication periods":0.001278772378516624,
       "medication therapy":0.002557544757033248,
       "medication-free weekends":0.001278772378516624,
       "mef2c":0.005541346973572037,
       "melchior adam weikard":0.0017050298380221654,
       "memory":0.0008525149190110827,
       "meta-analyses":0.011508951406649617,
       "metabolic disorders":0.0008525149190110827,
       "methamphetamine":0.0008525149190110827,
       "method of diagnosing adhd":0.001278772378516624,
       "methods to improve adherence":0.0008525149190110827,
       "methylphenidate treatment":0.004262574595055414,
       "methylphenidate users":0.001278772378516624,
       "methylphenidate users ages 46-65":0.001278772378516624,
       "methylphenidate users with previous alcohol and drug misuse":0.001278772378516624,
       "methyphenidate prescription":0.002557544757033248,
       "migraine":0.0017050298380221654,
       "milder adhd":0.001278772378516624,
       "mindfulness and positive aspects of adhd":0.0008525149190110827,
       "mindfulness meditation":0.0008525149190110827,
       "mindfulness-based treatments":0.0008525149190110827,
       "minimal brain dysfunction":0.002557544757033248,
       "minor structural and functional brain differences":0.001278772378516624,
       "misconceptions":0.0068201193520886615,
       "misdemeanors":0.0008525149190110827,
       "mismatch negativity":0.0008525149190110827,
       "misuse and diversion of these medications":0.001278772378516624,
       "mixed amphetamine salts":0.002131287297527707,
       "modafinil":0.005967604433077579,
       "molecular genetic data":0.001278772378516624,
       "mood":0.004688832054560955,
       "mood disorder":0.005541346973572037,
       "mortality rates":0.002131287297527707,
       "most cases of adhd":0.0008525149190110827,
       "mothers":0.0038363171355498722,
       "mothers who were obese before pregnancy":0.001278772378516624,
       "mothers with two or more prior miscarriages":0.001278772378516624,
       "motor vehicle collision":0.002557544757033248,
       "mtbi":0.0008525149190110827,
       "multidisciplinary efforts":0.001278772378516624,
       "multiple settings":0.001278772378516624,
       "narcolepsy":0.0008525149190110827,
       "national health and nutrition examination survey":0.0008525149190110827,
       "national health insurance data":0.0008525149190110827,
       "national institute for health and care excellence (nice)":0.0008525149190110827,
       "national institute of mental health":0.0008525149190110827,
       "nationwide population study":0.0017050298380221654,
       "nausea":0.014492753623188406,
       "negative parenting":0.002131287297527707,
       "negative reinforcement":0.0008525149190110827,
       "neglect":0.001278772378516624,
       "network meta-analyses":0.002557544757033248,
       "network of researchers with annual meeting":0.0008525149190110827,
       "neurobiological research":0.0008525149190110827,
       "neurobiology":0.0008525149190110827,
       "neurocognitive function":0.0034100596760443308,
       "neurocognitive impairment":0.001278772378516624,
       "neurodevelopment":0.001278772378516624,
       "neurodevelopmental condition":0.0008525149190110827,
       "neuroimaging scans":0.0017050298380221654,
       "neuroimaging studies":0.0008525149190110827,
       "neuronal and nicotinic signalling pathways":0.0008525149190110827,
       "neuronal development and migration":0.0017050298380221654,
       "neuropsychological tests":0.0017050298380221654,
       "new directions for diagnosis":0.005541346973572037,
       "new medications currently in development":0.001278772378516624,
       "nice guidelines":0.0034100596760443308,
       "nicotine":0.0017050298380221654,
       "nicotinic signalling":0.001278772378516624,
       "no association with adhd":0.0008525149190110827,
       "no significant effect on adhd":0.0008525149190110827,
       "non-medical treatments":0.005541346973572037,
       "non-responders":0.00937766410912191,
       "non-stimulant medications":0.0038363171355498722,
       "non-stimulants":0.017902813299232736,
       "nonstimulant medications":0.004262574595055414,
       "noradrenaline":0.0034100596760443308,
       "normal cognitive fluctuations":0.0008525149190110827,
       "normed scales":0.0008525149190110827,
       "north america":0.0008525149190110827,
       "number of children":0.008525149190110827,
       "number of sessions":0.0008525149190110827,
       "obesity":0.014066496163682864,
       "occupational functioning":0.0008525149190110827,
       "ocd":0.0076726342710997444,
       "odd":0.008525149190110827,
       "older adolescents and adults":0.0008525149190110827,
       "omni healthcare communications":0.001278772378516624,
       "onset":0.005541346973572037,
       "onset prior to the age 12 years cannot be documented":0.0008525149190110827,
       "oppositional defiant disorder":0.007246376811594203,
       "organisation skills":0.001278772378516624,
       "other approaches to emotion-regulatory processes disrupted in adhd":0.0008525149190110827,
       "other psychiatric and substance use disorder":0.0008525149190110827,
       "other psychiatric diagnosis":0.0029838022165387893,
       "other stimulant class":0.0008525149190110827,
       "out-of-home care":0.0008525149190110827,
       "outcomes":0.005541346973572037,
       "outcomes over longer periods of time":0.001278772378516624,
       "overused medication":0.005115089514066496,
       "oxidative stress":0.0008525149190110827,
       "paid tools":0.0008525149190110827,
       "parent":0.011935208866155157,
       "parent behavior management training (pbmt)":0.002557544757033248,
       "parent management training":0.001278772378516624,
       "parent referral for treatment":0.001278772378516624,
       "parent training":0.0068201193520886615,
       "parent training in behavior management (ptbm)":0.0008525149190110827,
       "parent-child behavior therapy":0.0029838022165387893,
       "parental criminality":0.0008525149190110827,
       "parental educational attainment":0.0008525149190110827,
       "parental outcomes":0.0008525149190110827,
       "parental relative income poverty":0.0008525149190110827,
       "parental unemployment":0.0008525149190110827,
       "parenting skills":0.0017050298380221654,
       "parents having low educational levels":0.0008525149190110827,
       "pargyline":0.0008525149190110827,
       "parietal region":0.002131287297527707,
       "paroxetine":0.0008525149190110827,
       "particulate matter":0.0008525149190110827,
       "pathophysiology":0.0008525149190110827,
       "patient":0.03111679454390452,
       "patient’s level of ei":0.0008525149190110827,
       "pbmt":0.0008525149190110827,
       "peer conflicts and social exclusion":0.0017050298380221654,
       "peers":0.0038363171355498722,
       "people":0.002131287297527707,
       "people all around the world":0.0008525149190110827,
       "people who have read this document and agree with its contents":0.001278772378516624,
       "performance deficits in psychological processes":0.0017050298380221654,
       "perpetrators of physical dating violence":0.0008525149190110827,
       "person":0.0017050298380221654,
       "personalized approach":0.001278772378516624,
       "personalized treatments":0.0008525149190110827,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":0.0017050298380221654,
       "pharmacotherapy":0.00639386189258312,
       "physical conditions":0.001278772378516624,
       "physical examination":0.002131287297527707,
       "placebo":0.0034100596760443308,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":0.001278772378516624,
       "poisoning in children":0.001278772378516624,
       "police station interrogations":0.0008525149190110827,
       "polr3c":0.0017050298380221654,
       "polygenic cause":0.0008525149190110827,
       "polythetic criteria":0.001278772378516624,
       "poor judgment":0.0008525149190110827,
       "poor work performance":0.0008525149190110827,
       "positive parenting":0.0008525149190110827,
       "positive reinforcement":0.0008525149190110827,
       "posterior corpus callosum":0.002131287297527707,
       "posterior parieto-temporal attention regions":0.0017050298380221654,
       "poverty":0.002131287297527707,
       "pre-existing type 1 diabetes":0.0008525149190110827,
       "prediction":0.001278772378516624,
       "predictive modelling":0.0008525149190110827,
       "predictor of treatment response":0.001278772378516624,
       "preeclampsia":0.001278772378516624,
       "pregnancies":0.011082693947144074,
       "pregnancy and adhd":0.0008525149190110827,
       "pregnant or breastfeeding women":0.001278772378516624,
       "premature death":0.008951406649616368,
       "prenatal exposure":0.002131287297527707,
       "prenatal exposure to maternal smoking":0.0008525149190110827,
       "preschool or daycare":0.0008525149190110827,
       "preschoolers with symptoms of adhd":0.0017050298380221654,
       "prescriber":0.002557544757033248,
       "prevalence":0.004688832054560955,
       "prevalence of adhd":0.002131287297527707,
       "prevalence of adhd among adolescents":0.0008525149190110827,
       "prevalence of adhd in prisons":0.0008525149190110827,
       "prevalence of false confessions":0.0008525149190110827,
       "prevalence of physical dating violence":0.0008525149190110827,
       "priapism":0.005967604433077579,
       "prior miscarriage":0.001278772378516624,
       "prisma diagram in supplemental figure 1":0.001278772378516624,
       "prison inmates":0.0008525149190110827,
       "prkn":0.0008525149190110827,
       "proband":0.002131287297527707,
       "problem behaviors (e.g., aggression, caregiver-child relations)":0.0017050298380221654,
       "problem solving":0.002557544757033248,
       "problematic substance use":0.0017050298380221654,
       "problems with connections between the two hemispheres":0.0017050298380221654,
       "professional health care associations":0.0008525149190110827,
       "proteins":0.0008525149190110827,
       "proton pump inhibitors":0.0017050298380221654,
       "provocation":0.0017050298380221654,
       "psoriasis":0.0008525149190110827,
       "comorbid psychiatric conditions":0.007246376811594203,
       "psychoeducation":0.0068201193520886615,
       "psychological tests":0.0008525149190110827,
       "psychological treatment":0.001278772378516624,
       "psychosocial domains of qol":0.002131287297527707,
       "psychosocial interventions":0.0038363171355498722,
       "psychosocial, school and emotional functioning":0.002131287297527707,
       "psychotherapy":0.00639386189258312,
       "psychotropic co-prescriptions":0.001278772378516624,
       "ptbm":0.0029838022165387893,
       "ptbm (behavior therapy)":0.005115089514066496,
       "qol domains":0.002131287297527707,
       "quality of life":0.005541346973572037,
       "racemic amphetamine sulfate":0.0008525149190110827,
       "racial and ethnic minority populations":0.0008525149190110827,
       "rage":0.0008525149190110827,
       "randomized controlled trials (rcts)":0.0008525149190110827,
       "rare genetic mutations":0.0008525149190110827,
       "rare single gene defects":0.0017050298380221654,
       "rct":0.002131287297527707,
       "rcts of adhd medications":0.0017050298380221654,
       "re-evaluate goals and behavior":0.0008525149190110827,
       "reading":0.001278772378516624,
       "reading, spelling and arithmetic":0.0008525149190110827,
       "rebound effect":0.0038363171355498722,
       "reduce self-esteem and wellbeing":0.0017050298380221654,
       "reducing inattention, hyperactivity, and impulsivity":0.0008525149190110827,
       "referral to a dietician":0.0017050298380221654,
       "regular check-ups":0.013640238704177323,
       "reinforcer":0.001278772378516624,
       "relationship quality":0.0017050298380221654,
       "reliability and validity":0.001278772378516624,
       "reliable diagnostic measure for adhd":0.0008525149190110827,
       "research":0.00937766410912191,
       "resilience":0.0008525149190110827,
       "resilience factors":0.0008525149190110827,
       "resources":0.0017050298380221654,
       "responders":0.00937766410912191,
       "response cost":0.0008525149190110827,
       "response to treatment":0.0008525149190110827,
       "response-inhibition":0.0008525149190110827,
       "restlessness":0.0008525149190110827,
       "reward":0.0029838022165387893,
       "right inferior frontal cortex":0.002557544757033248,
       "potential risks":0.002131287297527707,
       "risky driving behaviors":0.0017050298380221654,
       "robins and guze criteria":0.001278772378516624,
       "sagitatal striatum":0.002131287297527707,
       "scaffolding":0.0029838022165387893,
       "scales for emotion regulation":0.0008525149190110827,
       "schizophrenia":0.010230179028132991,
       "school":0.0017050298380221654,
       "school interventions":0.0017050298380221654,
       "school performance":0.0008525149190110827,
       "school-based accommodations":0.0017050298380221654,
       "screening measures":0.004688832054560955,
       "selective amplification of certain emotional states":0.001278772378516624,
       "selective noradrenaline reuptake inhibitors":0.004688832054560955,
       "self-esteem":0.0017050298380221654,
       "self-injury":0.0008525149190110827,
       "self-perceptions of competence":0.0008525149190110827,
       "self-referential thoughts and mind-wandering":0.0008525149190110827,
       "self-referral":0.001278772378516624,
       "self-regulatory skills":0.0017050298380221654,
       "self-regulatory strategies":0.001278772378516624,
       "self-report measures":0.001278772378516624,
       "self-report scale":0.001278772378516624,
       "self-reported executive function ratings":0.0017050298380221654,
       "serious transport accidents":0.002131287297527707,
       "serotonin syndrome":0.005115089514066496,
       "settings":0.001278772378516624,
       "severe adhd":0.001278772378516624,
       "severe marital discord":0.0017050298380221654,
       "severe mood dys-regulation (smd)":0.0008525149190110827,
       "sex":0.0017050298380221654,
       "sexual crimes victims":0.002557544757033248,
       "sexually transmitted infections":0.0017050298380221654,
       "shared components of etiology":0.001278772378516624,
       "shared mechanisms among disorders":0.001278772378516624,
       "short- and long-acting formulations of a-2 adrenergic agonists":0.002131287297527707,
       "simulant":0.0017050298380221654,
       "simulant medications":0.0017050298380221654,
       "single genetic abnormality":0.0017050298380221654,
       "six symptoms of hyperactivity-impulsivity":0.0008525149190110827,
       "six symptoms of inattention":0.0008525149190110827,
       "skills training":0.0029838022165387893,
       "sleep":0.0017050298380221654,
       "sleep efficiency":0.001278772378516624,
       "sleep onset":0.001278772378516624,
       "sleep onset delay":0.0017050298380221654,
       "small differences in brain structure and function":0.0008525149190110827,
       "small for gestational age":0.001278772378516624,
       "small particulate matter levels":0.0008525149190110827,
       "small to moderate difficulties":0.002131287297527707,
       "small-to-moderate reductions in mismatch negativity amplitude":0.0008525149190110827,
       "smaller brain areas":0.001278772378516624,
       "smaller brain volumes":0.0008525149190110827,
       "cigarette smoking":0.0034100596760443308,
       "smoking initiation":0.008525149190110827,
       "social acceptance":0.0008525149190110827,
       "social anxiety disorder":0.0017050298380221654,
       "social cognitive programs":0.0008525149190110827,
       "social function":0.001278772378516624,
       "social functioning":0.0017050298380221654,
       "social skills":0.002557544757033248,
       "social skills training":0.0029838022165387893,
       "socially and clinically important outcomes":0.001278772378516624,
       "society for developmental and behavioral pediatrics":0.0008525149190110827,
       "socioeconomic cost":0.0008525149190110827,
       "ses (socioeconomic status)":0.0017050298380221654,
       "solriamfetol":0.0076726342710997444,
       "somatic co-prescriptions":0.001278772378516624,
       "somatic disorders that co-occur with adhd":0.001278772378516624,
       "sorcs3":0.005541346973572037,
       "sorcs3, ptprf, and mef2c":0.0008525149190110827,
       "specialist":0.002131287297527707,
       "speech disorders":0.002557544757033248,
       "spelling":0.001278772378516624,
       "splenium of the corpus callosum":0.004688832054560955,
       "spouses":0.004688832054560955,
       "ssri/snri":0.0034100596760443308,
       "standard diagnostic criteria":0.001278772378516624,
       "standard therapies":0.002131287297527707,
       "stigma":0.008098891730605285,
       "adhd stigma":0.0038363171355498722,
       "stimulant":0.014066496163682864,
       "stimulant medication":0.04475703324808184,
       "stimulant therapy":0.008525149190110827,
       "stimulant-refractory":0.0008525149190110827,
       "stimulants are the first line of drug treatment for adhd":0.001278772378516624,
       "stress":0.001278772378516624,
       "stress-related strains on cognition":0.0008525149190110827,
       "stressed events during childhood":0.0008525149190110827,
       "subcortical regions":0.001278772378516624,
       "subjective well-being":0.008525149190110827,
       "subsequent substance use":0.0008525149190110827,
       "substance misuse":0.001278772378516624,
       "substance use":0.0038363171355498722,
       "sud":0.0008525149190110827,
       "suicide related events":0.0038363171355498722,
       "support groups":0.002131287297527707,
       "sustained release bupropion":0.0008525149190110827,
       "sweden":0.0008525149190110827,
       "swedish national registers":0.0029838022165387893,
       "swedish population-based study":0.0017050298380221654,
       "swedish registry study":0.0008525149190110827,
       "symptom change":0.002131287297527707,
       "symptom checklists":0.0008525149190110827,
       "symptom expression":0.0008525149190110827,
       "symptom severity":0.0008525149190110827,
       "synapse formation and plasticity":0.0029838022165387893,
       "synaptic development":0.0008525149190110827,
       "taiwan health insurance research database":0.0017050298380221654,
       "taiwanese study":0.0017050298380221654,
       "taiwanese youths":0.0017050298380221654,
       "tca (nortriptyline)":0.0034100596760443308,
       "tdcs":0.007246376811594203,
       "teacher-assessed social skills":0.0008525149190110827,
       "teachers of children with adhd":0.001278772378516624,
       "techniques":0.001278772378516624,
       "teenage pregnancy":0.002131287297527707,
       "teenage pregnancy and sexually transmitted diseases":0.0017050298380221654,
       "temper outbursts":0.002131287297527707,
       "temporal pole":0.002131287297527707,
       "temporal region":0.0029838022165387893,
       "temporo-parieto-occipital regions":0.002131287297527707,
       "test scores":0.001278772378516624,
       "testicular dysfunction":0.0008525149190110827,
       "tetrahydrocannabinol (marijuana)":0.001278772378516624,
       "therapeutic approaches":0.0017050298380221654,
       "therapies":0.001278772378516624,
       "therapy":0.010230179028132991,
       "those seeking treatment":0.0008525149190110827,
       "those with epilepsy":0.0008525149190110827,
       "thyroid problems in mothers during pregnancy":0.001278772378516624,
       "time management":0.002131287297527707,
       "time off medication":0.001278772378516624,
       "time-out":0.0008525149190110827,
       "tms":0.0029838022165387893,
       "tns":0.0038363171355498722,
       "token economy":0.0008525149190110827,
       "tolerability":0.004688832054560955,
       "total sleep time":0.001278772378516624,
       "toxic substances":0.0008525149190110827,
       "tracking and remote measurement technologies":0.001278772378516624,
       "trans-diagnostic phenomena":0.001278772378516624,
       "transport accidents":0.004688832054560955,
       "trauma":0.0038363171355498722,
       "trauma-related emergency room admission":0.002557544757033248,
       "traumatic brain injuries":0.005541346973572037,
       "traumatic brain injury early in life":0.0017050298380221654,
       "treating adhd and preventing adverse outcomes":0.0008525149190110827,
       "treatment efficacy":0.001278772378516624,
       "drug treatment initiation":0.013213981244671782,
       "treatment of coexisting conditions":0.004262574595055414,
       "treatment planning":0.0008525149190110827,
       "treatment targets":0.001278772378516624,
       "trial":0.002131287297527707,
       "trigeminal nerve stimulation":0.0038363171355498722,
       "trigeminal nerve stimulation (tns)":0.0017050298380221654,
       "twins":0.001278772378516624,
       "type 1 diabetes mellitus (t1dm)":0.002131287297527707,
       "type 2 diabetes":0.010656436487638534,
       "typically developing peers":0.0034100596760443308,
       "ulcerative colitis":0.0008525149190110827,
       "unemployment":0.002131287297527707,
       "unintended injuries":0.005967604433077579,
       "unmedicated adults":0.001278772378516624,
       "upper secondary school":0.0008525149190110827,
       "urbanization level":0.0017050298380221654,
       "us":0.0008525149190110827,
       "us population":0.002131287297527707,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":0.001278772378516624,
       "validated measure of symptom change":0.0008525149190110827,
       "validity of adhd as a mental disorder":0.001278772378516624,
       "valproate":0.002131287297527707,
       "vehicular crashes":0.0008525149190110827,
       "ventromedial orbito-frontal cortical thickness":0.002131287297527707,
       "viloxazine er":0.0008525149190110827,
       "viloxazine extended-release":0.0029838022165387893,
       "violent crimes":0.002557544757033248,
       "violent crimes against youth":0.0008525149190110827,
       "viral pneumonia":0.0008525149190110827,
       "visual attention":0.008098891730605285,
       "weak support systems":0.001278772378516624,
       "weight":0.0034100596760443308,
       "well-trained professionals":0.0008525149190110827,
       "wender-reimherr adult attention deficit disorder scale":0.004688832054560955,
       "wes study":0.0008525149190110827,
       "white blood cell disorders":0.0008525149190110827,
       "white matter":0.0017050298380221654,
       "white matter integrity":0.0008525149190110827,
       "white-majority countries":0.0008525149190110827,
       "work functioning":0.0017050298380221654,
       "work performance":0.001278772378516624,
       "working memory impairments":0.0017050298380221654,
       "world":0.002131287297527707,
       "worse social adjustment":0.0008525149190110827,
       "year of first adhd diagnosis":0.0008525149190110827,
       "years of schooling":0.0068201193520886615,
       "youth aged 14-20":0.0008525149190110827,
       "youth with adhd":0.008098891730605285,
       "α2 agonists":0.0029838022165387893,
       "emotional factors":0.0017050298380221654,
       "intellectual factors":0.0017050298380221654,
       "mood stabilizing medication":0.002131287297527707,
       "negative health behaviours":0.0017050298380221654,
       "oocyte leading to pregnancy":0.0017050298380221654,
       "psychosocial impairment":0.0017050298380221654,
       "resilience in those susceptible to adhd":0.004262574595055414,
       "sero tonergic medication":0.001278772378516624,
       "sero tonergic reuptake inhibitor":0.001278772378516624,
       "serotonin activity":0.0017050298380221654,
       "serotonin-norepinephrine reuptake inhibitors (snri)":0.002131287297527707,
       "social factors":0.0017050298380221654,
       "selective serotonin reuptake inhibitor (ssri)":0.0038363171355498722,
       "adhd and its mental and somatic comorbidities":0.0008525149190110827,
       "classroom":0.0008525149190110827,
       "covert smile":0.001278772378516624,
       "desr (delayed emotional return)":0.001278772378516624,
       "emotional experience and behavior dyssynchrony":0.0008525149190110827,
       "emotionally evocative situations":0.002557544757033248,
       "explosive giggle":0.0008525149190110827,
       "provoke- ing stimuli":0.0008525149190110827,
       "rapid emotional responses":0.0008525149190110827,
       "height gains":0.002557544757033248,
       "age at which adhd criteria were met":0.0008525149190110827,
       "children with high iq":0.0034100596760443308,
       "rates of learning disorders":0.0008525149190110827,
       "rates of psychiatric disorders":0.0008525149190110827,
       "rates of stimulant treatment":0.0008525149190110827,
       "rates of substance abuse":0.0008525149190110827,
       "nitric oxide":0.0008525149190110827,
       "nitrogen dioxide levels":0.0008525149190110827,
       "particulate matter levels":0.0017050298380221654,
       "sulphur dioxide levels":0.0008525149190110827,
       "genetic architecture of adhd":0.0008525149190110827,
       "affective reactivity":0.001278772378516624,
       "education":0.0034100596760443308,
       "expression of emotions":0.001278772378516624,
       "family life":0.001278772378516624,
       "financial":0.001278772378516624,
       "legal":0.001278772378516624,
       "predicting emotional symptoms":0.001278772378516624,
       "social relations":0.001278772378516624,
       "adhd europe":0.0008525149190110827,
       "health professionals and researchers":0.007246376811594203,
       "adhd evidence project":0.001278772378516624,
       "international consensus statement on adhd":0.011082693947144074,
       "adhd experts":0.0029838022165387893,
       "brainstorming session":0.001278772378516624,
       "existing guidelines":0.001278772378516624,
       "literature review":0.0017050298380221654,
       "qms (quality measures)":0.004262574595055414,
       "qms for adhd in youth":0.0017050298380221654,
       "survey":0.001278772378516624,
       "adhd follow-up care visit":0.0008525149190110827,
       "visit":0.0029838022165387893,
       "adhd guidelines group of the association of medical scientific societies in germany":0.005115089514066496,
       "adhd network of european college of neuropsychopharmacology":0.005115089514066496,
       "adhd section of the world psychiatric association":0.005115089514066496,
       "australian adhd professionals association":0.005115089514066496,
       "chinese society of child and adolescent psychiatry":0.005115089514066496,
       "federation of adhd":0.005541346973572037,
       "israeli society of adhd":0.005115089514066496,
       "large medical database called pubmed":0.00980392156862745,
       "latin american league of adhd":0.005115089514066496,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":0.00639386189258312,
       "pubmed":0.005541346973572037,
       "saudi adhd society":0.005115089514066496,
       "adhd in adults":0.002131287297527707,
       "adhd in big groups of people":0.001278772378516624,
       "adhd in offspring":0.0029838022165387893,
       "fetal growth restriction":0.001278772378516624,
       "maternal hyperthyroidism during pregnancy":0.001278772378516624,
       "maternal hypothyroidism during pregnancy":0.001278772378516624,
       "maternal preeclampsia":0.002557544757033248,
       "obesity in mothers":0.001278772378516624,
       "adhd in older adults":0.0008525149190110827,
       "mild cognitive impairment and dementia":0.0008525149190110827,
       "adhd malingering":0.0008525149190110827,
       "danish study":0.0008525149190110827,
       "reproductive-aged women":0.001278772378516624,
       "risk of a motor vehicle collision":0.0029838022165387893,
       "short-term effects":0.0008525149190110827,
       "adhd medication metabolism affect":0.001278772378516624,
       "mph":0.013640238704177323,
       "comorbid anxiety":0.002131287297527707,
       "duration of action":0.00639386189258312,
       "duration of response":0.0017050298380221654,
       "intervention":0.0017050298380221654,
       "level of function":0.002131287297527707,
       "methylin®":0.002131287297527707,
       "methylphenidate-based medications":0.002131287297527707,
       "mood dysregulation":0.0017050298380221654,
       "nonstimulants":0.005115089514066496,
       "pharmacokinetics":0.0017050298380221654,
       "pharmacotherapies":0.0008525149190110827,
       "second-line nonstimulants":0.004262574595055414,
       "short-acting methylphenidate":0.002131287297527707,
       "specifically learning disorders and low iq":0.001278772378516624,
       "stakeholders":0.0008525149190110827,
       "supplements":0.004262574595055414,
       "treatment alternatives":0.001278772378516624,
       "working memory training":0.002131287297527707,
       "ɑ2 agonists":0.0017050298380221654,
       "prof. faraone":0.0008525149190110827,
       "completed suicide":0.002557544757033248,
       "crime rates":0.001278772378516624,
       "criminality":0.0017050298380221654,
       "diversion could be fatal when diverted to a person who is medically at risk":0.001278772378516624,
       "diversion of medications is a felony":0.001278772378516624,
       "gateway to non-oral use of illicit drugs":0.0017050298380221654,
       "injecting":0.0034100596760443308,
       "intranasally":0.001278772378516624,
       "legal consequences of diverting medication":0.001278772378516624,
       "medical consequences of diverting medication":0.001278772378516624,
       "men with adhd":0.002557544757033248,
       "diversion or nmu":0.002131287297527707,
       "non-oral nmu":0.0017050298380221654,
       "non-oral routes":0.001278772378516624,
       "oral administration":0.001278772378516624,
       "repeated suicide attempts":0.004262574595055414,
       "suicide deaths":0.002557544757033248,
       "swedish national registers study":0.0008525149190110827,
       "teenagers with adhd":0.0017050298380221654,
       "youth with adhd and other psychiatric diagnoses":0.0038363171355498722,
       "adhd patients with ed but without smd":0.001278772378516624,
       "coping skills for managing anger":0.004262574595055414,
       "adhd pharmacotherapy":0.005115089514066496,
       "adolescents with adhd":0.002557544757033248,
       "driver's license":0.0008525149190110827,
       "females with adhd -i or controls":0.001278772378516624,
       "individuals (age 6 to 24 years) with adhd":0.001278772378516624,
       "motor vehicle crashes":0.005115089514066496,
       "natural causes":0.0008525149190110827,
       "st imulant medications":0.001278772378516624,
       "two-year mortality risk from all-causes":0.0008525149190110827,
       "unnatural causes such as suicide, accidental poisoning or injury":0.0008525149190110827,
       "employment":0.0008525149190110827,
       "employment status jobs":0.0008525149190110827,
       "prescription stimulant misuse":0.0008525149190110827,
       "adhd prs":0.001278772378516624,
       "irritability traits":0.001278772378516624,
       "adhd quality of life":0.0008525149190110827,
       "primerthe columbia impairment scale":0.0008525149190110827,
       "adhd rating scales":0.0017050298380221654,
       "cultural context":0.0008525149190110827,
       "culture":0.0008525149190110827,
       "adhd severity":0.0017050298380221654,
       "intelligence quotient":0.001278772378516624,
       "adhd symptom checklists":0.002557544757033248,
       "barkley deficits in executive function scale":0.0017050298380221654,
       "improvement in psychosocial functioning":0.0017050298380221654,
       "adhd symptom control extension":0.001278772378516624,
       "adult adhd symptoms":0.002131287297527707,
       "aggression":0.00639386189258312,
       "alpha-2-adrenergic agonists":0.0038363171355498722,
       "amphetamine derivatives":0.002131287297527707,
       "becoming unnaturally quiet":0.0008525149190110827,
       "broad-spectrum micronutrient supplements":0.0017050298380221654,
       "cbt alone":0.001278772378516624,
       "child behavior checklist":0.001278772378516624,
       "clinical prescriber with training in adhd diagnosis and management":0.0008525149190110827,
       "clinical subgroups":0.0008525149190110827,
       "combined treatment with medication and cbt":0.001278772378516624,
       "dietary approach to stop hypertension":0.0017050298380221654,
       "dietary interventions for adhd":0.0008525149190110827,
       "digital interventions":0.0008525149190110827,
       "digital therapies":0.0008525149190110827,
       "direct skills training":0.005115089514066496,
       "disruptive behavior disorders":0.005967604433077579,
       "drug treatment resistant patients":0.0008525149190110827,
       "effect":0.002131287297527707,
       "exclusion of food colour additives and preservatives":0.0017050298380221654,
       "exercise":0.010656436487638534,
       "extended-release preparations":0.0017050298380221654,
       "good sleep practice":0.001278772378516624,
       "hallucinogens":0.0017050298380221654,
       "healthy diets":0.004262574595055414,
       "heroin":0.0017050298380221654,
       "homicidality":0.0008525149190110827,
       "imipramine":0.0008525149190110827,
       "immediate-release stimulants":0.0017050298380221654,
       "inhalants":0.0017050298380221654,
       "jornay":0.0017050298380221654,
       "marijuana":0.002131287297527707,
       "medication alone":0.002557544757033248,
       "medication or psychosocial interventions":0.0008525149190110827,
       "mediterranean diet":0.0017050298380221654,
       "melatonin":0.0034100596760443308,
       "mirtazapine (remeron)":0.0008525149190110827,
       "negative mood symptoms":0.0017050298380221654,
       "nutrition":0.001278772378516624,
       "omega-3 fatty acid supplementation":0.0076726342710997444,
       "pain relievers":0.0017050298380221654,
       "parent behavior management program":0.001278772378516624,
       "parent-rated emotional lability symptoms":0.0008525149190110827,
       "parent-rated oppositional symptoms":0.0008525149190110827,
       "participants and their significant others":0.0008525149190110827,
       "poor dental hygiene":0.0008525149190110827,
       "prognosis":0.0029838022165387893,
       "remission of aggressive behavior":0.0017050298380221654,
       "restricting synthetic food colors":0.0008525149190110827,
       "ssri and stimulant combination":0.001278772378516624,
       "ssri antidepressants":0.0008525149190110827,
       "stimulant-refractory adhd":0.004262574595055414,
       "tca":0.0008525149190110827,
       "teacher-rated emotional lability symptoms":0.0008525149190110827,
       "teacher-rated oppositional symptoms":0.0008525149190110827,
       "tranquilizers/sedatives":0.0017050298380221654,
       "treatment selection":0.0008525149190110827,
       "treatment success":0.0017050298380221654,
       "venlafaxine":0.0029838022165387893,
       "youth adhd symptoms":0.0017050298380221654,
       "adhd trea tment":0.0008525149190110827,
       "administration of stimulants in conjunction with alcohol use":0.002131287297527707,
       "cardiotoxicity":0.001278772378516624,
       "ecg":0.0008525149190110827,
       "lower all-cause mortality":0.0008525149190110827,
       "males with adhd":0.0008525149190110827,
       "patients medicated for adhd":0.010230179028132991,
       "plasma levels":0.0008525149190110827,
       "polysubstance use":0.001278772378516624,
       "qtc prolongation":0.0008525149190110827,
       "tachycardia":0.0008525149190110827,
       "tca treatment":0.001278772378516624,
       "unnatural causes of mortality":0.0008525149190110827,
       "adhd treatment first line":0.0008525149190110827,
       "impulsive cognition":0.0008525149190110827,
       "learning problems":0.0008525149190110827,
       "poorly regulated emotions":0.0008525149190110827,
       "adhd treatment plan":0.0008525149190110827,
       "behaviors that we now associate with adhd":0.001278772378516624,
       "cam therapies":0.004688832054560955,
       "chelation therapy":0.0038363171355498722,
       "consensus statement":0.0017050298380221654,
       "large effect":0.001278772378516624,
       "medium effect":0.001278772378516624,
       "megavitamins":0.004262574595055414,
       "reviews":0.001278772378516624,
       "small effect":0.001278772378516624,
       "smaller studies":0.002131287297527707,
       "strong effects":0.001278772378516624,
       "treatment studies":0.002557544757033248,
       "vitamins":0.0038363171355498722,
       "adhd types":0.0008525149190110827,
       "adhd-like symptoms in children":0.001278772378516624,
       "adhd-related cost study":0.0008525149190110827,
       "adhd-related costs":0.0017050298380221654,
       "seven european studies":0.0008525149190110827,
       "annual national costs":0.0008525149190110827,
       "€1 billion":0.0008525149190110827,
       "adhd-specific problems in daily life":0.0008525149190110827,
       "adjunctive psychotherapy":0.0017050298380221654,
       "suboptimal response":0.0038363171355498722,
       "adjust the timing of the dose":0.002557544757033248,
       "excessive tiredness":0.014492753623188406,
       "stomachaches, nausea":0.00639386189258312,
       "adjusted odds ratio":0.0008525149190110827,
       "cardiovascular disease diagnosis":0.0034100596760443308,
       "drowsiness":0.014066496163682864,
       "trouble sleeping":0.004688832054560955,
       "adjusting the dose or timing may help":0.0017050298380221654,
       "adjustment":0.00042625745950554135,
       "administer the stimulant with meals to lessen its impact on appetite":0.0008525149190110827,
       "helping the noncompliant child":0.001278772378516624,
       "homework organization":0.001278772378516624,
       "incredible years parenting program":0.001278772378516624,
       "new forest parenting program":0.0017050298380221654,
       "nmu of amp":0.0029838022165387893,
       "parent-child interaction therapy":0.001278772378516624,
       "positive parenting program (triple p)":0.001278772378516624,
       "self-monitoring skills":0.001278772378516624,
       "study skills":0.001278772378516624,
       "teacher ratings":0.0068201193520886615,
       "young adults who do not attend college":0.0029838022165387893,
       "intuniv":0.0029838022165387893,
       "kapvay":0.0029838022165387893,
       "qelbree":0.002557544757033248,
       "adult adhd quality measures initiative (aaqmi)":0.0017050298380221654,
       "ahrq":0.002557544757033248,
       "candidate qms":0.0017050298380221654,
       "clinical and research experts":0.0017050298380221654,
       "delivery of quality health care to adults with adhd":0.0017050298380221654,
       "development of qms":0.0017050298380221654,
       "existing guidelines for adult adhd":0.0017050298380221654,
       "expert opinion":0.0008525149190110827,
       "extended-release":0.001278772378516624,
       "healthcare delivery":0.0008525149190110827,
       "healthcare processes":0.0017050298380221654,
       "immediate-release":0.001278772378516624,
       "limited access to treatment by skilled providers":0.0017050298380221654,
       "multidisciplinary panel":0.0017050298380221654,
       "clinical guidelines":0.0038363171355498722,
       "qms":0.0068201193520886615,
       "quality indicators":0.0017050298380221654,
       "us agency for healthcare research and quality (ahrq)":0.0017050298380221654,
       "adult adhd quality of life survey":0.0008525149190110827,
       "adult adhd self-report scale":0.0017050298380221654,
       "measure":0.0008525149190110827,
       "affective lability scale –short form (als-18) ":0.004262574595055414,
       "affective reactivity index (ari)":0.004262574595055414,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":0.004262574595055414,
       "behavior rating inventory of executive function (brief or emotion control subscale)":0.004262574595055414,
       "brown add rating scales for children, adolescents and adults (badds)":0.004262574595055414,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":0.005967604433077579,
       "difﬁculties in emotion regulation scale (ders)":0.0076726342710997444,
       "distress tolerance scale":0.0038363171355498722,
       "drug holidays":0.0008525149190110827,
       "emotion dysregulation scale, short version (eds-short)":0.005967604433077579,
       "emotion regulation checklist (erc)":0.005967604433077579,
       "emotion regulation index for adults and children (erica)":0.005967604433077579,
       "emotion regulation questionnaire (erq)":0.008525149190110827,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":0.002557544757033248,
       "expression and emotion scale for children (eesc)":0.0029838022165387893,
       "frustration discomfort scale":0.002557544757033248,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":0.0038363171355498722,
       "trials norms availability":0.005967604433077579,
       "adults (11 studies, 2909 participants)":0.0008525149190110827,
       "adults (cortese et al., 2018a)":0.0008525149190110827,
       "adults treated with viloxazine":0.001278772378516624,
       "adults unresponsive to mph trial":0.001278772378516624,
       "advancing age":0.002131287297527707,
       "adverse":0.0008525149190110827,
       "clinical response":0.0029838022165387893,
       "driving and work performance":0.002131287297527707,
       "emergency room visits":0.004688832054560955,
       "maximum daily dose":0.0029838022165387893,
       "discontinuation":0.0017050298380221654,
       "follow-up visit":0.008525149190110827,
       "medication response":0.008525149190110827,
       "health care facilities":0.0038363171355498722,
       "adverse outcomes":0.0017050298380221654,
       "prevalence of stimulant nmu":0.005967604433077579,
       "adverse side effects of atomoxetine":0.001278772378516624,
       "monitoring and management":0.005967604433077579,
       "adverse side effects of guanfacine":0.001278772378516624,
       "adzenys xr -odt":0.0029838022165387893,
       "dexedrine spansule":0.0029838022165387893,
       "dyanavel xr":0.0017050298380221654,
       "mydayis":0.0029838022165387893,
       "tips for using amphetamine-based medications":0.0017050298380221654,
       "aerobic activity":0.001278772378516624,
       "improvement in the core symptoms of adhd":0.0068201193520886615,
       "aerobic exercise":0.0017050298380221654,
       "affective components of executive control":0.002131287297527707,
       "dopaminergic system":0.00937766410912191,
       "executive control":0.010230179028132991,
       "mood regulation":0.00937766410912191,
       "noradrenergic system":0.00937766410912191,
       "affordable care act":0.0008525149190110827,
       "african-american students":0.0008525149190110827,
       "viloxazine dose":0.001278772378516624,
       "liver problems":0.00639386189258312,
       "nausea/vomiting":0.00639386189258312,
       "viloxazine (qelbree)":0.00937766410912191,
       "agitation":0.001278772378516624,
       "expert clinicians":0.001278772378516624,
       "ahrq, medicare and medicaid":0.0008525149190110827,
       "alcohol use disorder: treatment overview":0.0038363171355498722,
       "counseling":0.001278772378516624,
       "limit their alcohol consumption":0.0008525149190110827,
       "low-risk and risky alcohol use":0.001278772378516624,
       "opioid use disorder: treatment overview":0.0008525149190110827,
       "stimulant use disorder: treatment overview":0.0008525149190110827,
       "stimulants for adhd":0.0038363171355498722,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":0.001278772378516624,
       "all-cause treatment discontinuation":0.001278772378516624,
       "dizziness":0.01619778346121057,
       "increased blood pressure and heart rate":0.0017050298380221654,
       "itching":0.001278772378516624,
       "monitoring":0.0017050298380221654,
       "rash":0.001278772378516624,
       "vomiting":0.005115089514066496,
       "motor or vocal tics":0.001278772378516624,
       "nonstimulants for adhd":0.001278772378516624,
       "alpha agonists (clonidine and guanfacine)":0.0029838022165387893,
       "liver problems such as hepatitis":0.002131287297527707,
       "american academy of child and adolescent psychiatry adhd resource center":0.0034100596760443308,
       "attention deficit disorder association (adda)":0.0034100596760443308,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":0.002557544757033248,
       "centers for disease control and prevention (cdc) adhd":0.0034100596760443308,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":0.0034100596760443308,
       "national institute of mental health (nimh) adhd":0.002557544757033248,
       "the american professional society of adhd and related disorders (apsard)":0.0034100596760443308,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":0.002557544757033248,
       "american academy of pediatricians":0.001278772378516624,
       "american professional society of adhd and related disorders":0.002557544757033248,
       "canadian adhd resource alliance":0.002131287297527707,
       "world federation of adhd":0.008098891730605285,
       "american psychopathological association":0.0008525149190110827,
       "pau l hoch award":0.0008525149190110827,
       "state university o f new york":0.0017050298380221654,
       "reasonable accommodations":0.0008525149190110827,
       "amp":0.0008525149190110827,
       "attention and impulsivity":0.0008525149190110827,
       "cardiac arrest":0.001278772378516624,
       "cerebrovascular disease":0.001278772378516624,
       "daily timing":0.0008525149190110827,
       "heart failure":0.001278772378516624,
       "ischemic heart disease":0.001278772378516624,
       "misuse and diversion":0.0017050298380221654,
       "prescribing medications for adhd":0.0017050298380221654,
       "prescription refill requests":0.0017050298380221654,
       "risks of stimulant misuse and diversion":0.0017050298380221654,
       "schedule ii controlled substances":0.001278772378516624,
       "short-acting amphetamines":0.0008525149190110827,
       "studies regarding nmu of mph or amp":0.0038363171355498722,
       "symptom control":0.0008525149190110827,
       "tachyarrhythmias":0.001278772378516624,
       "venous thromboembolism":0.001278772378516624,
       "amphetamine formulations":0.001278772378516624,
       "lisdexamfetamine dimesylate (ldx)":0.002131287297527707,
       "amphetamine medication":0.001278772378516624,
       "amphetamine stimulants":0.0008525149190110827,
       "children (7 studies, 1930 participants)":0.001278772378516624,
       "growth suppression":0.0038363171355498722,
       "pregnant woman":0.0029838022165387893,
       "youths (9 studies, 2677 participants)":0.0008525149190110827,
       "analysis":0.0008525149190110827,
       "discontinuation due to adverse event":0.004262574595055414,
       "lisdexamphetamine":0.004262574595055414,
       "worse anorexia":0.004262574595055414,
       "antacids":0.0008525149190110827,
       "antecedents of behaviour":0.0008525149190110827,
       "reinforcement techniques":0.0008525149190110827,
       "anthony l. rostain":0.0008525149190110827,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":0.0008525149190110827,
       "anticipatory appraisal and valuation":0.002131287297527707,
       "emotion generation":0.008098891730605285,
       "emotional state":0.007246376811594203,
       "regulation":0.002131287297527707,
       "antipsychotics":0.001278772378516624,
       "not recommended adhd treatment":0.001278772378516624,
       "dry mouth":0.011508951406649617,
       "anxiety and substance use disorders":0.0008525149190110827,
       "benzodiazepines":0.0017050298380221654,
       "childhood irritability":0.001278772378516624,
       "opioid":0.002131287297527707,
       "any interpretation should keep in mind that the ratings are of relative importance":0.00639386189258312,
       "care coordination":0.0068201193520886615,
       "care coordination and the patient experience domains":0.0008525149190110827,
       "follow-up":0.0038363171355498722,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":0.005541346973572037,
       "low rating only means that the item is not essential for documenting the basics of quality care":0.0008525149190110827,
       "patient experience":0.0034100596760443308,
       "patients and health care systems":0.001278772378516624,
       "quality diagnosis":0.0038363171355498722,
       "quality in these domains may be viewed as less relevant":0.001278772378516624,
       "results may reflect a systematic bias in our sample of raters":0.001278772378516624,
       "should include other relevant stakeholders, including patients and health care systems":0.001278772378516624,
       "systematic bias in our sample of raters":0.001278772378516624,
       "apsard":0.0008525149190110827,
       "apten sio xr":0.0038363171355498722,
       "capsules":0.0038363171355498722,
       "daytrana":0.0038363171355498722,
       "focalin xr":0.0017050298380221654,
       "liquid":0.002131287297527707,
       "patches":0.0017050298380221654,
       "quillivant xr":0.002131287297527707,
       "ritalin la":0.0017050298380221654,
       "arterial disease":0.0008525149190110827,
       "asian federation of adhd":0.0008525149190110827,
       "asian resource":0.0008525149190110827,
       "assignments":0.0008525149190110827,
       "association for behavior and cognitive therapies":0.0017050298380221654,
       "behavioral therapist":0.007246376811594203,
       "caregivers of children age 6 to 12 years":0.007246376811594203,
       "centers for disease control and prevention (cdc)":0.007246376811594203,
       "association for child and adolescent mental health":0.0,
       "atomox etine":0.0008525149190110827,
       "atomoxetine levels":0.001278772378516624,
       "atypical antidepressants":0.002131287297527707,
       "blood monitoring":0.001278772378516624,
       "brain cells communication":0.001278772378516624,
       "cardiac malformations":0.002131287297527707,
       "chemical messengers (norepinephrine)":0.001278772378516624,
       "constipation":0.004262574595055414,
       "correct dose":0.0008525149190110827,
       "treatment discontinuation":0.001278772378516624,
       "tricyclic antidepressants (tcas)":0.002131287297527707,
       "atomoxetine treatment for adhd":0.001278772378516624,
       "attention and arousal":0.0017050298380221654,
       "behavioral functioning":0.002557544757033248,
       "chronic condition management":0.002557544757033248,
       "information provision":0.002557544757033248,
       "dizziness and lightheadedness":0.008525149190110827,
       "fatigue":0.00980392156862745,
       "sedation":0.008098891730605285,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":0.0038363171355498722,
       "behavioral management techniques that are used for children with adhd":0.0008525149190110827,
       "coexisting conditions that are associated with adhd or mimic its symptoms":0.0008525149190110827,
       "nonadherence to the treatment plan":0.0008525149190110827,
       "repetition of the diagnostic evaluation":0.0008525149190110827,
       "evidence-based statements about adhd":0.001278772378516624,
       "international consensus statement":0.0008525149190110827,
       "meta-analyses and very large studies":0.001278772378516624,
       "parents' medication guide":0.0008525149190110827,
       "parents' medication guidedysregulation":0.001278772378516624,
       "project steering committee":0.0008525149190110827,
       "research and clinical care of adhd":0.0008525149190110827,
       "scientific data":0.0008525149190110827,
       "attention-deﬁcit/hyperactivity disorder":0.0008525149190110827,
       "impulsive aggression":0.0034100596760443308,
       "liver damage":0.001278772378516624,
       "psychotic symptoms":0.001278772378516624,
       "self-harming behavior":0.001278772378516624,
       "unusual changes in behavior":0.001278772378516624,
       "atx or dex":0.001278772378516624,
       "atx treatment":0.001278772378516624,
       "liver disease evaluation":0.001278772378516624,
       "augmentation strategies":0.0008525149190110827,
       "charles bradley":0.001278772378516624,
       "child psychiatry":0.0008525149190110827,
       "minimal brain dysfunction-related behaviors":0.001278772378516624,
       "morris et al. and o'neal and robins":0.001278772378516624,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":0.001278772378516624,
       "u.s. food and drug administration":0.002131287297527707,
       "world health organization":0.0008525149190110827,
       "authors":0.0008525149190110827,
       "emotional problems":0.001278772378516624,
       "seizures":0.0034100596760443308,
       "sleep disorder":0.001278772378516624,
       "availability of treatment":0.001278772378516624,
       "avoid caffeine":0.0008525149190110827,
       "evening":0.0034100596760443308,
       "good sleep habits":0.004262574595055414,
       "avoid skipped doses":0.0008525149190110827,
       "maladaptive emotions":0.002557544757033248,
       "bachelor's degree":0.002131287297527707,
       "dorsal anterior cingulate cortex":0.0029838022165387893,
       "fmri meta-analyses":0.001278772378516624,
       "inferior frontal cortex":0.005115089514066496,
       "neutral fmri tasks":0.0008525149190110827,
       "supplementary motor area":0.0008525149190110827,
       "typically developing individuals":0.0008525149190110827,
       "ventral anterior cingulate cortex":0.0029838022165387893,
       "become unusually quiet or appear over-focused":0.0008525149190110827,
       "child development":0.0008525149190110827,
       "metacognitive executive function training":0.0034100596760443308,
       "pre-kindergarten academic curriculum (stp-pre-k)":0.0034100596760443308,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":0.0034100596760443308,
       "tools":0.0008525149190110827,
       "behavior modification system":0.0017050298380221654,
       "behavior problems":0.0017050298380221654,
       "blood pressure monitoring":0.002557544757033248,
       "chest pain":0.002557544757033248,
       "education on side effects":0.0034100596760443308,
       "growth monitoring":0.002557544757033248,
       "heart rate assessment":0.002557544757033248,
       "impulsiveness":0.002557544757033248,
       "long-term use":0.0029838022165387893,
       "mood monitoring":0.002557544757033248,
       "mood swings":0.008525149190110827,
       "palpitations":0.002557544757033248,
       "peripheral vasculopathy":0.0029838022165387893,
       "raynaud’s phenomenon":0.0029838022165387893,
       "severe allergic reactions":0.0029838022165387893,
       "severe psychiatric symptoms":0.002557544757033248,
       "side effects information":0.0029838022165387893,
       "sudden cardiac death":0.0038363171355498722,
       "swelling of the face, lips, tongue, or throat":0.0029838022165387893,
       "weight monitoring":0.002557544757033248,
       "blurred vision or other visual changes":0.0029838022165387893,
       "development or worsening of motor or vocal tics":0.0029838022165387893,
       "elevated blood pressure (hypertension)":0.002557544757033248,
       "especially in children":0.002557544757033248,
       "increased aggression or hostility":0.002557544757033248,
       "increased heart rate (tachycardia)":0.002557544757033248,
       "nervousness":0.002557544757033248,
       "rash or hypersensitivity reactions":0.0029838022165387893,
       "skin reactions":0.0029838022165387893,
       "trouble falling and staying asleep":0.002557544757033248,
       "visual disturbances":0.0029838022165387893,
       "behavioral disinhibition":0.0008525149190110827,
       "observed behavior":0.0029838022165387893,
       "behavioral expression":0.0029838022165387893,
       "behavioral indicators":0.0038363171355498722,
       "subjective emotionality":0.0038363171355498722,
       "high emotional thresholds":0.002131287297527707,
       "recovery times":0.0017050298380221654,
       "quick return to baseline":0.002557544757033248,
       "behavioral response system":0.0008525149190110827,
       "subjective/cognitive response system":0.0008525149190110827,
       "child’s behavior":0.0008525149190110827,
       "coping strategies":0.0008525149190110827,
       "negative behaviors":0.0008525149190110827,
       "negative thought patterns":0.001278772378516624,
       "parent -child relationship":0.0008525149190110827,
       "positive behaviors":0.0008525149190110827,
       "problematic behaviors":0.0008525149190110827,
       "finding activities in which the child can be successful (eg, hobbies, sports)":0.0017050298380221654,
       "identifying unintentional reinforcement of negative behaviors":0.0017050298380221654,
       "keeping environmental distractions to a minimum":0.0017050298380221654,
       "limiting choices":0.0017050298380221654,
       "maintaining a daily schedule":0.0017050298380221654,
       "national institute for children's health quality toolkit":0.0017050298380221654,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":0.0017050298380221654,
       "rewarding positive behavior (eg, with a 'token economy')":0.0017050298380221654,
       "setting small, reachable goals":0.0017050298380221654,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":0.0017050298380221654,
       "using charts and checklists to help the child stay 'on task'":0.0017050298380221654,
       "parenting context":0.0008525149190110827,
       "pharmaco logical therapy":0.0008525149190110827,
       "benefits and risks of treatment":0.0008525149190110827,
       "best practices":0.0008525149190110827,
       "best studies":0.0008525149190110827,
       "pulse":0.0008525149190110827,
       "blood pressure and pulse quarterly":0.0017050298380221654,
       "blood tests":0.0008525149190110827,
       "bone fractures":0.0008525149190110827,
       "borderline personality disorder":0.0008525149190110827,
       "boundaries between adhd and other disorders":0.0008525149190110827,
       "long-term side effects":0.002131287297527707,
       "broader scope of the review":0.0008525149190110827,
       "bupropion (wellbutrin, zyban)":0.001278772378516624,
       "caddra":0.0008525149190110827,
       "caffeine levels":0.0008525149190110827,
       "calendar year":0.0008525149190110827,
       "chelation":0.0008525149190110827,
       "primary care practitioner":0.002557544757033248,
       "risks and benefits":0.0008525149190110827,
       "nonmedical users":0.0008525149190110827,
       "cardiac history or cardiac symptoms":0.0008525149190110827,
       "cardiac review":0.002131287297527707,
       "cardiologist consultation":0.0008525149190110827,
       "findings outside of normal limits":0.0008525149190110827,
       "sudden death or ventricular arrhythmia":0.001278772378516624,
       "cardiovascular health":0.001278772378516624,
       "clinical response, duration of the effect during the day, and side effects":0.0008525149190110827,
       "electrocardiogram (ecg)":0.0008525149190110827,
       "low dose stimulant treatment":0.0008525149190110827,
       "short-acting dextroamphetamine-amphetamine":0.0008525149190110827,
       "child's height":0.0034100596760443308,
       "child's weight":0.0034100596760443308,
       "regular measurement":0.0034100596760443308,
       "qm":0.002131287297527707,
       "quality care":0.002557544757033248,
       "treatment follow-up":0.0029838022165387893,
       "care management plan":0.0008525149190110827,
       "careful dose titration required":0.0008525149190110827,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":0.0008525149190110827,
       "child's practitioner":0.004688832054560955,
       "caregiver decision":0.001278772378516624,
       "catapres":0.0008525149190110827,
       "category":0.0008525149190110827,
       "causes":0.0008525149190110827,
       "cbcl-dysregulation profile":0.0008525149190110827,
       "emotional dysregulation scores":0.0008525149190110827,
       "cbt group and individual therapy programs":0.001278772378516624,
       "cbt group treatment":0.0008525149190110827,
       "orthostatic hypotension":0.0029838022165387893,
       "slow heart rate (bradycardia)":0.0029838022165387893,
       "cereals":0.0008525149190110827,
       "certain children":0.0017050298380221654,
       "certain events":0.0008525149190110827,
       "certain foci in the literature may have been missed":0.0008525149190110827,
       "chadd website":0.0008525149190110827,
       "coalition to prevent adhd medication misuse":0.0008525149190110827,
       "college administrators":0.0008525149190110827,
       "collegiate student leaders":0.0008525149190110827,
       "cpamm":0.0029838022165387893,
       "information about misuse and diversion":0.002131287297527707,
       "personnel":0.0008525149190110827,
       "pharmaceutical industry":0.0008525149190110827,
       "changing the drug":0.001278772378516624,
       "heart symptoms":0.0038363171355498722,
       "height":0.001278772378516624,
       "long-term studies (lower risk of later cigarette or illegal substance use)":0.001278772378516624,
       "meal timing":0.0008525149190110827,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":0.0008525149190110827,
       "mental health challenges":0.0008525149190110827,
       "mirtazapine":0.0008525149190110827,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":0.001278772378516624,
       "mood problem":0.0017050298380221654,
       "moodiness":0.002131287297527707,
       "over-focused or repeated movements (tics or habits)":0.0008525149190110827,
       "preparation":0.001278772378516624,
       "separate issue":0.0017050298380221654,
       "sleep habits":0.0008525149190110827,
       "worsened heart problems":0.001278772378516624,
       "zombie effect":0.0008525149190110827,
       "child and adolescent psychiatrist":0.0008525149190110827,
       "child psychologist":0.0008525149190110827,
       "immediate action":0.002131287297527707,
       "medication holidays":0.0017050298380221654,
       "childhood diagnosis of adhd":0.0008525149190110827,
       "children in intervention group":0.001278772378516624,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":0.0008525149190110827,
       "loss of appetite (anorexia)":0.001278772378516624,
       "monitor for changes in behavior and report to the healthcare provider":0.0008525149190110827,
       "monitor your child closely for new or worsening tics":0.0008525149190110827,
       "offer high-calorie snacks such as instant breakfast drinks":0.0008525149190110827,
       "regularly check your child's weight to ensure they are growing normally":0.0008525149190110827,
       "sleep intervention":0.0008525149190110827,
       "teacher-reported behavior":0.001278772378516624,
       "cohort studies":0.0008525149190110827,
       "children and youth with special health care needs":0.0008525149190110827,
       "children who have not yet entered elementary school":0.0017050298380221654,
       "classroom modifications":0.0017050298380221654,
       "developmental behavioral pediatrician":0.0008525149190110827,
       "intentional and unintentional injury":0.0017050298380221654,
       "china adhd alliance":0.0008525149190110827,
       "classroom modifications and accommodations":0.004688832054560955,
       "combined medication and behavior treatment":0.0008525149190110827,
       "combined treatment":0.0008525149190110827,
       "lower doses of medication":0.0008525149190110827,
       "non-adhd symptoms":0.0008525149190110827,
       "provision of tutoring or resource room support":0.0008525149190110827,
       "school-aged children":0.002557544757033248,
       "stressors in family life":0.0008525149190110827,
       "suboptimal response to pharmacotherapy":0.0008525149190110827,
       "normative data":0.002131287297527707,
       "parents and teacher reports":0.0017050298380221654,
       "preschool teachers and clinicians":0.0017050298380221654,
       "ratings from other individuals":0.001278772378516624,
       "scales":0.0017050298380221654,
       "secondary school teachers":0.001278772378516624,
       "self-report":0.002557544757033248,
       "structured behavioural observations":0.0017050298380221654,
       "such as":0.0017050298380221654,
       "tools for screening":0.0008525149190110827,
       "longer acting than clonidine":0.0008525149190110827,
       "short-acting medication":0.0008525149190110827,
       "tenex":0.0008525149190110827,
       "tic problems":0.0008525149190110827,
       "close monitoring":0.0034100596760443308,
       "close monitoring by healthcare provider":0.001278772378516624,
       "persistent adhd":0.001278772378516624,
       "cognitive components of executive control":0.002131287297527707,
       "cognitive flexibility":0.0029838022165387893,
       "cognitive strengths and weaknesses":0.001278772378516624,
       "play-based interventions":0.002131287297527707,
       "problems with peers":0.0008525149190110827,
       "psychotherapy interventions":0.0008525149190110827,
       "students with disabilities":0.0008525149190110827,
       "summer treatment camp":0.0017050298380221654,
       "deficits":0.0017050298380221654,
       "guided walks":0.001278772378516624,
       "increases the effectiveness of":0.0017050298380221654,
       "organizational/planning skills":0.001278772378516624,
       "psychosocial well-being":0.001278772378516624,
       "yoga":0.001278772378516624,
       "patient's family":0.001278772378516624,
       "collateral report":0.0008525149190110827,
       "colleagues":0.0008525149190110827,
       "gpas":0.002131287297527707,
       "college peers":0.0008525149190110827,
       "common misconceptions":0.002131287297527707,
       "nmu of mph":0.0017050298380221654,
       "nmu population prevalence":0.0029838022165387893,
       "parents with suspected or diagnosed adhd":0.0008525149190110827,
       "peer behavior":0.0017050298380221654,
       "printed handouts":0.0017050298380221654,
       "repetition":0.0017050298380221654,
       "sanctions":0.0017050298380221654,
       "social situations":0.0008525149190110827,
       "us college populations":0.002131287297527707,
       "young adult populations":0.0017050298380221654,
       "enforcement":0.0008525149190110827,
       "incoming students":0.0008525149190110827,
       "com-ponents of emotional symptoms":0.0008525149190110827,
       "different terms used to describe them":0.0008525149190110827,
       "community psychosocial care":0.001278772378516624,
       "community support":0.0008525149190110827,
       "specific treatment approach":0.0017050298380221654,
       "medication adherence":0.001278772378516624,
       "diagnostic challenges":0.001278772378516624,
       "simplex adhd":0.0008525149190110827,
       "standard information gathering":0.001278772378516624,
       "comprehensive approach to literature on nmu":0.0008525149190110827,
       "concerns being discussed":0.001278772378516624,
       "extended-release tablets":0.0017050298380221654,
       "reduce the need to take multiple doses throughout the day":0.0017050298380221654,
       "consistent sleep schedule":0.0008525149190110827,
       "consult with healthcare provider":0.001278772378516624,
       "consult with the healthcare provider for further advice":0.0017050298380221654,
       "contents":0.001278772378516624,
       "contraindications to drug treatment":0.0008525149190110827,
       "cooperating":0.0008525149190110827,
       "ingroup therapy":0.001278772378516624,
       "integrative treatment program":0.001278772378516624,
       "parental satisfaction":0.001278772378516624,
       "core symptoms":0.001278772378516624,
       "corticocerebellar networks":0.0008525149190110827,
       "criteria":0.0008525149190110827,
       "critical care unit":0.0008525149190110827,
       "current adhd symptoms":0.0008525149190110827,
       "secular private schools":0.0008525149190110827,
       "decongestants":0.0008525149190110827,
       "food supplements":0.0034100596760443308,
       "hepatitis":0.0034100596760443308,
       "low dose medication":0.0034100596760443308,
       "medication adjustment":0.0068201193520886615,
       "medication with food":0.0034100596760443308,
       "executive control and corticocerebellar networks":0.0008525149190110827,
       "frontal and parietal cortical areas":0.0008525149190110827,
       "inferior parietal and medial temporal regions":0.0008525149190110827,
       "medial prefrontal and the posterior cingulate cortices":0.0008525149190110827,
       "orbitofrontal cortex":0.0008525149190110827,
       "reward system":0.001278772378516624,
       "thalamus":0.002557544757033248,
       "ventromedial prefrontal cortex":0.0008525149190110827,
       "denmark, finland, sweden, norway, and iceland":0.001278772378516624,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":0.0008525149190110827,
       "those reporting nmu in a survey of 4,297 us adults":0.0,
       "detect nmu":0.0008525149190110827,
       "medical/neurological history":0.0008525149190110827,
       "stimulant misuse risk assessment":0.001278772378516624,
       "deﬁcits in response inhibition to frustration":0.0008525149190110827,
       "documented dsm-5 diagnosis of adhd":0.0008525149190110827,
       "diagnostic guidelines":0.0008525149190110827,
       "diagnostic utility for adhd":0.0008525149190110827,
       "symptoms commonly occurring in other disorders":0.0008525149190110827,
       "dietary restrictions":0.001278772378516624,
       "disability services":0.0008525149190110827,
       "discontinuing medication":0.0008525149190110827,
       "discussions":0.0008525149190110827,
       "discussions of transfer of care with new clinician made":0.0008525149190110827,
       "emotional upsets":0.0008525149190110827,
       "motivation":0.0008525149190110827,
       "social payoff":0.0008525149190110827,
       "diurnal variation in symptoms":0.0017050298380221654,
       "malingering":0.002557544757033248,
       "pills per prescription":0.002131287297527707,
       "extended-release form":0.0008525149190110827,
       "hydration":0.0017050298380221654,
       "loss of appetite":0.002131287297527707,
       "medication form adjustment":0.002557544757033248,
       "more irritability or moodiness when taking medication":0.002557544757033248,
       "slowing of heart rate":0.0038363171355498722,
       "snacks":0.0008525149190110827,
       "supplemental medications":0.002557544757033248,
       "timing of medication":0.002131287297527707,
       "dmdd":0.0008525149190110827,
       "intensified negative mood":0.0008525149190110827,
       "document":0.0008525149190110827,
       "documentation":0.0008525149190110827,
       "frontal lobes":0.0017050298380221654,
       "learning and memory":0.0017050298380221654,
       "movement regulation":0.0017050298380221654,
       "novelty processing":0.0017050298380221654,
       "parietal cortex":0.002131287297527707,
       "reward processing":0.0017050298380221654,
       "signal-to-noise processing":0.0017050298380221654,
       "stress response":0.0017050298380221654,
       "mood symptoms":0.002557544757033248,
       "time":0.002131287297527707,
       "dose reduction":0.002131287297527707,
       "dosing":0.0008525149190110827,
       "driving licenses suspension/revocation":0.0008525149190110827,
       "driving performance improvement":0.0008525149190110827,
       "gradually increase dose":0.0008525149190110827,
       "monitor mood symptoms":0.001278772378516624,
       "excessive weight loss":0.001278772378516624,
       "dsm criteria":0.0008525149190110827,
       "us college-aged women":0.0008525149190110827,
       "eating foods high in added sugar":0.002131287297527707,
       "hyperactivity/impulsivity subtypes":0.002131287297527707,
       "inattention symptoms and unhealthy eating habits":0.002131287297527707,
       "monozygotic twins":0.002131287297527707,
       "unhealthy dietary habits":0.002131287297527707,
       "stimulant misuse":0.0008525149190110827,
       "history of psychosis":0.001278772378516624,
       "prescribed stimulants":0.002131287297527707,
       "size":0.0008525149190110827,
       "effect size findings":0.0008525149190110827,
       "effective self-regulation":0.0008525149190110827,
       "effortful strategy":0.0038363171355498722,
       "emotional arousal":0.0038363171355498722,
       "high ei":0.002131287297527707,
       "reappraisal":0.004262574595055414,
       "self-monitoring":0.004262574595055414,
       "valuation":0.002131287297527707,
       "el":0.0008525149190110827,
       "emotionally intense provocation":0.0008525149190110827,
       "hyperactive-impulsive adhd presentations":0.0008525149190110827,
       "inadequate self-control and weak behavioral inhibition":0.0008525149190110827,
       "patients with no ei":0.0008525149190110827,
       "rapid changes in emotional states":0.0008525149190110827,
       "self-regulatory processes":0.0008525149190110827,
       "elevated mood":0.0017050298380221654,
       "elevation of blood pressure or heart rate":0.0008525149190110827,
       "feeling sad":0.0008525149190110827,
       "healthcare facility utilization":0.0008525149190110827,
       "poison control centers data":0.0008525149190110827,
       "sleep difficulties":0.0008525149190110827,
       "study of 15,629 adults and adolescents":0.0008525149190110827,
       "regulatory processes":0.0017050298380221654,
       "emotional experience":0.002131287297527707,
       "emotional valence":0.0008525149190110827,
       "heterogeneity":0.0017050298380221654,
       "neural activation":0.001278772378516624,
       "poorly controlled emotionally driven behavior":0.0008525149190110827,
       "self-regulatory deficits":0.0008525149190110827,
       "self-regulatory deﬁcits":0.0008525149190110827,
       "executive function control of emotional response":0.001278772378516624,
       "extended-release methylphenidate":0.0008525149190110827,
       "intermittent explosive disorder":0.001278772378516624,
       "methylphenidate preparations":0.0008525149190110827,
       "oppositional deﬁant disorder":0.0008525149190110827,
       "emotional functioning":0.0008525149190110827,
       "impaired":0.0029838022165387893,
       "emotional instability":0.0008525149190110827,
       "negative emotion":0.0008525149190110827,
       "emotional reactivity":0.0008525149190110827,
       "high emotional impulsivity":0.0008525149190110827,
       "response systems":0.0008525149190110827,
       "future development of adhd criteria":0.0008525149190110827,
       "measurement tool/assessment instrument":0.0008525149190110827,
       "mistake for emotional symptoms to be specific for adhd":0.0008525149190110827,
       "multidimensional nature of emotional symptoms":0.0008525149190110827,
       "stephen v. faraone":0.0008525149190110827,
       "evidence-based assertions":0.001278772378516624,
       "findings":0.001278772378516624,
       "manuscript":0.001278772378516624,
       "participants":0.002131287297527707,
       "waiting-list controls":0.001278772378516624,
       "encourage good sleep habits":0.0017050298380221654,
       "eunethydis":0.001278772378516624,
       "euphoria":0.0017050298380221654,
       "european network adult adhd":0.0008525149190110827,
       "evaluation":0.0008525149190110827,
       "frozen yogurt":0.0008525149190110827,
       "instant breakfast drinks":0.0008525149190110827,
       "limit naps to less than 45 minutes":0.0008525149190110827,
       "reduce screen time before bed":0.0008525149190110827,
       "evidenced based fda approved medication":0.0008525149190110827,
       "exacerbation":0.0017050298380221654,
       "give medication with food to minimize stomach discomfort":0.0017050298380221654,
       "irritability or aggression (infrequent)":0.002131287297527707,
       "monitor headaches and consult with the healthcare provider":0.0017050298380221654,
       "monitor irritability and consult with the healthcare provider":0.002131287297527707,
       "some children do better with the daily dose divided into two doses":0.0017050298380221654,
       "start with a low dose and gradually increase":0.0017050298380221654,
       "this side effect usually improves over time":0.0017050298380221654,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":0.001278772378516624,
       "exclusion criteria":0.001278772378516624,
       "extended time":0.0008525149190110827,
       "factors leading to favorable outcomes":0.0008525149190110827,
       "fear of exposing nmu or minor unwanted effects":0.0008525149190110827,
       "individuals who experience minor unwanted effects":0.0008525149190110827,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":0.001278772378516624,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":0.001278772378516624,
       "feigned":0.0008525149190110827,
       "genu ine":0.0008525149190110827,
       "ferritin":0.001278772378516624,
       "serum":0.0008525149190110827,
       "serum iron":0.0008525149190110827,
       "findings of interest":0.001278772378516624,
       "misusers":0.0029838022165387893,
       "first drug treatment try":0.0008525149190110827,
       "fluctuating periods of remission and recurrence":0.0008525149190110827,
       "patient's symptoms":0.002131287297527707,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":0.0008525149190110827,
       "patients with neither one physician visit nor medication claim in 6 months":0.0008525149190110827,
       "use of outside provider for adhd diagnosis":0.0008525149190110827,
       "job/school performance":0.0017050298380221654,
       "medication side effects/toxicity or signs of abuse/diversion":0.0017050298380221654,
       "potential side effects of atx":0.002131287297527707,
       "relationship issues":0.0017050298380221654,
       "sexual dysfunction and dysmenorrhea":0.002131287297527707,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":0.0017050298380221654,
       "target symptoms":0.0017050298380221654,
       "vital signs":0.002557544757033248,
       "food":0.001278772378516624,
       "foxp1":0.001278772378516624,
       "synapse formation":0.001278772378516624,
       "friendships":0.0008525149190110827,
       "functional impairment related to adhd":0.0008525149190110827,
       "functional outcomes":0.0008525149190110827,
       "insights into key details of nmu":0.0008525149190110827,
       "general qol measures for adults":0.0008525149190110827,
       "generic medication preparations":0.0008525149190110827,
       "pharmacies":0.0008525149190110827,
       "united kingdom":0.0008525149190110827,
       "grade point average (gpa)":0.0008525149190110827,
       "greater family cohesion":0.0008525149190110827,
       "group of experts":0.001278772378516624,
       "organizations that study and treat adhd":0.001278772378516624,
       "severe hypotension":0.0008525149190110827,
       "guanfacine treatment for adhd":0.001278772378516624,
       "individuals who abused":0.0008525149190110827,
       "minor toxicity":0.0008525149190110827,
       "poison control centers":0.0008525149190110827,
       "health effects":0.001278772378516624,
       "icasa":0.0008525149190110827,
       "national health and medical research council (australia)":0.0008525149190110827,
       "ukaan":0.0008525149190110827,
       "heart rate monitoring":0.0008525149190110827,
       "high risk for nmu":0.001278772378516624,
       "high risk patients":0.00042625745950554135,
       "high-calorie foods":0.0008525149190110827,
       "high-quality studies":0.0008525149190110827,
       "high-risk populations":0.0017050298380221654,
       "prisoners":0.0008525149190110827,
       "vulnerability to psychosis":0.002131287297527707,
       "holidays":0.0008525149190110827,
       "household public assistance":0.0008525149190110827,
       "huybrechts et al., 2018":0.001278772378516624,
       "hyperactive-impulsive symptoms":0.0008525149190110827,
       "id":0.0008525149190110827,
       "immediate-release preparations allowed":0.0008525149190110827,
       "physical functioning":0.0008525149190110827,
       "school functioning":0.0008525149190110827,
       "popularity":0.0008525149190110827,
       "reciprocity":0.0008525149190110827,
       "rejection/likability":0.0008525149190110827,
       "sharing":0.0008525149190110827,
       "socializing with peers":0.0008525149190110827,
       "turn-taking":0.0008525149190110827,
       "meditation-based therapy":0.0008525149190110827,
       "in insomnia":0.0008525149190110827,
       "inclusion criteria":0.0008525149190110827,
       "medications misuse":0.0008525149190110827,
       "individuals at greatest risk":0.0008525149190110827,
       "study routes of administration":0.0008525149190110827,
       "individuals who die from stimulant overdoses":0.0008525149190110827,
       "information about negative academic or health effects":0.001278772378516624,
       "willingness to use stimulants":0.001278772378516624,
       "patient preference":0.001278772378516624,
       "insu fflation":0.0017050298380221654,
       "smok ing":0.002131287297527707,
       "stimulant s":0.0017050298380221654,
       "us adults":0.002131287297527707,
       "insurance companies":0.0008525149190110827,
       "large studies":0.002557544757033248,
       "new scientific findings from the past 20 years":0.0008525149190110827,
       "specific search terms":0.0008525149190110827,
       "international society of psychiatric geneti cs":0.0008525149190110827,
       "lifetime ach ievement award":0.0008525149190110827,
       "internet":0.0008525149190110827,
       "intolerance":0.0008525149190110827,
       "intuniv (guanfacine)":0.001278772378516624,
       "irritability in adhd":0.0008525149190110827,
       "irritability in odd":0.0008525149190110827,
       "vulnerability for emotional disorders (mood and anxiety)":0.0008525149190110827,
       "legal issue":0.0008525149190110827,
       "liver function tests":0.0008525149190110827,
       "long-acting preparations recommended":0.0008525149190110827,
       "long-term outcomes":0.0008525149190110827,
       "low initial doses recommended":0.0008525149190110827,
       "neuroenhancement":0.001278772378516624,
       "mania":0.0008525149190110827,
       "randomized trial":0.001278772378516624,
       "medial frontal reductions":0.0008525149190110827,
       "medical causes of adhd symptoms":0.0008525149190110827,
       "problems":0.001278772378516624,
       "safe storage":0.0008525149190110827,
       "medication choice":0.0008525149190110827,
       "medication contract":0.0008525149190110827,
       "patient commitment":0.0008525149190110827,
       "patient values and preferences":0.001278772378516624,
       "phone calls":0.0008525149190110827,
       "target outcomes":0.001278772378516624,
       "stimulant therapy dose":0.0008525149190110827,
       "medication trial":0.0008525149190110827,
       "naturalistic studies":0.0008525149190110827,
       "quality of life enjoyment and satisfaction questionnaire":0.0008525149190110827,
       "weiss functional impairment rating scale":0.001278772378516624,
       "neuronal development":0.0008525149190110827,
       "neuronal proliferation":0.0008525149190110827,
       "synapse development":0.0008525149190110827,
       "mental health assessment":0.0008525149190110827,
       "standardized mean difference":0.0008525149190110827,
       "pregnancies in denmark":0.0008525149190110827,
       "pregnancies in the united states":0.0008525149190110827,
       "time course for improvement":0.001278772378516624,
       "united states":0.001278772378516624,
       "new onset":0.0017050298380221654,
       "motiv ations":0.001278772378516624,
       "outcomes associated with nmu":0.001278772378516624,
       "risk factors":0.002131287297527707,
       "risk reduction methods":0.002131287297527707,
       "mon itoring body mass index":0.001278772378516624,
       "severe mood swings":0.0008525149190110827,
       "sweating of the face, lips, tongue, or throat":0.001278772378516624,
       "underlying heart conditions":0.001278772378516624,
       "national survey on drug use and health (nsduh)":0.0008525149190110827,
       "neurotransmitters":0.0017050298380221654,
       "new clinician":0.0008525149190110827,
       "us data bases":0.0008525149190110827,
       "pediatricians":0.0008525149190110827,
       "performance enhancement":0.0008525149190110827,
       "research methods":0.0008525149190110827,
       "stimulant-naïve college students":0.0008525149190110827,
       "nmu crisis":0.0008525149190110827,
       "nmu of prescription stimulants is highly prevalent":0.0008525149190110827,
       "wide variations in the definition of nmu":0.0008525149190110827,
       "performance enhancing drugs":0.001278772378516624,
       "performance validity tests":0.001278772378516624,
       "societal pressures to seek high levels of achievement":0.001278772378516624,
       "symptom validity tests":0.001278772378516624,
       "none":0.0008525149190110827,
       "nonmedical use and diversion":0.0008525149190110827,
       "nonmedical use and diversion of prescription stimulants":0.0008525149190110827,
       "overdose":0.0008525149190110827,
       "therapeutic range":0.0008525149190110827,
       "numbers":0.0008525149190110827,
       "offspring of mothers with a single prior miscarriage":0.0008525149190110827,
       "organizational structure or systems":0.0008525149190110827,
       "pill counts":0.0008525149190110827,
       "symptoms and prescription refill requests":0.0008525149190110827,
       "patient perceptions":0.0008525149190110827,
       "patient supply":0.0008525149190110827,
       "patient-generated goals discussed":0.0017050298380221654,
       "patients leaving practice":0.0008525149190110827,
       "patients seen within a timely fashion":0.001278772378516624,
       "seen within a timely fashion":0.001278772378516624,
       "patients with documentation of concerns being discussed":0.001278772378516624,
       "patients with documented satisfaction assessment":0.001278772378516624,
       "satisfaction assessment at least annually":0.001278772378516624,
       "psychosocial treatment":0.0008525149190110827,
       "transfer of care":0.0008525149190110827,
       "poison control centers and dawn data":0.0008525149190110827,
       "population":0.00042625745950554135,
       "preferential seating":0.0008525149190110827,
       "teacher":0.0008525149190110827,
       "safeguards":0.0008525149190110827,
       "prescription for adhd medication":0.001278772378516624,
       "suds":0.001278772378516624,
       "theft":0.0008525149190110827,
       "serious health outcomes":0.0008525149190110827,
       "trends in nmu":0.0008525149190110827,
       "stimulant treatment history":0.001278772378516624,
       "subsequent substance use, abuse, or dependence":0.001278772378516624,
       "surgical treatment":0.0008525149190110827,
       "primary inattentive adhd":0.0008525149190110827,
       "psychostimulant medications":0.0008525149190110827,
       "risk of psychosis":0.0008525149190110827,
       "qol benefits":0.0008525149190110827,
       "rating scales with adult norms":0.0008525149190110827,
       "sustained remission":0.0008525149190110827,
       "regional and national databases":0.0008525149190110827,
       "research participants":0.0008525149190110827,
       "signatories":0.0008525149190110827,
       "topic":0.0008525149190110827,
       "residential instability":0.0008525149190110827,
       "risk for adverse events":0.0008525149190110827,
       "risky behaviors":0.0008525149190110827,
       "treatment alternatives, benefits and risks have been discussed":0.0008525149190110827,
       "validated measure":0.0008525149190110827,
       "stimulant overdoses before contacting emergency services":0.0008525149190110827,
       "systematic literature review":0.0008525149190110827,
       "study selection":0.0008525149190110827,
       "structural magnetic resonance imaging (mri) data":0.0008525149190110827,
       "treatment discontinuity":0.0008525149190110827,
       "taking medication":0.001278772378516624,
       "verbal working memory":0.0008525149190110827
    },
    "betweenness_centrality":{
       "adhd":0.6421170554670176,
       "$77.5 to $115.9 billion":0.0,
       "adolescents and young adults with adhd":0.03080429682620801,
       "substantial impairments":4.047476658844374e-06,
       "traffic accidents":4.047476658844374e-06,
       "% of patients medicated for adhd ":7.725348413213436e-06,
       "prescription refills are coordinated with other prescribers":5.202744148878675e-05,
       "transition care coordinated for vacations and other times away":5.202744148878675e-05,
       "% patients evaluated with parent vanderbilt rating scales":0.0,
       "% patients meeting dsm criteria for adhd":2.7265935576047422e-06,
       "% patients treated with psychostimulant medication":2.7265935576047422e-06,
       "% patients evaluated with teacher vanderbilt rating scales":0.0,
       "% patients on medication with at least 2 follow-up visits a year in record":0.0,
       "% patients seen within 30 days medication initiation":0.0,
       "% patients whose medical record contains documentation of dsm criteria":0.0,
       "confirmation of impairment in 2+ settings":0.0,
       "seen within one month of first prescription":5.202744148878675e-05,
       "screening":0.006803464111618348,
       "% patients stabilized on an adhd medication ":0.0002867414674872118,
       "seen at least once per year":5.211832794070688e-05,
       "communication with other health care providers occurs at least annually":5.202744148878675e-05,
       "external treatment resources":5.202744148878675e-05,
       "prescription monitoring program consulted at least annually":5.202744148878675e-05,
       "psychosocial and educational needs have been re-evaluated at least annually":5.202744148878675e-05,
       "risks and benefits of stopping treatment discussed at least annually":5.202744148878675e-05,
       "substance use evaluated at least annually":5.202744148878675e-05,
       "vitals taken at least annually":5.202744148878675e-05,
       "% patients with adhd with documentation of impairment":0.0,
       "1.4 million individuals":0.0,
       "amphetamine":0.012424848341599291,
       "intentional, nontherapeutic use":0.00015490359354463235,
       "stimulants":0.0869309034017791,
       "2000 people":0.0,
       "adhd medication":0.03790545743274498,
       "medical literature":0.00018860599538760817,
       "studies":0.007620240843669745,
       "28 adhd experts":0.0,
       "draft list of 46 qms":1.2585134743073577e-05,
       "quality measure":0.004628771676364599,
       "2–4 hours":0.0,
       "adhd impairments":0.0003810020955989286,
       "long acting":3.7395735567281906e-05,
       "short acting":3.7395735567281906e-05,
       "4.4% of adults":0.0,
       "40-50 percent of participants met adhd criteria at any given follow-up":0.0,
       "recurrence":0.0019021409782919076,
       "remission":0.002383702385775673,
       "48 cohorts":0.0,
       "structural grey matter volume reductions":0.0016866707747342955,
       "5 mg orally in the morning on the first day":0.0,
       "cardiovascular history":0.005325791478346999,
       "5.9%":0.0,
       "thorough evaluation":0.0001624652678327019,
       "adolescence":0.0695912155417129,
       "50":0.0,
       "adult":0.024775481336396354,
       "daily report card":0.0006222061303389826,
       "5mg and 10mg":0.0,
       "concerta":2.8194838855877063e-06,
       "dose":0.006996126352318269,
       "long-acting medications":2.726593557604742e-07,
       "dexmethylphenidate":0.035053698058418084,
       "79 authors":0.0,
       "authors from 27 countries and 6 continents":3.635458076806323e-07,
       "empirically supported statements":0.0021944161148551447,
       "a death in the family":0.0,
       "rutter's indicators of adversity":2.629648008889907e-05,
       "a father or brother or sister with epilepsy":0.0,
       "epilepsy":9.815736807377072e-06,
       "a frequent complaint among users":0.0,
       "behavioral changes":0.00017092881464503601,
       "cardiovascular effects":0.0015467512003807427,
       "central nervous system effects":0.002033214349850235,
       "gastrointestinal issues":0.0016498692953619753,
       "mental conditions":0.01675257671873174,
       "sleep disturbances":0.002070413831046537,
       "a person's mother with epilepsy":0.0,
       "abdominal pain":0.0007378007337552141,
       "abnormalities of chromosomes":0.0,
       "adhd and many other psychiatric disorders":2.0903883941636353e-06,
       "high polygenic risk for adhd":2.3206340723613685e-05,
       "polygenic risk":6.402950537775135e-06,
       "abstinence is not an absolute precondition to start treatment":0.0,
       "drug treatment":0.05323676976625211,
       "stabilize substance use":0.0,
       "abstract problem solving":2.9072844798745817e-06,
       "basal ganglia":0.008936573864730518,
       "focused attention":0.0,
       "inhibitory control":0.0006482125509044051,
       "adhd individuals":0.0029638020464650993,
       "sustained attention":0.0034678867896799194,
       "verbal memory":0.0,
       "working memory":7.373305202304034e-05,
       "abuse":0.00013667656038024732,
       "diversion":0.00027582854921698915,
       "misuse":0.006346375090612683,
       "nmu":0.0141283754244782,
       "nmu of stimulants":0.012538218134467009,
       "abuse liability":0.0,
       "nortriptyline":0.0017644090109863635,
       "tricyclic antidepressant":0.0017644090109863635,
       "abuse of prescription drugs":0.0,
       "alcohol":0.000554100036003979,
       "atomoxetine":0.008128051662618846,
       "long -acting stimulants":0.0,
       "norepinephrine reuptake inhibitors":8.20725255654756e-06,
       "short-acting stimulants":0.0,
       "treatment ending early as the result of adverse events":0.0,
       "abuse, misuse and diversion":0.0023813111936231237,
       "adh d medications":0.0,
       "asthma medications":0.00030140540237270593,
       "multiple prescribers":0.0,
       "prescriptions at multiple pharmacies":0.0,
       "shopping behavior":0.0015630412893446431,
       "academic activity":0.0,
       "stimulant use":0.0005202978364650027,
       "weekends":0.00017858247104521032,
       "academic difficulties":9.627046963536061e-06,
       "academic dishonesty":0.0,
       "academic function":0.0,
       "academic integrity policies":0.00011635867570153766,
       "alcohol/drug use policies":0.0,
       "nmu (non-medical use)":0.006567283284318991,
       "students who reported nmu":0.0,
       "academic outcomes":0.0027872010833683942,
       "adverse medical outcomes":0.0006906561977776505,
       "amp abuse":0.0,
       "clinically significant effects":0.0,
       "clinician":0.006089456163208397,
       "co-occurring disorders":0.0,
       "college graduation":0.0,
       "exposures":0.0,
       "family or friends":3.845648209959246e-06,
       "disorders":7.820504696451648e-05,
       "intravenous abusers":0.0,
       "intravenous":1.2313084163688982e-05,
       "longitudinal study":0.0,
       "nasal abusers":0.0,
       "nmu behavior":7.27463694585168e-05,
       "patient education":0.001151854868657261,
       "poison control calls":0.0,
       "practitioner":0.0005048119747877919,
       "prevention strategies":0.00043595977935869946,
       "rating scales":0.00035004477967042044,
       "risk of dying":6.887377142061658e-05,
       "adverse effects":0.016518051196812402,
       "social interactions":0.0,
       "treatment plan":0.002320534603566904,
       "academic performance enhancement":0.0,
       "educational attainment":0.0023572786940556697,
       "misuse and diversion of stimulant medications":0.00019011099490620205,
       "non-medical use of prescribed stimulants":0.0006367880616506908,
       "psychotic events":0.00019011099490620205,
       "academic skills":0.00015610444377988131,
       "accommodations":0.001252225698107692,
       "symptoms":0.01219056835468541,
       "inattention symptoms":0.0001923972027615127,
       "accidental injuries":1.959920792191072e-05,
       "depression":0.0028459990200408692,
       "sleep issues":0.00021042031340115465,
       "substance abuse":0.008515108427446837,
       "attempted suicide":0.01591354773209037,
       "mortality":0.0007321913715192842,
       "motor tics":0.0030539136525904722,
       "accidental physical injuries":0.0,
       "bullying":0.0,
       "burn injuries":1.5149610996693332e-05,
       "accidental poisoning":0.0,
       "accidents":0.0,
       "further reduce qol":0.0,
       "americans with disabilities act":0.0002887861250448103,
       "classroom-based programs":0.0,
       "disability":0.0,
       "idea (pl-101-476)":0.0,
       "school-based interventions":0.002754885629929878,
       "section 504 of the rehabilitation act of 1973":0.0,
       "accommodations for children with adhd":0.0,
       "brand medication":3.1776509769052554e-05,
       "generic medication":0.0017171748741764625,
       "medications for children with adhd":3.1776509769052554e-05,
       "accurate diagnosis":0.0,
       "activated emotions":0.0,
       "adhd child":0.0001769945601382453,
       "ei (emotional impulsivity)":0.009104961744983178,
       "activation of mania or hypomania":0.0004151944179997584,
       "viloxazine":0.0022491206048000146,
       "active substance use disorder":1.3930856692561143e-05,
       "adhd patients with co-occurring sud":0.0,
       "cocaine use disorder":1.7200031514647682e-06,
       "dextroamphetamine-amphetamine":0.0003098837994634744,
       "nicotine dependence":1.7200031514647682e-06,
       "opioid dependence":0.0,
       "active substance use disorder (sud)":0.0018852101420005392,
       "tcas":0.00028165630877166224,
       "acupuncture, yoga, and ayurvedic therapies":0.0,
       "adhd symptoms or associated impairments":4.774337855006849e-05,
       "acute co-administration of alcohol and stimulants":0.0,
       "health consequences":0.0,
       "acute mania":0.0,
       "psychosis":0.00029973204786716995,
       "stimulant adverse effects":0.00020473332905871408,
       "adderall":0.0006001109836261656,
       "form":9.238528112726242e-07,
       "form and doses":0.0,
       "usage":3.083111246957961e-05,
       "adderall xr":0.0020593633167841794,
       "bubblegum flavor":0.0,
       "children who have trouble swallowing pills":0.0,
       "evekeo":0.0,
       "morning":0.001095385244735148,
       "procentra":0.001095385244735148,
       "adhd symptoms":0.06082135739452317,
       "symptoms throughout the day":0.0,
       "symptoms with just one dose":0.0,
       "vyvanse":0.0015759740992582177,
       "zenzedi":0.0,
       "addiction":0.0,
       "misuse of prescription drugs":3.0700479746236865e-05,
       "additional meals or snacks":0.0,
       "weight loss":0.005897385209641554,
       "weight loss in people with adhd":0.00040620373662476406,
       "additional pharmacotherapy":0.00012483311448664177,
       "adhd patients":0.03115123008501225,
       "aggression and emotionaldysregulation":0.0,
       "atomoxetine (atx)":0.00012483311448664177,
       "callous emotional traits":0.0,
       "child emotionality":0.0,
       "emotion dysregulation":0.015419292805514464,
       "emotional dysregulation symptoms":0.00011312867086696752,
       "odd symptoms":0.0,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":0.0,
       "additional problems the patient may have":0.0,
       "adhd clinical diagnoses":0.0040258420311147436,
       "address this growing public health problem":0.00011871138439801893,
       "consistent nomenclature":0.0,
       "definition of nmu":0.0,
       "epidemic levels":0.0,
       "health care professionals":0.00031354524169692954,
       "patient advocacy groups":0.0,
       "prescription stimulant":0.0027213084922548475,
       "surveys and databases":0.0,
       "genomewide study":0.0,
       "adhd -iv rating scales":0.0,
       "adhd aetiology":0.0,
       "adhd biological pathways":0.0,
       "adhd children":0.012461923298831336,
       "adhd controls":0.0,
       "adhd criteria":0.004586436589865585,
       "adhd and emotional dysregulation":0.006361234123296626,
       "adhd genetic liability":0.0,
       "adhd genetic risk":0.0,
       "adhd guideline ng87":0.0,
       "adhd guidelines":0.0,
       "adhd in females":0.0024173085595155094,
       "adhd in their children":0.0,
       "adhd investigator symptom rating scale (aisrs)":0.0,
       "adhd lifespan course":0.0,
       "adhd medication use":0.0,
       "adhd medications (primarily stimulants)":2.2072499657915223e-05,
       "adhd presentation":0.0,
       "adhd probands":0.0012637337002722351,
       "adhd prototype":0.0,
       "adhd research":0.00048380264614130894,
       "adhd severity fluctuations":0.0,
       "adhd symptoms (e.g., aggression, hyperactivity)":0.0,
       "adhd symptoms/b ehaviors":4.261936678397607e-05,
       "adhd traits":0.00018097098466373257,
       "adhd treatment effectiveness":0.0,
       "adhd outcomes":0.002297670995479685,
       "adhd treatment response":0.0,
       "adhd-associated iq deficits":0.0,
       "adhd-c":7.413909336611663e-06,
       "adhd-like behaviors and their associated impairments":0.0,
       "adhd-like symptoms":0.00030076310602397015,
       "adhd-related brain structural differences":0.0,
       "adhd-related hospital admissions":0.0,
       "adherence":3.899451810177971e-06,
       "adverse outcomes later in life":0.0,
       "age":0.0008015445073818441,
       "age 25":0.0,
       "age at diagnosis":0.0,
       "age at menopause":2.2721612980039519e-07,
       "age at onset":0.0,
       "age at onset variation":0.0,
       "age of first birth":2.2721612980039519e-07,
       "air pollution":0.0,
       "alexander crichton":0.0,
       "allergic reactions":0.0022331528165108494,
       "allergic rhinitis":3.635458076806323e-07,
       "alpha agonists":0.0002601505774133719,
       "alpha-2 adrenergic agonists (clonidine)":0.0,
       "alpha-2 adrenergic agonists (guanfacine)":0.0,
       "amblyopia":0.0,
       "amygdala":9.83168281540229e-05,
       "ankylosing spondylitis":0.0,
       "antidepressant":0.0002415172468342969,
       "antisocial behaviour":0.0,
       "antisocial personality disorder (aspd)":0.0,
       "anxiety":0.0008391401078575925,
       "anxiety disorder":0.0012798868089205543,
       "anxiety or depression":0.0,
       "anxiety or tics":0.0,
       "appetite suppression":1.2462688382324791e-05,
       "arbor pharmaceuticals, llc":0.0,
       "arithmetic":0.0,
       "arrested":0.0,
       "artificial food color exclusion":0.0,
       "artificial food dyes":1.8177290384031615e-07,
       "asd":0.0030468704908657705,
       "asd and adhd":0.0,
       "aspd":0.0,
       "assessment and treatment response":0.0,
       "assets and strengths":0.0,
       "asthma":7.52597361249194e-05,
       "asthmatic mothers":0.0,
       "astigmatism":0.0,
       "at all ages":0.0,
       "atomoxetine dosing":0.0013623724080824846,
       "atopic dermatitis":1.211819358935441e-07,
       "attention":0.004649922635220171,
       "attention and cognitive control networks":0.0,
       "attention and somatoform networks":0.0,
       "attention and working memory tasks":0.0,
       "atx":0.001473619348047383,
       "augusto vidal perera":0.003159920937990472,
       "autism":0.0017675282783664657,
       "autoimmune disease":3.186927534862686e-07,
       "autoimmune thyroid disease":0.0,
       "behavior":0.00288021320261147,
       "behavior management":2.0381917326875983e-05,
       "behavior management training":0.0,
       "behavior modification":0.0,
       "behavior therapy":0.006378484339174067,
       "behavior therapy principles":0.0,
       "behavioral and mental health assessment":0.0012503150063248518,
       "behavioral intervention":0.0001322964414968222,
       "behavior monitoring":1.044183489129358e-05,
       "behavioral regulation index of the brief-a":1.987132625254615e-05,
       "behavioral responses":0.0,
       "behavioral responses and emotional responses":0.0,
       "behavioural interventions":0.00013997305105795292,
       "benefits for adhd":0.0,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":0.0,
       "biologic vulnerability":0.0,
       "biological and psychological causal mechanisms":0.0,
       "biological pathways":0.0,
       "biological test":0.0,
       "bipolar disorder":0.0004078639420544825,
       "black and latin minority youth":0.0,
       "black individuals":0.0,
       "black patients with adhd":0.0,
       "blood lead levels":3.7566400126998665e-06,
       "blood pressure":0.0029876554183291774,
       "body mass index":0.000127142195321393,
       "boys":1.627123418906891e-05,
       "boys and girls":0.0,
       "boys born to women who lost a close relative during pregnancy":9.088645192015807e-08,
       "boys with adhd":4.1614505106204284e-05,
       "brain":0.000352348963433606,
       "brain areas involved in cognition":0.0,
       "brain differences":0.0,
       "brain functioning":0.0,
       "brain imaging":2.4816329300485074e-06,
       "brain imaging studies":5.301709695342554e-07,
       "brain volumes":0.0,
       "brain-specific neuronal subtypes":0.0,
       "brains of people with adhd":2.353648381819546e-06,
       "breastfeeding women":0.0,
       "brief behavioral sleep intervention":0.0,
       "bupropion":0.0015861400740524968,
       "bupropion extended-release":0.0,
       "cannabis abuse or dependence":0.0,
       "cannabis use disorder":3.295247028073639e-05,
       "cardiometabolic disease":0.0,
       "cardiac events":0.007098130599465291,
       "cardiovascular monitoring":0.001242683591022268,
       "care":0.0,
       "caregiver":0.01008562574657376,
       "cause of adhd":0.0,
       "cbt":0.0010279446371652247,
       "cbt methods for emotional dysregulation issues":0.0,
       "cbt and dbt program":0.0001409647850206259,
       "cd":0.0,
       "celiac disease":1.3865345772639335e-05,
       "central nervous system injury":0.0,
       "certain areas":0.0,
       "certain birth defects":0.0,
       "chadd":0.006793824767887847,
       "changing antecedent behavior and reinforcement":0.0,
       "characterization of ei/desr in adhd":0.0,
       "child's developmental stage":3.8126864868859078e-06,
       "child's health":2.0479747166008952e-06,
       "childhood adhd":0.0,
       "children and adolescents who do not respond to stimulants":0.0,
       "children and adolescents who have adhd plus other mental health conditions":0.0,
       "children and adolescents with adhd":9.585340770949681e-05,
       "children who experienced sexual abuse or physical neglect":0.0,
       "children who grow up in difficult family situations":0.0,
       "children who had a specific type of viral infection (enterovirus)":0.0,
       "children whose mothers were severely obese":0.0,
       "children with adhd and smd":0.0,
       "children with low lead levels":0.0,
       "children without adhd":4.1614505106204284e-05,
       "cholinesterase inhibitors":0.0,
       "chrna7":7.773688020608336e-06,
       "cigarettes smoked per day":2.2721612980039519e-07,
       "cingulate region":2.908366461445058e-07,
       "clinical assessment":0.0,
       "clinical experience":0.0,
       "clinical features":0.0,
       "clinical global impression ratings":0.0,
       "clinical research":0.00012442578573392676,
       "clinician interview":0.0,
       "clonidine":0.003401920452742835,
       "clonidine extended-release":4.893596031576906e-05,
       "close friends":0.0,
       "cnvs":0.0,
       "cnvs in the 1q21.1 region":0.0,
       "cnvs in the 6q26 region":0.0,
       "co-contraindication for stimulant prescription":0.0,
       "cocaine":7.086083922420905e-06,
       "cocaine or methamphetamine use":0.0012637337002722351,
       "coexisting condition":0.002134395646675736,
       "coexisting mental health disorders":0.0010942835250700416,
       "cognitive behavior therapy":0.012301450043717535,
       "cognitive errors":0.0,
       "cognitive function":0.0003571701357009065,
       "cognitive training":0.0005825290569754199,
       "college completion":0.0,
       "combination therapies":4.572493461624714e-06,
       "combinations of social disadvantages":0.0,
       "common adverse effects":0.0,
       "community controls":0.0,
       "comorbid anxiety or tics":0.0,
       "comorbid condition":0.004268314574848404,
       "comorbidities aggravate these outcomes":0.0,
       "complete specificity":0.0,
       "completion of no more than compulsory education":0.0,
       "complex cases":0.0008694573028422902,
       "complex psychosocial circumstances":0.0,
       "computer-based training":0.0,
       "condition":0.00023820622506060178,
       "conduct disorder":3.6876753551244804e-05,
       "conduct disorder (cd)":0.0,
       "conduct problems":2.0223701448238062e-05,
       "confounders":0.0,
       "conners global index (cgi) emotional lability scale":0.001220063078504919,
       "adhd index of the conners adult adhd rating scale":0.0001798573440755983,
       "consistent set of causes for the disorder":0.0,
       "consultation":0.0007084437786890067,
       "controls":0.0018346037677443986,
       "core disorder in adhd":0.0,
       "core symptoms of adhd":0.0,
       "coronary artery disease":2.2721612980039519e-07,
       "cortical surface area":5.836895611624454e-06,
       "cortical thickness":1.7660680250180658e-05,
       "crash risk":0.0,
       "crashes":0.0,
       "criminal offenses":0.0,
       "criminal records":0.0,
       "curative treatments for adhd":0.0,
       "d-amphetamine sulfate":0.0,
       "daily functioning":0.00016864746472695629,
       "daily life":0.0,
       "danish national register longitudinal cohort study":0.0,
       "danish national registers":1.712213287693576e-05,
       "danish population":0.0,
       "death by homicide":0.0,
       "death from natural causes":0.0,
       "decision-making":0.0,
       "decrease":0.0,
       "decreased appetite":0.0010764142067477898,
       "decreases in appetite":0.0,
       "default-mode network (dmn)":0.006682965739699101,
       "delayed onset of sleep":0.0,
       "delayed reinforcement":0.0,
       "deliberate self-poisoning":0.0,
       "dementia":0.0,
       "deprivation":9.088645192015807e-08,
       "desr":0.00035973215998403023,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":0.0,
       "developmental disability–children’s global assessment scale":0.0,
       "developmental history":0.00026632707209264366,
       "dex":0.00038158703619481767,
       "dexedrine":0.0,
       "dextro amphetamine":7.496021918247131e-05,
       "deﬁcient emotional self-regulation (desr)":0.0,
       "diagnoses":0.005262945874444084,
       "diagnosis of apparent adult-onset adhd":0.0,
       "diagnostic criteria":3.2669011203662836e-06,
       "diagnostic delays":0.0,
       "diets":0.0,
       "differ between children and adults":0.0,
       "differences between groups of people who are and are not diagnosed with adhd":2.353648381819546e-06,
       "difficult life circumstances":0.0,
       "difficulty breathing":0.0,
       "difficulty sustaining attention":0.0,
       "digital health interventions (dhis)":2.643088521553526e-05,
       "disability service options":0.0,
       "disinhibited emotionally expressive behavior":0.0,
       "disorder":3.6889398472137824e-06,
       "disruptive mood dysregulation disorder":0.00013740102764472429,
       "distress":0.0,
       "distress tolerance":0.0039286902217101636,
       "dlpfc":0.0,
       "dmn":3.635458076806323e-06,
       "doctor":0.0014104895553410826,
       "does not seem to listen":0.0,
       "domains":0.0,
       "dopamine":0.0,
       "dopamine levels in synapses":0.0,
       "dopamine regulation":0.0,
       "double-blind, placebo-controlled trials":0.0,
       "driver license suspensions":0.0,
       "drug contract or conducting periodic drug screens":0.0,
       "dsm and icd criteria":0.0,
       "dsm-5":8.415879446937258e-06,
       "dsm-5 diagnosis":0.0,
       "dsm-5 symptom criteria":0.0,
       "dsm-5’s dmdd":0.0,
       "duration":0.0,
       "duration of treatment":3.363266671769832e-05,
       "dusp6":7.773688020608336e-06,
       "dysfunctional cognitive beliefs":0.0,
       "dysphoria":5.334219878327313e-06,
       "dysregulation":0.0,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":0.0,
       "earnings reduction":0.0,
       "anorexia":0.0017842721453070517,
       "editorial support":0.0,
       "education planning":0.0,
       "educational and occupational failure":2.745517894471701e-05,
       "eeg neurofeedback":1.9530337895955703e-06,
       "efficacy":1.2563090778199998e-05,
       "efficacy in treating adhd":7.331507121559416e-06,
       "ei":0.00439507744800621,
       "ei and desr":0.00014016883150394684,
       "electrical stimulation":0.0,
       "electrophysiology":0.0,
       "elevations in the theta/beta on the electroencephalogram":0.0,
       "elimination diets":3.645005651823531e-06,
       "embryogenesis":0.0,
       "emergent health conditions":0.0,
       "emerging problems":0.0,
       "emotion processing":0.00018097098466373257,
       "emotion regulation":0.01864339497140655,
       "emotional and behavioral trajectories":0.0,
       "emotional control scores":0.0,
       "emotional control subscale":0.0,
       "emotional intensity (ei)":2.2115703300571797e-06,
       "emotional lability":0.0025452502560438257,
       "emotion":0.004775395271197007,
       "emotional symptoms":0.013907090241867082,
       "employed":0.0,
       "employment reduction":0.0,
       "enigma-adhd working group set of cohort from around the world":0.0,
       "enterovirus patients":0.0,
       "environment":0.0,
       "environmental correlates":2.1985865512114427e-07,
       "environmental correlates of adhd":1.4208581983518044e-05,
       "environmental factors":0.0003190805234487195,
       "environmental risks":4.5443225960079037e-07,
       "epidemiologic studies":0.0002107331993706001,
       "essential fatty acid supplementation":9.570921669861762e-05,
       "europe":0.0,
       "european network for hyper kinetic disorders (eunethydis)":0.007312467229380054,
       "euthymic baseline":0.0,
       "evaluate care-giver burden in children":0.0,
       "evaluate family-related qol and activities of daily living in children":0.0,
       "evaluate overall functioning in children":0.0,
       "evidence":0.0008163015033781106,
       "exaggerated delay discounting":0.0,
       "executive dysfunction":0.0005026294734323618,
       "executive function":0.0003188601821135446,
       "executive function control":5.700487647711702e-06,
       "executive functioning":8.595784871143814e-06,
       "exposure‐response trend":0.0,
       "externalizing behavior problems":0.0,
       "extreme deprivation early in life":0.0,
       "fails to give close attention":0.0,
       "false positive diagnoses":7.270916153612646e-07,
       "familial co-aggregation":0.0,
       "familial or genetic factors":0.0,
       "family":5.485213769695634e-06,
       "family conflict":0.0,
       "family function":0.0,
       "family history of adhd":0.0,
       "family history of mental health issues":0.0,
       "family problems":0.0,
       "family strain index":0.0,
       "fatty acid concentrations":0.0,
       "fda approval":0.0,
       "fda approved medication":0.0,
       "fda-approved treatment for adhd":0.0,
       "felony":0.0,
       "female":3.3048194147395915e-06,
       "fidgeting":0.0,
       "fidgets with hands or feet":0.0,
       "financial problems":0.0,
       "financial stability":0.0,
       "fmri neurofeedback":0.0,
       "fmri studies of cognitive control":0.0,
       "dietary interventions":0.000408312355270497,
       "foster care":0.0,
       "foxp1 and foxp2":0.0,
       "foxp2":0.0,
       "franz kramer and hans pollnow":0.003159920937990472,
       "free fatty acids":0.0,
       "free tools":0.0,
       "frontal region":2.908366461445058e-07,
       "functional impairment":0.0,
       "functioning":9.000485057107697e-06,
       "funding for manuscript development":0.0,
       "fusiform gyrus":0.0,
       "future patient outcomes":0.0,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":0.0,
       "general behavior":0.0,
       "general population":0.0,
       "general psychopathology and several psychiatric disorders":0.0,
       "generalized emotional under-control":0.0,
       "genes and environment":0.0,
       "genetic and environmental risk factors":0.0,
       "genetic correlation":0.0,
       "genetic factors":4.5443225960079037e-07,
       "genetic influence":3.635458076806323e-07,
       "genetic or familial causes":0.0,
       "genetic risk":9.088645192015807e-07,
       "genetic variants":0.0005840929891165061,
       "genetics":1.1512283909886689e-06,
       "genomic loci":0.0,
       "geographic region":0.0,
       "george still":0.00029017480192903157,
       "girls":0.0,
       "girls with adhd":0.0,
       "glaucoma":0.0,
       "glutamatergic neurotransmission":0.0,
       "gonzalo rodriguez-lafora":0.0,
       "grade point sum":0.0,
       "growth issues":0.0016987373965322828,
       "guanfacine":0.004030910763323125,
       "extended release guanfacine":0.00039346194852662964,
       "gudjonsson et al.":0.0,
       "guidelines":0.0024698260959534818,
       "gwas":0.0,
       "hba1c":0.0,
       "headache":0.005134659312217756,
       "health-care disparities":0.0,
       "health care provider":0.0024852012489011625,
       "healthcare systems":1.1423179545259081e-06,
       "heart rate":0.000596348959052072,
       "heinrich hoffmann":0.0,
       "high blood pressure":0.0005567347132691017,
       "high iqs":0.0,
       "high lead levels":0.0,
       "high risk of substance abuse":0.0,
       "high school and collegiate athletes":0.0,
       "high ses":0.0,
       "higher adhd symptom severity and poorer outcomes":0.0,
       "hippocampus":0.00015344028579369575,
       "hippocampus volume":0.0,
       "history of illicit stimulant use":0.0,
       "hong kong database":0.0,
       "hyperactivity":0.0004945066358123439,
       "hyperactivity in children":0.0,
       "hyperkinetic disorder":0.0,
       "hyperthyroidism (overactive thyroid)":0.0,
       "hypospadias":0.0,
       "hypotension":0.00012119830521353434,
       "hypothyroidism (underactive thyroid)":0.0,
       "icd-11":0.0,
       "icd-11 criteria":0.0,
       "ifc":0.0,
       "ifc and insula":0.0,
       "illegally used drugs":0.0,
       "imaging studies":0.0,
       "immediate reinforcement":0.0,
       "immediate rewards":3.635458076806323e-07,
       "impaired academic functioning":3.635458076806323e-07,
       "impairment":0.009463822183197204,
       "impairments in quality of life":0.0,
       "improved academic performance":0.0,
       "improved brain function, most prominently in inferior frontal and striatal regions":0.0,
       "improved parent-reported child behavior":0.0,
       "improved relationships with caregivers, teachers, siblings, or peers":0.0,
       "improved rule following":0.0,
       "improved sleep":0.0,
       "improvements":0.00018547645494271917,
       "improvements in living":0.0,
       "impulsive decision-making":3.635458076806323e-07,
       "impulsivity":6.969428046436747e-05,
       "high inattentive factor":0.005001901379119542,
       "inattention and hyperactivity":0.0,
       "inattentive type":0.0,
       "adhd inattentive type":0.0,
       "incarceration":0.0,
       "increase the risks of suicidality":0.0,
       "increased rate of rare genetic mutations":0.0,
       "incredible years (iy)":3.6354580768063225e-07,
       "individual":0.0002165129123826526,
       "infection":5.195122130552911e-06,
       "inferior frontal dysfunction":0.0,
       "inflammation":0.0,
       "health professionals, patients and families":0.011215700397565781,
       "inhibition":0.0,
       "initial treatment":0.002673307969718768,
       "injuries":0.0002272223136525656,
       "insomnia":0.005448623848001494,
       "insula":0.0,
       "insulin resistance":0.0,
       "integrative treatment":0.0001825186166236622,
       "integrity of auditory sensory memory and involuntary attention switching":0.0,
       "intellectual disabilities":2.6223298789950363e-06,
       "intellectual functioning":0.0,
       "intelligence":2.8574343236298065e-05,
       "intelligent individuals":0.0,
       "intensity":0.0,
       "intensity of subjective states and behavior":0.0,
       "intentional exposures":0.0,
       "interdisciplinary collaborations":0.0,
       "international resources":0.0,
       "interventions":0.0011146170222604927,
       "intracranial brain volume":0.0,
       "iq":0.00019167673277925378,
       "iq differences":1.534157274301009e-05,
       "iq scores":0.0,
       "iq tests":0.0,
       "irritability":0.015150011366674116,
       "juvenile detention":0.0,
       "kidney failure":0.0,
       "kidscreen-10":0.0,
       "l-deprenyl":0.0,
       "large family size":0.0,
       "large population studies":0.0,
       "larger delayed ones":0.0,
       "lead burden":0.0,
       "learning disorder":3.047991161165965e-06,
       "leaves seat in situations":0.0,
       "licensed clinician":0.0,
       "limbic volume":0.0,
       "lines of communication":0.0,
       "lisdexamfetamine":0.000334343435613748,
       "long-range fronto-posterior association tracts":0.0,
       "long-term medication use":0.0,
       "low ses":0.0,
       "low social class":0.0,
       "low social class conditions":0.0,
       "lower achievement scores":0.0,
       "lower family income":0.0,
       "lower quality of life":0.0,
       "lung cancer":2.2721612980039519e-07,
       "major depression":3.57862991880357e-05,
       "makes careless mistakes":0.0,
       "male":0.0004350075148732834,
       "male-to-female sex ratio of adhd":0.00022613849870235407,
       "maois":0.0007110606486610244,
       "map1a":0.0,
       "maternal alcohol use during pregnancy":0.0,
       "maternal mental disorder":0.0,
       "maternal pre-existing type 1 diabetes":0.00021045006075940163,
       "maternal prenatal use of acetaminophen":0.0,
       "maternal smoking":6.816483894011856e-06,
       "maximimum tolerated dose":0.0,
       "measurement tools":0.0,
       "measurement-based care":0.0,
       "measures of neurocognitive functioning":0.0,
       "measures to evaluate qol or functional impairment":0.0,
       "mechanisms of disease onset":0.0,
       "mechanisms/pathophysiology":0.0,
       "medical history":0.0,
       "medical problem":0.0,
       "medication periods":0.0,
       "medication therapy":0.0008100590467371868,
       "medication-free weekends":0.0,
       "mef2c":0.002110648876881651,
       "melchior adam weikard":0.0,
       "memory":0.0,
       "meta-analyses":0.004212830035013237,
       "metabolic disorders":0.0,
       "methamphetamine":0.0,
       "method of diagnosing adhd":0.0,
       "methods to improve adherence":0.0,
       "methylphenidate treatment":2.5023586649238056e-05,
       "methylphenidate users":0.0,
       "methylphenidate users ages 46-65":0.0,
       "methylphenidate users with previous alcohol and drug misuse":0.0,
       "methyphenidate prescription":0.0,
       "migraine":2.6816497077541146e-07,
       "milder adhd":0.0,
       "mindfulness and positive aspects of adhd":0.0,
       "mindfulness meditation":0.0,
       "mindfulness-based treatments":0.0,
       "minimal brain dysfunction":0.00027270328538635925,
       "minor structural and functional brain differences":0.0,
       "misconceptions":0.002153643586938505,
       "misdemeanors":0.0,
       "mismatch negativity":0.0,
       "misuse and diversion of these medications":0.0,
       "mixed amphetamine salts":6.43272434812082e-05,
       "modafinil":0.00019650027527395137,
       "molecular genetic data":0.0,
       "mood":0.0005413085109353054,
       "mood disorder":0.00011611470703424663,
       "mortality rates":0.0,
       "most cases of adhd":0.0,
       "mothers":2.5145251697910398e-06,
       "mothers who were obese before pregnancy":0.0,
       "mothers with two or more prior miscarriages":0.0,
       "motor vehicle collision":1.2488305512222647e-05,
       "mtbi":0.0,
       "multidisciplinary efforts":0.0,
       "multiple settings":0.0,
       "narcolepsy":0.0,
       "national health and nutrition examination survey":0.0,
       "national health insurance data":0.0,
       "national institute for health and care excellence (nice)":0.0,
       "national institute of mental health":0.0,
       "nationwide population study":5.453187115209484e-07,
       "nausea":0.0019968490464236655,
       "negative parenting":7.6260502481607496e-06,
       "negative reinforcement":0.0,
       "neglect":0.0,
       "network meta-analyses":1.0429791521037894e-05,
       "network of researchers with annual meeting":0.0,
       "neurobiological research":0.0,
       "neurobiology":0.0,
       "neurocognitive function":0.0003945153661164022,
       "neurocognitive impairment":0.0,
       "neurodevelopment":0.0,
       "neurodevelopmental condition":0.0,
       "neuroimaging scans":0.0,
       "neuroimaging studies":0.0,
       "neuronal and nicotinic signalling pathways":0.0,
       "neuronal development and migration":0.0,
       "neuropsychological tests":0.0,
       "new directions for diagnosis":8.449554744386756e-05,
       "new medications currently in development":0.0,
       "nice guidelines":9.088645192015807e-07,
       "nicotine":4.216521243032514e-06,
       "nicotinic signalling":0.0,
       "no association with adhd":0.0,
       "no significant effect on adhd":0.0,
       "non-medical treatments":0.0005608021085489447,
       "non-responders":3.572544428157643e-05,
       "non-stimulant medications":0.0001628039148707056,
       "non-stimulants":0.0009457849285387198,
       "nonstimulant medications":0.0002953127914957962,
       "noradrenaline":5.293692346113772e-06,
       "normal cognitive fluctuations":0.0,
       "normed scales":0.0,
       "north america":0.0,
       "number of children":2.2721612980039519e-07,
       "number of sessions":0.0,
       "obesity":0.0006251187069025441,
       "occupational functioning":0.0,
       "ocd":0.000980927056507057,
       "odd":0.003711921586913924,
       "older adolescents and adults":0.0,
       "omni healthcare communications":0.0,
       "onset":6.46795284384168e-06,
       "onset prior to the age 12 years cannot be documented":0.0,
       "oppositional defiant disorder":0.00039478096128216857,
       "organisation skills":1.839888895295094e-06,
       "other approaches to emotion-regulatory processes disrupted in adhd":0.0,
       "other psychiatric and substance use disorder":0.0,
       "other psychiatric diagnosis":4.693730377429787e-05,
       "other stimulant class":0.0,
       "out-of-home care":0.0,
       "outcomes":0.0017615092115222635,
       "outcomes over longer periods of time":0.0,
       "overused medication":5.026296905526264e-05,
       "oxidative stress":0.0,
       "paid tools":0.0,
       "parent":0.001896006115795698,
       "parent behavior management training (pbmt)":3.6354580768063225e-07,
       "parent management training":0.0,
       "parent referral for treatment":0.0,
       "parent training":0.0025601322230388098,
       "parent training in behavior management (ptbm)":0.0,
       "parent-child behavior therapy":5.453187115209484e-07,
       "parental criminality":0.0,
       "parental educational attainment":0.0,
       "parental outcomes":0.0,
       "parental relative income poverty":0.0,
       "parental unemployment":0.0,
       "parenting skills":0.0,
       "parents having low educational levels":0.0,
       "pargyline":0.0,
       "parietal region":0.0,
       "paroxetine":0.0,
       "particulate matter":0.0,
       "pathophysiology":0.0,
       "patient":0.010243881495237531,
       "patient’s level of ei":0.0,
       "pbmt":0.0,
       "peer conflicts and social exclusion":0.0,
       "peers":0.002249579275273172,
       "people":0.0003382467577231426,
       "people all around the world":0.0,
       "people who have read this document and agree with its contents":0.0,
       "performance deficits in psychological processes":0.0,
       "perpetrators of physical dating violence":0.0,
       "person":0.0,
       "personalized approach":0.0,
       "personalized treatments":0.0,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":0.0,
       "pharmacotherapy":0.00033131913228274916,
       "physical conditions":0.0,
       "physical examination":0.00018025177843577632,
       "placebo":1.3775113615575328e-05,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":0.0,
       "poisoning in children":0.0,
       "police station interrogations":0.0,
       "polr3c":0.0,
       "polygenic cause":0.0,
       "polythetic criteria":0.0,
       "poor judgment":0.0,
       "poor work performance":0.0,
       "positive parenting":0.0,
       "positive reinforcement":0.0,
       "posterior corpus callosum":0.0,
       "posterior parieto-temporal attention regions":0.0,
       "poverty":5.195122130552911e-06,
       "pre-existing type 1 diabetes":0.0,
       "prediction":0.0,
       "predictive modelling":0.0,
       "predictor of treatment response":0.0,
       "preeclampsia":0.0,
       "pregnancies":0.002144348666310662,
       "pregnancy and adhd":0.0,
       "pregnant or breastfeeding women":0.0,
       "premature death":0.0011238461796856134,
       "prenatal exposure":5.453187115209484e-07,
       "prenatal exposure to maternal smoking":0.0,
       "preschool or daycare":0.0,
       "preschoolers with symptoms of adhd":0.0,
       "prescriber":0.00020541406302438973,
       "prevalence":0.00043793429038083717,
       "prevalence of adhd":0.00010965791742207567,
       "prevalence of adhd among adolescents":0.0,
       "prevalence of adhd in prisons":0.0,
       "prevalence of false confessions":0.0,
       "prevalence of physical dating violence":0.0,
       "priapism":0.0012076574467902973,
       "prior miscarriage":0.0,
       "prisma diagram in supplemental figure 1":0.0,
       "prison inmates":0.0,
       "prkn":0.0,
       "proband":5.138781954866463e-05,
       "problem behaviors (e.g., aggression, caregiver-child relations)":0.0,
       "problem solving":0.00017995548705947734,
       "problematic substance use":0.0,
       "problems with connections between the two hemispheres":0.0,
       "professional health care associations":0.0,
       "proteins":0.0,
       "proton pump inhibitors":0.0,
       "provocation":0.00030265994546529903,
       "psoriasis":0.0,
       "comorbid psychiatric conditions":0.0008822919168089011,
       "psychoeducation":0.003686034768839157,
       "psychological tests":0.0,
       "psychological treatment":0.0,
       "psychosocial domains of qol":0.0,
       "psychosocial interventions":0.001893234613747059,
       "psychosocial, school and emotional functioning":0.0,
       "psychotherapy":0.0007877127646069218,
       "psychotropic co-prescriptions":0.0,
       "ptbm":1.9637259289014134e-05,
       "ptbm (behavior therapy)":0.0008529864779042477,
       "qol domains":0.0,
       "quality of life":0.0004508385120365954,
       "racemic amphetamine sulfate":0.0,
       "racial and ethnic minority populations":0.0,
       "rage":0.0,
       "randomized controlled trials (rcts)":0.0,
       "rare genetic mutations":0.0,
       "rare single gene defects":0.0,
       "rct":3.249601165931066e-05,
       "rcts of adhd medications":0.0,
       "re-evaluate goals and behavior":0.0,
       "reading":0.0,
       "reading, spelling and arithmetic":0.0,
       "rebound effect":3.1123675528535658e-06,
       "reduce self-esteem and wellbeing":0.0,
       "reducing inattention, hyperactivity, and impulsivity":0.0,
       "referral to a dietician":0.0,
       "regular check-ups":0.001242683591022268,
       "reinforcer":0.0,
       "relationship quality":0.0,
       "reliability and validity":0.0,
       "reliable diagnostic measure for adhd":0.0,
       "research":0.008224491808231128,
       "resilience":0.0,
       "resilience factors":0.0,
       "resources":0.0,
       "responders":3.572544428157643e-05,
       "response cost":0.0,
       "response to treatment":0.0,
       "response-inhibition":0.0,
       "restlessness":0.0,
       "reward":2.0061269986288673e-05,
       "right inferior frontal cortex":2.2851450768496888e-07,
       "potential risks":0.00022175036277976993,
       "risky driving behaviors":0.00020200920598178513,
       "robins and guze criteria":0.0,
       "sagitatal striatum":0.0,
       "scaffolding":2.7265935576047422e-06,
       "scales for emotion regulation":0.0,
       "schizophrenia":0.0004626482956554355,
       "school":1.9999577990556164e-06,
       "school interventions":0.0,
       "school performance":0.0,
       "school-based accommodations":0.0,
       "screening measures":0.001759934339594568,
       "selective amplification of certain emotional states":0.0,
       "selective noradrenaline reuptake inhibitors":4.893596031576906e-05,
       "self-esteem":1.156062065005033e-06,
       "self-injury":0.0,
       "self-perceptions of competence":0.0,
       "self-referential thoughts and mind-wandering":0.0,
       "self-referral":0.0,
       "self-regulatory skills":0.00038710097543936554,
       "self-regulatory strategies":0.0,
       "self-report measures":0.0,
       "self-report scale":0.0,
       "self-reported executive function ratings":0.0,
       "serious transport accidents":0.0,
       "serotonin syndrome":0.0001751685490698449,
       "settings":0.0,
       "severe adhd":0.0,
       "severe marital discord":4.0826771259372595e-07,
       "severe mood dys-regulation (smd)":0.0,
       "sex":0.0,
       "sexual crimes victims":7.270916153612646e-07,
       "sexually transmitted infections":0.0,
       "shared components of etiology":0.0,
       "shared mechanisms among disorders":0.0,
       "short- and long-acting formulations of a-2 adrenergic agonists":0.0,
       "simulant":0.0,
       "simulant medications":0.0,
       "single genetic abnormality":0.0,
       "six symptoms of hyperactivity-impulsivity":0.0,
       "six symptoms of inattention":0.0,
       "skills training":0.0,
       "sleep":1.30005229763297e-05,
       "sleep efficiency":0.0,
       "sleep onset":0.0,
       "sleep onset delay":0.0,
       "small differences in brain structure and function":0.0,
       "small for gestational age":0.0,
       "small particulate matter levels":0.0,
       "small to moderate difficulties":0.0,
       "small-to-moderate reductions in mismatch negativity amplitude":0.0,
       "smaller brain areas":0.0,
       "smaller brain volumes":0.0,
       "cigarette smoking":0.0003540333307092369,
       "smoking initiation":2.2721612980039519e-07,
       "social acceptance":0.0,
       "social anxiety disorder":0.0,
       "social cognitive programs":0.0,
       "social function":0.0,
       "social functioning":8.565956711256046e-05,
       "social skills":9.123918587080333e-05,
       "social skills training":0.00033880158594574414,
       "socially and clinically important outcomes":0.0,
       "society for developmental and behavioral pediatrics":0.0,
       "socioeconomic cost":0.0,
       "ses (socioeconomic status)":0.0,
       "solriamfetol":0.000813631760183877,
       "somatic co-prescriptions":0.0,
       "somatic disorders that co-occur with adhd":0.0,
       "sorcs3":0.002110648876881651,
       "sorcs3, ptprf, and mef2c":0.0,
       "specialist":5.020501405282869e-06,
       "speech disorders":3.4888856400588935e-06,
       "spelling":0.0,
       "splenium of the corpus callosum":1.534157274301009e-05,
       "spouses":3.7099419891873366e-06,
       "ssri/snri":6.92545571829233e-06,
       "standard diagnostic criteria":0.0,
       "standard therapies":0.0,
       "stigma":0.011096451494715033,
       "adhd stigma":0.00022557234596105562,
       "stimulant":0.0032384716152457724,
       "stimulant medication":0.015729357457166585,
       "stimulant therapy":0.0008606331550199571,
       "stimulant-refractory":0.0,
       "stimulants are the first line of drug treatment for adhd":0.0,
       "stress":0.0,
       "stress-related strains on cognition":0.0,
       "stressed events during childhood":0.0,
       "subcortical regions":0.0,
       "subjective well-being":2.2721612980039519e-07,
       "subsequent substance use":0.0,
       "substance misuse":0.0,
       "substance use":5.4760414306969785e-05,
       "sud":0.0,
       "suicide related events":4.227649799229443e-05,
       "support groups":0.0,
       "sustained release bupropion":0.0,
       "sweden":0.0,
       "swedish national registers":0.0031682558863705486,
       "swedish population-based study":0.0,
       "swedish registry study":0.0,
       "symptom change":4.752082729931881e-06,
       "symptom checklists":0.0,
       "symptom expression":0.0,
       "symptom severity":0.0,
       "synapse formation and plasticity":3.3948253755319997e-06,
       "synaptic development":0.0,
       "taiwan health insurance research database":0.0,
       "taiwanese study":0.0,
       "taiwanese youths":0.0,
       "tca (nortriptyline)":6.92545571829233e-06,
       "tdcs":0.0008731607142693278,
       "teacher-assessed social skills":0.0,
       "teachers of children with adhd":0.0,
       "techniques":0.0,
       "teenage pregnancy":2.132505522293564e-05,
       "teenage pregnancy and sexually transmitted diseases":0.0,
       "temper outbursts":7.161053409533335e-07,
       "temporal pole":0.0,
       "temporal region":2.908366461445058e-07,
       "temporo-parieto-occipital regions":0.0,
       "test scores":0.0,
       "testicular dysfunction":0.0,
       "tetrahydrocannabinol (marijuana)":0.0,
       "therapeutic approaches":2.5069704370977884e-07,
       "therapies":0.0,
       "therapy":0.0024468214954615937,
       "those seeking treatment":0.0,
       "those with epilepsy":0.0,
       "thyroid problems in mothers during pregnancy":0.0,
       "time management":0.0001487373408634922,
       "time off medication":0.0,
       "time-out":0.0,
       "tms":1.9530337895955703e-06,
       "tns":2.643088521553526e-05,
       "token economy":0.0,
       "tolerability":6.47222449950576e-05,
       "total sleep time":0.0,
       "toxic substances":0.0,
       "tracking and remote measurement technologies":0.0,
       "trans-diagnostic phenomena":0.0,
       "transport accidents":0.00034632580443579947,
       "trauma":4.4492300372640335e-05,
       "trauma-related emergency room admission":0.0,
       "traumatic brain injuries":0.0006957771464067194,
       "traumatic brain injury early in life":0.0,
       "treating adhd and preventing adverse outcomes":0.0,
       "treatment efficacy":0.0,
       "drug treatment initiation":0.005503243077830758,
       "treatment of coexisting conditions":0.0001324792685944825,
       "treatment planning":0.0,
       "treatment targets":0.0,
       "trial":0.0,
       "trigeminal nerve stimulation":2.233209961466741e-06,
       "trigeminal nerve stimulation (tns)":0.0,
       "twins":0.0,
       "type 1 diabetes mellitus (t1dm)":5.453187115209484e-07,
       "type 2 diabetes":2.2356838404477443e-05,
       "typically developing peers":5.162562570945782e-05,
       "ulcerative colitis":0.0,
       "unemployment":1.0187097015266596e-05,
       "unintended injuries":0.0002431649668266357,
       "unmedicated adults":0.0,
       "upper secondary school":0.0,
       "urbanization level":0.0,
       "us":0.0,
       "us population":0.0,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":0.0,
       "validated measure of symptom change":0.0,
       "validity of adhd as a mental disorder":0.0,
       "valproate":2.0572822111826297e-05,
       "vehicular crashes":0.0,
       "ventromedial orbito-frontal cortical thickness":0.0,
       "viloxazine er":0.0,
       "viloxazine extended-release":1.162861628955156e-06,
       "violent crimes":0.0,
       "violent crimes against youth":0.0,
       "viral pneumonia":0.0,
       "visual attention":0.00018097098466373257,
       "weak support systems":0.0,
       "weight":2.752816941372276e-05,
       "well-trained professionals":0.0,
       "wender-reimherr adult attention deficit disorder scale":0.0007501818773086007,
       "wes study":0.0,
       "white blood cell disorders":0.0,
       "white matter":2.331145182834854e-06,
       "white matter integrity":0.0,
       "white-majority countries":0.0,
       "work functioning":0.0,
       "work performance":0.0,
       "working memory impairments":6.253012776842296e-07,
       "world":0.0005224173579483591,
       "worse social adjustment":0.0,
       "year of first adhd diagnosis":0.0,
       "years of schooling":0.0,
       "youth aged 14-20":0.0,
       "youth with adhd":0.00016938064319845894,
       "α2 agonists":1.162861628955156e-06,
       "emotional factors":0.0,
       "intellectual factors":0.0,
       "mood stabilizing medication":0.0002697259911699082,
       "negative health behaviours":0.0,
       "oocyte leading to pregnancy":0.0,
       "psychosocial impairment":0.0,
       "resilience in those susceptible to adhd":1.9086154903233196e-06,
       "sero tonergic medication":0.0,
       "sero tonergic reuptake inhibitor":0.0,
       "serotonin activity":0.0,
       "serotonin-norepinephrine reuptake inhibitors (snri)":8.923827499353744e-08,
       "social factors":0.0,
       "selective serotonin reuptake inhibitor (ssri)":2.6071316417303346e-06,
       "adhd and its mental and somatic comorbidities":0.0,
       "classroom":0.0,
       "covert smile":0.0,
       "desr (delayed emotional return)":0.0,
       "emotional experience and behavior dyssynchrony":0.0,
       "emotionally evocative situations":9.98063079871793e-06,
       "explosive giggle":0.0,
       "provoke- ing stimuli":0.0,
       "rapid emotional responses":0.0,
       "height gains":2.3717682217251224e-05,
       "age at which adhd criteria were met":0.0,
       "children with high iq":0.0005075411477897465,
       "rates of learning disorders":0.0,
       "rates of psychiatric disorders":0.0,
       "rates of stimulant treatment":0.0,
       "rates of substance abuse":0.0,
       "nitric oxide":0.0,
       "nitrogen dioxide levels":0.0,
       "particulate matter levels":5.453187115209484e-07,
       "sulphur dioxide levels":0.0,
       "genetic architecture of adhd":0.0,
       "affective reactivity":0.0,
       "education":0.00016657878627843043,
       "expression of emotions":0.0,
       "family life":0.0,
       "financial":0.0,
       "legal":0.0,
       "predicting emotional symptoms":0.0,
       "social relations":0.0,
       "adhd europe":0.0,
       "health professionals and researchers":0.0016424779552059751,
       "adhd evidence project":0.0,
       "international consensus statement on adhd":0.01133009355716905,
       "adhd experts":1.0906374230418967e-06,
       "brainstorming session":0.0,
       "existing guidelines":0.0,
       "literature review":0.0,
       "qms (quality measures)":2.0669754140542082e-05,
       "qms for adhd in youth":0.0,
       "survey":0.0,
       "adhd follow-up care visit":0.0,
       "visit":0.00020095240789413612,
       "adhd guidelines group of the association of medical scientific societies in germany":0.00018637781740426216,
       "adhd network of european college of neuropsychopharmacology":0.00018637781740426216,
       "adhd section of the world psychiatric association":0.00018637781740426216,
       "australian adhd professionals association":0.00018637781740426216,
       "chinese society of child and adolescent psychiatry":0.00018637781740426216,
       "federation of adhd":3.2719122691256907e-06,
       "israeli society of adhd":0.00018637781740426216,
       "large medical database called pubmed":0.006840542628010551,
       "latin american league of adhd":0.00018637781740426216,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":0.002705750264631122,
       "pubmed":3.2719122691256907e-06,
       "saudi adhd society":0.00018637781740426216,
       "adhd in adults":0.00024588900428559906,
       "adhd in big groups of people":0.0,
       "adhd in offspring":5.4432328847610855e-06,
       "fetal growth restriction":0.0,
       "maternal hyperthyroidism during pregnancy":0.0,
       "maternal hypothyroidism during pregnancy":0.0,
       "maternal preeclampsia":7.270916153612646e-07,
       "obesity in mothers":0.0,
       "adhd in older adults":0.0,
       "mild cognitive impairment and dementia":0.0,
       "adhd malingering":0.0,
       "danish study":0.0,
       "reproductive-aged women":0.0,
       "risk of a motor vehicle collision":7.335491751445566e-05,
       "short-term effects":0.0,
       "adhd medication metabolism affect":0.0,
       "mph":0.0012493972151334694,
       "comorbid anxiety":0.0,
       "duration of action":4.9759281709459934e-05,
       "duration of response":0.0,
       "intervention":0.0,
       "level of function":0.0,
       "methylin®":0.0,
       "methylphenidate-based medications":0.0,
       "mood dysregulation":0.0,
       "nonstimulants":0.00020630406597068804,
       "pharmacokinetics":0.0,
       "pharmacotherapies":0.0,
       "second-line nonstimulants":0.00013030896641218748,
       "short-acting methylphenidate":0.0,
       "specifically learning disorders and low iq":0.0,
       "stakeholders":0.0,
       "supplements":4.9711521532735196e-05,
       "treatment alternatives":0.0001114091343378793,
       "working memory training":5.9942015333384833e-05,
       "ɑ2 agonists":0.0,
       "prof. faraone":0.0,
       "completed suicide":0.0,
       "crime rates":0.0,
       "criminality":2.0689426609832426e-05,
       "diversion could be fatal when diverted to a person who is medically at risk":0.0,
       "diversion of medications is a felony":0.0,
       "gateway to non-oral use of illicit drugs":0.0,
       "injecting":5.868040378182665e-05,
       "intranasally":0.0,
       "legal consequences of diverting medication":0.0,
       "medical consequences of diverting medication":0.0,
       "men with adhd":0.0,
       "diversion or nmu":5.933029782110551e-05,
       "non-oral nmu":0.0,
       "non-oral routes":0.0,
       "oral administration":0.0,
       "repeated suicide attempts":8.619987166183763e-06,
       "suicide deaths":0.0,
       "swedish national registers study":0.0,
       "teenagers with adhd":0.0,
       "youth with adhd and other psychiatric diagnoses":8.858285156394693e-06,
       "adhd patients with ed but without smd":0.0,
       "coping skills for managing anger":1.3222680376498427e-05,
       "adhd pharmacotherapy":0.0025302049406162944,
       "adolescents with adhd":0.0002724420394194713,
       "driver's license":0.0,
       "females with adhd -i or controls":0.0,
       "individuals (age 6 to 24 years) with adhd":0.0,
       "motor vehicle crashes":0.0025302049406162944,
       "natural causes":0.0,
       "st imulant medications":0.0,
       "two-year mortality risk from all-causes":0.0,
       "unnatural causes such as suicide, accidental poisoning or injury":0.0,
       "employment":0.0,
       "employment status jobs":0.0,
       "prescription stimulant misuse":0.0,
       "adhd prs":0.0,
       "irritability traits":0.0,
       "adhd quality of life":0.0,
       "primerthe columbia impairment scale":0.0,
       "adhd rating scales":1.0019386234334808e-05,
       "cultural context":0.0,
       "culture":0.0,
       "adhd severity":3.672727494444629e-05,
       "intelligence quotient":0.0,
       "adhd symptom checklists":1.6030039219586133e-06,
       "barkley deficits in executive function scale":0.0,
       "improvement in psychosocial functioning":0.0,
       "adhd symptom control extension":0.0,
       "adult adhd symptoms":2.0826880324649488e-05,
       "aggression":0.00015204589598407135,
       "alpha-2-adrenergic agonists":0.00041725538203745294,
       "amphetamine derivatives":1.4541832307225294e-07,
       "becoming unnaturally quiet":0.0,
       "broad-spectrum micronutrient supplements":0.0,
       "cbt alone":0.0,
       "child behavior checklist":0.0,
       "clinical prescriber with training in adhd diagnosis and management":0.0,
       "clinical subgroups":0.0,
       "combined treatment with medication and cbt":0.0,
       "dietary approach to stop hypertension":0.0,
       "dietary interventions for adhd":0.0,
       "digital interventions":0.0,
       "digital therapies":0.0,
       "direct skills training":0.00012027622516244278,
       "disruptive behavior disorders":0.00031308876120010555,
       "drug treatment resistant patients":0.0,
       "effect":0.0001817067901169707,
       "exclusion of food colour additives and preservatives":0.0,
       "exercise":0.0029561917922464598,
       "extended-release preparations":0.0,
       "good sleep practice":0.0,
       "hallucinogens":0.0,
       "healthy diets":6.150299598404737e-05,
       "heroin":0.0,
       "homicidality":0.0,
       "imipramine":0.0,
       "immediate-release stimulants":0.0,
       "inhalants":0.0,
       "jornay":0.0,
       "marijuana":1.21681421478425e-05,
       "medication alone":0.0014417033990519333,
       "medication or psychosocial interventions":0.0,
       "mediterranean diet":0.0,
       "melatonin":5.8264388094541147e-05,
       "mirtazapine (remeron)":0.0,
       "negative mood symptoms":0.0,
       "nutrition":0.0,
       "omega-3 fatty acid supplementation":0.00018937153253798086,
       "pain relievers":0.0,
       "parent behavior management program":0.0,
       "parent-rated emotional lability symptoms":0.0,
       "parent-rated oppositional symptoms":0.0,
       "participants and their significant others":0.0,
       "poor dental hygiene":0.0,
       "prognosis":4.929836214886192e-05,
       "remission of aggressive behavior":0.0,
       "restricting synthetic food colors":0.0,
       "ssri and stimulant combination":0.0,
       "ssri antidepressants":0.0,
       "stimulant-refractory adhd":6.150299598404737e-05,
       "tca":0.0,
       "teacher-rated emotional lability symptoms":0.0,
       "teacher-rated oppositional symptoms":0.0,
       "tranquilizers/sedatives":0.0,
       "treatment selection":0.0,
       "treatment success":1.7645588836726785e-05,
       "venlafaxine":3.0213467707782358e-05,
       "youth adhd symptoms":0.0,
       "adhd trea tment":0.0,
       "administration of stimulants in conjunction with alcohol use":0.00020411129157945889,
       "cardiotoxicity":0.0,
       "ecg":0.0,
       "lower all-cause mortality":0.0,
       "males with adhd":0.0,
       "patients medicated for adhd":0.0005049351664219834,
       "plasma levels":0.0,
       "polysubstance use":0.0,
       "qtc prolongation":0.0,
       "tachycardia":0.0,
       "tca treatment":0.0,
       "unnatural causes of mortality":0.0,
       "adhd treatment first line":0.0,
       "impulsive cognition":0.0,
       "learning problems":0.0,
       "poorly regulated emotions":0.0,
       "adhd treatment plan":0.0,
       "behaviors that we now associate with adhd":0.0,
       "cam therapies":0.00014558760520344508,
       "chelation therapy":3.174952654419999e-05,
       "consensus statement":0.0,
       "large effect":0.0,
       "medium effect":0.0,
       "megavitamins":5.693041168488128e-05,
       "reviews":0.0,
       "small effect":0.0,
       "smaller studies":0.00019482054204348844,
       "strong effects":0.0,
       "treatment studies":0.00011558551162597543,
       "vitamins":3.174952654419999e-05,
       "adhd types":0.0,
       "adhd-like symptoms in children":0.0,
       "adhd-related cost study":0.0,
       "adhd-related costs":1.4541832307225292e-06,
       "seven european studies":0.0,
       "annual national costs":0.0,
       "€1 billion":0.0,
       "adhd-specific problems in daily life":0.0,
       "adjunctive psychotherapy":8.587868640560014e-07,
       "suboptimal response":0.00036956579653873257,
       "adjust the timing of the dose":5.475987481687925e-06,
       "excessive tiredness":0.002413071200214061,
       "stomachaches, nausea":3.634790036015789e-05,
       "adjusted odds ratio":0.0,
       "cardiovascular disease diagnosis":6.310255993165206e-05,
       "drowsiness":0.010340347690031405,
       "trouble sleeping":0.0008642847136636605,
       "adjusting the dose or timing may help":0.0,
       "adjustment":0.0,
       "administer the stimulant with meals to lessen its impact on appetite":0.0,
       "helping the noncompliant child":0.0,
       "homework organization":0.0,
       "incredible years parenting program":0.0,
       "new forest parenting program":0.0,
       "nmu of amp":3.499298081666242e-05,
       "parent-child interaction therapy":0.0,
       "positive parenting program (triple p)":0.0,
       "self-monitoring skills":0.0,
       "study skills":0.0,
       "teacher ratings":0.0003653981623597376,
       "young adults who do not attend college":3.499298081666242e-05,
       "intuniv":1.2233659723421305e-05,
       "kapvay":1.2233659723421305e-05,
       "qelbree":1.947549478790992e-05,
       "adult adhd quality measures initiative (aaqmi)":0.0,
       "ahrq":4.41906430241382e-05,
       "candidate qms":0.0,
       "clinical and research experts":0.0,
       "delivery of quality health care to adults with adhd":0.0,
       "development of qms":0.0,
       "existing guidelines for adult adhd":0.0,
       "expert opinion":0.0,
       "extended-release":0.0,
       "healthcare delivery":0.0,
       "healthcare processes":2.45826212812618e-07,
       "immediate-release":0.0,
       "limited access to treatment by skilled providers":0.0,
       "multidisciplinary panel":0.0,
       "clinical guidelines":0.0003546004752775728,
       "qms":0.0021280793511219776,
       "quality indicators":0.0,
       "us agency for healthcare research and quality (ahrq)":0.0,
       "adult adhd quality of life survey":0.0,
       "adult adhd self-report scale":0.0,
       "measure":0.0,
       "affective lability scale –short form (als-18) ":0.0,
       "affective reactivity index (ari)":0.0,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":0.0,
       "behavior rating inventory of executive function (brief or emotion control subscale)":0.0,
       "brown add rating scales for children, adolescents and adults (badds)":0.0,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":3.635458076806323e-07,
       "difﬁculties in emotion regulation scale (ders)":4.597973696197365e-06,
       "distress tolerance scale":3.029548397338602e-07,
       "drug holidays":0.0,
       "emotion dysregulation scale, short version (eds-short)":3.635458076806323e-07,
       "emotion regulation checklist (erc)":3.635458076806323e-07,
       "emotion regulation index for adults and children (erica)":3.635458076806323e-07,
       "emotion regulation questionnaire (erq)":7.747150414866772e-06,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":0.0,
       "expression and emotion scale for children (eesc)":0.0,
       "frustration discomfort scale":0.0,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":3.029548397338602e-07,
       "trials norms availability":3.635458076806323e-07,
       "adults (11 studies, 2909 participants)":0.0,
       "adults (cortese et al., 2018a)":0.0,
       "adults treated with viloxazine":0.0,
       "adults unresponsive to mph trial":0.0,
       "advancing age":0.0,
       "adverse":0.0,
       "clinical response":0.0007395414358699037,
       "driving and work performance":0.0,
       "emergency room visits":0.001988710302959798,
       "maximum daily dose":9.549690489503957e-07,
       "discontinuation":0.0,
       "follow-up visit":0.00018643571714234178,
       "medication response":0.00018643571714234178,
       "health care facilities":8.55909497990985e-05,
       "adverse outcomes":3.929069111297831e-05,
       "prevalence of stimulant nmu":0.0026127672058210583,
       "adverse side effects of atomoxetine":0.0,
       "monitoring and management":0.0001767528611050084,
       "adverse side effects of guanfacine":0.0,
       "adzenys xr -odt":5.453187115209484e-07,
       "dexedrine spansule":5.453187115209484e-07,
       "dyanavel xr":0.0,
       "mydayis":5.453187115209484e-07,
       "tips for using amphetamine-based medications":0.0,
       "aerobic activity":0.0,
       "improvement in the core symptoms of adhd":0.00016057994857352026,
       "aerobic exercise":0.0,
       "affective components of executive control":0.0,
       "dopaminergic system":0.0021756058372529477,
       "executive control":0.00274369366738326,
       "mood regulation":0.0021756058372529477,
       "noradrenergic system":0.0021756058372529477,
       "affordable care act":0.0,
       "african-american students":0.0,
       "viloxazine dose":0.0,
       "liver problems":4.81588324661473e-06,
       "nausea/vomiting":4.81588324661473e-06,
       "viloxazine (qelbree)":0.0006131524912154877,
       "agitation":0.0,
       "expert clinicians":0.0,
       "ahrq, medicare and medicaid":0.0,
       "alcohol use disorder: treatment overview":0.002108085936978945,
       "counseling":0.0,
       "limit their alcohol consumption":0.0,
       "low-risk and risky alcohol use":0.0,
       "opioid use disorder: treatment overview":0.0,
       "stimulant use disorder: treatment overview":0.0,
       "stimulants for adhd":0.002108085936978945,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":0.0,
       "all-cause treatment discontinuation":0.0,
       "dizziness":0.0021470917199615377,
       "increased blood pressure and heart rate":0.0,
       "itching":0.0,
       "monitoring":0.0,
       "rash":0.0,
       "vomiting":2.63923681896484e-06,
       "motor or vocal tics":4.293210159890744e-06,
       "nonstimulants for adhd":0.0,
       "alpha agonists (clonidine and guanfacine)":2.255131580102654e-06,
       "liver problems such as hepatitis":0.0,
       "american academy of child and adolescent psychiatry adhd resource center":1.8177290384031615e-07,
       "attention deficit disorder association (adda)":1.8177290384031615e-07,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":0.0,
       "centers for disease control and prevention (cdc) adhd":1.8177290384031615e-07,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":1.8177290384031615e-07,
       "national institute of mental health (nimh) adhd":0.0,
       "the american professional society of adhd and related disorders (apsard)":1.8177290384031615e-07,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":0.0,
       "american academy of pediatricians":2.5006910947140197e-05,
       "american professional society of adhd and related disorders":5.31469347418829e-06,
       "canadian adhd resource alliance":0.0,
       "world federation of adhd":0.010749702682383655,
       "american psychopathological association":0.0,
       "pau l hoch award":0.0,
       "state university o f new york":1.4541832307225292e-06,
       "reasonable accommodations":0.0,
       "amp":0.0,
       "attention and impulsivity":0.0,
       "cardiac arrest":0.0,
       "cerebrovascular disease":0.0,
       "daily timing":0.0,
       "heart failure":0.0,
       "ischemic heart disease":0.0,
       "misuse and diversion":0.0,
       "prescribing medications for adhd":0.0,
       "prescription refill requests":0.0,
       "risks of stimulant misuse and diversion":0.0,
       "schedule ii controlled substances":0.0,
       "short-acting amphetamines":0.0,
       "studies regarding nmu of mph or amp":0.0002491641946620705,
       "symptom control":0.0,
       "tachyarrhythmias":0.0,
       "venous thromboembolism":0.0,
       "amphetamine formulations":1.1169084152602109e-05,
       "lisdexamfetamine dimesylate (ldx)":3.580278030447303e-05,
       "amphetamine medication":0.0,
       "amphetamine stimulants":0.0,
       "children (7 studies, 1930 participants)":0.0,
       "growth suppression":3.1911324240058857e-06,
       "pregnant woman":8.633172426941103e-06,
       "youths (9 studies, 2677 participants)":0.0,
       "analysis":0.0,
       "discontinuation due to adverse event":0.0,
       "lisdexamphetamine":0.0,
       "worse anorexia":0.0,
       "antacids":0.0,
       "antecedents of behaviour":0.0,
       "reinforcement techniques":0.0,
       "anthony l. rostain":0.0,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":0.0,
       "anticipatory appraisal and valuation":1.0752067387123518e-05,
       "emotion generation":0.0003001954197246733,
       "emotional state":0.0030941317478134123,
       "regulation":9.088645192015807e-08,
       "antipsychotics":0.0,
       "not recommended adhd treatment":0.0,
       "dry mouth":0.00016010470565451653,
       "anxiety and substance use disorders":0.0,
       "benzodiazepines":0.0,
       "childhood irritability":0.0,
       "opioid":0.0,
       "any interpretation should keep in mind that the ratings are of relative importance":0.002809058338064511,
       "care coordination":0.003881640867184774,
       "care coordination and the patient experience domains":0.0,
       "follow-up":0.0006476071854600219,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":0.002809058338064511,
       "low rating only means that the item is not essential for documenting the basics of quality care":0.0,
       "patient experience":1.676334638032619e-05,
       "patients and health care systems":0.0,
       "quality diagnosis":0.0004785219414387598,
       "quality in these domains may be viewed as less relevant":0.0,
       "results may reflect a systematic bias in our sample of raters":0.0,
       "should include other relevant stakeholders, including patients and health care systems":0.0,
       "systematic bias in our sample of raters":0.0,
       "apsard":0.0,
       "apten sio xr":6.30844084104359e-05,
       "capsules":6.30844084104359e-05,
       "daytrana":6.30844084104359e-05,
       "focalin xr":0.0,
       "liquid":0.0,
       "patches":0.0,
       "quillivant xr":0.0,
       "ritalin la":0.0,
       "arterial disease":0.0,
       "asian federation of adhd":0.0,
       "asian resource":0.0,
       "assignments":0.0,
       "association for behavior and cognitive therapies":0.0,
       "behavioral therapist":0.00033638794025135437,
       "caregivers of children age 6 to 12 years":0.00033638794025135437,
       "centers for disease control and prevention (cdc)":0.00033638794025135437,
       "association for child and adolescent mental health":0.0,
       "atomox etine":1.9350315647549683e-05,
       "atomoxetine levels":0.0,
       "atypical antidepressants":0.0,
       "blood monitoring":0.0,
       "brain cells communication":0.0,
       "cardiac malformations":9.252890420688436e-06,
       "chemical messengers (norepinephrine)":0.0,
       "constipation":2.431321064719301e-06,
       "correct dose":0.0,
       "treatment discontinuation":0.0,
       "tricyclic antidepressants (tcas)":0.0,
       "atomoxetine treatment for adhd":0.0,
       "attention and arousal":0.0,
       "behavioral functioning":0.0,
       "chronic condition management":0.0,
       "information provision":0.0,
       "dizziness and lightheadedness":0.0002749950407042104,
       "fatigue":0.0003255131317367484,
       "sedation":0.00026810305317448083,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":0.0018756840636492756,
       "behavioral management techniques that are used for children with adhd":0.0,
       "coexisting conditions that are associated with adhd or mimic its symptoms":0.0,
       "nonadherence to the treatment plan":0.0,
       "repetition of the diagnostic evaluation":0.0,
       "evidence-based statements about adhd":0.0,
       "international consensus statement":0.0,
       "meta-analyses and very large studies":0.0,
       "parents' medication guide":0.0,
       "parents' medication guidedysregulation":0.0,
       "project steering committee":0.0,
       "research and clinical care of adhd":0.0,
       "scientific data":0.0,
       "attention-deﬁcit/hyperactivity disorder":0.0,
       "impulsive aggression":3.716140229245912e-05,
       "liver damage":0.0,
       "psychotic symptoms":0.0,
       "self-harming behavior":0.0,
       "unusual changes in behavior":0.0,
       "atx or dex":0.0,
       "atx treatment":0.0,
       "liver disease evaluation":0.0,
       "augmentation strategies":0.0,
       "charles bradley":0.0,
       "child psychiatry":0.0,
       "minimal brain dysfunction-related behaviors":0.0,
       "morris et al. and o'neal and robins":0.0,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":0.0,
       "u.s. food and drug administration":0.00010938468689010238,
       "world health organization":0.0,
       "authors":0.0,
       "emotional problems":0.0,
       "seizures":1.2879553039528689e-05,
       "sleep disorder":0.0,
       "availability of treatment":0.0,
       "avoid caffeine":0.0,
       "evening":3.817230980646639e-06,
       "good sleep habits":0.00672796048984162,
       "avoid skipped doses":0.0,
       "maladaptive emotions":3.600381657124131e-05,
       "bachelor's degree":7.596324457054347e-06,
       "dorsal anterior cingulate cortex":6.010163894991325e-05,
       "fmri meta-analyses":0.0,
       "inferior frontal cortex":0.00011696066181514744,
       "neutral fmri tasks":0.0,
       "supplementary motor area":0.0,
       "typically developing individuals":0.0,
       "ventral anterior cingulate cortex":6.010163894991307e-05,
       "become unusually quiet or appear over-focused":0.0,
       "child development":0.0,
       "metacognitive executive function training":5.0247987537552555e-05,
       "pre-kindergarten academic curriculum (stp-pre-k)":5.0247987537552555e-05,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":5.0247987537552555e-05,
       "tools":0.0,
       "behavior modification system":0.0,
       "behavior problems":0.0,
       "blood pressure monitoring":0.0,
       "chest pain":0.0,
       "education on side effects":2.188962444013806e-06,
       "growth monitoring":0.0,
       "heart rate assessment":0.0,
       "impulsiveness":0.0,
       "long-term use":0.0,
       "mood monitoring":0.0,
       "mood swings":8.658935627943423e-05,
       "palpitations":0.0,
       "peripheral vasculopathy":0.0,
       "raynaud’s phenomenon":0.0,
       "severe allergic reactions":0.0,
       "severe psychiatric symptoms":0.0,
       "side effects information":0.0,
       "sudden cardiac death":5.5508321153162194e-05,
       "swelling of the face, lips, tongue, or throat":0.0,
       "weight monitoring":0.0,
       "blurred vision or other visual changes":0.0,
       "development or worsening of motor or vocal tics":0.0,
       "elevated blood pressure (hypertension)":0.0,
       "especially in children":0.0,
       "increased aggression or hostility":0.0,
       "increased heart rate (tachycardia)":0.0,
       "nervousness":0.0,
       "rash or hypersensitivity reactions":0.0,
       "skin reactions":0.0,
       "trouble falling and staying asleep":0.0,
       "visual disturbances":0.0,
       "behavioral disinhibition":0.0,
       "observed behavior":0.001723379314471388,
       "behavioral expression":0.0011918212625656945,
       "behavioral indicators":1.1404372638632056e-05,
       "subjective emotionality":1.1404372638632056e-05,
       "high emotional thresholds":0.0,
       "recovery times":0.0,
       "quick return to baseline":3.3101422735011154e-05,
       "behavioral response system":0.0,
       "subjective/cognitive response system":0.0,
       "child’s behavior":0.0,
       "coping strategies":0.0,
       "negative behaviors":0.0,
       "negative thought patterns":0.0,
       "parent -child relationship":0.0,
       "positive behaviors":0.0,
       "problematic behaviors":0.0,
       "finding activities in which the child can be successful (eg, hobbies, sports)":0.0,
       "identifying unintentional reinforcement of negative behaviors":0.0,
       "keeping environmental distractions to a minimum":0.0,
       "limiting choices":0.0,
       "maintaining a daily schedule":0.0,
       "national institute for children's health quality toolkit":0.0,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":0.0,
       "rewarding positive behavior (eg, with a 'token economy')":0.0,
       "setting small, reachable goals":0.0,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":0.0,
       "using charts and checklists to help the child stay 'on task'":0.0,
       "parenting context":0.0,
       "pharmaco logical therapy":0.0,
       "benefits and risks of treatment":0.0,
       "best practices":0.0,
       "best studies":0.0,
       "pulse":0.0,
       "blood pressure and pulse quarterly":0.0,
       "blood tests":0.0,
       "bone fractures":0.0,
       "borderline personality disorder":0.0,
       "boundaries between adhd and other disorders":0.0,
       "long-term side effects":0.0,
       "broader scope of the review":0.0,
       "bupropion (wellbutrin, zyban)":0.0,
       "caddra":0.0,
       "caffeine levels":0.0,
       "calendar year":0.0,
       "chelation":0.0,
       "primary care practitioner":1.9762613509854744e-05,
       "risks and benefits":0.0,
       "nonmedical users":0.0,
       "cardiac history or cardiac symptoms":0.0,
       "cardiac review":0.0,
       "cardiologist consultation":0.0,
       "findings outside of normal limits":0.0,
       "sudden death or ventricular arrhythmia":0.0,
       "cardiovascular health":0.0,
       "clinical response, duration of the effect during the day, and side effects":0.0,
       "electrocardiogram (ecg)":0.0,
       "low dose stimulant treatment":0.0,
       "short-acting dextroamphetamine-amphetamine":0.0,
       "child's height":2.7490868174055158e-05,
       "child's weight":2.7490868174055158e-05,
       "regular measurement":2.7490868174055158e-05,
       "qm":0.0,
       "quality care":2.918464956102854e-07,
       "treatment follow-up":3.349197249966452e-05,
       "care management plan":0.0,
       "careful dose titration required":0.0,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":0.0,
       "child's practitioner":0.00022859004434193174,
       "caregiver decision":0.0,
       "catapres":0.0,
       "category":0.0,
       "causes":0.0,
       "cbcl-dysregulation profile":0.0,
       "emotional dysregulation scores":0.0,
       "cbt group and individual therapy programs":0.0,
       "cbt group treatment":0.0,
       "orthostatic hypotension":0.0,
       "slow heart rate (bradycardia)":0.0,
       "cereals":0.0,
       "certain children":0.0,
       "certain events":0.0,
       "certain foci in the literature may have been missed":0.0,
       "chadd website":0.0,
       "coalition to prevent adhd medication misuse":0.0,
       "college administrators":0.0,
       "collegiate student leaders":0.0,
       "cpamm":2.7265935576047422e-06,
       "information about misuse and diversion":0.0,
       "personnel":0.0,
       "pharmaceutical industry":0.0,
       "changing the drug":0.0,
       "heart symptoms":6.255887408100833e-05,
       "height":0.0,
       "long-term studies (lower risk of later cigarette or illegal substance use)":0.0,
       "meal timing":0.0,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":0.0,
       "mental health challenges":0.0,
       "mirtazapine":0.0,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":0.0,
       "mood problem":0.0,
       "moodiness":1.096783553812085e-05,
       "over-focused or repeated movements (tics or habits)":0.0,
       "preparation":0.0,
       "separate issue":0.0,
       "sleep habits":0.0,
       "worsened heart problems":0.0,
       "zombie effect":0.0,
       "child and adolescent psychiatrist":0.0,
       "child psychologist":0.0,
       "immediate action":0.0,
       "medication holidays":0.0,
       "childhood diagnosis of adhd":0.0,
       "children in intervention group":0.0,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":0.0,
       "loss of appetite (anorexia)":2.1872629301965058e-05,
       "monitor for changes in behavior and report to the healthcare provider":0.0,
       "monitor your child closely for new or worsening tics":0.0,
       "offer high-calorie snacks such as instant breakfast drinks":0.0,
       "regularly check your child's weight to ensure they are growing normally":0.0,
       "sleep intervention":0.0,
       "teacher-reported behavior":0.0,
       "cohort studies":0.0,
       "children and youth with special health care needs":0.0,
       "children who have not yet entered elementary school":0.0,
       "classroom modifications":0.0,
       "developmental behavioral pediatrician":0.0,
       "intentional and unintentional injury":0.0,
       "china adhd alliance":0.0,
       "classroom modifications and accommodations":0.002379317149374887,
       "combined medication and behavior treatment":0.0,
       "combined treatment":0.0,
       "lower doses of medication":0.0,
       "non-adhd symptoms":0.0,
       "provision of tutoring or resource room support":0.0,
       "school-aged children":0.001066374394883355,
       "stressors in family life":0.0,
       "suboptimal response to pharmacotherapy":0.0,
       "normative data":1.3621277817607956e-06,
       "parents and teacher reports":0.0,
       "preschool teachers and clinicians":0.0,
       "ratings from other individuals":0.0,
       "scales":0.0,
       "secondary school teachers":0.0,
       "self-report":2.4937461605000096e-05,
       "structured behavioural observations":0.0,
       "such as":0.0,
       "tools for screening":0.0,
       "longer acting than clonidine":0.0,
       "short-acting medication":0.0,
       "tenex":0.0,
       "tic problems":0.0,
       "close monitoring":0.0,
       "close monitoring by healthcare provider":0.0,
       "persistent adhd":0.0,
       "cognitive components of executive control":0.0,
       "cognitive flexibility":0.00017594152137694055,
       "cognitive strengths and weaknesses":0.0,
       "play-based interventions":1.7135232391197216e-05,
       "problems with peers":0.0,
       "psychotherapy interventions":0.0,
       "students with disabilities":0.0,
       "summer treatment camp":0.0,
       "deficits":0.0,
       "guided walks":0.0,
       "increases the effectiveness of":0.0,
       "organizational/planning skills":0.0,
       "psychosocial well-being":0.0,
       "yoga":0.0,
       "patient's family":0.0,
       "collateral report":0.0,
       "colleagues":0.0,
       "gpas":0.0008502300783578841,
       "college peers":0.0,
       "common misconceptions":0.0,
       "nmu of mph":0.0,
       "nmu population prevalence":0.00017035622589939317,
       "parents with suspected or diagnosed adhd":0.0,
       "peer behavior":0.0,
       "printed handouts":0.0,
       "repetition":0.0,
       "sanctions":0.0,
       "social situations":0.0,
       "us college populations":4.007413534967321e-06,
       "young adult populations":0.0,
       "enforcement":0.0,
       "incoming students":0.0,
       "com-ponents of emotional symptoms":0.0,
       "different terms used to describe them":0.0,
       "community psychosocial care":0.0,
       "community support":0.0,
       "specific treatment approach":0.0,
       "medication adherence":0.0,
       "diagnostic challenges":0.0,
       "simplex adhd":0.0,
       "standard information gathering":0.0,
       "comprehensive approach to literature on nmu":0.0,
       "concerns being discussed":0.0,
       "extended-release tablets":0.0,
       "reduce the need to take multiple doses throughout the day":0.0,
       "consistent sleep schedule":0.0,
       "consult with healthcare provider":0.0,
       "consult with the healthcare provider for further advice":0.0,
       "contents":0.0,
       "contraindications to drug treatment":0.0,
       "cooperating":0.0,
       "ingroup therapy":0.0,
       "integrative treatment program":0.0,
       "parental satisfaction":0.0,
       "core symptoms":0.0,
       "corticocerebellar networks":0.0,
       "criteria":0.0,
       "critical care unit":0.0,
       "current adhd symptoms":0.0,
       "secular private schools":0.0,
       "decongestants":0.0,
       "food supplements":0.0,
       "hepatitis":0.0,
       "low dose medication":0.0,
       "medication adjustment":0.00023172427968824359,
       "medication with food":0.0,
       "executive control and corticocerebellar networks":0.0,
       "frontal and parietal cortical areas":0.0,
       "inferior parietal and medial temporal regions":0.0,
       "medial prefrontal and the posterior cingulate cortices":0.0,
       "orbitofrontal cortex":0.0,
       "reward system":6.967961313878786e-06,
       "thalamus":1.0634895218189922e-05,
       "ventromedial prefrontal cortex":0.0,
       "denmark, finland, sweden, norway, and iceland":0.0,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":0.0,
       "those reporting nmu in a survey of 4,297 us adults":0.0,
       "detect nmu":0.0,
       "medical/neurological history":0.0,
       "stimulant misuse risk assessment":0.0,
       "deﬁcits in response inhibition to frustration":0.0,
       "documented dsm-5 diagnosis of adhd":0.0,
       "diagnostic guidelines":0.0,
       "diagnostic utility for adhd":0.0,
       "symptoms commonly occurring in other disorders":0.0,
       "dietary restrictions":0.0,
       "disability services":0.0,
       "discontinuing medication":0.0,
       "discussions":0.0,
       "discussions of transfer of care with new clinician made":0.0,
       "emotional upsets":0.0,
       "motivation":0.0,
       "social payoff":0.0,
       "diurnal variation in symptoms":0.0,
       "malingering":5.6610868084073315e-05,
       "pills per prescription":2.0550992709697497e-05,
       "extended-release form":0.0,
       "hydration":9.922842492351069e-07,
       "loss of appetite":3.7611376615810696e-07,
       "medication form adjustment":9.443314880074761e-05,
       "more irritability or moodiness when taking medication":7.270916153612647e-08,
       "slowing of heart rate":2.574453343250899e-05,
       "snacks":0.0,
       "supplemental medications":7.270916153612647e-08,
       "timing of medication":0.0,
       "dmdd":0.0,
       "intensified negative mood":0.0,
       "document":0.0,
       "documentation":0.0,
       "frontal lobes":0.0,
       "learning and memory":0.0,
       "movement regulation":0.0,
       "novelty processing":0.0,
       "parietal cortex":0.0,
       "reward processing":0.0,
       "signal-to-noise processing":0.0,
       "stress response":0.0,
       "mood symptoms":0.00019603884189107757,
       "time":3.384990941786748e-05,
       "dose reduction":0.0,
       "dosing":0.0,
       "driving licenses suspension/revocation":0.0,
       "driving performance improvement":0.0,
       "gradually increase dose":0.0,
       "monitor mood symptoms":0.0,
       "excessive weight loss":0.0,
       "dsm criteria":0.0,
       "us college-aged women":0.0,
       "eating foods high in added sugar":0.0,
       "hyperactivity/impulsivity subtypes":0.0,
       "inattention symptoms and unhealthy eating habits":0.0,
       "monozygotic twins":0.0,
       "unhealthy dietary habits":0.0,
       "stimulant misuse":0.0,
       "history of psychosis":0.0,
       "prescribed stimulants":5.877290286310555e-05,
       "size":0.0,
       "effect size findings":0.0,
       "effective self-regulation":0.0,
       "effortful strategy":0.000399906720679917,
       "emotional arousal":0.000399906720679917,
       "high ei":0.0,
       "reappraisal":0.000505136356821972,
       "self-monitoring":0.000505136356821972,
       "valuation":0.0,
       "el":0.0,
       "emotionally intense provocation":0.0,
       "hyperactive-impulsive adhd presentations":0.0,
       "inadequate self-control and weak behavioral inhibition":0.0,
       "patients with no ei":0.0,
       "rapid changes in emotional states":0.0,
       "self-regulatory processes":0.0,
       "elevated mood":0.0,
       "elevation of blood pressure or heart rate":0.0,
       "feeling sad":0.0,
       "healthcare facility utilization":0.0,
       "poison control centers data":0.0,
       "sleep difficulties":0.0,
       "study of 15,629 adults and adolescents":0.0,
       "regulatory processes":0.0,
       "emotional experience":0.0005209254200198087,
       "emotional valence":0.0,
       "heterogeneity":0.00011738102631298262,
       "neural activation":0.0,
       "poorly controlled emotionally driven behavior":0.0,
       "self-regulatory deficits":0.0,
       "self-regulatory deﬁcits":0.0,
       "executive function control of emotional response":0.0,
       "extended-release methylphenidate":0.0,
       "intermittent explosive disorder":9.923245659345103e-06,
       "methylphenidate preparations":0.0,
       "oppositional deﬁant disorder":0.0,
       "emotional functioning":0.0,
       "impaired":0.00038835502967545817,
       "emotional instability":0.0,
       "negative emotion":0.0,
       "emotional reactivity":0.0,
       "high emotional impulsivity":0.0,
       "response systems":0.0,
       "future development of adhd criteria":0.0,
       "measurement tool/assessment instrument":0.0,
       "mistake for emotional symptoms to be specific for adhd":0.0,
       "multidimensional nature of emotional symptoms":0.0,
       "stephen v. faraone":0.0,
       "evidence-based assertions":0.0,
       "findings":0.0,
       "manuscript":0.0,
       "participants":3.964191829389555e-05,
       "waiting-list controls":0.0,
       "encourage good sleep habits":0.0,
       "eunethydis":0.0,
       "euphoria":0.0,
       "european network adult adhd":0.0,
       "evaluation":0.0,
       "frozen yogurt":0.0,
       "instant breakfast drinks":0.0,
       "limit naps to less than 45 minutes":0.0,
       "reduce screen time before bed":0.0,
       "evidenced based fda approved medication":0.0,
       "exacerbation":0.0,
       "give medication with food to minimize stomach discomfort":0.0,
       "irritability or aggression (infrequent)":0.0,
       "monitor headaches and consult with the healthcare provider":0.0,
       "monitor irritability and consult with the healthcare provider":0.0,
       "some children do better with the daily dose divided into two doses":0.0,
       "start with a low dose and gradually increase":0.0,
       "this side effect usually improves over time":0.0,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":0.0,
       "exclusion criteria":0.0,
       "extended time":0.0,
       "factors leading to favorable outcomes":0.0,
       "fear of exposing nmu or minor unwanted effects":0.0,
       "individuals who experience minor unwanted effects":0.0,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":0.0,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":0.0,
       "feigned":0.0,
       "genu ine":0.0,
       "ferritin":1.8177290384031615e-07,
       "serum":0.0,
       "serum iron":0.0,
       "findings of interest":0.0,
       "misusers":1.7874335544297752e-06,
       "first drug treatment try":0.0,
       "fluctuating periods of remission and recurrence":0.0,
       "patient's symptoms":0.0,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":0.0,
       "patients with neither one physician visit nor medication claim in 6 months":0.0,
       "use of outside provider for adhd diagnosis":0.0,
       "job/school performance":0.0,
       "medication side effects/toxicity or signs of abuse/diversion":0.0,
       "potential side effects of atx":0.0,
       "relationship issues":0.0,
       "sexual dysfunction and dysmenorrhea":0.0,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":0.0,
       "target symptoms":0.0,
       "vital signs":0.000182215808202686,
       "food":0.0,
       "foxp1":0.0,
       "synapse formation":0.0,
       "friendships":0.0,
       "functional impairment related to adhd":0.0,
       "functional outcomes":0.0,
       "insights into key details of nmu":0.0,
       "general qol measures for adults":0.0,
       "generic medication preparations":0.0,
       "pharmacies":0.0,
       "united kingdom":0.0,
       "grade point average (gpa)":2.5872582503150778e-06,
       "greater family cohesion":0.0,
       "group of experts":0.0,
       "organizations that study and treat adhd":0.0,
       "severe hypotension":0.0,
       "guanfacine treatment for adhd":0.0,
       "individuals who abused":0.0,
       "minor toxicity":0.0,
       "poison control centers":0.0,
       "health effects":0.0,
       "icasa":0.0,
       "national health and medical research council (australia)":0.0,
       "ukaan":0.0,
       "heart rate monitoring":0.0,
       "high risk for nmu":0.0,
       "high risk patients":0.0,
       "high-calorie foods":0.0,
       "high-quality studies":0.0,
       "high-risk populations":3.198425457145468e-05,
       "prisoners":0.0,
       "vulnerability to psychosis":0.0016896488081054502,
       "holidays":0.0,
       "household public assistance":0.0,
       "huybrechts et al., 2018":0.0,
       "hyperactive-impulsive symptoms":0.0,
       "id":0.0,
       "immediate-release preparations allowed":0.0,
       "physical functioning":0.0,
       "school functioning":0.0,
       "popularity":0.0,
       "reciprocity":0.0,
       "rejection/likability":0.0,
       "sharing":0.0,
       "socializing with peers":0.0,
       "turn-taking":0.0,
       "meditation-based therapy":0.0,
       "in insomnia":0.0,
       "inclusion criteria":0.0,
       "medications misuse":0.0,
       "individuals at greatest risk":0.0,
       "study routes of administration":0.0,
       "individuals who die from stimulant overdoses":0.0,
       "information about negative academic or health effects":0.0,
       "willingness to use stimulants":0.0,
       "patient preference":0.0,
       "insu fflation":0.0,
       "smok ing":9.088645192015807e-08,
       "stimulant s":0.0,
       "us adults":9.088645192015807e-08,
       "insurance companies":0.0,
       "large studies":0.0007733757443363951,
       "new scientific findings from the past 20 years":0.0,
       "specific search terms":0.0,
       "international society of psychiatric geneti cs":0.0,
       "lifetime ach ievement award":0.0,
       "internet":0.0,
       "intolerance":0.0,
       "intuniv (guanfacine)":0.0,
       "irritability in adhd":0.0,
       "irritability in odd":0.0,
       "vulnerability for emotional disorders (mood and anxiety)":0.0,
       "legal issue":0.0,
       "liver function tests":0.0,
       "long-acting preparations recommended":0.0,
       "long-term outcomes":0.0,
       "low initial doses recommended":0.0,
       "neuroenhancement":0.0,
       "mania":0.0,
       "randomized trial":0.0,
       "medial frontal reductions":0.0,
       "medical causes of adhd symptoms":0.0,
       "problems":0.0,
       "safe storage":0.0,
       "medication choice":0.0,
       "medication contract":0.0,
       "patient commitment":0.0,
       "patient values and preferences":0.0,
       "phone calls":0.0,
       "target outcomes":0.0,
       "stimulant therapy dose":0.0,
       "medication trial":0.0,
       "naturalistic studies":0.0,
       "quality of life enjoyment and satisfaction questionnaire":0.0,
       "weiss functional impairment rating scale":2.726593557604742e-07,
       "neuronal development":0.0,
       "neuronal proliferation":0.0,
       "synapse development":0.0,
       "mental health assessment":0.0,
       "standardized mean difference":0.0,
       "pregnancies in denmark":0.0,
       "pregnancies in the united states":0.0,
       "time course for improvement":0.0,
       "united states":0.0,
       "new onset":0.0,
       "motiv ations":0.0,
       "outcomes associated with nmu":0.0,
       "risk factors":2.1942492715962364e-05,
       "risk reduction methods":0.0002887794463728427,
       "mon itoring body mass index":0.0,
       "severe mood swings":0.0,
       "sweating of the face, lips, tongue, or throat":0.0,
       "underlying heart conditions":0.0,
       "national survey on drug use and health (nsduh)":0.0,
       "neurotransmitters":1.8117062005274214e-06,
       "new clinician":0.0,
       "us data bases":0.0,
       "pediatricians":0.0,
       "performance enhancement":0.0,
       "research methods":0.0,
       "stimulant-naïve college students":0.0,
       "nmu crisis":0.0,
       "nmu of prescription stimulants is highly prevalent":0.0,
       "wide variations in the definition of nmu":0.0,
       "performance enhancing drugs":0.0,
       "performance validity tests":0.0,
       "societal pressures to seek high levels of achievement":0.0,
       "symptom validity tests":0.0,
       "none":0.0,
       "nonmedical use and diversion":0.0,
       "nonmedical use and diversion of prescription stimulants":0.0,
       "overdose":0.0,
       "therapeutic range":0.0,
       "numbers":0.0,
       "offspring of mothers with a single prior miscarriage":0.0,
       "organizational structure or systems":0.0,
       "pill counts":0.0,
       "symptoms and prescription refill requests":0.0,
       "patient perceptions":0.0,
       "patient supply":0.0,
       "patient-generated goals discussed":0.0,
       "patients leaving practice":0.0,
       "patients seen within a timely fashion":0.0,
       "seen within a timely fashion":0.0,
       "patients with documentation of concerns being discussed":0.0,
       "patients with documented satisfaction assessment":0.0,
       "satisfaction assessment at least annually":0.0,
       "psychosocial treatment":0.0,
       "transfer of care":0.0,
       "poison control centers and dawn data":0.0,
       "population":0.0,
       "preferential seating":0.0,
       "teacher":0.0,
       "safeguards":0.0,
       "prescription for adhd medication":0.0,
       "suds":0.0,
       "theft":0.0,
       "serious health outcomes":0.0,
       "trends in nmu":0.0,
       "stimulant treatment history":0.0,
       "subsequent substance use, abuse, or dependence":0.0,
       "surgical treatment":0.0,
       "primary inattentive adhd":0.0,
       "psychostimulant medications":0.0,
       "risk of psychosis":0.0,
       "qol benefits":0.0,
       "rating scales with adult norms":0.0,
       "sustained remission":0.0,
       "regional and national databases":0.0,
       "research participants":0.0,
       "signatories":0.0,
       "topic":0.0,
       "residential instability":0.0,
       "risk for adverse events":0.0,
       "risky behaviors":0.0,
       "treatment alternatives, benefits and risks have been discussed":0.0,
       "validated measure":0.0,
       "stimulant overdoses before contacting emergency services":0.0,
       "systematic literature review":0.0,
       "study selection":0.0,
       "structural magnetic resonance imaging (mri) data":0.0,
       "treatment discontinuity":0.0,
       "taking medication":0.0,
       "verbal working memory":1.1332729575754959e-05
    },
    "closeness_centrality":{
       "adhd":0.6320353030420457,
       "$77.5 to $115.9 billion":0.30594587945627755,
       "adolescents and young adults with adhd":0.44274182748796326,
       "substantial impairments":0.3064362428265828,
       "traffic accidents":0.3064362428265828,
       "% of patients medicated for adhd ":0.24209012873721913,
       "prescription refills are coordinated with other prescribers":0.3028763234379704,
       "transition care coordinated for vacations and other times away":0.3028763234379704,
       "% patients evaluated with parent vanderbilt rating scales":0.0017405512929809606,
       "% patients meeting dsm criteria for adhd":0.0029838022165387893,
       "% patients treated with psychostimulant medication":0.0029838022165387893,
       "% patients evaluated with teacher vanderbilt rating scales":0.0017405512929809606,
       "% patients on medication with at least 2 follow-up visits a year in record":0.0017405512929809606,
       "% patients seen within 30 days medication initiation":0.0017405512929809606,
       "% patients whose medical record contains documentation of dsm criteria":0.0017405512929809606,
       "confirmation of impairment in 2+ settings":0.0017405512929809606,
       "seen within one month of first prescription":0.3028763234379704,
       "screening":0.39991078090336857,
       "% patients stabilized on an adhd medication ":0.319583249762171,
       "seen at least once per year":0.30295631190315936,
       "communication with other health care providers occurs at least annually":0.3028763234379704,
       "external treatment resources":0.3028763234379704,
       "prescription monitoring program consulted at least annually":0.3028763234379704,
       "psychosocial and educational needs have been re-evaluated at least annually":0.3028763234379704,
       "risks and benefits of stopping treatment discussed at least annually":0.3028763234379704,
       "substance use evaluated at least annually":0.3028763234379704,
       "vitals taken at least annually":0.3029163123901011,
       "% patients with adhd with documentation of impairment":0.2913751778057691,
       "1.4 million individuals":0.32644965140048743,
       "amphetamine":0.4406161225355532,
       "intentional, nontherapeutic use":0.34014650111825434,
       "stimulants":0.4776781490823705,
       "2000 people":0.31593061829284297,
       "adhd medication":0.457850359218245,
       "medical literature":0.33216854640837207,
       "studies":0.4114577026618769,
       "28 adhd experts":0.3063135046785882,
       "draft list of 46 qms":0.3086209510415154,
       "quality measure":0.32137388290273505,
       "2–4 hours":0.38585404474312573,
       "adhd impairments":0.394886084344686,
       "long acting":0.38781070825602193,
       "short acting":0.38781070825602193,
       "4.4% of adults":0.30594587945627755,
       "40-50 percent of participants met adhd criteria at any given follow-up":0.28986584334082444,
       "recurrence":0.3998410857515904,
       "remission":0.4065003809430591,
       "48 cohorts":0.22370204271086444,
       "structural grey matter volume reductions":0.2890259700230065,
       "5 mg orally in the morning on the first day":0.23630529921131171,
       "cardiovascular history":0.3104164727428799,
       "5.9%":0.3927903013255651,
       "thorough evaluation":0.3933964591979811,
       "adolescence":0.4768838391275464,
       "50":0.39543056705319296,
       "adult":0.4392663507644315,
       "daily report card":0.31597412891373444,
       "5mg and 10mg":0.3158001582990538,
       "concerta":0.31601765152102285,
       "dose":0.41495535359787045,
       "long-acting medications":0.31588711965339744,
       "dexmethylphenidate":0.4599615376990027,
       "79 authors":0.38624379630347233,
       "authors from 27 countries and 6 continents":0.38637388852182986,
       "empirically supported statements":0.3900523886505654,
       "a death in the family":0.38572430229364923,
       "rutter's indicators of adversity":0.3868299022159207,
       "a father or brother or sister with epilepsy":0.38572430229364923,
       "epilepsy":0.38637388852182986,
       "a frequent complaint among users":0.3017212191008187,
       "behavioral changes":0.3198059869030702,
       "cardiovascular effects":0.39907603931859903,
       "central nervous system effects":0.40385286922066993,
       "gastrointestinal issues":0.4018017775906525,
       "mental conditions":0.42692373465623845,
       "sleep disturbances":0.404066246925436,
       "a person's mother with epilepsy":0.38572430229364923,
       "abdominal pain":0.4178270169445685,
       "abnormalities of chromosomes":0.38585404474312573,
       "adhd and many other psychiatric disorders":0.38630883146028383,
       "high polygenic risk for adhd":0.38696038961757895,
       "polygenic risk":0.3866343360368429,
       "abstinence is not an absolute precondition to start treatment":0.4010993269305289,
       "drug treatment":0.47432047757755336,
       "stabilize substance use":0.4010993269305289,
       "abstract problem solving":0.38787627219655546,
       "basal ganglia":0.3950220644012785,
       "focused attention":0.3873523805575934,
       "inhibitory control":0.3923201350962082,
       "adhd individuals":0.41101543354400316,
       "sustained attention":0.3947501978738172,
       "verbal memory":0.3873523805575934,
       "working memory":0.3903842351612431,
       "abuse":0.40823632563036044,
       "diversion":0.40736650391381846,
       "misuse":0.41989168192581,
       "nmu":0.42835850448891444,
       "nmu of stimulants":0.4234566537546374,
       "abuse liability":0.28873497986944696,
       "nortriptyline":0.4076560323458823,
       "tricyclic antidepressant":0.4076560323458823,
       "abuse of prescription drugs":0.32644965140048743,
       "alcohol":0.41767488622658394,
       "atomoxetine":0.4357622317269944,
       "long -acting stimulants":0.39258866359387845,
       "norepinephrine reuptake inhibitors":0.3933290159510759,
       "short-acting stimulants":0.39258866359387845,
       "treatment ending early as the result of adverse events":0.39258866359387845,
       "abuse, misuse and diversion":0.32724121381295473,
       "adh d medications":0.2459307696476177,
       "asthma medications":0.2897560179392051,
       "multiple prescribers":0.2459307696476177,
       "prescriptions at multiple pharmacies":0.2459307696476177,
       "shopping behavior":0.39900663479002185,
       "academic activity":0.3905171319221491,
       "stimulant use":0.40264797298045374,
       "weekends":0.3955669224211424,
       "academic difficulties":0.31071074621379,
       "academic dishonesty":0.3240519985935912,
       "academic function":0.3903842351612431,
       "academic integrity policies":0.39942342445031787,
       "alcohol/drug use policies":0.32409777511550014,
       "nmu (non-medical use)":0.41234510245194567,
       "students who reported nmu":0.23016534410539982,
       "academic outcomes":0.4114577026618769,
       "adverse medical outcomes":0.4125675508078809,
       "amp abuse":0.3235493089892294,
       "clinically significant effects":0.32359494358852264,
       "clinician":0.41286452223189235,
       "co-occurring disorders":0.3870256663364753,
       "college graduation":0.32359494358852264,
       "exposures":0.3235493089892294,
       "family or friends":0.39721055229269836,
       "disorders":0.3927230657382105,
       "intravenous abusers":0.3235493089892294,
       "intravenous":0.33999528008930435,
       "longitudinal study":0.32359494358852264,
       "nasal abusers":0.3235493089892294,
       "nmu behavior":0.312148047624847,
       "patient education":0.35075495337756085,
       "poison control calls":0.32359494358852264,
       "practitioner":0.40005024412251533,
       "prevention strategies":0.3351772315621075,
       "rating scales":0.3955669224211424,
       "risk of dying":0.330303505620879,
       "adverse effects":0.44941981391628316,
       "social interactions":0.3881387497957411,
       "treatment plan":0.4094749509267581,
       "academic performance enhancement":0.30529449767699607,
       "educational attainment":0.3974858194807044,
       "misuse and diversion of stimulant medications":0.3297812491077513,
       "non-medical use of prescribed stimulants":0.30891182846945275,
       "psychotic events":0.3297812491077513,
       "academic skills":0.38754867399368675,
       "accommodations":0.38879650060034326,
       "symptoms":0.4342775222492193,
       "inattention symptoms":0.3897211058336378,
       "accidental injuries":0.40307240865119914,
       "depression":0.4270826787123279,
       "sleep issues":0.4114577026618769,
       "substance abuse":0.4327212655682055,
       "attempted suicide":0.44696827392219474,
       "mortality":0.39872925791495056,
       "motor tics":0.4242396727149826,
       "accidental physical injuries":0.38578916261016066,
       "bullying":0.38578916261016066,
       "burn injuries":0.3918510930901154,
       "accidental poisoning":0.3129997476183664,
       "accidents":0.38591894870355353,
       "further reduce qol":0.38591894870355353,
       "americans with disabilities act":0.3039597443087739,
       "classroom-based programs":0.3021185343748519,
       "disability":0.30188001974245077,
       "idea (pl-101-476)":0.30188001974245077,
       "school-based interventions":0.39631856107145025,
       "section 504 of the rehabilitation act of 1973":0.3018403039129885,
       "accommodations for children with adhd":0.3246940489729162,
       "brand medication":0.339191033418484,
       "generic medication":0.33929135611396416,
       "medications for children with adhd":0.339191033418484,
       "accurate diagnosis":0.38578916261016066,
       "activated emotions":0.2819228495997328,
       "adhd child":0.2938381339706232,
       "ei (emotional impulsivity)":0.3941398642918099,
       "activation of mania or hypomania":0.3390406605648922,
       "viloxazine":0.43028659978293804,
       "active substance use disorder":0.38853313294540653,
       "adhd patients with co-occurring sud":0.3860488221508709,
       "cocaine use disorder":0.38748322074693897,
       "dextroamphetamine-amphetamine":0.3967983656248055,
       "nicotine dependence":0.38748322074693897,
       "opioid dependence":0.38572430229364923,
       "active substance use disorder (sud)":0.3919849906103922,
       "tcas":0.3275682681385816,
       "acupuncture, yoga, and ayurvedic therapies":0.38572430229364923,
       "adhd symptoms or associated impairments":0.3908497700242974,
       "acute co-administration of alcohol and stimulants":0.31312790364987386,
       "health consequences":0.31312790364987386,
       "acute mania":0.3234580783931518,
       "psychosis":0.40830897847350517,
       "stimulant adverse effects":0.34968574150931653,
       "adderall":0.3934639255775383,
       "form":0.292750816644459,
       "form and doses":0.3161047327146081,
       "usage":0.29951542428754907,
       "adderall xr":0.33063671278896467,
       "bubblegum flavor":0.24787037057504596,
       "children who have trouble swallowing pills":0.24787037057504596,
       "evekeo":0.24789715289493522,
       "morning":0.32114895717281994,
       "procentra":0.32114895717281994,
       "adhd symptoms":0.47353728587051097,
       "symptoms throughout the day":0.24789715289493522,
       "symptoms with just one dose":0.24787037057504596,
       "vyvanse":0.40563793317585317,
       "zenzedi":0.32065522711986383,
       "addiction":0.32332132892370713,
       "misuse of prescription drugs":0.3412595790633089,
       "additional meals or snacks":0.292601473031836,
       "weight loss":0.4154061470292641,
       "weight loss in people with adhd":0.32552329030116706,
       "additional pharmacotherapy":0.3194497563412177,
       "adhd patients":0.43625939342890774,
       "aggression and emotionaldysregulation":0.30271647315511624,
       "atomoxetine (atx)":0.3194497563412177,
       "callous emotional traits":0.30271647315511624,
       "child emotionality":0.30271647315511624,
       "emotion dysregulation":0.4360106708556871,
       "emotional dysregulation symptoms":0.33999528008930435,
       "odd symptoms":0.30271647315511624,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":0.30271647315511624,
       "additional problems the patient may have":0.3860488221508709,
       "adhd clinical diagnoses":0.40420862403851754,
       "address this growing public health problem":0.3105004939833029,
       "consistent nomenclature":0.29900796950900893,
       "definition of nmu":0.29900796950900893,
       "epidemic levels":0.30191974602482247,
       "health care professionals":0.31325616466993794,
       "patient advocacy groups":0.29896900573920066,
       "prescription stimulant":0.418512978847615,
       "surveys and databases":0.29896900573920066,
       "genomewide study":0.0,
       "adhd -iv rating scales":0.38591894870355353,
       "adhd aetiology":0.38572430229364923,
       "adhd biological pathways":0.38591894870355353,
       "adhd children":0.435348795074502,
       "adhd controls":0.38572430229364923,
       "adhd criteria":0.39734813821313225,
       "adhd and emotional dysregulation":0.4085998486273599,
       "adhd genetic liability":0.38886239831230945,
       "adhd genetic risk":0.38572430229364923,
       "adhd guideline ng87":0.38572430229364923,
       "adhd guidelines":0.3997714148880686,
       "adhd in females":0.3919849906103922,
       "adhd in their children":0.38572430229364923,
       "adhd investigator symptom rating scale (aisrs)":0.38591894870355353,
       "adhd lifespan course":0.38572430229364923,
       "adhd medication use":0.3991454679962814,
       "adhd medications (primarily stimulants)":0.3976925203748701,
       "adhd presentation":0.38572430229364923,
       "adhd probands":0.38637388852182986,
       "adhd prototype":0.38578916261016066,
       "adhd research":0.3978994363584158,
       "adhd severity fluctuations":0.38572430229364923,
       "adhd symptoms (e.g., aggression, hyperactivity)":0.38591894870355353,
       "adhd symptoms/b ehaviors":0.39292484158976293,
       "adhd traits":0.39803750000739513,
       "adhd treatment effectiveness":0.38572430229364923,
       "adhd outcomes":0.39618168710803414,
       "adhd treatment response":0.38572430229364923,
       "adhd-associated iq deficits":0.38611379165981585,
       "adhd-c":0.38866477215697537,
       "adhd-like behaviors and their associated impairments":0.38572430229364923,
       "adhd-like symptoms":0.4008890704250613,
       "adhd-related brain structural differences":0.3964555296427554,
       "adhd-related hospital admissions":0.38572430229364923,
       "adherence":0.40293083070646746,
       "adverse outcomes later in life":0.38572430229364923,
       "age":0.42259866458696366,
       "age 25":0.39543056705319296,
       "age at diagnosis":0.3927230657382105,
       "age at menopause":0.38748322074693897,
       "age at onset":0.38572430229364923,
       "age at onset variation":0.38572430229364923,
       "age of first birth":0.38748322074693897,
       "air pollution":0.38572430229364923,
       "alexander crichton":0.38591894870355353,
       "allergic reactions":0.40736650391381846,
       "allergic rhinitis":0.38585404474312573,
       "alpha agonists":0.39928439784939534,
       "alpha-2 adrenergic agonists (clonidine)":0.38578916261016066,
       "alpha-2 adrenergic agonists (guanfacine)":0.38578916261016066,
       "amblyopia":0.38572430229364923,
       "amygdala":0.39205197369149447,
       "ankylosing spondylitis":0.38572430229364923,
       "antidepressant":0.39998050035610627,
       "antisocial behaviour":0.3870256663364753,
       "antisocial personality disorder (aspd)":0.38572430229364923,
       "anxiety":0.42166663297971435,
       "anxiety disorder":0.41428099495172005,
       "anxiety or depression":0.38585404474312573,
       "anxiety or tics":0.3926558531649197,
       "appetite suppression":0.39447870530306495,
       "arbor pharmaceuticals, llc":0.38578916261016066,
       "arithmetic":0.3872216286991773,
       "arrested":0.389456484475068,
       "artificial food color exclusion":0.40130980410051176,
       "artificial food dyes":0.38578916261016066,
       "asd":0.4067886790855719,
       "asd and adhd":0.38591894870355353,
       "aspd":0.389456484475068,
       "assessment and treatment response":0.38578916261016066,
       "assets and strengths":0.38585404474312573,
       "asthma":0.3940721659296849,
       "asthmatic mothers":0.3926558531649197,
       "astigmatism":0.38572430229364923,
       "at all ages":0.38578916261016066,
       "atomoxetine dosing":0.4039950959751058,
       "atopic dermatitis":0.38585404474312573,
       "attention":0.3988678981298028,
       "attention and cognitive control networks":0.38572430229364923,
       "attention and somatoform networks":0.38572430229364923,
       "attention and working memory tasks":0.38578916261016066,
       "atx":0.4205073588787804,
       "augusto vidal perera":0.3933290159510759,
       "autism":0.4080910974817904,
       "autoimmune disease":0.3860488221508709,
       "autoimmune thyroid disease":0.38572430229364923,
       "behavior":0.41881857430497,
       "behavior management":0.3931268248873588,
       "behavior management training":0.386438967499179,
       "behavior modification":0.39118297528433515,
       "behavior therapy":0.4189715394526343,
       "behavior therapy principles":0.3870256663364753,
       "behavioral and mental health assessment":0.4025066929899343,
       "behavioral intervention":0.39292484158976293,
       "behavior monitoring":0.3945465434295143,
       "behavioral regulation index of the brief-a":0.3997714148880686,
       "behavioral responses":0.386438967499179,
       "behavioral responses and emotional responses":0.386438967499179,
       "behavioural interventions":0.40485056468018804,
       "benefits for adhd":0.38578916261016066,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":0.38572430229364923,
       "biologic vulnerability":0.39018505953105875,
       "biological and psychological causal mechanisms":0.38578916261016066,
       "biological pathways":0.38578916261016066,
       "biological test":0.3860488221508709,
       "bipolar disorder":0.3991454679962814,
       "black and latin minority youth":0.38572430229364923,
       "black individuals":0.3876796468473514,
       "black patients with adhd":0.38572430229364923,
       "blood lead levels":0.38611379165981585,
       "blood pressure":0.4151806279483579,
       "body mass index":0.388467346773218,
       "boys":0.3960449076545185,
       "boys and girls":0.38572430229364923,
       "boys born to women who lost a close relative during pregnancy":0.3927903013255651,
       "boys with adhd":0.39803750000739513,
       "brain":0.4015907841839009,
       "brain areas involved in cognition":0.4018721580036128,
       "brain differences":0.38585404474312573,
       "brain functioning":0.38572430229364923,
       "brain imaging":0.38728699359261065,
       "brain imaging studies":0.38611379165981585,
       "brain volumes":0.39638703352498716,
       "brain-specific neuronal subtypes":0.38572430229364923,
       "brains of people with adhd":0.3866995027882396,
       "breastfeeding women":0.3903842351612431,
       "brief behavioral sleep intervention":0.38578916261016066,
       "bupropion":0.42158914921768204,
       "bupropion extended-release":0.38637388852182986,
       "cannabis abuse or dependence":0.39907603931859903,
       "cannabis use disorder":0.38919222222945304,
       "cardiometabolic disease":0.38611379165981585,
       "cardiac events":0.4292400654897335,
       "cardiovascular monitoring":0.40236551210849275,
       "care":0.38906022554563774,
       "caregiver":0.4080910974817904,
       "cause of adhd":0.38572430229364923,
       "cbt":0.42471087560951976,
       "cbt methods for emotional dysregulation issues":0.3926558531649197,
       "cbt and dbt program":0.38827012185524207,
       "cd":0.4015907841839009,
       "celiac disease":0.3868299022159207,
       "central nervous system injury":0.3919849906103922,
       "certain areas":0.38572430229364923,
       "certain birth defects":0.3859838745024606,
       "chadd":0.40349774007081,
       "changing antecedent behavior and reinforcement":0.38578916261016066,
       "characterization of ei/desr in adhd":0.38578916261016066,
       "child's developmental stage":0.3919849906103922,
       "child's health":0.3915167491540317,
       "childhood adhd":0.3859838745024606,
       "children and adolescents who do not respond to stimulants":0.3926558531649197,
       "children and adolescents who have adhd plus other mental health conditions":0.3926558531649197,
       "children and adolescents with adhd":0.404066246925436,
       "children who experienced sexual abuse or physical neglect":0.3927903013255651,
       "children who grow up in difficult family situations":0.3927230657382105,
       "children who had a specific type of viral infection (enterovirus)":0.3927230657382105,
       "children whose mothers were severely obese":0.3927230657382105,
       "children with adhd and smd":0.38585404474312573,
       "children with low lead levels":0.38572430229364923,
       "children without adhd":0.39803750000739513,
       "cholinesterase inhibitors":0.38572430229364923,
       "chrna7":0.3866995027882396,
       "cigarettes smoked per day":0.38748322074693897,
       "cingulate region":0.38748322074693897,
       "clinical assessment":0.3860488221508709,
       "clinical experience":0.38591894870355353,
       "clinical features":0.38572430229364923,
       "clinical global impression ratings":0.38591894870355353,
       "clinical research":0.4051365265835468,
       "clinician interview":0.38591894870355353,
       "clonidine":0.4144306629412257,
       "clonidine extended-release":0.39872925791495056,
       "close friends":0.3880730970978731,
       "cnvs":0.38572430229364923,
       "cnvs in the 1q21.1 region":0.38578916261016066,
       "cnvs in the 6q26 region":0.3861787830403342,
       "co-contraindication for stimulant prescription":0.4022244302318769,
       "cocaine":0.40700517119791124,
       "cocaine or methamphetamine use":0.38637388852182986,
       "coexisting condition":0.3873523805575934,
       "coexisting mental health disorders":0.39831391493795587,
       "cognitive behavior therapy":0.4217441452284238,
       "cognitive errors":0.38578916261016066,
       "cognitive function":0.39590822261305014,
       "cognitive training":0.41116275090369636,
       "college completion":0.3872216286991773,
       "combination therapies":0.3891262126937967,
       "combinations of social disadvantages":0.38572430229364923,
       "common adverse effects":0.38820442471110417,
       "community controls":0.389456484475068,
       "comorbid anxiety or tics":0.38591894870355353,
       "comorbid condition":0.42684430698467457,
       "comorbidities aggravate these outcomes":0.38585404474312573,
       "complete specificity":0.38689513491443944,
       "completion of no more than compulsory education":0.38572430229364923,
       "complex cases":0.3871562858661198,
       "complex psychosocial circumstances":0.38728699359261065,
       "computer-based training":0.40130980410051176,
       "condition":0.3877451664766986,
       "conduct disorder":0.3913831712798747,
       "conduct disorder (cd)":0.38709096508227187,
       "conduct problems":0.3974169669223325,
       "confounders":0.39118297528433515,
       "conners global index (cgi) emotional lability scale":0.39672975100166447,
       "adhd index of the conners adult adhd rating scale":0.3975546959006456,
       "consistent set of causes for the disorder":0.3860488221508709,
       "consultation":0.4003993281051703,
       "controls":0.38709096508227187,
       "core disorder in adhd":0.3884015828750001,
       "core symptoms of adhd":0.38591894870355353,
       "coronary artery disease":0.38748322074693897,
       "cortical surface area":0.3876796468473514,
       "cortical thickness":0.3964555296427554,
       "crash risk":0.3861787830403342,
       "crashes":0.39104962502857094,
       "criminal offenses":0.3926558531649197,
       "criminal records":0.3860488221508709,
       "curative treatments for adhd":0.3870256663364753,
       "d-amphetamine sulfate":0.38820442471110417,
       "daily functioning":0.39810656776724374,
       "daily life":0.3885989414028837,
       "danish national register longitudinal cohort study":0.38572430229364923,
       "danish national registers":0.39468228970284286,
       "danish population":0.3926558531649197,
       "death by homicide":0.3880730970978731,
       "death from natural causes":0.3861787830403342,
       "decision-making":0.38572430229364923,
       "decrease":0.38572430229364923,
       "decreased appetite":0.41101543354400316,
       "decreases in appetite":0.4018721580036128,
       "default-mode network (dmn)":0.3891262126937967,
       "delayed onset of sleep":0.4018721580036128,
       "delayed reinforcement":0.38578916261016066,
       "deliberate self-poisoning":0.38585404474312573,
       "dementia":0.3945465434295143,
       "deprivation":0.3927903013255651,
       "desr":0.38886239831230945,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":0.38572430229364923,
       "developmental disability–children’s global assessment scale":0.38591894870355353,
       "developmental history":0.3866343360368429,
       "dex":0.4059968412745754,
       "dexedrine":0.39258866359387845,
       "dextro amphetamine":0.3983830786668911,
       "deﬁcient emotional self-regulation (desr)":0.38781070825602193,
       "diagnoses":0.4165374273860976,
       "diagnosis of apparent adult-onset adhd":0.38572430229364923,
       "diagnostic criteria":0.3873523805575934,
       "diagnostic delays":0.3927230657382105,
       "diets":0.40130980410051176,
       "differ between children and adults":0.38591894870355353,
       "differences between groups of people who are and are not diagnosed with adhd":0.3866995027882396,
       "difficult life circumstances":0.3860488221508709,
       "difficulty breathing":0.3899198079610173,
       "difficulty sustaining attention":0.3861787830403342,
       "digital health interventions (dhis)":0.3899198079610173,
       "disability service options":0.3937340226604815,
       "disinhibited emotionally expressive behavior":0.38572430229364923,
       "disorder":0.3872216286991773,
       "disruptive mood dysregulation disorder":0.3902514288216747,
       "distress":0.3895226061192913,
       "distress tolerance":0.39191803041384105,
       "dlpfc":0.38578916261016066,
       "dmn":0.38611379165981585,
       "doctor":0.4066444789157436,
       "does not seem to listen":0.3861787830403342,
       "domains":0.38709096508227187,
       "dopamine":0.3915835722892346,
       "dopamine levels in synapses":0.38578916261016066,
       "dopamine regulation":0.38585404474312573,
       "double-blind, placebo-controlled trials":0.39625011226988355,
       "driver license suspensions":0.38781070825602193,
       "drug contract or conducting periodic drug screens":0.4010993269305289,
       "dsm and icd criteria":0.38572430229364923,
       "dsm-5":0.3933964591979811,
       "dsm-5 diagnosis":0.38754867399368675,
       "dsm-5 symptom criteria":0.38611379165981585,
       "dsm-5’s dmdd":0.38578916261016066,
       "duration":0.38572430229364923,
       "duration of treatment":0.39991078090336857,
       "dusp6":0.3866995027882396,
       "dysfunctional cognitive beliefs":0.38591894870355353,
       "dysphoria":0.4068608175283961,
       "dysregulation":0.38578916261016066,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":0.38572430229364923,
       "earnings reduction":0.38585404474312573,
       "anorexia":0.4144306629412257,
       "editorial support":0.38578916261016066,
       "education planning":0.40130980410051176,
       "educational and occupational failure":0.392186008554295,
       "eeg neurofeedback":0.38728699359261065,
       "efficacy":0.3941398642918099,
       "efficacy in treating adhd":0.386438967499179,
       "ei":0.394886084344686,
       "ei and desr":0.39319419880764794,
       "electrical stimulation":0.38591894870355353,
       "electrophysiology":0.38572430229364923,
       "elevations in the theta/beta on the electroencephalogram":0.38572430229364923,
       "elimination diets":0.4027186501742366,
       "embryogenesis":0.38578916261016066,
       "emergent health conditions":0.38572430229364923,
       "emerging problems":0.38578916261016066,
       "emotion processing":0.39803750000739513,
       "emotion regulation":0.41435581543121286,
       "emotional and behavioral trajectories":0.38578916261016066,
       "emotional control scores":0.39618168710803414,
       "emotional control subscale":0.39618168710803414,
       "emotional intensity (ei)":0.38611379165981585,
       "emotional lability":0.40236551210849275,
       "emotion":0.3983830786668911,
       "emotional symptoms":0.42283231663151966,
       "employed":0.38572430229364923,
       "employment reduction":0.38585404474312573,
       "enigma-adhd working group set of cohort from around the world":0.405064998241989,
       "enterovirus patients":0.3927230657382105,
       "environment":0.3861787830403342,
       "environmental correlates":0.38728699359261065,
       "environmental correlates of adhd":0.3937340226604815,
       "environmental factors":0.3891262126937967,
       "environmental risks":0.38591894870355353,
       "epidemiologic studies":0.3891262126937967,
       "essential fatty acid supplementation":0.388467346773218,
       "europe":0.38572430229364923,
       "european network for hyper kinetic disorders (eunethydis)":0.38958875021949835,
       "euthymic baseline":0.38578916261016066,
       "evaluate care-giver burden in children":0.38591894870355353,
       "evaluate family-related qol and activities of daily living in children":0.38591894870355353,
       "evaluate overall functioning in children":0.38591894870355353,
       "evidence":0.3945465434295143,
       "exaggerated delay discounting":0.38572430229364923,
       "executive dysfunction":0.40371074257304695,
       "executive function":0.4004692180210553,
       "executive function control":0.39468228970284286,
       "executive functioning":0.38932430850884536,
       "exposure‐response trend":0.3927230657382105,
       "externalizing behavior problems":0.39515813814030754,
       "extreme deprivation early in life":0.38761414935675376,
       "fails to give close attention":0.3861787830403342,
       "false positive diagnoses":0.3860488221508709,
       "familial co-aggregation":0.38585404474312573,
       "familial or genetic factors":0.38572430229364923,
       "family":0.3866343360368429,
       "family conflict":0.38585404474312573,
       "family function":0.3903842351612431,
       "family history of adhd":0.38585404474312573,
       "family history of mental health issues":0.38728699359261065,
       "family problems":0.3860488221508709,
       "family strain index":0.38591894870355353,
       "fatty acid concentrations":0.38591894870355353,
       "fda approval":0.392992146290275,
       "fda approved medication":0.38754867399368675,
       "fda-approved treatment for adhd":0.38585404474312573,
       "felony":0.389456484475068,
       "female":0.39700435197138356,
       "fidgeting":0.38578916261016066,
       "fidgets with hands or feet":0.3861787830403342,
       "financial problems":0.38781070825602193,
       "financial stability":0.38585404474312573,
       "fmri neurofeedback":0.3860488221508709,
       "fmri studies of cognitive control":0.3872216286991773,
       "dietary interventions":0.39434309901042036,
       "foster care":0.3860488221508709,
       "foxp1 and foxp2":0.38572430229364923,
       "foxp2":0.3861787830403342,
       "franz kramer and hans pollnow":0.3933290159510759,
       "free fatty acids":0.40130980410051176,
       "free tools":0.38572430229364923,
       "frontal region":0.38748322074693897,
       "functional impairment":0.4012396205041318,
       "functioning":0.3992149208356753,
       "funding for manuscript development":0.38578916261016066,
       "fusiform gyrus":0.38591894870355353,
       "future patient outcomes":0.3860488221508709,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":0.38958875021949835,
       "general behavior":0.38578916261016066,
       "general population":0.38572430229364923,
       "general psychopathology and several psychiatric disorders":0.38572430229364923,
       "generalized emotional under-control":0.38578916261016066,
       "genes and environment":0.38572430229364923,
       "genetic and environmental risk factors":0.38761414935675376,
       "genetic correlation":0.3872216286991773,
       "genetic factors":0.38591894870355353,
       "genetic influence":0.3860488221508709,
       "genetic or familial causes":0.38572430229364923,
       "genetic risk":0.38591894870355353,
       "genetic variants":0.4060686991225886,
       "genetics":0.3859838745024606,
       "genomic loci":0.38572430229364923,
       "geographic region":0.39118297528433515,
       "george still":0.386438967499179,
       "girls":0.38578916261016066,
       "girls with adhd":0.39118297528433515,
       "glaucoma":0.38572430229364923,
       "glutamatergic neurotransmission":0.38572430229364923,
       "gonzalo rodriguez-lafora":0.38637388852182986,
       "grade point sum":0.39018505953105875,
       "growth issues":0.39292484158976293,
       "guanfacine":0.42189925524873584,
       "extended release guanfacine":0.41413143502574473,
       "gudjonsson et al.":0.3945465434295143,
       "guidelines":0.4044936794856533,
       "gwas":0.38572430229364923,
       "hba1c":0.38578916261016066,
       "headache":0.42891907834036747,
       "health-care disparities":0.38572430229364923,
       "health care provider":0.419814849047141,
       "healthcare systems":0.386438967499179,
       "heart rate":0.41638623412751824,
       "heinrich hoffmann":0.38591894870355353,
       "high blood pressure":0.41153150673410327,
       "high iqs":0.38578916261016066,
       "high lead levels":0.38572430229364923,
       "high risk of substance abuse":0.4010993269305289,
       "high school and collegiate athletes":0.3861787830403342,
       "high ses":0.38572430229364923,
       "higher adhd symptom severity and poorer outcomes":0.3866995027882396,
       "hippocampus":0.39998050035610627,
       "hippocampus volume":0.3860488221508709,
       "history of illicit stimulant use":0.4010292169275696,
       "hong kong database":0.38572430229364923,
       "hyperactivity":0.4139819830463056,
       "hyperactivity in children":0.38572430229364923,
       "hyperkinetic disorder":0.39205197369149447,
       "hyperthyroidism (overactive thyroid)":0.3927230657382105,
       "hypospadias":0.38572430229364923,
       "hypotension":0.39734813821313225,
       "hypothyroidism (underactive thyroid)":0.3927230657382105,
       "icd-11":0.3927230657382105,
       "icd-11 criteria":0.38572430229364923,
       "ifc":0.38572430229364923,
       "ifc and insula":0.39638703352498716,
       "illegally used drugs":0.39065011919676923,
       "imaging studies":0.38572430229364923,
       "immediate reinforcement":0.38572430229364923,
       "immediate rewards":0.38585404474312573,
       "impaired academic functioning":0.3872216286991773,
       "impairment":0.40563793317585317,
       "impairments in quality of life":0.3895226061192913,
       "improved academic performance":0.38572430229364923,
       "improved brain function, most prominently in inferior frontal and striatal regions":0.39018505953105875,
       "improved parent-reported child behavior":0.3866343360368429,
       "improved relationships with caregivers, teachers, siblings, or peers":0.38572430229364923,
       "improved rule following":0.38572430229364923,
       "improved sleep":0.38578916261016066,
       "improvements":0.3938016048820161,
       "improvements in living":0.3895226061192913,
       "impulsive decision-making":0.38585404474312573,
       "impulsivity":0.39590822261305014,
       "high inattentive factor":0.4060686991225886,
       "inattention and hyperactivity":0.38689513491443944,
       "inattentive type":0.3927230657382105,
       "adhd inattentive type":0.3927903013255651,
       "incarceration":0.3926558531649197,
       "increase the risks of suicidality":0.38585404474312573,
       "increased rate of rare genetic mutations":0.38591894870355353,
       "incredible years (iy)":0.3954987329844209,
       "individual":0.3881387497957411,
       "infection":0.3931268248873588,
       "inferior frontal dysfunction":0.3860488221508709,
       "inflammation":0.38572430229364923,
       "health professionals, patients and families":0.3960449076545185,
       "inhibition":0.3926558531649197,
       "initial treatment":0.3915167491540317,
       "injuries":0.3897211058336378,
       "insomnia":0.429883483238266,
       "insula":0.3874177896053066,
       "insulin resistance":0.38572430229364923,
       "integrative treatment":0.38879650060034326,
       "integrity of auditory sensory memory and involuntary attention switching":0.38572430229364923,
       "intellectual disabilities":0.38728699359261065,
       "intellectual functioning":0.38572430229364923,
       "intelligence":0.3885989414028837,
       "intelligent individuals":0.38578916261016066,
       "intensity":0.38572430229364923,
       "intensity of subjective states and behavior":0.386438967499179,
       "intentional exposures":0.39065011919676923,
       "interdisciplinary collaborations":0.38572430229364923,
       "international resources":0.38572430229364923,
       "interventions":0.39447870530306495,
       "intracranial brain volume":0.38585404474312573,
       "iq":0.39468228970284286,
       "iq differences":0.38833584123944237,
       "iq scores":0.3872216286991773,
       "iq tests":0.3860488221508709,
       "irritability":0.4460991930862582,
       "juvenile detention":0.38572430229364923,
       "kidney failure":0.38572430229364923,
       "kidscreen-10":0.38591894870355353,
       "l-deprenyl":0.38572430229364923,
       "large family size":0.38572430229364923,
       "large population studies":0.38585404474312573,
       "larger delayed ones":0.38572430229364923,
       "lead burden":0.38572430229364923,
       "learning disorder":0.39319419880764794,
       "leaves seat in situations":0.3861787830403342,
       "licensed clinician":0.38578916261016066,
       "limbic volume":0.38591894870355353,
       "lines of communication":0.3865691912455983,
       "lisdexamfetamine":0.40371074257304695,
       "long-range fronto-posterior association tracts":0.3860488221508709,
       "long-term medication use":0.3964555296427554,
       "low ses":0.38572430229364923,
       "low social class":0.38572430229364923,
       "low social class conditions":0.3860488221508709,
       "lower achievement scores":0.38709096508227187,
       "lower family income":0.3927230657382105,
       "lower quality of life":0.38781070825602193,
       "lung cancer":0.38748322074693897,
       "major depression":0.38958875021949835,
       "makes careless mistakes":0.3861787830403342,
       "male":0.3986599739431148,
       "male-to-female sex ratio of adhd":0.3974169669223325,
       "maois":0.3931268248873588,
       "map1a":0.38572430229364923,
       "maternal alcohol use during pregnancy":0.38611379165981585,
       "maternal mental disorder":0.38572430229364923,
       "maternal pre-existing type 1 diabetes":0.38624379630347233,
       "maternal prenatal use of acetaminophen":0.38572430229364923,
       "maternal smoking":0.386438967499179,
       "maximimum tolerated dose":0.39638703352498716,
       "measurement tools":0.3859838745024606,
       "measurement-based care":0.38572430229364923,
       "measures of neurocognitive functioning":0.38572430229364923,
       "measures to evaluate qol or functional impairment":0.38591894870355353,
       "mechanisms of disease onset":0.38572430229364923,
       "mechanisms/pathophysiology":0.38572430229364923,
       "medical history":0.38728699359261065,
       "medical problem":0.39111628879008276,
       "medication periods":0.3902514288216747,
       "medication therapy":0.3927230657382105,
       "medication-free weekends":0.3903842351612431,
       "mef2c":0.38794185830954103,
       "melchior adam weikard":0.38591894870355353,
       "memory":0.38572430229364923,
       "meta-analyses":0.4121969367665515,
       "metabolic disorders":0.38572430229364923,
       "methamphetamine":0.38820442471110417,
       "method of diagnosing adhd":0.38578916261016066,
       "methods to improve adherence":0.389456484475068,
       "methylphenidate treatment":0.391249684522958,
       "methylphenidate users":0.38611379165981585,
       "methylphenidate users ages 46-65":0.38611379165981585,
       "methylphenidate users with previous alcohol and drug misuse":0.38611379165981585,
       "methyphenidate prescription":0.3905836142394664,
       "migraine":0.3861787830403342,
       "milder adhd":0.38578916261016066,
       "mindfulness and positive aspects of adhd":0.38572430229364923,
       "mindfulness meditation":0.38820442471110417,
       "mindfulness-based treatments":0.38820442471110417,
       "minimal brain dysfunction":0.3921189796688815,
       "minor structural and functional brain differences":0.3873523805575934,
       "misconceptions":0.38978731737047667,
       "misdemeanors":0.389456484475068,
       "mismatch negativity":0.38572430229364923,
       "misuse and diversion of these medications":0.3902514288216747,
       "mixed amphetamine salts":0.39803750000739513,
       "modafinil":0.406140582411511,
       "molecular genetic data":0.38696038961757895,
       "mood":0.40293083070646746,
       "mood disorder":0.4133107818487886,
       "mortality rates":0.38998608703767224,
       "most cases of adhd":0.38572430229364923,
       "mothers":0.3931268248873588,
       "mothers who were obese before pregnancy":0.3927230657382105,
       "mothers with two or more prior miscarriages":0.3927230657382105,
       "motor vehicle collision":0.39319419880764794,
       "mtbi":0.3861787830403342,
       "multidisciplinary efforts":0.38578916261016066,
       "multiple settings":0.3872216286991773,
       "narcolepsy":0.38591894870355353,
       "national health and nutrition examination survey":0.38572430229364923,
       "national health insurance data":0.3913164165175892,
       "national institute for health and care excellence (nice)":0.38572430229364923,
       "national institute of mental health":0.3880730970978731,
       "nationwide population study":0.38585404474312573,
       "nausea":0.40918283396515526,
       "negative parenting":0.3939368389496266,
       "negative reinforcement":0.38572430229364923,
       "neglect":0.38585404474312573,
       "network meta-analyses":0.40420862403851754,
       "network of researchers with annual meeting":0.38748322074693897,
       "neurobiological research":0.38572430229364923,
       "neurobiology":0.38572430229364923,
       "neurocognitive function":0.38800746660622787,
       "neurocognitive impairment":0.38709096508227187,
       "neurodevelopment":0.38578916261016066,
       "neurodevelopmental condition":0.3870256663364753,
       "neuroimaging scans":0.3859838745024606,
       "neuroimaging studies":0.38572430229364923,
       "neuronal and nicotinic signalling pathways":0.38572430229364923,
       "neuronal development and migration":0.38585404474312573,
       "neuropsychological tests":0.38754867399368675,
       "new directions for diagnosis":0.39091636565728843,
       "new medications currently in development":0.3902514288216747,
       "nice guidelines":0.3861787830403342,
       "nicotine":0.4004692180210553,
       "nicotinic signalling":0.38578916261016066,
       "no association with adhd":0.38572430229364923,
       "no significant effect on adhd":0.38572430229364923,
       "non-medical treatments":0.4009591314300289,
       "non-responders":0.40570966402168446,
       "non-stimulant medications":0.4042798502277754,
       "non-stimulants":0.4222875299176561,
       "nonstimulant medications":0.40838165718095865,
       "noradrenaline":0.3960449076545185,
       "normal cognitive fluctuations":0.38572430229364923,
       "normed scales":0.38572430229364923,
       "north america":0.38572430229364923,
       "number of children":0.38748322074693897,
       "number of sessions":0.38572430229364923,
       "obesity":0.40236551210849275,
       "occupational functioning":0.38578916261016066,
       "ocd":0.38892831836626984,
       "odd":0.41458043911142495,
       "older adolescents and adults":0.38578916261016066,
       "omni healthcare communications":0.38578916261016066,
       "onset":0.38978731737047667,
       "onset prior to the age 12 years cannot be documented":0.38572430229364923,
       "oppositional defiant disorder":0.3930594740521887,
       "organisation skills":0.3866995027882396,
       "other approaches to emotion-regulatory processes disrupted in adhd":0.38637388852182986,
       "other psychiatric and substance use disorder":0.3861787830403342,
       "other psychiatric diagnosis":0.394886084344686,
       "other stimulant class":0.39638703352498716,
       "out-of-home care":0.38572430229364923,
       "outcomes":0.4093288403287468,
       "outcomes over longer periods of time":0.38578916261016066,
       "overused medication":0.39468228970284286,
       "oxidative stress":0.38572430229364923,
       "paid tools":0.38572430229364923,
       "parent":0.4146553678009445,
       "parent behavior management training (pbmt)":0.3954987329844209,
       "parent management training":0.39111628879008276,
       "parent referral for treatment":0.38578916261016066,
       "parent training":0.4121969367665515,
       "parent training in behavior management (ptbm)":0.38572430229364923,
       "parent-child behavior therapy":0.38611379165981585,
       "parental criminality":0.38572430229364923,
       "parental educational attainment":0.38572430229364923,
       "parental outcomes":0.38572430229364923,
       "parental relative income poverty":0.38572430229364923,
       "parental unemployment":0.38572430229364923,
       "parenting skills":0.38585404474312573,
       "parents having low educational levels":0.3860488221508709,
       "pargyline":0.38572430229364923,
       "parietal region":0.38591894870355353,
       "paroxetine":0.38591894870355353,
       "particulate matter":0.38572430229364923,
       "pathophysiology":0.38572430229364923,
       "patient":0.4356794815880413,
       "patient’s level of ei":0.38572430229364923,
       "pbmt":0.38578916261016066,
       "peer conflicts and social exclusion":0.38585404474312573,
       "peers":0.3936664636311986,
       "people":0.3859838745024606,
       "people all around the world":0.38578916261016066,
       "people who have read this document and agree with its contents":0.38624379630347233,
       "performance deficits in psychological processes":0.3859838745024606,
       "perpetrators of physical dating violence":0.38572430229364923,
       "person":0.38761414935675376,
       "personalized approach":0.3919849906103922,
       "personalized treatments":0.38572430229364923,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":0.4032140861234843,
       "pharmacotherapy":0.4093288403287468,
       "physical conditions":0.3900523886505654,
       "physical examination":0.3970730616203921,
       "placebo":0.40152050228257363,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":0.38578916261016066,
       "poisoning in children":0.38585404474312573,
       "police station interrogations":0.38572430229364923,
       "polr3c":0.38585404474312573,
       "polygenic cause":0.38572430229364923,
       "polythetic criteria":0.38689513491443944,
       "poor judgment":0.39018505953105875,
       "poor work performance":0.38781070825602193,
       "positive parenting":0.38572430229364923,
       "positive reinforcement":0.38572430229364923,
       "posterior corpus callosum":0.38591894870355353,
       "posterior parieto-temporal attention regions":0.3860488221508709,
       "poverty":0.39319419880764794,
       "pre-existing type 1 diabetes":0.3926558531649197,
       "prediction":0.3919849906103922,
       "predictive modelling":0.38572430229364923,
       "predictor of treatment response":0.38578916261016066,
       "preeclampsia":0.38611379165981585,
       "pregnancies":0.4139819830463056,
       "pregnancy and adhd":0.38572430229364923,
       "pregnant or breastfeeding women":0.3903842351612431,
       "premature death":0.39734813821313225,
       "prenatal exposure":0.38591894870355353,
       "prenatal exposure to maternal smoking":0.38572430229364923,
       "preschool or daycare":0.3919849906103922,
       "preschoolers with symptoms of adhd":0.39118297528433515,
       "prescriber":0.40874543916668904,
       "prevalence":0.4064283702467007,
       "prevalence of adhd":0.39326159582492726,
       "prevalence of adhd among adolescents":0.38572430229364923,
       "prevalence of adhd in prisons":0.38572430229364923,
       "prevalence of false confessions":0.38572430229364923,
       "prevalence of physical dating violence":0.38572430229364923,
       "priapism":0.4052796590783652,
       "prior miscarriage":0.3927230657382105,
       "prisma diagram in supplemental figure 1":0.38624379630347233,
       "prison inmates":0.38572430229364923,
       "prkn":0.38572430229364923,
       "proband":0.3933964591979811,
       "problem behaviors (e.g., aggression, caregiver-child relations)":0.38591894870355353,
       "problem solving":0.38932430850884536,
       "problematic substance use":0.4041374229421571,
       "problems with connections between the two hemispheres":0.3860488221508709,
       "professional health care associations":0.3865691912455983,
       "proteins":0.38585404474312573,
       "proton pump inhibitors":0.38958875021949835,
       "provocation":0.3893903852753947,
       "psoriasis":0.38572430229364923,
       "comorbid psychiatric conditions":0.409255824124621,
       "psychoeducation":0.40264797298045374,
       "psychological tests":0.3860488221508709,
       "psychological treatment":0.4010292169275696,
       "psychosocial domains of qol":0.38591894870355353,
       "psychosocial interventions":0.394886084344686,
       "psychosocial, school and emotional functioning":0.38591894870355353,
       "psychotherapy":0.4160087307420899,
       "psychotropic co-prescriptions":0.3895226061192913,
       "ptbm":0.38820442471110417,
       "ptbm (behavior therapy)":0.39638703352498716,
       "qol domains":0.38591894870355353,
       "quality of life":0.41338525225993256,
       "racemic amphetamine sulfate":0.38820442471110417,
       "racial and ethnic minority populations":0.38572430229364923,
       "rage":0.3881387497957411,
       "randomized controlled trials (rcts)":0.39018505953105875,
       "rare genetic mutations":0.3859838745024606,
       "rare single gene defects":0.38585404474312573,
       "rct":0.39727933334071436,
       "rcts of adhd medications":0.3924543534113284,
       "re-evaluate goals and behavior":0.38611379165981585,
       "reading":0.3872216286991773,
       "reading, spelling and arithmetic":0.3860488221508709,
       "rebound effect":0.38958875021949835,
       "reduce self-esteem and wellbeing":0.38585404474312573,
       "reducing inattention, hyperactivity, and impulsivity":0.38585404474312573,
       "referral to a dietician":0.38591894870355353,
       "regular check-ups":0.40236551210849275,
       "reinforcer":0.38578916261016066,
       "relationship quality":0.38585404474312573,
       "reliability and validity":0.3877451664766986,
       "reliable diagnostic measure for adhd":0.38572430229364923,
       "research":0.39700435197138356,
       "resilience":0.38572430229364923,
       "resilience factors":0.38585404474312573,
       "resources":0.3978994363584158,
       "responders":0.40570966402168446,
       "response cost":0.38572430229364923,
       "response to treatment":0.3860488221508709,
       "response-inhibition":0.3913164165175892,
       "restlessness":0.38578916261016066,
       "reward":0.38787627219655546,
       "right inferior frontal cortex":0.38761414935675376,
       "potential risks":0.3908497700242974,
       "risky driving behaviors":0.3885989414028837,
       "robins and guze criteria":0.38611379165981585,
       "sagitatal striatum":0.38591894870355353,
       "scaffolding":0.3860488221508709,
       "scales for emotion regulation":0.3860488221508709,
       "schizophrenia":0.38833584123944237,
       "school":0.38932430850884536,
       "school interventions":0.38591894870355353,
       "school performance":0.38611379165981585,
       "school-based accommodations":0.3881387497957411,
       "screening measures":0.3914499488214683,
       "selective amplification of certain emotional states":0.38578916261016066,
       "selective noradrenaline reuptake inhibitors":0.39872925791495056,
       "self-esteem":0.3885989414028837,
       "self-injury":0.38572430229364923,
       "self-perceptions of competence":0.38572430229364923,
       "self-referential thoughts and mind-wandering":0.38572430229364923,
       "self-referral":0.38578916261016066,
       "self-regulatory skills":0.3872216286991773,
       "self-regulatory strategies":0.38578916261016066,
       "self-report measures":0.38748322074693897,
       "self-report scale":0.38754867399368675,
       "self-reported executive function ratings":0.3871562858661198,
       "serious transport accidents":0.3905171319221491,
       "serotonin syndrome":0.40264797298045374,
       "settings":0.3871562858661198,
       "severe adhd":0.38578916261016066,
       "severe marital discord":0.3861787830403342,
       "severe mood dys-regulation (smd)":0.38578916261016066,
       "sex":0.39118297528433515,
       "sexual crimes victims":0.3860488221508709,
       "sexually transmitted infections":0.39078319707760617,
       "shared components of etiology":0.38689513491443944,
       "shared mechanisms among disorders":0.38689513491443944,
       "short- and long-acting formulations of a-2 adrenergic agonists":0.39625011226988355,
       "simulant":0.38754867399368675,
       "simulant medications":0.38754867399368675,
       "single genetic abnormality":0.38761414935675376,
       "six symptoms of hyperactivity-impulsivity":0.38611379165981585,
       "six symptoms of inattention":0.38611379165981585,
       "skills training":0.4013800122537834,
       "sleep":0.39776146845399196,
       "sleep efficiency":0.4018721580036128,
       "sleep onset":0.399701768300109,
       "sleep onset delay":0.38591894870355353,
       "small differences in brain structure and function":0.38572430229364923,
       "small for gestational age":0.38611379165981585,
       "small particulate matter levels":0.38572430229364923,
       "small to moderate difficulties":0.38637388852182986,
       "small-to-moderate reductions in mismatch negativity amplitude":0.3873523805575934,
       "smaller brain areas":0.3874177896053066,
       "smaller brain volumes":0.38572430229364923,
       "cigarette smoking":0.4070773864518498,
       "smoking initiation":0.38748322074693897,
       "social acceptance":0.38572430229364923,
       "social anxiety disorder":0.3938016048820161,
       "social cognitive programs":0.38578916261016066,
       "social function":0.3903842351612431,
       "social functioning":0.3861787830403342,
       "social skills":0.39118297528433515,
       "social skills training":0.3948181294170755,
       "socially and clinically important outcomes":0.38591894870355353,
       "society for developmental and behavioral pediatrics":0.38572430229364923,
       "socioeconomic cost":0.38572430229364923,
       "ses (socioeconomic status)":0.38585404474312573,
       "solriamfetol":0.3940044908196163,
       "somatic co-prescriptions":0.3895226061192913,
       "somatic disorders that co-occur with adhd":0.3902514288216747,
       "sorcs3":0.38794185830954103,
       "sorcs3, ptprf, and mef2c":0.38572430229364923,
       "specialist":0.3946144048920925,
       "speech disorders":0.38696038961757895,
       "spelling":0.3872216286991773,
       "splenium of the corpus callosum":0.38833584123944237,
       "spouses":0.38958875021949835,
       "ssri/snri":0.38892831836626984,
       "standard diagnostic criteria":0.3874177896053066,
       "standard therapies":0.3880730970978731,
       "stigma":0.392992146290275,
       "adhd stigma":0.39171728701427794,
       "stimulant":0.40889113349538864,
       "stimulant medication":0.4451470993485886,
       "stimulant therapy":0.40991390924470705,
       "stimulant-refractory":0.39638703352498716,
       "stimulants are the first line of drug treatment for adhd":0.4010292169275696,
       "stress":0.3927230657382105,
       "stress-related strains on cognition":0.38572430229364923,
       "stressed events during childhood":0.3860488221508709,
       "subcortical regions":0.3874177896053066,
       "subjective well-being":0.38748322074693897,
       "subsequent substance use":0.39018505953105875,
       "substance misuse":0.4010292169275696,
       "substance use":0.39031782069456034,
       "sud":0.3926558531649197,
       "suicide related events":0.39672975100166447,
       "support groups":0.38906022554563774,
       "sustained release bupropion":0.38637388852182986,
       "sweden":0.38572430229364923,
       "swedish national registers":0.39205197369149447,
       "swedish population-based study":0.39078319707760617,
       "swedish registry study":0.38572430229364923,
       "symptom change":0.3938016048820161,
       "symptom checklists":0.38572430229364923,
       "symptom expression":0.38585404474312573,
       "symptom severity":0.3926558531649197,
       "synapse formation and plasticity":0.3866995027882396,
       "synaptic development":0.38572430229364923,
       "taiwan health insurance research database":0.39078319707760617,
       "taiwanese study":0.39078319707760617,
       "taiwanese youths":0.39118297528433515,
       "tca (nortriptyline)":0.38892831836626984,
       "tdcs":0.3946144048920925,
       "teacher-assessed social skills":0.38578916261016066,
       "teachers of children with adhd":0.3926558531649197,
       "techniques":0.38578916261016066,
       "teenage pregnancy":0.3992149208356753,
       "teenage pregnancy and sexually transmitted diseases":0.38585404474312573,
       "temper outbursts":0.3860488221508709,
       "temporal pole":0.38591894870355353,
       "temporal region":0.38748322074693897,
       "temporo-parieto-occipital regions":0.38591894870355353,
       "test scores":0.3902514288216747,
       "testicular dysfunction":0.38572430229364923,
       "tetrahydrocannabinol (marijuana)":0.38578916261016066,
       "therapeutic approaches":0.3921189796688815,
       "therapies":0.38578916261016066,
       "therapy":0.405064998241989,
       "those seeking treatment":0.38572430229364923,
       "those with epilepsy":0.38572430229364923,
       "thyroid problems in mothers during pregnancy":0.3927230657382105,
       "time management":0.39292484158976293,
       "time off medication":0.3924543534113284,
       "time-out":0.38572430229364923,
       "tms":0.38728699359261065,
       "tns":0.3899198079610173,
       "token economy":0.38572430229364923,
       "tolerability":0.39686700398592384,
       "total sleep time":0.4018721580036128,
       "toxic substances":0.3859838745024606,
       "tracking and remote measurement technologies":0.38578916261016066,
       "trans-diagnostic phenomena":0.38689513491443944,
       "transport accidents":0.4012396205041318,
       "trauma":0.394886084344686,
       "trauma-related emergency room admission":0.3905836142394664,
       "traumatic brain injuries":0.3955669224211424,
       "traumatic brain injury early in life":0.38761414935675376,
       "treating adhd and preventing adverse outcomes":0.39104962502857094,
       "treatment efficacy":0.3895226061192913,
       "drug treatment initiation":0.4055662276900523,
       "treatment of coexisting conditions":0.3975546959006456,
       "treatment planning":0.38591894870355353,
       "treatment targets":0.38689513491443944,
       "trial":0.38906022554563774,
       "trigeminal nerve stimulation":0.38624379630347233,
       "trigeminal nerve stimulation (tns)":0.38585404474312573,
       "twins":0.38585404474312573,
       "type 1 diabetes mellitus (t1dm)":0.3859838745024606,
       "type 2 diabetes":0.38787627219655546,
       "typically developing peers":0.3983830786668911,
       "ulcerative colitis":0.38572430229364923,
       "unemployment":0.38833584123944237,
       "unintended injuries":0.4033558632283097,
       "unmedicated adults":0.38585404474312573,
       "upper secondary school":0.39018505953105875,
       "urbanization level":0.39118297528433515,
       "us":0.38572430229364923,
       "us population":0.3876796468473514,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":0.4010292169275696,
       "validated measure of symptom change":0.389456484475068,
       "validity of adhd as a mental disorder":0.38611379165981585,
       "valproate":0.392992146290275,
       "vehicular crashes":0.3861787830403342,
       "ventromedial orbito-frontal cortical thickness":0.38591894870355353,
       "viloxazine er":0.3873523805575934,
       "viloxazine extended-release":0.3899198079610173,
       "violent crimes":0.3945465434295143,
       "violent crimes against youth":0.38572430229364923,
       "viral pneumonia":0.38572430229364923,
       "visual attention":0.39803750000739513,
       "weak support systems":0.3927230657382105,
       "weight":0.4130131683245051,
       "well-trained professionals":0.3860488221508709,
       "wender-reimherr adult attention deficit disorder scale":0.39831391493795587,
       "wes study":0.38572430229364923,
       "white blood cell disorders":0.38572430229364923,
       "white matter":0.38781070825602193,
       "white matter integrity":0.39638703352498716,
       "white-majority countries":0.38572430229364923,
       "work functioning":0.38585404474312573,
       "work performance":0.38853313294540653,
       "working memory impairments":0.38754867399368675,
       "world":0.3956351353755175,
       "worse social adjustment":0.38781070825602193,
       "year of first adhd diagnosis":0.3860488221508709,
       "years of schooling":0.3872216286991773,
       "youth aged 14-20":0.38572430229364923,
       "youth with adhd":0.3925214970132807,
       "α2 agonists":0.3899198079610173,
       "emotional factors":0.38585404474312573,
       "intellectual factors":0.38585404474312573,
       "mood stabilizing medication":0.3866343360368429,
       "negative health behaviours":0.38585404474312573,
       "oocyte leading to pregnancy":0.38585404474312573,
       "psychosocial impairment":0.38585404474312573,
       "resilience in those susceptible to adhd":0.38624379630347233,
       "sero tonergic medication":0.38630883146028383,
       "sero tonergic reuptake inhibitor":0.38630883146028383,
       "serotonin activity":0.386438967499179,
       "serotonin-norepinephrine reuptake inhibitors (snri)":0.3872216286991773,
       "social factors":0.38585404474312573,
       "selective serotonin reuptake inhibitor (ssri)":0.39515813814030754,
       "adhd and its mental and somatic comorbidities":0.3082477697222391,
       "classroom":0.28188821108767975,
       "covert smile":0.2934622857562837,
       "desr (delayed emotional return)":0.2819228495997328,
       "emotional experience and behavior dyssynchrony":0.28188821108767975,
       "emotionally evocative situations":0.2858213716260901,
       "explosive giggle":0.28188821108767975,
       "provoke- ing stimuli":0.28188821108767975,
       "rapid emotional responses":0.28188821108767975,
       "height gains":0.3441260162055836,
       "age at which adhd criteria were met":0.2835254757838144,
       "children with high iq":0.32332132892370713,
       "rates of learning disorders":0.2835254757838144,
       "rates of psychiatric disorders":0.2835254757838144,
       "rates of stimulant treatment":0.2835254757838144,
       "rates of substance abuse":0.2835254757838144,
       "nitric oxide":0.2870012697076089,
       "nitrogen dioxide levels":0.2870012697076089,
       "particulate matter levels":0.2870730918471754,
       "sulphur dioxide levels":0.2870012697076089,
       "genetic architecture of adhd":0.38624379630347233,
       "affective reactivity":0.3251081408590939,
       "education":0.35054058824180684,
       "expression of emotions":0.3251081408590939,
       "family life":0.3251081408590939,
       "financial":0.3251081408590939,
       "legal":0.3251081408590939,
       "predicting emotional symptoms":0.3251081408590939,
       "social relations":0.3251081408590939,
       "adhd europe":0.28286131796851505,
       "health professionals and researchers":0.31193584636881383,
       "adhd evidence project":0.28391141567165273,
       "international consensus statement on adhd":0.28786551443445746,
       "adhd experts":0.30610915944531364,
       "brainstorming session":0.30594587945627755,
       "existing guidelines":0.30594587945627755,
       "literature review":0.3059866831211824,
       "qms (quality measures)":0.30791680982990544,
       "qms for adhd in youth":0.3059866831211824,
       "survey":0.30594587945627755,
       "adhd follow-up care visit":0.2876850344881035,
       "visit":0.3222314817475598,
       "adhd guidelines group of the association of medical scientific societies in germany":0.22333185535312233,
       "adhd network of european college of neuropsychopharmacology":0.22333185535312233,
       "adhd section of the world psychiatric association":0.22333185535312233,
       "australian adhd professionals association":0.22333185535312233,
       "chinese society of child and adolescent psychiatry":0.22333185535312233,
       "federation of adhd":0.18241934881471145,
       "israeli society of adhd":0.22333185535312233,
       "large medical database called pubmed":0.284615823104159,
       "latin american league of adhd":0.22333185535312233,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":0.2233970934802946,
       "pubmed":0.18241934881471145,
       "saudi adhd society":0.22333185535312233,
       "adhd in adults":0.32182468088688815,
       "adhd in big groups of people":0.23028085416467184,
       "adhd in offspring":0.3026765369449374,
       "fetal growth restriction":0.3024371407912768,
       "maternal hyperthyroidism during pregnancy":0.3024371407912768,
       "maternal hypothyroidism during pregnancy":0.3024371407912768,
       "maternal preeclampsia":0.30255679151294024,
       "obesity in mothers":0.3024371407912768,
       "adhd in older adults":0.30791680982990544,
       "mild cognitive impairment and dementia":0.30791680982990544,
       "adhd malingering":0.3240519985935912,
       "danish study":0.33279491587505444,
       "reproductive-aged women":0.3235036872592535,
       "risk of a motor vehicle collision":0.32029710317501403,
       "short-term effects":0.31304245463809877,
       "adhd medication metabolism affect":0.3248319623449845,
       "mph":0.3471460357153314,
       "comorbid anxiety":0.33236102419855507,
       "duration of action":0.34325077050308583,
       "duration of response":0.33216854640837207,
       "intervention":0.3292133950412721,
       "level of function":0.3365539313543532,
       "methylin®":0.3380415721294571,
       "methylphenidate-based medications":0.3380415721294571,
       "mood dysregulation":0.33216854640837207,
       "nonstimulants":0.35231697635789705,
       "pharmacokinetics":0.33216854640837207,
       "pharmacotherapies":0.31724117118952233,
       "second-line nonstimulants":0.35188468558935976,
       "short-acting methylphenidate":0.3380415721294571,
       "specifically learning disorders and low iq":0.3291661621295015,
       "stakeholders":0.31985057159384156,
       "supplements":0.3328431960021218,
       "treatment alternatives":0.31588711965339744,
       "working memory training":0.33240917850516166,
       "ɑ2 agonists":0.33216854640837207,
       "prof. faraone":0.2825130094868398,
       "completed suicide":0.3234124823854843,
       "crime rates":0.3029163123901011,
       "criminality":0.31287169644656015,
       "diversion could be fatal when diverted to a person who is medically at risk":0.3298286587180313,
       "diversion of medications is a felony":0.3298286587180313,
       "gateway to non-oral use of illicit drugs":0.32987608196155654,
       "injecting":0.33011340288383106,
       "intranasally":0.3298286587180313,
       "legal consequences of diverting medication":0.3298286587180313,
       "medical consequences of diverting medication":0.3298286587180313,
       "men with adhd":0.3234124823854843,
       "diversion or nmu":0.33087512980135936,
       "non-oral nmu":0.32987608196155654,
       "non-oral routes":0.3298286587180313,
       "oral administration":0.3298286587180313,
       "repeated suicide attempts":0.32752150607318,
       "suicide deaths":0.3234124823854843,
       "swedish national registers study":0.30553844054369766,
       "teenagers with adhd":0.30299632198132936,
       "youth with adhd and other psychiatric diagnoses":0.3091615887404158,
       "adhd patients with ed but without smd":0.29211715686817236,
       "coping skills for managing anger":0.2930873978082046,
       "adhd pharmacotherapy":0.2825130094868398,
       "adolescents with adhd":0.29939816651998247,
       "driver's license":0.2197804531126186,
       "females with adhd -i or controls":0.2198015089138365,
       "individuals (age 6 to 24 years) with adhd":0.28123169282209187,
       "motor vehicle crashes":0.2825130094868398,
       "natural causes":0.2197804531126186,
       "st imulant medications":0.2198015089138365,
       "two-year mortality risk from all-causes":0.2197804531126186,
       "unnatural causes such as suicide, accidental poisoning or injury":0.2197804531126186,
       "employment":0.27789342902648084,
       "employment status jobs":0.27789342902648084,
       "prescription stimulant misuse":0.27789342902648084,
       "adhd prs":0.30953698732361384,
       "irritability traits":0.30953698732361384,
       "adhd quality of life":0.32065522711986383,
       "primerthe columbia impairment scale":0.32065522711986383,
       "adhd rating scales":0.32506207849853014,
       "cultural context":0.3207000489296374,
       "culture":0.3207000489296374,
       "adhd severity":0.3025168974212323,
       "intelligence quotient":0.28891678000788634,
       "adhd symptom checklists":0.31253073832483663,
       "barkley deficits in executive function scale":0.3102066184481646,
       "improvement in psychosocial functioning":0.3102066184481646,
       "adhd symptom control extension":0.32332132892370713,
       "adult adhd symptoms":0.33327834835017806,
       "aggression":0.3450576252132089,
       "alpha-2-adrenergic agonists":0.39721055229269836,
       "amphetamine derivatives":0.33016090805045695,
       "becoming unnaturally quiet":0.32566190916147986,
       "broad-spectrum micronutrient supplements":0.32038655914573744,
       "cbt alone":0.3230481765759822,
       "child behavior checklist":0.3247400070831742,
       "clinical prescriber with training in adhd diagnosis and management":0.32164421001578936,
       "clinical subgroups":0.32029710317501403,
       "combined treatment with medication and cbt":0.32065522711986383,
       "dietary approach to stop hypertension":0.32038655914573744,
       "dietary interventions for adhd":0.32029710317501403,
       "digital interventions":0.3208345895738534,
       "digital therapies":0.32078973015137385,
       "direct skills training":0.33420075018829215,
       "disruptive behavior disorders":0.34500573684851515,
       "drug treatment resistant patients":0.32078973015137385,
       "effect":0.32464810386905696,
       "exclusion of food colour additives and preservatives":0.32038655914573744,
       "exercise":0.3979684562086081,
       "extended-release preparations":0.3468311640276078,
       "good sleep practice":0.32589320313105474,
       "hallucinogens":0.32409777511550014,
       "healthy diets":0.33429814221807164,
       "heroin":0.32409777511550014,
       "homicidality":0.3272878958691335,
       "imipramine":0.32566190916147986,
       "immediate-release stimulants":0.3468311640276078,
       "inhalants":0.32409777511550014,
       "jornay":0.3468311640276078,
       "marijuana":0.32992351884420845,
       "medication alone":0.32110400980302667,
       "medication or psychosocial interventions":0.32029710317501403,
       "mediterranean diet":0.32038655914573744,
       "melatonin":0.34936624791268855,
       "mirtazapine (remeron)":0.32566190916147986,
       "negative mood symptoms":0.3247859782053547,
       "nutrition":0.39205197369149447,
       "omega-3 fatty acid supplementation":0.33459065918661596,
       "pain relievers":0.32409777511550014,
       "parent behavior management program":0.3247400070831742,
       "parent-rated emotional lability symptoms":0.32029710317501403,
       "parent-rated oppositional symptoms":0.32029710317501403,
       "participants and their significant others":0.32029710317501403,
       "poor dental hygiene":0.32150898963601815,
       "prognosis":0.3270546186803458,
       "remission of aggressive behavior":0.3247859782053547,
       "restricting synthetic food colors":0.32029710317501403,
       "ssri and stimulant combination":0.32386902174514764,
       "ssri antidepressants":0.32029710317501403,
       "stimulant-refractory adhd":0.33429814221807164,
       "tca":0.3232302268304629,
       "teacher-rated emotional lability symptoms":0.32029710317501403,
       "teacher-rated oppositional symptoms":0.32029710317501403,
       "tranquilizers/sedatives":0.32409777511550014,
       "treatment selection":0.32029710317501403,
       "treatment success":0.3302084268915696,
       "venlafaxine":0.3388403707048627,
       "youth adhd symptoms":0.33322994190887806,
       "adhd trea tment":0.31940528331374435,
       "administration of stimulants in conjunction with alcohol use":0.31385610807696657,
       "cardiotoxicity":0.31312790364987386,
       "ecg":0.3130851733136771,
       "lower all-cause mortality":0.31304245463809877,
       "males with adhd":0.31304245463809877,
       "patients medicated for adhd":0.32034182491519486,
       "plasma levels":0.3130851733136771,
       "polysubstance use":0.31993977827954617,
       "qtc prolongation":0.3130851733136771,
       "tachycardia":0.3130851733136771,
       "tca treatment":0.31312790364987386,
       "unnatural causes of mortality":0.31304245463809877,
       "adhd treatment first line":0.32327577145873265,
       "impulsive cognition":0.28293108275282103,
       "learning problems":0.2908211623833979,
       "poorly regulated emotions":0.28293108275282103,
       "adhd treatment plan":0.2822697034993388,
       "behaviors that we now associate with adhd":0.31593061829284297,
       "cam therapies":0.32973385312483844,
       "chelation therapy":0.332746649752375,
       "consensus statement":0.31601765152102285,
       "large effect":0.31593061829284297,
       "medium effect":0.31593061829284297,
       "megavitamins":0.3355203495236364,
       "reviews":0.31593061829284297,
       "small effect":0.31593061829284297,
       "smaller studies":0.3189612331492598,
       "strong effects":0.31593061829284297,
       "treatment studies":0.317197310941881,
       "vitamins":0.332746649752375,
       "adhd types":0.3018403039129885,
       "adhd-like symptoms in children":0.28150774847148785,
       "adhd-related cost study":0.0011366865586814436,
       "adhd-related costs":0.0017050298380221654,
       "seven european studies":0.0011366865586814436,
       "annual national costs":0.0011366865586814436,
       "€1 billion":0.0011366865586814436,
       "adhd-specific problems in daily life":0.32065522711986383,
       "adjunctive psychotherapy":0.30557913559438277,
       "suboptimal response":0.31287169644656015,
       "adjust the timing of the dose":0.30574202425941177,
       "excessive tiredness":0.3957033718597147,
       "stomachaches, nausea":0.3089534271535989,
       "adjusted odds ratio":0.31304245463809877,
       "cardiovascular disease diagnosis":0.3287887861912619,
       "drowsiness":0.3998410857515904,
       "trouble sleeping":0.3158001582990538,
       "adjusting the dose or timing may help":0.30476728879418513,
       "adjustment":0.3206104178371472,
       "administer the stimulant with meals to lessen its impact on appetite":0.3381412159237473,
       "helping the noncompliant child":0.3218698302528936,
       "homework organization":0.3218698302528936,
       "incredible years parenting program":0.3218698302528936,
       "new forest parenting program":0.33376318737890975,
       "nmu of amp":0.33087512980135936,
       "parent-child interaction therapy":0.3218698302528936,
       "positive parenting program (triple p)":0.3218698302528936,
       "self-monitoring skills":0.3218698302528936,
       "study skills":0.3218698302528936,
       "teacher ratings":0.3293079015419299,
       "young adults who do not attend college":0.33087512980135936,
       "intuniv":0.32973385312483844,
       "kapvay":0.32973385312483844,
       "qelbree":0.3383406798470175,
       "adult adhd quality measures initiative (aaqmi)":0.3059866831211824,
       "ahrq":0.31024856660481753,
       "candidate qms":0.30635440646850387,
       "clinical and research experts":0.30635440646850387,
       "delivery of quality health care to adults with adhd":0.3059866831211824,
       "development of qms":0.30635440646850387,
       "existing guidelines for adult adhd":0.30635440646850387,
       "expert opinion":0.3062726138089208,
       "extended-release":0.3358641706986716,
       "healthcare delivery":0.3062726138089208,
       "healthcare processes":0.3064362428265828,
       "immediate-release":0.3358641706986716,
       "limited access to treatment by skilled providers":0.3062726138089208,
       "multidisciplinary panel":0.30635440646850387,
       "clinical guidelines":0.3103324969623462,
       "qms":0.31087915312230696,
       "quality indicators":0.3082891897396702,
       "us agency for healthcare research and quality (ahrq)":0.30635440646850387,
       "adult adhd quality of life survey":0.32065522711986383,
       "adult adhd self-report scale":0.2894635566543812,
       "measure":0.3062726138089208,
       "affective lability scale –short form (als-18) ":0.32747475735692627,
       "affective reactivity index (ari)":0.32747475735692627,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":0.32747475735692627,
       "behavior rating inventory of executive function (brief or emotion control subscale)":0.32747475735692627,
       "brown add rating scales for children, adolescents and adults (badds)":0.32747475735692627,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":0.32766183233970664,
       "difﬁculties in emotion regulation scale (ders)":0.3278491211835704,
       "distress tolerance scale":0.32724121381295473,
       "drug holidays":0.32845929134468516,
       "emotion dysregulation scale, short version (eds-short)":0.32766183233970664,
       "emotion regulation checklist (erc)":0.32766183233970664,
       "emotion regulation index for adults and children (erica)":0.32766183233970664,
       "emotion regulation questionnaire (erq)":0.32794284591804257,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":0.32710124751106723,
       "expression and emotion scale for children (eesc)":0.3271478896396158,
       "frustration discomfort scale":0.32710124751106723,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":0.32724121381295473,
       "trials norms availability":0.32766183233970664,
       "adults (11 studies, 2909 participants)":0.31597412891373444,
       "adults (cortese et al., 2018a)":0.31597412891373444,
       "adults treated with viloxazine":0.31334173040735125,
       "adults unresponsive to mph trial":0.32332132892370713,
       "advancing age":0.3093283200812492,
       "adverse":0.3235493089892294,
       "clinical response":0.3249699929238847,
       "driving and work performance":0.32451034654068256,
       "emergency room visits":0.3220957672388917,
       "maximum daily dose":0.32501602918864225,
       "discontinuation":0.3129997476183664,
       "follow-up visit":0.3369493538027061,
       "medication response":0.3369493538027061,
       "health care facilities":0.3077103205529273,
       "adverse outcomes":0.255318066997844,
       "prevalence of stimulant nmu":0.33503039574220583,
       "adverse side effects of atomoxetine":0.29830817189476344,
       "monitoring and management":0.3157132448111498,
       "adverse side effects of guanfacine":0.29830817189476344,
       "adzenys xr -odt":0.292601473031836,
       "dexedrine spansule":0.292601473031836,
       "dyanavel xr":0.2924522817135278,
       "mydayis":0.292601473031836,
       "tips for using amphetamine-based medications":0.2924522817135278,
       "aerobic activity":0.2961135970628066,
       "improvement in the core symptoms of adhd":0.3137273554003317,
       "aerobic exercise":0.2961900529360477,
       "affective components of executive control":0.22446807064305113,
       "dopaminergic system":0.2899024703111733,
       "executive control":0.29019581963605184,
       "mood regulation":0.2899024703111733,
       "noradrenergic system":0.2899024703111733,
       "affordable care act":0.24342579841301068,
       "african-american students":0.30566055822576943,
       "viloxazine dose":0.3261248258767059,
       "liver problems":0.32043130587187507,
       "nausea/vomiting":0.32043130587187507,
       "viloxazine (qelbree)":0.3991454679962814,
       "agitation":0.3247400070831742,
       "expert clinicians":0.28764896565228504,
       "ahrq, medicare and medicaid":0.24342579841301068,
       "alcohol use disorder: treatment overview":0.2970336807408889,
       "counseling":0.22849199781322832,
       "limit their alcohol consumption":0.22846924417871198,
       "low-risk and risky alcohol use":0.22849199781322832,
       "opioid use disorder: treatment overview":0.22846924417871198,
       "stimulant use disorder: treatment overview":0.22846924417871198,
       "stimulants for adhd":0.2970336807408889,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":0.3190499443808407,
       "all-cause treatment discontinuation":0.3210590750129619,
       "dizziness":0.34709351740433064,
       "increased blood pressure and heart rate":0.2914862342831439,
       "itching":0.29144920605216285,
       "monitoring":0.2914862342831439,
       "rash":0.29144920605216285,
       "vomiting":0.3169344039290822,
       "motor or vocal tics":0.3382907918081135,
       "nonstimulants for adhd":0.3235036872592535,
       "alpha agonists (clonidine and guanfacine)":0.3914499488214683,
       "liver problems such as hepatitis":0.38886239831230945,
       "american academy of child and adolescent psychiatry adhd resource center":0.38611379165981585,
       "attention deficit disorder association (adda)":0.38611379165981585,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":0.3859838745024606,
       "centers for disease control and prevention (cdc) adhd":0.38611379165981585,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":0.38611379165981585,
       "national institute of mental health (nimh) adhd":0.3859838745024606,
       "the american professional society of adhd and related disorders (apsard)":0.38611379165981585,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":0.3859838745024606,
       "american academy of pediatricians":0.30820636083323827,
       "american professional society of adhd and related disorders":0.2835955686084828,
       "canadian adhd resource alliance":0.28356051786461817,
       "world federation of adhd":0.39536242461530685,
       "american psychopathological association":0.0011366865586814436,
       "pau l hoch award":0.0011366865586814436,
       "state university o f new york":0.0017050298380221654,
       "reasonable accommodations":0.2395122820798231,
       "amp":0.29657292528989476,
       "attention and impulsivity":0.31597412891373444,
       "cardiac arrest":0.31715346282037954,
       "cerebrovascular disease":0.31715346282037954,
       "daily timing":0.31597412891373444,
       "heart failure":0.31715346282037954,
       "ischemic heart disease":0.31715346282037954,
       "misuse and diversion":0.32649610787571165,
       "prescribing medications for adhd":0.32649610787571165,
       "prescription refill requests":0.32649610787571165,
       "risks of stimulant misuse and diversion":0.32649610787571165,
       "schedule ii controlled substances":0.32644965140048743,
       "short-acting amphetamines":0.31597412891373444,
       "studies regarding nmu of mph or amp":0.3212388896727283,
       "symptom control":0.31597412891373444,
       "tachyarrhythmias":0.31715346282037954,
       "venous thromboembolism":0.31715346282037954,
       "amphetamine formulations":0.31519276686943615,
       "lisdexamfetamine dimesylate (ldx)":0.3169344039290822,
       "amphetamine medication":0.28150774847148785,
       "amphetamine stimulants":0.32218623087243725,
       "children (7 studies, 1930 participants)":0.31632264580761416,
       "growth suppression":0.3253386486163678,
       "pregnant woman":0.3163662644846423,
       "youths (9 studies, 2677 participants)":0.31597412891373444,
       "analysis":0.28543022518569616,
       "discontinuation due to adverse event":0.32409777511550014,
       "lisdexamphetamine":0.32409777511550014,
       "worse anorexia":0.32409777511550014,
       "antacids":0.3210590750129619,
       "antecedents of behaviour":0.2943659417555332,
       "reinforcement techniques":0.2943659417555332,
       "anthony l. rostain":0.28920813690188146,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":0.28920813690188146,
       "anticipatory appraisal and valuation":0.29661126697383655,
       "emotion generation":0.2979595000055358,
       "emotional state":0.31754853287787205,
       "regulation":0.28575017437322525,
       "antipsychotics":0.32332132892370713,
       "not recommended adhd treatment":0.32332132892370713,
       "dry mouth":0.3355203495236364,
       "anxiety and substance use disorders":0.29222877977870665,
       "benzodiazepines":0.30610915944531364,
       "childhood irritability":0.38833584123944237,
       "opioid":0.32845929134468516,
       "any interpretation should keep in mind that the ratings are of relative importance":0.3224126124286995,
       "care coordination":0.3893903852753947,
       "care coordination and the patient experience domains":0.2431935711302338,
       "follow-up":0.3339089142836015,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":0.3224126124286995,
       "low rating only means that the item is not essential for documenting the basics of quality care":0.2431935711302338,
       "patient experience":0.28440413413197296,
       "patients and health care systems":0.24321935227845073,
       "quality diagnosis":0.32400623500107695,
       "quality in these domains may be viewed as less relevant":0.25041346322229047,
       "results may reflect a systematic bias in our sample of raters":0.24321935227845073,
       "should include other relevant stakeholders, including patients and health care systems":0.24321935227845073,
       "systematic bias in our sample of raters":0.24321935227845073,
       "apsard":0.28286131796851505,
       "apten sio xr":0.3347859550623998,
       "capsules":0.3347859550623998,
       "daytrana":0.3347859550623998,
       "focalin xr":0.32191499228884884,
       "liquid":0.3219601670000878,
       "patches":0.32191499228884884,
       "quillivant xr":0.3219601670000878,
       "ritalin la":0.32191499228884884,
       "arterial disease":0.31304245463809877,
       "asian federation of adhd":0.22300623542404993,
       "asian resource":0.28254780172938737,
       "assignments":0.28621359157218385,
       "association for behavior and cognitive therapies":0.2890259700230065,
       "behavioral therapist":0.3132989416963847,
       "caregivers of children age 6 to 12 years":0.3132989416963847,
       "centers for disease control and prevention (cdc)":0.3132989416963847,
       "association for child and adolescent mental health":0.0,
       "atomox etine":0.32691481191829946,
       "atomoxetine levels":0.3025966961280171,
       "atypical antidepressants":0.3267751246321928,
       "blood monitoring":0.3025966961280171,
       "brain cells communication":0.3025966961280171,
       "cardiac malformations":0.3213288725549896,
       "chemical messengers (norepinephrine)":0.3025966961280171,
       "constipation":0.3094117532087155,
       "correct dose":0.30255679151294024,
       "treatment discontinuation":0.3210590750129619,
       "tricyclic antidepressants (tcas)":0.3267751246321928,
       "atomoxetine treatment for adhd":0.29830817189476344,
       "attention and arousal":0.2244461113326771,
       "behavioral functioning":0.38748322074693897,
       "chronic condition management":0.38748322074693897,
       "information provision":0.38748322074693897,
       "dizziness and lightheadedness":0.3961132855736577,
       "fatigue":0.3985214782078558,
       "sedation":0.3957716318859109,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":0.3130851733136771,
       "behavioral management techniques that are used for children with adhd":0.2838060551759804,
       "coexisting conditions that are associated with adhd or mimic its symptoms":0.23784865747901987,
       "nonadherence to the treatment plan":0.2910425155451764,
       "repetition of the diagnostic evaluation":0.23784865747901987,
       "evidence-based statements about adhd":0.3876796468473514,
       "international consensus statement":0.38761414935675376,
       "meta-analyses and very large studies":0.3876796468473514,
       "parents' medication guide":0.38611379165981585,
       "parents' medication guidedysregulation":0.38696038961757895,
       "project steering committee":0.38761414935675376,
       "research and clinical care of adhd":0.38761414935675376,
       "scientific data":0.38761414935675376,
       "attention-deﬁcit/hyperactivity disorder":0.3026765369449374,
       "impulsive aggression":0.3086209510415154,
       "liver damage":0.3247400070831742,
       "psychotic symptoms":0.3247400070831742,
       "self-harming behavior":0.3247400070831742,
       "unusual changes in behavior":0.3247400070831742,
       "atx or dex":0.32332132892370713,
       "atx treatment":0.32332132892370713,
       "liver disease evaluation":0.32332132892370713,
       "augmentation strategies":0.2805439166107393,
       "charles bradley":0.28150774847148785,
       "child psychiatry":0.28147321188107294,
       "minimal brain dysfunction-related behaviors":0.28150774847148785,
       "morris et al. and o'neal and robins":0.28150774847148785,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":0.28682187148926436,
       "u.s. food and drug administration":0.3325537251837405,
       "world health organization":0.28147321188107294,
       "authors":0.27979123781007625,
       "emotional problems":0.30355757476086603,
       "seizures":0.3325537251837405,
       "sleep disorder":0.30355757476086603,
       "availability of treatment":0.2805782255157913,
       "avoid caffeine":0.22149914559206657,
       "evening":0.22162752608603414,
       "good sleep habits":0.28535922264211766,
       "avoid skipped doses":0.2847924714551422,
       "maladaptive emotions":0.2901224266619405,
       "bachelor's degree":0.29994615636588123,
       "dorsal anterior cingulate cortex":0.28331540504354474,
       "fmri meta-analyses":0.2824086841509879,
       "inferior frontal cortex":0.2922660063748568,
       "neutral fmri tasks":0.28237392615909235,
       "supplementary motor area":0.28237392615909235,
       "typically developing individuals":0.28237392615909235,
       "ventral anterior cingulate cortex":0.28331540504354474,
       "become unusually quiet or appear over-focused":0.3381412159237473,
       "child development":0.29429042458217364,
       "metacognitive executive function training":0.3158001582990538,
       "pre-kindergarten academic curriculum (stp-pre-k)":0.3158001582990538,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":0.3158001582990538,
       "tools":0.29429042458217364,
       "behavior modification system":0.29580816787553194,
       "behavior problems":0.33313317119829033,
       "blood pressure monitoring":0.31940528331374435,
       "chest pain":0.31940528331374435,
       "education on side effects":0.32400623500107695,
       "growth monitoring":0.31940528331374435,
       "heart rate assessment":0.31940528331374435,
       "impulsiveness":0.31940528331374435,
       "long-term use":0.3194497563412177,
       "mood monitoring":0.31940528331374435,
       "mood swings":0.32775545000608935,
       "palpitations":0.31940528331374435,
       "peripheral vasculopathy":0.3194497563412177,
       "raynaud’s phenomenon":0.3194497563412177,
       "severe allergic reactions":0.3194497563412177,
       "severe psychiatric symptoms":0.31940528331374435,
       "side effects information":0.3194497563412177,
       "sudden cardiac death":0.3236405910625794,
       "swelling of the face, lips, tongue, or throat":0.3194497563412177,
       "weight monitoring":0.31940528331374435,
       "blurred vision or other visual changes":0.30092971537809887,
       "development or worsening of motor or vocal tics":0.3087870996019685,
       "elevated blood pressure (hypertension)":0.3008902491859181,
       "especially in children":0.3008902491859181,
       "increased aggression or hostility":0.3008902491859181,
       "increased heart rate (tachycardia)":0.3008902491859181,
       "nervousness":0.3008902491859181,
       "rash or hypersensitivity reactions":0.30092971537809887,
       "skin reactions":0.30092971537809887,
       "trouble falling and staying asleep":0.3008902491859181,
       "visual disturbances":0.30092971537809887,
       "behavioral disinhibition":0.22844649507543818,
       "observed behavior":0.2407185132769516,
       "behavioral expression":0.2967263515316381,
       "behavioral indicators":0.2970721416603167,
       "subjective emotionality":0.2970721416603167,
       "high emotional thresholds":0.2938757717487672,
       "recovery times":0.29252685835045594,
       "quick return to baseline":0.29398874295779415,
       "behavioral response system":0.19362715419382442,
       "subjective/cognitive response system":0.19362715419382442,
       "child’s behavior":0.29444149769540884,
       "coping strategies":0.29444149769540884,
       "negative behaviors":0.29444149769540884,
       "negative thought patterns":0.29971105813750826,
       "parent -child relationship":0.29444149769540884,
       "positive behaviors":0.29444149769540884,
       "problematic behaviors":0.29444149769540884,
       "finding activities in which the child can be successful (eg, hobbies, sports)":0.2890259700230065,
       "identifying unintentional reinforcement of negative behaviors":0.2890259700230065,
       "keeping environmental distractions to a minimum":0.2890259700230065,
       "limiting choices":0.2890259700230065,
       "maintaining a daily schedule":0.2890259700230065,
       "national institute for children's health quality toolkit":0.2890259700230065,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":0.2890259700230065,
       "rewarding positive behavior (eg, with a 'token economy')":0.2890259700230065,
       "setting small, reachable goals":0.2890259700230065,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":0.2890259700230065,
       "using charts and checklists to help the child stay 'on task'":0.2890259700230065,
       "parenting context":0.2953131870308438,
       "pharmaco logical therapy":0.29916392620193316,
       "benefits and risks of treatment":0.2870012697076089,
       "best practices":0.24342579841301068,
       "best studies":0.22300623542404993,
       "pulse":0.293537378459906,
       "blood pressure and pulse quarterly":0.32236731067059515,
       "blood tests":0.3228663312753484,
       "bone fractures":0.30795814094531887,
       "borderline personality disorder":0.3026765369449374,
       "boundaries between adhd and other disorders":0.30096919192478366,
       "long-term side effects":0.3246940489729162,
       "broader scope of the review":0.2813006559640296,
       "bupropion (wellbutrin, zyban)":0.30275641990533464,
       "caddra":0.28286131796851505,
       "caffeine levels":0.3228663312753484,
       "calendar year":0.2876850344881035,
       "chelation":0.30920325472272586,
       "primary care practitioner":0.3219601670000878,
       "risks and benefits":0.30920325472272586,
       "nonmedical users":0.30509150931417894,
       "cardiac history or cardiac symptoms":0.23630529921131171,
       "cardiac review":0.3234580783931518,
       "cardiologist consultation":0.23630529921131171,
       "findings outside of normal limits":0.23630529921131171,
       "sudden death or ventricular arrhythmia":0.3233668992308141,
       "cardiovascular health":0.2961135970628066,
       "clinical response, duration of the effect during the day, and side effects":0.3094534866526336,
       "electrocardiogram (ecg)":0.23630529921131171,
       "low dose stimulant treatment":0.24488079304542915,
       "short-acting dextroamphetamine-amphetamine":0.23630529921131171,
       "child's height":0.3284122745551998,
       "child's weight":0.3284122745551998,
       "regular measurement":0.3284122745551998,
       "qm":0.28384116665132075,
       "quality care":0.2840168544246875,
       "treatment follow-up":0.2865353003675067,
       "care management plan":0.2904897632365948,
       "careful dose titration required":0.32327577145873265,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":0.32182468088688815,
       "child's practitioner":0.34381659673949133,
       "caregiver decision":0.30899503704277786,
       "catapres":0.29815310591846983,
       "category":0.28272189156409433,
       "causes":0.3113854709612684,
       "cbcl-dysregulation profile":0.3026765369449374,
       "emotional dysregulation scores":0.3026765369449374,
       "cbt group and individual therapy programs":0.29211715686817236,
       "cbt group treatment":0.31891689603039,
       "orthostatic hypotension":0.29854107352539044,
       "slow heart rate (bradycardia)":0.29854107352539044,
       "cereals":0.22149914559206657,
       "certain children":0.3090366581415175,
       "certain events":0.28074989599151073,
       "certain foci in the literature may have been missed":0.2813006559640296,
       "chadd website":0.2866426974066249,
       "coalition to prevent adhd medication misuse":0.2866426974066249,
       "college administrators":0.2866426974066249,
       "collegiate student leaders":0.2866426974066249,
       "cpamm":0.28682187148926436,
       "information about misuse and diversion":0.30635440646850387,
       "personnel":0.2866426974066249,
       "pharmaceutical industry":0.2866426974066249,
       "changing the drug":0.29263879464829406,
       "heart symptoms":0.34615089771312996,
       "height":0.33454187081403114,
       "long-term studies (lower risk of later cigarette or illegal substance use)":0.33819105985298137,
       "meal timing":0.3344443367409075,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":0.32182468088688815,
       "mental health challenges":0.32282090193367463,
       "mirtazapine":0.3344443367409075,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":0.3269614008896431,
       "mood problem":0.33459065918661596,
       "moodiness":0.340247389892129,
       "over-focused or repeated movements (tics or habits)":0.32182468088688815,
       "preparation":0.33454187081403114,
       "separate issue":0.33459065918661596,
       "sleep habits":0.3344443367409075,
       "worsened heart problems":0.32273008159271704,
       "zombie effect":0.32182468088688815,
       "child and adolescent psychiatrist":0.30275641990533464,
       "child psychologist":0.32182468088688815,
       "immediate action":0.3254309432684575,
       "medication holidays":0.30713362115697795,
       "childhood diagnosis of adhd":0.32029710317501403,
       "children in intervention group":0.3218698302528936,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":0.3381412159237473,
       "loss of appetite (anorexia)":0.3396429533741859,
       "monitor for changes in behavior and report to the healthcare provider":0.3381412159237473,
       "monitor your child closely for new or worsening tics":0.3381412159237473,
       "offer high-calorie snacks such as instant breakfast drinks":0.3381412159237473,
       "regularly check your child's weight to ensure they are growing normally":0.3381412159237473,
       "sleep intervention":0.32182468088688815,
       "teacher-reported behavior":0.3218698302528936,
       "cohort studies":0.3344443367409075,
       "children and youth with special health care needs":0.2957319090026586,
       "children who have not yet entered elementary school":0.2985799258254328,
       "classroom modifications":0.3033970047662822,
       "developmental behavioral pediatrician":0.30275641990533464,
       "intentional and unintentional injury":0.3033970047662822,
       "china adhd alliance":0.28286131796851505,
       "classroom modifications and accommodations":0.28924459783694223,
       "combined medication and behavior treatment":0.24288462312541031,
       "combined treatment":0.22383299024806105,
       "lower doses of medication":0.22383299024806105,
       "non-adhd symptoms":0.24288462312541031,
       "provision of tutoring or resource room support":0.28349044236286,
       "school-aged children":0.32359494358852264,
       "stressors in family life":0.2789068988624636,
       "suboptimal response to pharmacotherapy":0.2444633084755062,
       "normative data":0.29951542428754907,
       "parents and teacher reports":0.29893005212281765,
       "preschool teachers and clinicians":0.300574891922262,
       "ratings from other individuals":0.29854107352539044,
       "scales":0.2985799258254328,
       "secondary school teachers":0.29854107352539044,
       "self-report":0.3375939008302863,
       "structured behavioural observations":0.2985799258254328,
       "such as":0.30717474227374825,
       "tools for screening":0.30295631190315936,
       "longer acting than clonidine":0.29815310591846983,
       "short-acting medication":0.29815310591846983,
       "tenex":0.29815310591846983,
       "tic problems":0.29815310591846983,
       "close monitoring":0.3182533153062319,
       "close monitoring by healthcare provider":0.3100389391949494,
       "persistent adhd":0.29342475381028593,
       "cognitive components of executive control":0.22446807064305113,
       "cognitive flexibility":0.28265222989314104,
       "cognitive strengths and weaknesses":0.29596080366906935,
       "play-based interventions":0.3078341808724843,
       "problems with peers":0.29854107352539044,
       "psychotherapy interventions":0.3874177896053066,
       "students with disabilities":0.2957319090026586,
       "summer treatment camp":0.29580816787553194,
       "deficits":0.29615182006488006,
       "guided walks":0.2961135970628066,
       "increases the effectiveness of":0.31117430490202436,
       "organizational/planning skills":0.2961135970628066,
       "psychosocial well-being":0.2961135970628066,
       "yoga":0.2961135970628066,
       "patient's family":0.29908592752478497,
       "collateral report":0.28482782744166674,
       "colleagues":0.28335039521336614,
       "gpas":0.29994615636588123,
       "college peers":0.30188001974245077,
       "common misconceptions":0.30660004677838104,
       "nmu of mph":0.3073805131354,
       "nmu population prevalence":0.3085379437927146,
       "parents with suspected or diagnosed adhd":0.30566055822576943,
       "peer behavior":0.3059866831211824,
       "printed handouts":0.3059866831211824,
       "repetition":0.3059866831211824,
       "sanctions":0.3059866831211824,
       "social situations":0.30566055822576943,
       "us college populations":0.3155829642424519,
       "young adult populations":0.3059866831211824,
       "enforcement":0.32973385312483844,
       "incoming students":0.30570128581514,
       "com-ponents of emotional symptoms":0.2962665483009589,
       "different terms used to describe them":0.2962665483009589,
       "community psychosocial care":0.29211715686817236,
       "community support":0.301087683732628,
       "specific treatment approach":0.31253073832483663,
       "medication adherence":0.29990694771799026,
       "diagnostic challenges":0.2877571993029757,
       "simplex adhd":0.28772111237053244,
       "standard information gathering":0.2877571993029757,
       "comprehensive approach to literature on nmu":0.2813006559640296,
       "concerns being discussed":0.3028363450425853,
       "extended-release tablets":0.3158001582990538,
       "reduce the need to take multiple doses throughout the day":0.3158001582990538,
       "consistent sleep schedule":0.22149914559206657,
       "consult with healthcare provider":0.30845498118346676,
       "consult with the healthcare provider for further advice":0.30476728879418513,
       "contents":0.27982536285432685,
       "contraindications to drug treatment":0.290049070801849,
       "cooperating":0.28772111237053244,
       "ingroup therapy":0.29211715686817236,
       "integrative treatment program":0.29211715686817236,
       "parental satisfaction":0.29211715686817236,
       "core symptoms":0.30899503704277786,
       "corticocerebellar networks":0.2801670716867292,
       "criteria":0.28696537211289874,
       "critical care unit":0.29657292528989476,
       "current adhd symptoms":0.32029710317501403,
       "secular private schools":0.30476728879418513,
       "decongestants":0.3278022789030755,
       "food supplements":0.3182533153062319,
       "hepatitis":0.3182533153062319,
       "low dose medication":0.3182533153062319,
       "medication adjustment":0.3198059869030702,
       "medication with food":0.3182533153062319,
       "executive control and corticocerebellar networks":0.29126420592136926,
       "frontal and parietal cortical areas":0.2794164109173823,
       "inferior parietal and medial temporal regions":0.27931435963508955,
       "medial prefrontal and the posterior cingulate cortices":0.27931435963508955,
       "orbitofrontal cortex":0.27931435963508955,
       "reward system":0.3874177896053066,
       "thalamus":0.2803039890094839,
       "ventromedial prefrontal cortex":0.27931435963508955,
       "denmark, finland, sweden, norway, and iceland":0.31428604795104464,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":0.28920813690188146,
       "those reporting nmu in a survey of 4,297 us adults":0.0,
       "detect nmu":0.2910794405027437,
       "medical/neurological history":0.28986584334082444,
       "stimulant misuse risk assessment":0.3239147465823275,
       "deﬁcits in response inhibition to frustration":0.29219156266462376,
       "documented dsm-5 diagnosis of adhd":0.29368767921692596,
       "diagnostic guidelines":0.3017212191008187,
       "diagnostic utility for adhd":0.2962665483009589,
       "symptoms commonly occurring in other disorders":0.2962665483009589,
       "dietary restrictions":0.28261741192937,
       "disability services":0.3027963771997659,
       "discontinuing medication":0.30791680982990544,
       "discussions":0.3027963771997659,
       "discussions of transfer of care with new clinician made":0.3027963771997659,
       "emotional upsets":0.28074989599151073,
       "motivation":0.28074989599151073,
       "social payoff":0.28074989599151073,
       "diurnal variation in symptoms":0.32236731067059515,
       "malingering":0.30754532842394444,
       "pills per prescription":0.3346394617915148,
       "extended-release form":0.3218698302528936,
       "hydration":0.3237776107878388,
       "loss of appetite":0.31394200192154154,
       "medication form adjustment":0.3224579269209593,
       "more irritability or moodiness when taking medication":0.2897194279634582,
       "slowing of heart rate":0.33087512980135936,
       "snacks":0.3218698302528936,
       "supplemental medications":0.2897194279634582,
       "timing of medication":0.28968284722760423,
       "dmdd":0.3075041080341276,
       "intensified negative mood":0.3075041080341276,
       "document":0.28335039521336614,
       "documentation":0.31312790364987386,
       "frontal lobes":0.2244461113326771,
       "learning and memory":0.2244461113326771,
       "movement regulation":0.2244461113326771,
       "novelty processing":0.2244461113326771,
       "parietal cortex":0.2259937106030955,
       "reward processing":0.2244461113326771,
       "signal-to-noise processing":0.2244461113326771,
       "stress response":0.2244461113326771,
       "mood symptoms":0.32428101060673153,
       "time":0.335913345540648,
       "dose reduction":0.32668206607470107,
       "dosing":0.28873497986944696,
       "driving licenses suspension/revocation":0.38578916261016066,
       "driving performance improvement":0.3070925110484039,
       "gradually increase dose":0.2847924714551422,
       "monitor mood symptoms":0.28772111237053244,
       "excessive weight loss":0.3221409927046652,
       "dsm criteria":0.2913751778057691,
       "us college-aged women":0.3043226091050041,
       "eating foods high in added sugar":0.28804622097208105,
       "hyperactivity/impulsivity subtypes":0.28804622097208105,
       "inattention symptoms and unhealthy eating habits":0.28804622097208105,
       "monozygotic twins":0.28804622097208105,
       "unhealthy dietary habits":0.28804622097208105,
       "stimulant misuse":0.3232302268304629,
       "history of psychosis":0.28363062801862104,
       "prescribed stimulants":0.32173442014340564,
       "size":0.28714494994275663,
       "effect size findings":0.2910055999546709,
       "effective self-regulation":0.284509939241397,
       "effortful strategy":0.3246940489729162,
       "emotional arousal":0.3246940489729162,
       "high ei":0.2502222870588533,
       "reappraisal":0.32798972838350615,
       "self-monitoring":0.32798972838350615,
       "valuation":0.24744263913315637,
       "el":0.2822697034993388,
       "emotionally intense provocation":0.30907829045434804,
       "hyperactive-impulsive adhd presentations":0.2822697034993388,
       "inadequate self-control and weak behavioral inhibition":0.3042015579478422,
       "patients with no ei":0.2822697034993388,
       "rapid changes in emotional states":0.2867501749834553,
       "self-regulatory processes":0.2827915875807501,
       "elevated mood":0.3129997476183664,
       "elevation of blood pressure or heart rate":0.3094534866526336,
       "feeling sad":0.3084964569103974,
       "healthcare facility utilization":0.2986965434243752,
       "poison control centers data":0.24301325601553075,
       "sleep difficulties":0.2597993602131837,
       "study of 15,629 adults and adolescents":0.24301325601553075,
       "regulatory processes":0.2857145890464042,
       "emotional experience":0.3023574262048795,
       "emotional valence":0.3017212191008187,
       "heterogeneity":0.3053351277671847,
       "neural activation":0.30188001974245077,
       "poorly controlled emotionally driven behavior":0.2920799681785647,
       "self-regulatory deficits":0.30566055822576943,
       "self-regulatory deﬁcits":0.2920799681785647,
       "executive function control of emotional response":0.31776844183415864,
       "extended-release methylphenidate":0.30561984148696225,
       "intermittent explosive disorder":0.31445835389838617,
       "methylphenidate preparations":0.3043226091050041,
       "oppositional deﬁant disorder":0.3026765369449374,
       "emotional functioning":0.281645979627133,
       "impaired":0.32318469503347313,
       "emotional instability":0.29342475381028593,
       "negative emotion":0.2819921521684643,
       "emotional reactivity":0.29338723146325135,
       "high emotional impulsivity":0.2862493013153619,
       "response systems":0.24051663172687135,
       "future development of adhd criteria":0.2962665483009589,
       "measurement tool/assessment instrument":0.2962665483009589,
       "mistake for emotional symptoms to be specific for adhd":0.2962665483009589,
       "multidimensional nature of emotional symptoms":0.2962665483009589,
       "stephen v. faraone":0.28920813690188146,
       "evidence-based assertions":0.38624379630347233,
       "findings":0.2838060551759804,
       "manuscript":0.27982536285432685,
       "participants":0.2962665483009589,
       "waiting-list controls":0.2818189595925102,
       "encourage good sleep habits":0.30476728879418513,
       "eunethydis":0.3059050866723501,
       "euphoria":0.3129997476183664,
       "european network adult adhd":0.28286131796851505,
       "evaluation":0.28482782744166674,
       "frozen yogurt":0.22149914559206657,
       "instant breakfast drinks":0.22149914559206657,
       "limit naps to less than 45 minutes":0.22149914559206657,
       "reduce screen time before bed":0.22149914559206657,
       "evidenced based fda approved medication":0.32182468088688815,
       "exacerbation":0.3129997476183664,
       "give medication with food to minimize stomach discomfort":0.30476728879418513,
       "irritability or aggression (infrequent)":0.30480777866914116,
       "monitor headaches and consult with the healthcare provider":0.30476728879418513,
       "monitor irritability and consult with the healthcare provider":0.30480777866914116,
       "some children do better with the daily dose divided into two doses":0.30476728879418513,
       "start with a low dose and gradually increase":0.30476728879418513,
       "this side effect usually improves over time":0.30476728879418513,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":0.18227442202610836,
       "exclusion criteria":0.30271647315511624,
       "extended time":0.28621359157218385,
       "factors leading to favorable outcomes":0.24342579841301068,
       "fear of exposing nmu or minor unwanted effects":0.2813006559640296,
       "individuals who experience minor unwanted effects":0.2813006559640296,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":0.18227442202610836,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":0.18227442202610836,
       "feigned":0.32218623087243725,
       "genu ine":0.32218623087243725,
       "ferritin":0.29067378057045806,
       "serum":0.290636958454855,
       "serum iron":0.290636958454855,
       "findings of interest":0.30164188141501785,
       "misusers":0.30188001974245077,
       "first drug treatment try":0.32327577145873265,
       "fluctuating periods of remission and recurrence":0.28815475383604944,
       "patient's symptoms":0.3228663312753484,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":0.0008525149190110827,
       "patients with neither one physician visit nor medication claim in 6 months":0.0008525149190110827,
       "use of outside provider for adhd diagnosis":0.0008525149190110827,
       "job/school performance":0.32236731067059515,
       "medication side effects/toxicity or signs of abuse/diversion":0.32236731067059515,
       "potential side effects of atx":0.3224126124286995,
       "relationship issues":0.32236731067059515,
       "sexual dysfunction and dysmenorrhea":0.3224126124286995,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":0.32236731067059515,
       "target symptoms":0.32236731067059515,
       "vital signs":0.3247400070831742,
       "food":0.29263879464829406,
       "foxp1":0.27873747418814554,
       "synapse formation":0.27873747418814554,
       "friendships":0.28772111237053244,
       "functional impairment related to adhd":0.32065522711986383,
       "functional outcomes":0.32065522711986383,
       "insights into key details of nmu":0.2813006559640296,
       "general qol measures for adults":0.32065522711986383,
       "generic medication preparations":0.2526749063923596,
       "pharmacies":0.2526749063923596,
       "united kingdom":0.2883358238082978,
       "grade point average (gpa)":0.2982693902811526,
       "greater family cohesion":0.301087683732628,
       "group of experts":0.22302791387602078,
       "organizations that study and treat adhd":0.22302791387602078,
       "severe hypotension":0.30791680982990544,
       "guanfacine treatment for adhd":0.29830817189476344,
       "individuals who abused":0.29657292528989476,
       "minor toxicity":0.29657292528989476,
       "poison control centers":0.29657292528989476,
       "health effects":0.3275682681385816,
       "icasa":0.28286131796851505,
       "national health and medical research council (australia)":0.28286131796851505,
       "ukaan":0.28286131796851505,
       "heart rate monitoring":0.2982693902811526,
       "high risk for nmu":0.3275682681385816,
       "high risk patients":0.2847924714551422,
       "high-calorie foods":0.292601473031836,
       "high-quality studies":0.22300623542404993,
       "high-risk populations":0.3214639414379467,
       "prisoners":0.3206104178371472,
       "vulnerability to psychosis":0.31291436852736304,
       "holidays":0.32074488327172174,
       "household public assistance":0.301087683732628,
       "huybrechts et al., 2018":0.31428604795104464,
       "hyperactive-impulsive symptoms":0.3018403039129885,
       "id":0.32218623087243725,
       "immediate-release preparations allowed":0.32327577145873265,
       "physical functioning":0.281645979627133,
       "school functioning":0.281645979627133,
       "popularity":0.28772111237053244,
       "reciprocity":0.28772111237053244,
       "rejection/likability":0.28772111237053244,
       "sharing":0.28772111237053244,
       "socializing with peers":0.28772111237053244,
       "turn-taking":0.28772111237053244,
       "meditation-based therapy":0.32043130587187507,
       "in insomnia":0.3094534866526336,
       "inclusion criteria":0.28935403582325964,
       "medications misuse":0.3027963771997659,
       "individuals at greatest risk":0.2910794405027437,
       "study routes of administration":0.2910794405027437,
       "individuals who die from stimulant overdoses":0.2813006559640296,
       "information about negative academic or health effects":0.32332132892370713,
       "willingness to use stimulants":0.32332132892370713,
       "patient preference":0.2805782255157913,
       "insu fflation":0.3222767453353878,
       "smok ing":0.3223220216412792,
       "stimulant s":0.3222767453353878,
       "us adults":0.3223220216412792,
       "insurance companies":0.24342579841301068,
       "large studies":0.2954272662944406,
       "new scientific findings from the past 20 years":0.22300623542404993,
       "specific search terms":0.22300623542404993,
       "international society of psychiatric geneti cs":0.0011366865586814436,
       "lifetime ach ievement award":0.0011366865586814436,
       "internet":0.3291189427689895,
       "intolerance":0.32584691805746707,
       "intuniv (guanfacine)":0.3109634250532157,
       "irritability in adhd":0.29219156266462376,
       "irritability in odd":0.29219156266462376,
       "vulnerability for emotional disorders (mood and anxiety)":0.29219156266462376,
       "legal issue":0.3240519985935912,
       "liver function tests":0.2982693902811526,
       "long-acting preparations recommended":0.32327577145873265,
       "long-term outcomes":0.30791680982990544,
       "low initial doses recommended":0.32327577145873265,
       "neuroenhancement":0.2909317968605917,
       "mania":0.290049070801849,
       "randomized trial":0.28261741192937,
       "medial frontal reductions":0.2883720651134522,
       "medical causes of adhd symptoms":0.32034182491519486,
       "problems":0.33611018898954376,
       "safe storage":0.3330364566762412,
       "medication choice":0.3098295948740885,
       "medication contract":0.32218623087243725,
       "patient commitment":0.32218623087243725,
       "patient values and preferences":0.30899503704277786,
       "phone calls":0.2876850344881035,
       "target outcomes":0.30899503704277786,
       "stimulant therapy dose":0.2822697034993388,
       "medication trial":0.32327577145873265,
       "naturalistic studies":0.32065522711986383,
       "quality of life enjoyment and satisfaction questionnaire":0.32065522711986383,
       "weiss functional impairment rating scale":0.32074488327172174,
       "neuronal development":0.27870361395075627,
       "neuronal proliferation":0.27870361395075627,
       "synapse development":0.27870361395075627,
       "mental health assessment":0.2982693902811526,
       "standardized mean difference":0.2910055999546709,
       "pregnancies in denmark":0.31402794279258495,
       "pregnancies in the united states":0.31402794279258495,
       "time course for improvement":0.31428604795104464,
       "united states":0.31428604795104464,
       "new onset":0.3129997476183664,
       "motiv ations":0.30164188141501785,
       "outcomes associated with nmu":0.30164188141501785,
       "risk factors":0.30509150931417894,
       "risk reduction methods":0.30215832346142835,
       "mon itoring body mass index":0.29263879464829406,
       "severe mood swings":0.2982693902811526,
       "sweating of the face, lips, tongue, or throat":0.3002994960788777,
       "underlying heart conditions":0.29830817189476344,
       "national survey on drug use and health (nsduh)":0.30188001974245077,
       "neurotransmitters":0.3220957672388917,
       "new clinician":0.3027963771997659,
       "us data bases":0.30188001974245077,
       "pediatricians":0.32327577145873265,
       "performance enhancement":0.32327577145873265,
       "research methods":0.2910794405027437,
       "stimulant-naïve college students":0.32327577145873265,
       "nmu crisis":0.297149093387207,
       "nmu of prescription stimulants is highly prevalent":0.2813006559640296,
       "wide variations in the definition of nmu":0.2813006559640296,
       "performance enhancing drugs":0.32409777511550014,
       "performance validity tests":0.32409777511550014,
       "societal pressures to seek high levels of achievement":0.32409777511550014,
       "symptom validity tests":0.32409777511550014,
       "none":0.0,
       "nonmedical use and diversion":0.29455490435776427,
       "nonmedical use and diversion of prescription stimulants":0.2377008029468116,
       "overdose":0.28873497986944696,
       "therapeutic range":0.28873497986944696,
       "numbers":0.28335039521336614,
       "offspring of mothers with a single prior miscarriage":0.0,
       "organizational structure or systems":0.24342579841301068,
       "pill counts":0.3025168974212323,
       "symptoms and prescription refill requests":0.30355757476086603,
       "patient perceptions":0.24342579841301068,
       "patient supply":0.32218623087243725,
       "patient-generated goals discussed":0.3027963771997659,
       "patients leaving practice":0.3027963771997659,
       "patients seen within a timely fashion":0.3028363450425853,
       "seen within a timely fashion":0.3028363450425853,
       "patients with documentation of concerns being discussed":0.3028363450425853,
       "patients with documented satisfaction assessment":0.3028363450425853,
       "satisfaction assessment at least annually":0.3028363450425853,
       "psychosocial treatment":0.3027963771997659,
       "transfer of care":0.3027963771997659,
       "poison control centers and dawn data":0.2813006559640296,
       "population":0.2502768790272309,
       "preferential seating":0.28621359157218385,
       "teacher":0.28621359157218385,
       "safeguards":0.32218623087243725,
       "prescription for adhd medication":0.3222314817475598,
       "suds":0.3222314817475598,
       "theft":0.3098295948740885,
       "serious health outcomes":0.3002994960788777,
       "trends in nmu":0.25145639522606594,
       "stimulant treatment history":0.3222314817475598,
       "subsequent substance use, abuse, or dependence":0.3222314817475598,
       "surgical treatment":0.32218623087243725,
       "primary inattentive adhd":0.3018403039129885,
       "psychostimulant medications":0.2377500673619301,
       "risk of psychosis":0.2377500673619301,
       "qol benefits":0.30791680982990544,
       "rating scales with adult norms":0.32029710317501403,
       "sustained remission":0.28815475383604944,
       "regional and national databases":0.28331540504354474,
       "research participants":0.28335039521336614,
       "signatories":0.28335039521336614,
       "topic":0.28335039521336614,
       "residential instability":0.301087683732628,
       "risk for adverse events":0.28924459783694223,
       "risky behaviors":0.3018403039129885,
       "treatment alternatives, benefits and risks have been discussed":0.2904897632365948,
       "validated measure":0.28136965293630434,
       "stimulant overdoses before contacting emergency services":0.2813006559640296,
       "systematic literature review":0.2813006559640296,
       "study selection":0.28935403582325964,
       "structural magnetic resonance imaging (mri) data":0.22370204271086444,
       "treatment discontinuity":0.30791680982990544,
       "taking medication":0.29263879464829406,
       "verbal working memory":0.32191499228884884
    },
    "eigenvector_centrality":{
       "adhd":0.5517308863126106,
       "$77.5 to $115.9 billion":0.0015110778221744156,
       "adolescents and young adults with adhd":0.05918989171823355,
       "substantial impairments":0.002220426374809201,
       "traffic accidents":0.002220426374809201,
       "% of patients medicated for adhd ":0.0005361888288254224,
       "prescription refills are coordinated with other prescribers":0.0015859252618896187,
       "transition care coordinated for vacations and other times away":0.0015859252618896187,
       "% patients evaluated with parent vanderbilt rating scales":1.911678540154288e-29,
       "% patients meeting dsm criteria for adhd":3.8233570803162887e-29,
       "% patients treated with psychostimulant medication":3.8233570803162887e-29,
       "% patients evaluated with teacher vanderbilt rating scales":1.911678540154288e-29,
       "% patients on medication with at least 2 follow-up visits a year in record":1.911678540154288e-29,
       "% patients seen within 30 days medication initiation":1.911678540154288e-29,
       "% patients whose medical record contains documentation of dsm criteria":1.911678540154288e-29,
       "confirmation of impairment in 2+ settings":1.911678540154288e-29,
       "seen within one month of first prescription":0.0015859252618896187,
       "screening":0.021928493518849745,
       "% patients stabilized on an adhd medication ":0.004413157067736815,
       "seen at least once per year":0.0017293636445820685,
       "communication with other health care providers occurs at least annually":0.0015859252618896187,
       "external treatment resources":0.0015859252618896187,
       "prescription monitoring program consulted at least annually":0.0015859252618896187,
       "psychosocial and educational needs have been re-evaluated at least annually":0.0015859252618896187,
       "risks and benefits of stopping treatment discussed at least annually":0.0015859252618896187,
       "substance use evaluated at least annually":0.0015859252618896187,
       "vitals taken at least annually":0.0016269925983945835,
       "% patients with adhd with documentation of impairment":0.0011910750329247116,
       "1.4 million individuals":0.006517099271229316,
       "amphetamine":0.08935561243218773,
       "intentional, nontherapeutic use":0.013984008178095036,
       "stimulants":0.17110252263991138,
       "2000 people":0.0037534096175375663,
       "adhd medication":0.11732846798878989,
       "medical literature":0.008099254053455037,
       "studies":0.03262999498516506,
       "28 adhd experts":0.0015769713615808078,
       "draft list of 46 qms":0.002532978036369408,
       "quality measure":0.0046827713121998125,
       "2–4 hours":0.01497672404469686,
       "adhd impairments":0.02913373773833271,
       "long acting":0.024934297516516574,
       "short acting":0.024934297516516574,
       "4.4% of adults":0.0015110778221744156,
       "40-50 percent of participants met adhd criteria at any given follow-up":0.0017426706499633886,
       "recurrence":0.023456459639214458,
       "remission":0.027600777991716615,
       "48 cohorts":2.7446689221767523e-05,
       "structural grey matter volume reductions":0.0011284280832088939,
       "5 mg orally in the morning on the first day":7.917337673768434e-05,
       "cardiovascular history":0.003254927144999716,
       "5.9%":0.017092358912843466,
       "thorough evaluation":0.019574060132880256,
       "adolescence":0.1485230479748904,
       "50":0.018063247589428944,
       "adult":0.06045915746394909,
       "daily report card":0.0036211260035949773,
       "5mg and 10mg":0.003922723816284268,
       "concerta":0.004719691882659742,
       "dose":0.0369188998173101,
       "long-acting medications":0.004104709236384359,
       "dexmethylphenidate":0.11944289043303734,
       "79 authors":0.013896038047537968,
       "authors from 27 countries and 6 continents":0.014540802586207406,
       "empirically supported statements":0.01895142745741682,
       "a death in the family":0.013545893143206648,
       "rutter's indicators of adversity":0.01874966885701458,
       "a father or brother or sister with epilepsy":0.01350296481020787,
       "epilepsy":0.016941584951567466,
       "a frequent complaint among users":0.006827233860043714,
       "behavioral changes":0.020036350162871787,
       "cardiovascular effects":0.03639294190267857,
       "central nervous system effects":0.044655308973119597,
       "gastrointestinal issues":0.038137983270887514,
       "mental conditions":0.07137875694395586,
       "sleep disturbances":0.04517813353944388,
       "a person's mother with epilepsy":0.01350296481020787,
       "abdominal pain":0.037140336615730206,
       "abnormalities of chromosomes":0.014407983433583741,
       "adhd and many other psychiatric disorders":0.01662373145340474,
       "high polygenic risk for adhd":0.020536119842895394,
       "polygenic risk":0.01788963976497405,
       "abstinence is not an absolute precondition to start treatment":0.021387850307958298,
       "drug treatment":0.15649547640302516,
       "stabilize substance use":0.021387850307958298,
       "abstract problem solving":0.01707978134179508,
       "basal ganglia":0.029083869668428863,
       "focused attention":0.015872033805865805,
       "inhibitory control":0.022980779002529365,
       "adhd individuals":0.04092042950068276,
       "sustained attention":0.01890911007646647,
       "verbal memory":0.015872033805865805,
       "working memory":0.02391731172195515,
       "abuse":0.031298276326466666,
       "diversion":0.02916962463301127,
       "misuse":0.05021963939027501,
       "nmu":0.04741726250655167,
       "nmu of stimulants":0.04178000529611523,
       "abuse liability":0.0015224921694042771,
       "nortriptyline":0.032054322310750616,
       "tricyclic antidepressant":0.032054322310750616,
       "abuse of prescription drugs":0.006517099271229316,
       "alcohol":0.0401705883588997,
       "atomoxetine":0.09647046666282488,
       "long -acting stimulants":0.01973988432255442,
       "norepinephrine reuptake inhibitors":0.021950833608025466,
       "short-acting stimulants":0.01973988432255442,
       "treatment ending early as the result of adverse events":0.01973988432255442,
       "abuse, misuse and diversion":0.007137833115248435,
       "adh d medications":0.00018783684506844394,
       "asthma medications":0.0007719115003096627,
       "multiple prescribers":0.00018783684506844394,
       "prescriptions at multiple pharmacies":0.00018783684506844394,
       "shopping behavior":0.024802430018955476,
       "academic activity":0.017083884336352245,
       "stimulant use":0.02959522466637826,
       "weekends":0.02081156084912538,
       "academic difficulties":0.003146784956543712,
       "academic dishonesty":0.005055265713353936,
       "academic function":0.016589617693211565,
       "academic integrity policies":0.019027297827433114,
       "alcohol/drug use policies":0.005507159646159213,
       "nmu (non-medical use)":0.031186361525463117,
       "students who reported nmu":4.207284064253223e-05,
       "academic outcomes":0.03544918467192895,
       "adverse medical outcomes":0.030838204463076727,
       "amp abuse":0.004566296957307517,
       "clinically significant effects":0.00467737490812371,
       "clinician":0.04057216922177125,
       "co-occurring disorders":0.014555034511616551,
       "college graduation":0.00467737490812371,
       "exposures":0.004566296957307517,
       "family or friends":0.020033381744821773,
       "disorders":0.021988004200068908,
       "intravenous abusers":0.004566296957307517,
       "intravenous":0.009361730669832147,
       "longitudinal study":0.00467737490812371,
       "nasal abusers":0.004566296957307517,
       "nmu behavior":0.004979497206672402,
       "patient education":0.015682832272277063,
       "poison control calls":0.00467737490812371,
       "practitioner":0.025792984789109727,
       "prevention strategies":0.009671761714158999,
       "rating scales":0.02633219941963069,
       "risk of dying":0.00831976256794574,
       "adverse effects":0.08963817087627035,
       "social interactions":0.015531329110567205,
       "treatment plan":0.03289008285535373,
       "academic performance enhancement":0.002308950493743836,
       "educational attainment":0.020660287200890658,
       "misuse and diversion of stimulant medications":0.006107561850311428,
       "non-medical use of prescribed stimulants":0.003893044895392785,
       "psychotic events":0.006107561850311428,
       "academic skills":0.016225347990489677,
       "accommodations":0.016808175575188544,
       "symptoms":0.0713734946271406,
       "inattention symptoms":0.019355104714519494,
       "accidental injuries":0.03133326554845989,
       "depression":0.06798177487041683,
       "sleep issues":0.03361431265828883,
       "substance abuse":0.07280337401787258,
       "attempted suicide":0.08116189018163857,
       "mortality":0.03471404799396226,
       "motor tics":0.06382118231525961,
       "accidental physical injuries":0.013846682456645812,
       "bullying":0.013846682456645812,
       "burn injuries":0.017566493878255006,
       "accidental poisoning":0.005661285733713366,
       "accidents":0.015341076498103944,
       "further reduce qol":0.015341076498103944,
       "americans with disabilities act":0.0021833736274404613,
       "classroom-based programs":0.002479462839338388,
       "disability":0.002145048121663502,
       "idea (pl-101-476)":0.002145048121663502,
       "school-based interventions":0.020963686090175425,
       "section 504 of the rehabilitation act of 1973":0.002094110388316326,
       "accommodations for children with adhd":0.006564894540417904,
       "brand medication":0.013838005470069888,
       "generic medication":0.013853639237685525,
       "medications for children with adhd":0.013838005470069888,
       "accurate diagnosis":0.013565487120246434,
       "activated emotions":0.0004772435766988894,
       "adhd child":0.001448998581843867,
       "ei (emotional impulsivity)":0.018168831749400774,
       "activation of mania or hypomania":0.016788168378977786,
       "viloxazine":0.05156106355717606,
       "active substance use disorder":0.018529564031284078,
       "adhd patients with co-occurring sud":0.01407017916445142,
       "cocaine use disorder":0.015332704497703707,
       "dextroamphetamine-amphetamine":0.02229538926008499,
       "nicotine dependence":0.015332704497703707,
       "opioid dependence":0.013540682337486384,
       "active substance use disorder (sud)":0.017404554313533962,
       "tcas":0.010212460069278013,
       "acupuncture, yoga, and ayurvedic therapies":0.013567730733311429,
       "adhd symptoms or associated impairments":0.019668746929536393,
       "acute co-administration of alcohol and stimulants":0.0031023497067356478,
       "health consequences":0.0031023497067356478,
       "acute mania":0.0053148205649943105,
       "psychosis":0.032343173412725114,
       "stimulant adverse effects":0.020366726599888814,
       "adderall":0.01915596412582599,
       "form":0.0014644270639553468,
       "form and doses":0.005413303482996189,
       "usage":0.002396278951085278,
       "adderall xr":0.006944670450085112,
       "bubblegum flavor":0.0003631632980345789,
       "children who have trouble swallowing pills":0.0003631632980345789,
       "evekeo":0.0003719971427088418,
       "morning":0.004174059755669898,
       "procentra":0.004174059755669898,
       "adhd symptoms":0.13279206082636863,
       "symptoms throughout the day":0.0003719971427088417,
       "symptoms with just one dose":0.0003631632980345789,
       "vyvanse":0.026509915579244366,
       "zenzedi":0.0035165472065192705,
       "addiction":0.005038610222709191,
       "misuse of prescription drugs":0.011404531837647964,
       "additional meals or snacks":0.0010919060678331678,
       "weight loss":0.03930502378226128,
       "weight loss in people with adhd":0.006673631706854763,
       "additional pharmacotherapy":0.005456966318779582,
       "adhd patients":0.061059067267594004,
       "aggression and emotionaldysregulation":0.0015380808569030453,
       "atomoxetine (atx)":0.0054569663187795815,
       "callous emotional traits":0.0015380808569030453,
       "child emotionality":0.0015380808569030453,
       "emotion dysregulation":0.05385333701602787,
       "emotional dysregulation symptoms":0.012376723156102186,
       "odd symptoms":0.0015380808569030453,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":0.0015380808569030453,
       "additional problems the patient may have":0.013872194382704416,
       "adhd clinical diagnoses":0.03249040275041503,
       "address this growing public health problem":0.004655752394039143,
       "consistent nomenclature":0.0012667052857070395,
       "definition of nmu":0.0012667052857070395,
       "epidemic levels":0.0022288275100065787,
       "health care professionals":0.004659872572083439,
       "patient advocacy groups":0.0012366256369035844,
       "prescription stimulant":0.03449692074287051,
       "surveys and databases":0.0012366256369035844,
       "genomewide study":1.436854441826503e-49,
       "adhd -iv rating scales":0.014282055080112514,
       "adhd aetiology":0.013456773252208495,
       "adhd biological pathways":0.013556500713992828,
       "adhd children":0.06012719599110862,
       "adhd controls":0.013438344652487177,
       "adhd criteria":0.022321491023900877,
       "adhd and emotional dysregulation":0.036012401179929425,
       "adhd genetic liability":0.014795691096394347,
       "adhd genetic risk":0.01341933513504327,
       "adhd guideline ng87":0.01341933513504327,
       "adhd guidelines":0.02045421431152493,
       "adhd in females":0.017724298317448883,
       "adhd in their children":0.01341933513504327,
       "adhd investigator symptom rating scale (aisrs)":0.013649660891833242,
       "adhd lifespan course":0.01341933513504327,
       "adhd medication use":0.019978560534837563,
       "adhd medications (primarily stimulants)":0.022383516916761947,
       "adhd presentation":0.013450291286720872,
       "adhd probands":0.014667055620055767,
       "adhd prototype":0.013777512809085285,
       "adhd research":0.022511178671306514,
       "adhd severity fluctuations":0.01341933513504327,
       "adhd symptoms (e.g., aggression, hyperactivity)":0.014663035928506585,
       "adhd symptoms/b ehaviors":0.020016651241797873,
       "adhd traits":0.025127448511529312,
       "adhd treatment effectiveness":0.01341933513504327,
       "adhd outcomes":0.020104194446552957,
       "adhd treatment response":0.01341933513504327,
       "adhd-associated iq deficits":0.014912062523961732,
       "adhd-c":0.017178894022311222,
       "adhd-like behaviors and their associated impairments":0.01341933513504327,
       "adhd-like symptoms":0.02781332380192314,
       "adhd-related brain structural differences":0.01758123715218651,
       "adhd-related hospital admissions":0.01341933513504327,
       "adherence":0.02806073562571612,
       "adverse outcomes later in life":0.013567730733311429,
       "age":0.03920775763793841,
       "age 25":0.018063247589428944,
       "age at diagnosis":0.017032002048977823,
       "age at menopause":0.025836822313673062,
       "age at onset":0.01341933513504327,
       "age at onset variation":0.01341933513504327,
       "age of first birth":0.025836822313673062,
       "air pollution":0.01341933513504327,
       "alexander crichton":0.014122500692346855,
       "allergic reactions":0.03690872965545904,
       "allergic rhinitis":0.014509465800714348,
       "alpha agonists":0.02253702934943727,
       "alpha-2 adrenergic agonists (clonidine)":0.014065191501885574,
       "alpha-2 adrenergic agonists (guanfacine)":0.014065191501885574,
       "amblyopia":0.01341933513504327,
       "amygdala":0.01950721961293989,
       "ankylosing spondylitis":0.01350296481020787,
       "antidepressant":0.026595368700524348,
       "antisocial behaviour":0.014829515728762703,
       "antisocial personality disorder (aspd)":0.013519000233150304,
       "anxiety":0.05702982890220627,
       "anxiety disorder":0.04651784596037529,
       "anxiety or depression":0.014407983433583741,
       "anxiety or tics":0.019107725442417556,
       "appetite suppression":0.01989810915104432,
       "arbor pharmaceuticals, llc":0.013930100168772296,
       "arithmetic":0.014337045163021155,
       "arrested":0.014550606878642635,
       "artificial food color exclusion":0.02453724362836153,
       "artificial food dyes":0.014302714402061939,
       "asd":0.02607466035505931,
       "asd and adhd":0.014758499040267955,
       "aspd":0.014550606878642635,
       "assessment and treatment response":0.013937445272185319,
       "assets and strengths":0.013797091282870317,
       "asthma":0.02319546164936578,
       "asthmatic mothers":0.01662748992616355,
       "astigmatism":0.01341933513504327,
       "at all ages":0.013493449152063464,
       "atomoxetine dosing":0.027677646060490953,
       "atopic dermatitis":0.014501602235739234,
       "attention":0.027985597720377665,
       "attention and cognitive control networks":0.013467589755616193,
       "attention and somatoform networks":0.013467589755616193,
       "attention and working memory tasks":0.013795232157575546,
       "atx":0.04176817305728934,
       "augusto vidal perera":0.01880469893086918,
       "autism":0.05457325617007927,
       "autoimmune disease":0.01476370108719746,
       "autoimmune thyroid disease":0.01350296481020787,
       "behavior":0.03798056961623314,
       "behavior management":0.01843920169547882,
       "behavior management training":0.014534688887551854,
       "behavior modification":0.01769827627915763,
       "behavior therapy":0.0429070856035319,
       "behavior therapy principles":0.014343244956581869,
       "behavioral and mental health assessment":0.03476688093899333,
       "behavioral intervention":0.021931429717156538,
       "behavior monitoring":0.02211935147441659,
       "behavioral regulation index of the brief-a":0.02483392327528658,
       "behavioral responses":0.013990937990303551,
       "behavioral responses and emotional responses":0.013990937990303551,
       "behavioural interventions":0.028202786524828098,
       "benefits for adhd":0.013819318384214905,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":0.013564388406246545,
       "biologic vulnerability":0.01588678260290875,
       "biological and psychological causal mechanisms":0.013894385538092663,
       "biological pathways":0.013954223797187516,
       "biological test":0.013872194382704416,
       "bipolar disorder":0.03820114310894501,
       "black and latin minority youth":0.01341933513504327,
       "black individuals":0.015705405338140285,
       "black patients with adhd":0.01341933513504327,
       "blood lead levels":0.015457659206675599,
       "blood pressure":0.0354354848285173,
       "body mass index":0.02690340139817321,
       "boys":0.01931608161671099,
       "boys and girls":0.013668612967887716,
       "boys born to women who lost a close relative during pregnancy":0.017646160058037135,
       "boys with adhd":0.024956922528977375,
       "brain":0.02166050181551492,
       "brain areas involved in cognition":0.020000088046201545,
       "brain differences":0.013797091282870317,
       "brain functioning":0.01341933513504327,
       "brain imaging":0.015047054022765436,
       "brain imaging studies":0.014391625224369153,
       "brain volumes":0.017163681973817457,
       "brain-specific neuronal subtypes":0.01341933513504327,
       "brains of people with adhd":0.016888621953865948,
       "breastfeeding women":0.016589617693211565,
       "brief behavioral sleep intervention":0.013949627891263076,
       "bupropion":0.05957943212362251,
       "bupropion extended-release":0.014515488544982011,
       "cannabis abuse or dependence":0.01949659366226388,
       "cannabis use disorder":0.027231570960907024,
       "cardiometabolic disease":0.01570909391697055,
       "cardiac events":0.060531565794695104,
       "cardiovascular monitoring":0.034104957280881816,
       "care":0.017206852674810928,
       "caregiver":0.030392567446828635,
       "cause of adhd":0.013451040448695377,
       "cbt":0.048345353515931236,
       "cbt methods for emotional dysregulation issues":0.01662748992616355,
       "cbt and dbt program":0.01403812838176792,
       "cd":0.024791585965412914,
       "celiac disease":0.018854317046269147,
       "central nervous system injury":0.01625400204205121,
       "certain areas":0.01341933513504327,
       "certain birth defects":0.014396588063062632,
       "chadd":0.023633431834313264,
       "changing antecedent behavior and reinforcement":0.013836243540483423,
       "characterization of ei/desr in adhd":0.013930100168772296,
       "child's developmental stage":0.01896100685949135,
       "child's health":0.019415809619200527,
       "childhood adhd":0.013546437949322974,
       "children and adolescents who do not respond to stimulants":0.019107725442417556,
       "children and adolescents who have adhd plus other mental health conditions":0.019107725442417556,
       "children and adolescents with adhd":0.02477626968299235,
       "children who experienced sexual abuse or physical neglect":0.017601191441035915,
       "children who grow up in difficult family situations":0.01718316343942324,
       "children who had a specific type of viral infection (enterovirus)":0.01718316343942324,
       "children whose mothers were severely obese":0.017601191441035915,
       "children with adhd and smd":0.014012384365386052,
       "children with low lead levels":0.01341933513504327,
       "children without adhd":0.024956922528977375,
       "cholinesterase inhibitors":0.01349110391589659,
       "chrna7":0.0171836068507969,
       "cigarettes smoked per day":0.025836822313673062,
       "cingulate region":0.01674455150366832,
       "clinical assessment":0.013872194382704416,
       "clinical experience":0.014282055080112514,
       "clinical features":0.01341933513504327,
       "clinical global impression ratings":0.013649660891833242,
       "clinical research":0.028613038745442812,
       "clinician interview":0.01381710366217463,
       "clonidine":0.04825373587209532,
       "clonidine extended-release":0.024298156863592872,
       "close friends":0.017356403136780052,
       "cnvs":0.01341933513504327,
       "cnvs in the 1q21.1 region":0.013916807666405075,
       "cnvs in the 6q26 region":0.014536052309771707,
       "co-contraindication for stimulant prescription":0.02260879247098044,
       "cocaine":0.02711891235776084,
       "cocaine or methamphetamine use":0.014667055620055767,
       "coexisting condition":0.013784043921860046,
       "coexisting mental health disorders":0.024359023366346173,
       "cognitive behavior therapy":0.04685925639525989,
       "cognitive errors":0.013775542484999643,
       "cognitive function":0.022032334435094433,
       "cognitive training":0.03717094723879534,
       "college completion":0.023606983424729684,
       "combination therapies":0.015198094394554884,
       "combinations of social disadvantages":0.013545893143206648,
       "common adverse effects":0.015222568247479524,
       "community controls":0.014550606878642635,
       "comorbid anxiety or tics":0.015091740484247334,
       "comorbid condition":0.06110679834862304,
       "comorbidities aggravate these outcomes":0.01497672404469686,
       "complete specificity":0.014295354424246598,
       "completion of no more than compulsory education":0.013545893143206648,
       "complex cases":0.015036405083991237,
       "complex psychosocial circumstances":0.017311376459975242,
       "computer-based training":0.02483724714857695,
       "condition":0.016113159381642744,
       "conduct disorder":0.020979303328417975,
       "conduct disorder (cd)":0.015214248636901863,
       "conduct problems":0.02164957567313395,
       "confounders":0.018002229649881966,
       "conners global index (cgi) emotional lability scale":0.02072602369287521,
       "adhd index of the conners adult adhd rating scale":0.022830849201704632,
       "consistent set of causes for the disorder":0.013872194382704416,
       "consultation":0.022475936873235822,
       "controls":0.014590329260378884,
       "core disorder in adhd":0.014911792325437469,
       "core symptoms of adhd":0.014663035928506585,
       "coronary artery disease":0.025836822313673062,
       "cortical surface area":0.017818740111442598,
       "cortical thickness":0.017530653595867137,
       "crash risk":0.013668058310662874,
       "crashes":0.01681683103553331,
       "criminal offenses":0.01662748992616355,
       "criminal records":0.01407235991962259,
       "curative treatments for adhd":0.014795538350643005,
       "d-amphetamine sulfate":0.015222568247479524,
       "daily functioning":0.022372146918721397,
       "daily life":0.016384393612196787,
       "danish national register longitudinal cohort study":0.013545893143206648,
       "danish national registers":0.020252825536803593,
       "danish population":0.01662748992616355,
       "death by homicide":0.015595456105665428,
       "death from natural causes":0.013668058310662874,
       "decision-making":0.013668612967887716,
       "decrease":0.0135825850061402,
       "decreased appetite":0.03988530908454926,
       "decreases in appetite":0.020000088046201545,
       "default-mode network (dmn)":0.014557080858810077,
       "delayed onset of sleep":0.020000088046201545,
       "delayed reinforcement":0.013808472459888303,
       "deliberate self-poisoning":0.013980720755827463,
       "dementia":0.017691497309448037,
       "deprivation":0.017646160058037135,
       "desr":0.016003690203138795,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":0.013564388406246545,
       "developmental disability–children’s global assessment scale":0.015341076498103944,
       "developmental history":0.015155762873270535,
       "dex":0.028922053069873326,
       "dexedrine":0.018688559528480676,
       "dextro amphetamine":0.022643895811070975,
       "deﬁcient emotional self-regulation (desr)":0.014056575391767873,
       "diagnoses":0.04378358623446538,
       "diagnosis of apparent adult-onset adhd":0.01341933513504327,
       "diagnostic criteria":0.014752201735684157,
       "diagnostic delays":0.017032002048977823,
       "diets":0.02453724362836153,
       "differ between children and adults":0.015341076498103944,
       "differences between groups of people who are and are not diagnosed with adhd":0.016888621953865948,
       "difficult life circumstances":0.01407235991962259,
       "difficulty breathing":0.01762392763032435,
       "difficulty sustaining attention":0.014226466486865366,
       "digital health interventions (dhis)":0.017617921678759616,
       "disability service options":0.0177669866228193,
       "disinhibited emotionally expressive behavior":0.013450291286720872,
       "disorder":0.015513523643793837,
       "disruptive mood dysregulation disorder":0.018861379570905258,
       "distress":0.015075559097905943,
       "distress tolerance":0.016303570131351357,
       "dlpfc":0.013795232157575546,
       "dmn":0.01545171007219411,
       "doctor":0.027399621415196012,
       "does not seem to listen":0.014226466486865366,
       "domains":0.015155484169223375,
       "dopamine":0.01714536499792041,
       "dopamine levels in synapses":0.013916807666405075,
       "dopamine regulation":0.014255376390152456,
       "double-blind, placebo-controlled trials":0.019075935525424928,
       "driver license suspensions":0.014056575391767873,
       "drug contract or conducting periodic drug screens":0.021387850307958298,
       "dsm and icd criteria":0.01341933513504327,
       "dsm-5":0.018022334558950706,
       "dsm-5 diagnosis":0.01493159020359398,
       "dsm-5 symptom criteria":0.014347577176191648,
       "dsm-5’s dmdd":0.013511563745447387,
       "duration":0.01349110391589659,
       "duration of treatment":0.02123695856886892,
       "dusp6":0.0171836068507969,
       "dysfunctional cognitive beliefs":0.015341076498103944,
       "dysphoria":0.030964550429815496,
       "dysregulation":0.013548561333405314,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":0.01341933513504327,
       "earnings reduction":0.013980720755827463,
       "anorexia":0.04402129547939775,
       "editorial support":0.013930100168772296,
       "education planning":0.02312986729747258,
       "educational and occupational failure":0.01813010795318155,
       "eeg neurofeedback":0.016608816708303928,
       "efficacy":0.02063066190994957,
       "efficacy in treating adhd":0.016442012158173192,
       "ei":0.021484736570729298,
       "ei and desr":0.02099637050243995,
       "electrical stimulation":0.014282055080112514,
       "electrophysiology":0.013458198761211656,
       "elevations in the theta/beta on the electroencephalogram":0.01341933513504327,
       "elimination diets":0.02596591887957892,
       "embryogenesis":0.013916807666405075,
       "emergent health conditions":0.01341933513504327,
       "emerging problems":0.013725961918476868,
       "emotion processing":0.025127448511529312,
       "emotion regulation":0.0373122919078258,
       "emotional and behavioral trajectories":0.013777512809085285,
       "emotional control scores":0.01862288762580439,
       "emotional control subscale":0.01862288762580439,
       "emotional intensity (ei)":0.014723139536876479,
       "emotional lability":0.024954539936199928,
       "emotion":0.021879037547762648,
       "emotional symptoms":0.04025439389728275,
       "employed":0.013519000233150304,
       "employment reduction":0.013980720755827463,
       "enigma-adhd working group set of cohort from around the world":0.022786252515543774,
       "enterovirus patients":0.017090486544777444,
       "environment":0.014248738250280278,
       "environmental correlates":0.01586045844795647,
       "environmental correlates of adhd":0.02339841719086068,
       "environmental factors":0.021596503749400964,
       "environmental risks":0.014796199204851422,
       "epidemiologic studies":0.01627882003898208,
       "essential fatty acid supplementation":0.01807491089650298,
       "europe":0.01341933513504327,
       "european network for hyper kinetic disorders (eunethydis)":0.01400114028842857,
       "euthymic baseline":0.013548561333405314,
       "evaluate care-giver burden in children":0.015341076498103944,
       "evaluate family-related qol and activities of daily living in children":0.015341076498103944,
       "evaluate overall functioning in children":0.015341076498103944,
       "evidence":0.0189947775321994,
       "exaggerated delay discounting":0.013480515691250682,
       "executive dysfunction":0.026403322997765603,
       "executive function":0.02599298232817993,
       "executive function control":0.01968230412519191,
       "executive functioning":0.017884389693871326,
       "exposure‐response trend":0.017090486544777444,
       "externalizing behavior problems":0.01842771752924019,
       "extreme deprivation early in life":0.01533240336256717,
       "fails to give close attention":0.014226466486865366,
       "false positive diagnoses":0.013865406514337038,
       "familial co-aggregation":0.01461710023670369,
       "familial or genetic factors":0.01341933513504327,
       "family":0.01545393579927495,
       "family conflict":0.01497672404469686,
       "family function":0.016589617693211565,
       "family history of adhd":0.01419789016134354,
       "family history of mental health issues":0.015046837171459358,
       "family problems":0.01407235991962259,
       "family strain index":0.015341076498103944,
       "fatty acid concentrations":0.014282055080112514,
       "fda approval":0.018711567807124567,
       "fda approved medication":0.01493159020359398,
       "fda-approved treatment for adhd":0.014276515686742671,
       "felony":0.014550606878642635,
       "female":0.020504828544063936,
       "fidgeting":0.013560280999930747,
       "fidgets with hands or feet":0.014226466486865366,
       "financial problems":0.014056575391767873,
       "financial stability":0.01497672404469686,
       "fmri neurofeedback":0.014443772153438035,
       "fmri studies of cognitive control":0.023606983424729684,
       "dietary interventions":0.019195434412033634,
       "foster care":0.01407235991962259,
       "foxp1 and foxp2":0.013457544074644383,
       "foxp2":0.014237037558752717,
       "franz kramer and hans pollnow":0.01880469893086918,
       "free fatty acids":0.024571170232344956,
       "free tools":0.01341933513504327,
       "frontal region":0.01674455150366832,
       "functional impairment":0.023954501084471704,
       "functioning":0.022819040807546504,
       "funding for manuscript development":0.013930100168772296,
       "fusiform gyrus":0.015508124474213684,
       "future patient outcomes":0.013872194382704416,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":0.015442315370988021,
       "general behavior":0.013549922262202686,
       "general population":0.013640925685047612,
       "general psychopathology and several psychiatric disorders":0.013588315407464671,
       "generalized emotional under-control":0.013930100168772296,
       "genes and environment":0.013564388406246545,
       "genetic and environmental risk factors":0.01533240336256717,
       "genetic correlation":0.023606983424729684,
       "genetic factors":0.01515689273835529,
       "genetic influence":0.015581376945189554,
       "genetic or familial causes":0.013467731157701347,
       "genetic risk":0.014754578991416746,
       "genetic variants":0.029326924798676855,
       "genetics":0.014995964453089037,
       "genomic loci":0.01341933513504327,
       "geographic region":0.018002229649881966,
       "george still":0.014781354208433016,
       "girls":0.013565487120246434,
       "girls with adhd":0.018002229649881966,
       "glaucoma":0.013548386818572218,
       "glutamatergic neurotransmission":0.01341933513504327,
       "gonzalo rodriguez-lafora":0.013993817393951781,
       "grade point sum":0.01588678260290875,
       "growth issues":0.019133177516640475,
       "guanfacine":0.0553264497553345,
       "extended release guanfacine":0.03524486353617669,
       "gudjonsson et al.":0.019508814513029438,
       "guidelines":0.024381427400921456,
       "gwas":0.01341933513504327,
       "hba1c":0.014107119124072994,
       "headache":0.06523123260413888,
       "health-care disparities":0.01341933513504327,
       "health care provider":0.040140676185818146,
       "healthcare systems":0.015391835812116053,
       "heart rate":0.039540147208675804,
       "heinrich hoffmann":0.014122500692346855,
       "high blood pressure":0.03920105830785103,
       "high iqs":0.013565487120246434,
       "high lead levels":0.01341933513504327,
       "high risk of substance abuse":0.021387850307958298,
       "high school and collegiate athletes":0.013668058310662874,
       "high ses":0.01341933513504327,
       "higher adhd symptom severity and poorer outcomes":0.014551764906400292,
       "hippocampus":0.022610496546459267,
       "hippocampus volume":0.014464876797333158,
       "history of illicit stimulant use":0.020879894875784254,
       "hong kong database":0.01359444774484473,
       "hyperactivity":0.037176788169323335,
       "hyperactivity in children":0.013440311828696068,
       "hyperkinetic disorder":0.01724039661239229,
       "hyperthyroidism (overactive thyroid)":0.01718316343942324,
       "hypospadias":0.013467731157701347,
       "hypotension":0.027127911846111,
       "hypothyroidism (underactive thyroid)":0.01718316343942324,
       "icd-11":0.01705551747920261,
       "icd-11 criteria":0.01341933513504327,
       "ifc":0.013467589755616193,
       "ifc and insula":0.017163681973817457,
       "illegally used drugs":0.0170113372686849,
       "imaging studies":0.01341933513504327,
       "immediate reinforcement":0.013480515691250682,
       "immediate rewards":0.014087235777567502,
       "impaired academic functioning":0.016199405755600235,
       "impairment":0.02822423341838895,
       "impairments in quality of life":0.015075559097905943,
       "improved academic performance":0.013618319139195707,
       "improved brain function, most prominently in inferior frontal and striatal regions":0.01588678260290875,
       "improved parent-reported child behavior":0.01452659033366276,
       "improved relationships with caregivers, teachers, siblings, or peers":0.013618319139195707,
       "improved rule following":0.013618319139195707,
       "improved sleep":0.013949627891263076,
       "improvements":0.020940526326432257,
       "improvements in living":0.015075559097905943,
       "impulsive decision-making":0.014330362688535062,
       "impulsivity":0.02352542954244472,
       "high inattentive factor":0.03318021153392539,
       "inattention and hyperactivity":0.014523928540652467,
       "inattentive type":0.017090486544777444,
       "adhd inattentive type":0.017601191441035915,
       "incarceration":0.01662748992616355,
       "increase the risks of suicidality":0.01497672404469686,
       "increased rate of rare genetic mutations":0.014758499040267955,
       "incredible years (iy)":0.019245386581282355,
       "individual":0.01654042407695799,
       "infection":0.018154905225479308,
       "inferior frontal dysfunction":0.014464876797333158,
       "inflammation":0.013564388406246545,
       "health professionals, patients and families":0.016753583849259308,
       "inhibition":0.01662748992616355,
       "initial treatment":0.018540952636072132,
       "injuries":0.015647383397921256,
       "insomnia":0.06858131434270011,
       "insula":0.01428382961509817,
       "insulin resistance":0.013564388406246545,
       "integrative treatment":0.01730348905109951,
       "integrity of auditory sensory memory and involuntary attention switching":0.01341933513504327,
       "intellectual disabilities":0.01713980726098548,
       "intellectual functioning":0.01341933513504327,
       "intelligence":0.02530190364180617,
       "intelligent individuals":0.013565487120246434,
       "intensity":0.01349110391589659,
       "intensity of subjective states and behavior":0.013990937990303551,
       "intentional exposures":0.0170113372686849,
       "interdisciplinary collaborations":0.01341933513504327,
       "international resources":0.01341933513504327,
       "interventions":0.021479335291127555,
       "intracranial brain volume":0.013797091282870317,
       "iq":0.019985390331311272,
       "iq differences":0.018352623967237712,
       "iq scores":0.014337045163021155,
       "iq tests":0.01407235991962259,
       "irritability":0.09161729163372664,
       "juvenile detention":0.01341933513504327,
       "kidney failure":0.013548386818572218,
       "kidscreen-10":0.015341076498103944,
       "l-deprenyl":0.01349110391589659,
       "large family size":0.013545893143206648,
       "large population studies":0.01419789016134354,
       "larger delayed ones":0.013435193184179375,
       "lead burden":0.013467731157701347,
       "learning disorder":0.019926078145335344,
       "leaves seat in situations":0.014226466486865366,
       "licensed clinician":0.013565487120246434,
       "limbic volume":0.015508124474213684,
       "lines of communication":0.014053889598812468,
       "lisdexamfetamine":0.029425744172547612,
       "long-range fronto-posterior association tracts":0.014464876797333158,
       "long-term medication use":0.01758123715218651,
       "low ses":0.01341933513504327,
       "low social class":0.013545893143206648,
       "low social class conditions":0.01407235991962259,
       "lower achievement scores":0.015214248636901863,
       "lower family income":0.01718316343942324,
       "lower quality of life":0.014056575391767873,
       "lung cancer":0.025836822313673062,
       "major depression":0.031359579085262455,
       "makes careless mistakes":0.014226466486865366,
       "male":0.021254584415945653,
       "male-to-female sex ratio of adhd":0.022750941158260953,
       "maois":0.020067360274860474,
       "map1a":0.01341933513504327,
       "maternal alcohol use during pregnancy":0.014347577176191648,
       "maternal mental disorder":0.013545893143206648,
       "maternal pre-existing type 1 diabetes":0.014153331844051055,
       "maternal prenatal use of acetaminophen":0.01341933513504327,
       "maternal smoking":0.01739157980338703,
       "maximimum tolerated dose":0.017163681973817457,
       "measurement tools":0.013578079247944085,
       "measurement-based care":0.01341933513504327,
       "measures of neurocognitive functioning":0.01341933513504327,
       "measures to evaluate qol or functional impairment":0.015341076498103944,
       "mechanisms of disease onset":0.01341933513504327,
       "mechanisms/pathophysiology":0.01341933513504327,
       "medical history":0.015046837171459358,
       "medical problem":0.01727794380090177,
       "medication periods":0.01627327466708645,
       "medication therapy":0.01759603354587464,
       "medication-free weekends":0.016589617693211565,
       "mef2c":0.01641069878368756,
       "melchior adam weikard":0.014122500692346855,
       "memory":0.013668612967887716,
       "meta-analyses":0.03353360699112046,
       "metabolic disorders":0.013548386818572218,
       "methamphetamine":0.015222568247479524,
       "method of diagnosing adhd":0.013894385538092663,
       "methods to improve adherence":0.014550606878642635,
       "methylphenidate treatment":0.020793644176014058,
       "methylphenidate users":0.014225172799342668,
       "methylphenidate users ages 46-65":0.014225172799342668,
       "methylphenidate users with previous alcohol and drug misuse":0.014225172799342668,
       "methyphenidate prescription":0.018047349071068926,
       "migraine":0.01580997011067984,
       "milder adhd":0.01397278448180992,
       "mindfulness and positive aspects of adhd":0.01341933513504327,
       "mindfulness meditation":0.013986705216604514,
       "mindfulness-based treatments":0.013986705216604514,
       "minimal brain dysfunction":0.017270626183945398,
       "minor structural and functional brain differences":0.015178226111917489,
       "misconceptions":0.017646945083336463,
       "misdemeanors":0.014550606878642635,
       "mismatch negativity":0.01341933513504327,
       "misuse and diversion of these medications":0.016350552875588776,
       "mixed amphetamine salts":0.02139603053990425,
       "modafinil":0.03210431976473136,
       "molecular genetic data":0.014342455438254452,
       "mood":0.02544234390222353,
       "mood disorder":0.03449874076305883,
       "mortality rates":0.018761903867279883,
       "most cases of adhd":0.01341933513504327,
       "mothers":0.01949518855509817,
       "mothers who were obese before pregnancy":0.01718316343942324,
       "mothers with two or more prior miscarriages":0.017090486544777444,
       "motor vehicle collision":0.019532664018794436,
       "mtbi":0.013668058310662874,
       "multidisciplinary efforts":0.013930100168772296,
       "multiple settings":0.014689473395120299,
       "narcolepsy":0.013649660891833242,
       "national health and nutrition examination survey":0.013467731157701347,
       "national health insurance data":0.0159370242059506,
       "national institute for health and care excellence (nice)":0.01341933513504327,
       "national institute of mental health":0.013498510436379264,
       "nationwide population study":0.014219946851974507,
       "nausea":0.047803369933828874,
       "negative parenting":0.018228825084163444,
       "negative reinforcement":0.013480515691250682,
       "neglect":0.01427401164517233,
       "network meta-analyses":0.025745475225951275,
       "network of researchers with annual meeting":0.013433150727629605,
       "neurobiological research":0.01341933513504327,
       "neurobiology":0.013599254864308706,
       "neurocognitive function":0.015959944580566366,
       "neurocognitive impairment":0.015155484169223375,
       "neurodevelopment":0.013954223797187516,
       "neurodevelopmental condition":0.014795538350643005,
       "neuroimaging scans":0.014437422763332033,
       "neuroimaging studies":0.01341933513504327,
       "neuronal and nicotinic signalling pathways":0.01341933513504327,
       "neuronal development and migration":0.014288607495704627,
       "neuropsychological tests":0.015461049644258196,
       "new directions for diagnosis":0.019528070815252083,
       "new medications currently in development":0.01635389520265366,
       "nice guidelines":0.015607396428183467,
       "nicotine":0.020924463235387547,
       "nicotinic signalling":0.013916807666405075,
       "no association with adhd":0.01341933513504327,
       "no significant effect on adhd":0.01341933513504327,
       "non-medical treatments":0.02313276168459,
       "non-responders":0.03537129790460402,
       "non-stimulant medications":0.027373726227583935,
       "non-stimulants":0.058726495233780825,
       "nonstimulant medications":0.029944375368561416,
       "noradrenaline":0.024369663422339632,
       "normal cognitive fluctuations":0.01341933513504327,
       "normed scales":0.01341933513504327,
       "north america":0.01341933513504327,
       "number of children":0.025836822313673062,
       "number of sessions":0.01349110391589659,
       "obesity":0.04066104982655485,
       "occupational functioning":0.013560280999930747,
       "ocd":0.020739773486899794,
       "odd":0.03524779487882763,
       "older adolescents and adults":0.013560280999930747,
       "omni healthcare communications":0.013930100168772296,
       "onset":0.024073509765543216,
       "onset prior to the age 12 years cannot be documented":0.01341933513504327,
       "oppositional defiant disorder":0.027252624960328334,
       "organisation skills":0.014579243998612957,
       "other approaches to emotion-regulatory processes disrupted in adhd":0.013610855469137064,
       "other psychiatric and substance use disorder":0.013668058310662874,
       "other psychiatric diagnosis":0.01962896287062072,
       "other stimulant class":0.017163681973817457,
       "out-of-home care":0.013545893143206648,
       "outcomes":0.027651898836679845,
       "outcomes over longer periods of time":0.01407209860167667,
       "overused medication":0.022549813158638264,
       "oxidative stress":0.013564388406246545,
       "paid tools":0.01341933513504327,
       "parent":0.0400614663014881,
       "parent behavior management training (pbmt)":0.019245386581282355,
       "parent management training":0.01727794380090177,
       "parent referral for treatment":0.01397278448180992,
       "parent training":0.027588477002992703,
       "parent training in behavior management (ptbm)":0.013621461090605578,
       "parent-child behavior therapy":0.015683553404272195,
       "parental criminality":0.013545893143206648,
       "parental educational attainment":0.013545893143206648,
       "parental outcomes":0.013507627334980551,
       "parental relative income poverty":0.013545893143206648,
       "parental unemployment":0.013545893143206648,
       "parenting skills":0.01497672404469686,
       "parents having low educational levels":0.01407235991962259,
       "pargyline":0.01349110391589659,
       "parietal region":0.015508124474213684,
       "paroxetine":0.013649660891833242,
       "particulate matter":0.01341933513504327,
       "pathophysiology":0.013622805693245608,
       "patient":0.0652990525001947,
       "patient’s level of ei":0.01341933513504327,
       "pbmt":0.013511563745447387,
       "peer conflicts and social exclusion":0.01497672404469686,
       "peers":0.01844718727302624,
       "people":0.014370377665340875,
       "people all around the world":0.013565487120246434,
       "people who have read this document and agree with its contents":0.013896038047537968,
       "performance deficits in psychological processes":0.014437422763332033,
       "perpetrators of physical dating violence":0.01341933513504327,
       "person":0.01533240336256717,
       "personalized approach":0.017856600098715234,
       "personalized treatments":0.01341933513504327,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":0.023212806564230675,
       "pharmacotherapy":0.02817387504293394,
       "physical conditions":0.016490611313470835,
       "physical examination":0.0205177839591034,
       "placebo":0.0266983756159406,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":0.013894385538092663,
       "poisoning in children":0.013980720755827463,
       "police station interrogations":0.01341933513504327,
       "polr3c":0.014255376390152456,
       "polygenic cause":0.01341933513504327,
       "polythetic criteria":0.014295354424246598,
       "poor judgment":0.01588678260290875,
       "poor work performance":0.014056575391767873,
       "positive parenting":0.013458198761211656,
       "positive reinforcement":0.013621461090605578,
       "posterior corpus callosum":0.015508124474213684,
       "posterior parieto-temporal attention regions":0.014464876797333158,
       "poverty":0.018693587448603905,
       "pre-existing type 1 diabetes":0.01662748992616355,
       "prediction":0.017856600098715234,
       "predictive modelling":0.01341933513504327,
       "predictor of treatment response":0.013894385538092663,
       "preeclampsia":0.014372936756859184,
       "pregnancies":0.0392375287096729,
       "pregnancy and adhd":0.01341933513504327,
       "pregnant or breastfeeding women":0.016589617693211565,
       "premature death":0.023893600201367462,
       "prenatal exposure":0.014612007353489331,
       "prenatal exposure to maternal smoking":0.013467731157701347,
       "preschool or daycare":0.01625400204205121,
       "preschoolers with symptoms of adhd":0.01769827627915763,
       "prescriber":0.026851311360043473,
       "prevalence":0.02545501536644094,
       "prevalence of adhd":0.01849748755402085,
       "prevalence of adhd among adolescents":0.01341933513504327,
       "prevalence of adhd in prisons":0.01341933513504327,
       "prevalence of false confessions":0.01341933513504327,
       "prevalence of physical dating violence":0.01341933513504327,
       "priapism":0.02645064523876808,
       "prior miscarriage":0.017090486544777444,
       "prisma diagram in supplemental figure 1":0.013896038047537968,
       "prison inmates":0.01341933513504327,
       "prkn":0.01341933513504327,
       "proband":0.017616179556456092,
       "problem behaviors (e.g., aggression, caregiver-child relations)":0.014663035928506585,
       "problem solving":0.016773197460478905,
       "problematic substance use":0.023666059345126486,
       "problems with connections between the two hemispheres":0.014464876797333158,
       "professional health care associations":0.013679657075025903,
       "proteins":0.013797091282870317,
       "proton pump inhibitors":0.015442315370988021,
       "provocation":0.01585645397142427,
       "psoriasis":0.01350296481020787,
       "comorbid psychiatric conditions":0.03016948394490748,
       "psychoeducation":0.027037568132717977,
       "psychological tests":0.01407235991962259,
       "psychological treatment":0.020879894875784254,
       "psychosocial domains of qol":0.015341076498103944,
       "psychosocial interventions":0.018825066032295452,
       "psychosocial, school and emotional functioning":0.015341076498103944,
       "psychotherapy":0.03334723900544465,
       "psychotropic co-prescriptions":0.015075559097905943,
       "ptbm":0.01713755782140977,
       "ptbm (behavior therapy)":0.02211170440656324,
       "qol domains":0.015341076498103944,
       "quality of life":0.03286717634890226,
       "racemic amphetamine sulfate":0.015222568247479524,
       "racial and ethnic minority populations":0.013640925685047612,
       "rage":0.015276287696376347,
       "randomized controlled trials (rcts)":0.01588678260290875,
       "rare genetic mutations":0.014396588063062632,
       "rare single gene defects":0.014407983433583741,
       "rct":0.02108744736315479,
       "rcts of adhd medications":0.01867041222818254,
       "re-evaluate goals and behavior":0.013487823178011926,
       "reading":0.014337045163021155,
       "reading, spelling and arithmetic":0.01407235991962259,
       "rebound effect":0.02050688444371282,
       "reduce self-esteem and wellbeing":0.01497672404469686,
       "reducing inattention, hyperactivity, and impulsivity":0.013649997855867983,
       "referral to a dietician":0.014282055080112514,
       "regular check-ups":0.034104957280881816,
       "reinforcer":0.013808472459888303,
       "relationship quality":0.01497672404469686,
       "reliability and validity":0.014995604130418035,
       "reliable diagnostic measure for adhd":0.01341933513504327,
       "research":0.021513402666989506,
       "resilience":0.013458198761211656,
       "resilience factors":0.013797091282870317,
       "resources":0.020904983028183843,
       "responders":0.03537129790460402,
       "response cost":0.013621461090605578,
       "response to treatment":0.013872194382704416,
       "response-inhibition":0.0159370242059506,
       "restlessness":0.013560280999930747,
       "reward":0.01599594962921167,
       "right inferior frontal cortex":0.01582984615197431,
       "potential risks":0.01663651266971067,
       "risky driving behaviors":0.015817919800087687,
       "robins and guze criteria":0.014209679283621771,
       "sagitatal striatum":0.015508124474213684,
       "scaffolding":0.015056187873621974,
       "scales for emotion regulation":0.01407235991962259,
       "schizophrenia":0.027375525840662822,
       "school":0.01627505850530051,
       "school interventions":0.014663035928506585,
       "school performance":0.014147091346991067,
       "school-based accommodations":0.015962558460675527,
       "screening measures":0.018771867007028202,
       "selective amplification of certain emotional states":0.013930100168772296,
       "selective noradrenaline reuptake inhibitors":0.02429815686359288,
       "self-esteem":0.016567207791259378,
       "self-injury":0.013508609699185783,
       "self-perceptions of competence":0.013458198761211656,
       "self-referential thoughts and mind-wandering":0.013467589755616193,
       "self-referral":0.01397278448180992,
       "self-regulatory skills":0.01385971408891239,
       "self-regulatory strategies":0.013930100168772296,
       "self-report measures":0.014646355440646566,
       "self-report scale":0.01493159020359398,
       "self-reported executive function ratings":0.014786491129910349,
       "serious transport accidents":0.017618731653907437,
       "serotonin syndrome":0.02853386358350415,
       "settings":0.015726659532000215,
       "severe adhd":0.01397278448180992,
       "severe marital discord":0.014893533455454633,
       "severe mood dys-regulation (smd)":0.013511563745447387,
       "sex":0.018002229649881966,
       "sexual crimes victims":0.014953761277347943,
       "sexually transmitted infections":0.0180560344376499,
       "shared components of etiology":0.014295354424246598,
       "shared mechanisms among disorders":0.014295354424246598,
       "short- and long-acting formulations of a-2 adrenergic agonists":0.019075935525424928,
       "simulant":0.016866804530156532,
       "simulant medications":0.016866804530156532,
       "single genetic abnormality":0.01533240336256717,
       "six symptoms of hyperactivity-impulsivity":0.013888583174168646,
       "six symptoms of inattention":0.013888583174168646,
       "skills training":0.025102612330179283,
       "sleep":0.01962349045130026,
       "sleep efficiency":0.020000088046201545,
       "sleep onset":0.019949846443159693,
       "sleep onset delay":0.015091740484247334,
       "small differences in brain structure and function":0.013442424497175174,
       "small for gestational age":0.014372936756859184,
       "small particulate matter levels":0.01341933513504327,
       "small to moderate difficulties":0.015409164549388107,
       "small-to-moderate reductions in mismatch negativity amplitude":0.014528487706690189,
       "smaller brain areas":0.01428382961509817,
       "smaller brain volumes":0.01341933513504327,
       "cigarette smoking":0.026061083929024533,
       "smoking initiation":0.025836822313673062,
       "social acceptance":0.013458198761211656,
       "social anxiety disorder":0.02015929083797702,
       "social cognitive programs":0.013511563745447387,
       "social function":0.016589617693211565,
       "social functioning":0.014124068228177319,
       "social skills":0.017221153398175846,
       "social skills training":0.018918350563683115,
       "socially and clinically important outcomes":0.014010010732769532,
       "society for developmental and behavioral pediatrics":0.013538544002927012,
       "socioeconomic cost":0.013438344652487177,
       "ses (socioeconomic status)":0.014390691248612334,
       "solriamfetol":0.0231189742049965,
       "somatic co-prescriptions":0.015075559097905943,
       "somatic disorders that co-occur with adhd":0.01635389520265366,
       "sorcs3":0.01641069878368756,
       "sorcs3, ptprf, and mef2c":0.01341933513504327,
       "specialist":0.019167647896047225,
       "speech disorders":0.015028538457521704,
       "spelling":0.014337045163021155,
       "splenium of the corpus callosum":0.018352623967237712,
       "spouses":0.022653910012361732,
       "ssri/snri":0.020307473241550966,
       "standard diagnostic criteria":0.015567114599780905,
       "standard therapies":0.017356403136780052,
       "stigma":0.017216215012885203,
       "adhd stigma":0.01862269631361834,
       "stimulant":0.044066044447555165,
       "stimulant medication":0.09823969888752587,
       "stimulant therapy":0.03595482778653451,
       "stimulant-refractory":0.017163681973817457,
       "stimulants are the first line of drug treatment for adhd":0.020879894875784254,
       "stress":0.01718316343942324,
       "stress-related strains on cognition":0.01341933513504327,
       "stressed events during childhood":0.01407235991962259,
       "subcortical regions":0.01541123377079543,
       "subjective well-being":0.025836822313673062,
       "subsequent substance use":0.01588678260290875,
       "substance misuse":0.020879894875784254,
       "substance use":0.019606241753141983,
       "sud":0.01662748992616355,
       "suicide related events":0.02336327579445668,
       "support groups":0.017206852674810928,
       "sustained release bupropion":0.014515488544982011,
       "sweden":0.01341933513504327,
       "swedish national registers":0.018129696858336278,
       "swedish population-based study":0.0180560344376499,
       "swedish registry study":0.01359444774484473,
       "symptom change":0.018114532660307846,
       "symptom checklists":0.013429926829687027,
       "symptom expression":0.013797091282870317,
       "symptom severity":0.01662748992616355,
       "synapse formation and plasticity":0.01565490378469897,
       "synaptic development":0.01341933513504327,
       "taiwan health insurance research database":0.0180560344376499,
       "taiwanese study":0.0180560344376499,
       "taiwanese youths":0.018002229649881966,
       "tca (nortriptyline)":0.020307473241550966,
       "tdcs":0.02333809895913636,
       "teacher-assessed social skills":0.013549922262202686,
       "teachers of children with adhd":0.015956230162494135,
       "techniques":0.013836243540483423,
       "teenage pregnancy":0.020293672588389024,
       "teenage pregnancy and sexually transmitted diseases":0.01497672404469686,
       "temper outbursts":0.01553968368408613,
       "temporal pole":0.015508124474213684,
       "temporal region":0.01674455150366832,
       "temporo-parieto-occipital regions":0.015508124474213684,
       "test scores":0.01627327466708645,
       "testicular dysfunction":0.013548386818572218,
       "tetrahydrocannabinol (marijuana)":0.013819318384214905,
       "therapeutic approaches":0.018947506785249937,
       "therapies":0.013930100168772296,
       "therapy":0.028052936571970805,
       "those seeking treatment":0.013640925685047612,
       "those with epilepsy":0.01350296481020787,
       "thyroid problems in mothers during pregnancy":0.01718316343942324,
       "time management":0.017573296504202328,
       "time off medication":0.017300475255475758,
       "time-out":0.013621461090605578,
       "tms":0.016608816708303928,
       "tns":0.017617921678759616,
       "token economy":0.013621461090605578,
       "tolerability":0.02616369279842288,
       "total sleep time":0.020000088046201545,
       "toxic substances":0.014396588063062632,
       "tracking and remote measurement technologies":0.013937445272185319,
       "trans-diagnostic phenomena":0.014295354424246598,
       "transport accidents":0.02384664119087323,
       "trauma":0.02268209129191343,
       "trauma-related emergency room admission":0.018047349071068926,
       "traumatic brain injuries":0.02206793224488133,
       "traumatic brain injury early in life":0.01533240336256717,
       "treating adhd and preventing adverse outcomes":0.01681683103553331,
       "treatment efficacy":0.014980822153477067,
       "drug treatment initiation":0.03331614512728656,
       "treatment of coexisting conditions":0.021798784202928297,
       "treatment planning":0.013479664408404445,
       "treatment targets":0.014295354424246598,
       "trial":0.017206852674810928,
       "trigeminal nerve stimulation":0.016063674801170904,
       "trigeminal nerve stimulation (tns)":0.014276515686742671,
       "twins":0.01427401164517233,
       "type 1 diabetes mellitus (t1dm)":0.014772080836168275,
       "type 2 diabetes":0.027609146580390643,
       "typically developing peers":0.02143794493848509,
       "ulcerative colitis":0.01350296481020787,
       "unemployment":0.015827316820882634,
       "unintended injuries":0.02669702022311441,
       "unmedicated adults":0.01461710023670369,
       "upper secondary school":0.01588678260290875,
       "urbanization level":0.018002229649881966,
       "us":0.01341933513504327,
       "us population":0.015705405338140285,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":0.020879894875784254,
       "validated measure of symptom change":0.014550606878642635,
       "validity of adhd as a mental disorder":0.014209679283621771,
       "valproate":0.017850635701266444,
       "vehicular crashes":0.013668058310662874,
       "ventromedial orbito-frontal cortical thickness":0.015508124474213684,
       "viloxazine er":0.015391512540450758,
       "viloxazine extended-release":0.019979074085349963,
       "violent crimes":0.019508814513029438,
       "violent crimes against youth":0.01341933513504327,
       "viral pneumonia":0.013548386818572218,
       "visual attention":0.025127448511529305,
       "weak support systems":0.017319342903300422,
       "weight":0.030803942485330076,
       "well-trained professionals":0.013872194382704416,
       "wender-reimherr adult attention deficit disorder scale":0.020081241745769564,
       "wes study":0.01341933513504327,
       "white blood cell disorders":0.013548386818572218,
       "white matter":0.015255571401154243,
       "white matter integrity":0.017163681973817457,
       "white-majority countries":0.01341933513504327,
       "work functioning":0.01497672404469686,
       "work performance":0.01589742084059131,
       "working memory impairments":0.0160276037223686,
       "world":0.018423039596271253,
       "worse social adjustment":0.014056575391767873,
       "year of first adhd diagnosis":0.013872194382704416,
       "years of schooling":0.023606983424729684,
       "youth aged 14-20":0.01341933513504327,
       "youth with adhd":0.02210478668640862,
       "α2 agonists":0.019979074085349963,
       "emotional factors":0.014390691248612334,
       "intellectual factors":0.014390691248612334,
       "mood stabilizing medication":0.015937413267213856,
       "negative health behaviours":0.014390691248612334,
       "oocyte leading to pregnancy":0.014390691248612334,
       "psychosocial impairment":0.014390691248612334,
       "resilience in those susceptible to adhd":0.016393826970415144,
       "sero tonergic medication":0.015054283470867591,
       "sero tonergic reuptake inhibitor":0.015054283470867591,
       "serotonin activity":0.015731924645813498,
       "serotonin-norepinephrine reuptake inhibitors (snri)":0.01757385396423909,
       "social factors":0.014390691248612334,
       "selective serotonin reuptake inhibitor (ssri)":0.02500235984304795,
       "adhd and its mental and somatic comorbidities":0.0023140181660208947,
       "classroom":0.00046591166720746723,
       "covert smile":0.0013519987502454648,
       "desr (delayed emotional return)":0.0004772435766988894,
       "emotional experience and behavior dyssynchrony":0.00046591166720746723,
       "emotionally evocative situations":0.0008981207071805587,
       "explosive giggle":0.00046591166720746723,
       "provoke- ing stimuli":0.00046591166720746723,
       "rapid emotional responses":0.00046591166720746723,
       "height gains":0.011896754275224113,
       "age at which adhd criteria were met":0.0006395298435893599,
       "children with high iq":0.004607551745606136,
       "rates of learning disorders":0.0006395298435893599,
       "rates of psychiatric disorders":0.0006395298435893599,
       "rates of stimulant treatment":0.0006395298435893599,
       "rates of substance abuse":0.0006395298435893599,
       "nitric oxide":0.0007912370677500294,
       "nitrogen dioxide levels":0.0007912370677500294,
       "particulate matter levels":0.0008279435569953576,
       "sulphur dioxide levels":0.0007912370677500294,
       "genetic architecture of adhd":0.013630729280267203,
       "affective reactivity":0.004964558100355645,
       "education":0.014926198660073577,
       "expression of emotions":0.004964558100355645,
       "family life":0.004964558100355645,
       "financial":0.004964558100355645,
       "legal":0.004964558100355645,
       "predicting emotional symptoms":0.004964558100355645,
       "social relations":0.004964558100355645,
       "adhd europe":0.0004751872870836535,
       "health professionals and researchers":0.003255073412880043,
       "adhd evidence project":0.0005084108225358171,
       "international consensus statement on adhd":0.0013991944832453516,
       "adhd experts":0.001640331292056378,
       "brainstorming session":0.0014995094334084335,
       "existing guidelines":0.0014995094334084335,
       "literature review":0.001535984052802173,
       "qms (quality measures)":0.002313347238310585,
       "qms for adhd in youth":0.001535984052802173,
       "survey":0.0014995094334084335,
       "adhd follow-up care visit":0.0009024118802427165,
       "visit":0.004682910382104719,
       "adhd guidelines group of the association of medical scientific societies in germany":6.898116944171795e-05,
       "adhd network of european college of neuropsychopharmacology":6.898116944171795e-05,
       "adhd section of the world psychiatric association":6.898116944171795e-05,
       "australian adhd professionals association":6.898116944171795e-05,
       "chinese society of child and adolescent psychiatry":6.898116944171795e-05,
       "federation of adhd":1.527973563594458e-05,
       "israeli society of adhd":6.898116944171795e-05,
       "large medical database called pubmed":0.0009232364197091421,
       "latin american league of adhd":6.898116944171796e-05,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":6.914593585182281e-05,
       "pubmed":1.527973563594458e-05,
       "saudi adhd society":6.898116944171796e-05,
       "adhd in adults":0.004335518056758774,
       "adhd in big groups of people":7.93797931597106e-05,
       "adhd in offspring":0.0019461021894807225,
       "fetal growth restriction":0.0015124990402926542,
       "maternal hyperthyroidism during pregnancy":0.0015124990402926542,
       "maternal hypothyroidism during pregnancy":0.0015124990402926542,
       "maternal preeclampsia":0.001617751320188866,
       "obesity in mothers":0.0015124990402926542,
       "adhd in older adults":0.0019742806478271163,
       "mild cognitive impairment and dementia":0.0019742806478271163,
       "adhd malingering":0.005055265713353936,
       "danish study":0.0063130362619392665,
       "reproductive-aged women":0.006554400527812731,
       "risk of a motor vehicle collision":0.0049328915891525705,
       "short-term effects":0.0029033071044960944,
       "adhd medication metabolism affect":0.005161746660535293,
       "mph":0.016937306701721153,
       "comorbid anxiety":0.010147232212484375,
       "duration of action":0.019044105726476343,
       "duration of response":0.008752621240075132,
       "intervention":0.0076431334970363096,
       "level of function":0.010447541457151618,
       "methylin®":0.01016860099709253,
       "methylphenidate-based medications":0.01016860099709253,
       "mood dysregulation":0.008752621240075132,
       "nonstimulants":0.016968198165074385,
       "pharmacokinetics":0.008752621240075132,
       "pharmacotherapies":0.003898973102025186,
       "second-line nonstimulants":0.016462388567929996,
       "short-acting methylphenidate":0.01016860099709253,
       "specifically learning disorders and low iq":0.00733288275861511,
       "stakeholders":0.00419178775319373,
       "supplements":0.009679105226788741,
       "treatment alternatives":0.0033211896106301797,
       "working memory training":0.007053504169159697,
       "ɑ2 agonists":0.008752621240075132,
       "prof. faraone":0.00048662073281578136,
       "completed suicide":0.006528344737054208,
       "crime rates":0.0020805441399146317,
       "criminality":0.003809441735110818,
       "diversion could be fatal when diverted to a person who is medically at risk":0.00706373787168731,
       "diversion of medications is a felony":0.00706373787168731,
       "gateway to non-oral use of illicit drugs":0.007235566505205873,
       "injecting":0.008112510139517862,
       "intranasally":0.00706373787168731,
       "legal consequences of diverting medication":0.00706373787168731,
       "medical consequences of diverting medication":0.00706373787168731,
       "men with adhd":0.006528344737054208,
       "diversion or nmu":0.007477205982786468,
       "non-oral nmu":0.007235566505205873,
       "non-oral routes":0.00706373787168731,
       "oral administration":0.00706373787168731,
       "repeated suicide attempts":0.008681321030631633,
       "suicide deaths":0.006528344737054208,
       "swedish national registers study":0.0020163250587305515,
       "teenagers with adhd":0.0024521700465886037,
       "youth with adhd and other psychiatric diagnoses":0.004483337188473126,
       "adhd patients with ed but without smd":0.0009603144798595568,
       "coping skills for managing anger":0.002165629946186575,
       "adhd pharmacotherapy":0.0013048942650274984,
       "adolescents with adhd":0.0023273098630597518,
       "driver's license":6.196708666033255e-05,
       "females with adhd -i or controls":6.347468557620026e-05,
       "individuals (age 6 to 24 years) with adhd":0.0004925439276095297,
       "motor vehicle crashes":0.0013048942650274984,
       "natural causes":6.196708666033255e-05,
       "st imulant medications":6.347468557620026e-05,
       "two-year mortality risk from all-causes":6.196708666033255e-05,
       "unnatural causes such as suicide, accidental poisoning or injury":6.196708666033255e-05,
       "employment":0.0006966901107736441,
       "employment status jobs":0.0006966901107736441,
       "prescription stimulant misuse":0.0006966901107736441,
       "adhd prs":0.003360162906284376,
       "irritability traits":0.003360162906284376,
       "adhd quality of life":0.0038066131557717912,
       "primerthe columbia impairment scale":0.0038066131557717912,
       "adhd rating scales":0.007044982566089568,
       "cultural context":0.003687997508530623,
       "culture":0.003687997508530623,
       "adhd severity":0.002198548656362812,
       "intelligence quotient":0.0012647652909348107,
       "adhd symptom checklists":0.0039307625761256775,
       "barkley deficits in executive function scale":0.0033240228978885598,
       "improvement in psychosocial functioning":0.0033240228978885598,
       "adhd symptom control extension":0.004868231893687489,
       "adult adhd symptoms":0.008654364173126983,
       "aggression":0.018019558686750734,
       "alpha-2-adrenergic agonists":0.021162098090556275,
       "amphetamine derivatives":0.007734535029988518,
       "becoming unnaturally quiet":0.005486295596931112,
       "broad-spectrum micronutrient supplements":0.0038754104294062334,
       "cbt alone":0.005017835303417664,
       "child behavior checklist":0.004834501270446467,
       "clinical prescriber with training in adhd diagnosis and management":0.003944586915330231,
       "clinical subgroups":0.0036559688512463203,
       "combined treatment with medication and cbt":0.003753355675883704,
       "dietary approach to stop hypertension":0.0038754104294062334,
       "dietary interventions for adhd":0.003663500362239521,
       "digital interventions":0.00363084502286226,
       "digital therapies":0.0036766286995128144,
       "direct skills training":0.008225728039555484,
       "disruptive behavior disorders":0.0122455816718676,
       "drug treatment resistant patients":0.003945341913745077,
       "effect":0.0052084540721888005,
       "exclusion of food colour additives and preservatives":0.0038754104294062334,
       "exercise":0.026515407651894383,
       "extended-release preparations":0.01326557233914885,
       "good sleep practice":0.006284590127561767,
       "hallucinogens":0.006668339188839034,
       "healthy diets":0.009752472110860555,
       "heroin":0.006668339188839034,
       "homicidality":0.005080781703487246,
       "imipramine":0.005486295596931112,
       "immediate-release stimulants":0.01326557233914885,
       "inhalants":0.006668339188839034,
       "jornay":0.01326557233914885,
       "marijuana":0.008096208761962705,
       "medication alone":0.00378379541446953,
       "medication or psychosocial interventions":0.0032300914798013003,
       "mediterranean diet":0.0038754104294062334,
       "melatonin":0.016581890809838053,
       "mirtazapine (remeron)":0.005486295596931112,
       "negative mood symptoms":0.004952100702901312,
       "nutrition":0.01676411849580604,
       "omega-3 fatty acid supplementation":0.010899348783461797,
       "pain relievers":0.006668339188839034,
       "parent behavior management program":0.004834501270446467,
       "parent-rated emotional lability symptoms":0.0034122150309507807,
       "parent-rated oppositional symptoms":0.0034122150309507807,
       "participants and their significant others":0.003663500362239521,
       "poor dental hygiene":0.0041189972710962,
       "prognosis":0.006084242862141479,
       "remission of aggressive behavior":0.004952100702901312,
       "restricting synthetic food colors":0.0034122150309507807,
       "ssri and stimulant combination":0.00544541947247217,
       "ssri antidepressants":0.0036559688512463203,
       "stimulant-refractory adhd":0.009752472110860555,
       "tca":0.004767778297526263,
       "teacher-rated emotional lability symptoms":0.0034122150309507807,
       "teacher-rated oppositional symptoms":0.0034122150309507807,
       "tranquilizers/sedatives":0.006668339188839034,
       "treatment selection":0.0032300914798013003,
       "treatment success":0.007015060653327758,
       "venlafaxine":0.011816409095508535,
       "youth adhd symptoms":0.008574597697306861,
       "adhd trea tment":0.00423615321441835,
       "administration of stimulants in conjunction with alcohol use":0.003506451625101244,
       "cardiotoxicity":0.0031023497067356478,
       "ecg":0.0030286753831251564,
       "lower all-cause mortality":0.0029033071044960944,
       "males with adhd":0.0029033071044960944,
       "patients medicated for adhd":0.005188043778634541,
       "plasma levels":0.0030286753831251564,
       "polysubstance use":0.004434298666976654,
       "qtc prolongation":0.0030286753831251564,
       "tachycardia":0.0030286753831251564,
       "tca treatment":0.0031023497067356478,
       "unnatural causes of mortality":0.0029033071044960944,
       "adhd treatment first line":0.004465273511231494,
       "impulsive cognition":0.0004890739738856436,
       "learning problems":0.0011045154847755707,
       "poorly regulated emotions":0.0004890739738856436,
       "adhd treatment plan":0.0008649910229202237,
       "behaviors that we now associate with adhd":0.0037534096175375663,
       "cam therapies":0.009009845431602164,
       "chelation therapy":0.00951548690950853,
       "consensus statement":0.0041956896169956705,
       "large effect":0.0037534096175375663,
       "medium effect":0.0037534096175375663,
       "megavitamins":0.011594790829897159,
       "reviews":0.0037534096175375663,
       "small effect":0.0037534096175375663,
       "smaller studies":0.004574010517783093,
       "strong effects":0.0037534096175375663,
       "treatment studies":0.004645845630718272,
       "vitamins":0.00951548690950853,
       "adhd types":0.001736149034180107,
       "adhd-like symptoms in children":0.0013033724064416853,
       "adhd-related cost study":1.2341557623048535e-33,
       "adhd-related costs":1.92719940207137e-33,
       "seven european studies":1.2341557623048537e-33,
       "annual national costs":1.2341557623048535e-33,
       "€1 billion":1.2341557623048535e-33,
       "adhd-specific problems in daily life":0.0038066131557717912,
       "adjunctive psychotherapy":0.003129901679845874,
       "suboptimal response":0.005289435833048569,
       "adjust the timing of the dose":0.005107023475376763,
       "excessive tiredness":0.031145513083487536,
       "stomachaches, nausea":0.00730574005868259,
       "adjusted odds ratio":0.0030207909412267296,
       "cardiovascular disease diagnosis":0.009880160720601057,
       "drowsiness":0.037293259866254064,
       "trouble sleeping":0.0054948017162824575,
       "adjusting the dose or timing may help":0.004090894785526001,
       "adjustment":0.0037162129019667964,
       "administer the stimulant with meals to lessen its impact on appetite":0.0075899356328479745,
       "helping the noncompliant child":0.0040130155042715845,
       "homework organization":0.0040130155042715845,
       "incredible years parenting program":0.0040130155042715845,
       "new forest parenting program":0.007166399412756276,
       "nmu of amp":0.007415784110862978,
       "parent-child interaction therapy":0.0040130155042715845,
       "positive parenting program (triple p)":0.0040130155042715845,
       "self-monitoring skills":0.0040130155042715845,
       "study skills":0.0040130155042715845,
       "teacher ratings":0.008768754343826618,
       "young adults who do not attend college":0.007415784110862978,
       "intuniv":0.00834951403821711,
       "kapvay":0.00834951403821711,
       "qelbree":0.009026997010826376,
       "adult adhd quality measures initiative (aaqmi)":0.0015478338617282558,
       "ahrq":0.002223762634502587,
       "candidate qms":0.001615330334508834,
       "clinical and research experts":0.001615330334508834,
       "delivery of quality health care to adults with adhd":0.0015478338617282558,
       "development of qms":0.001615330334508834,
       "existing guidelines for adult adhd":0.001615330334508834,
       "expert opinion":0.001516822267294335,
       "extended-release":0.008305093196486528,
       "healthcare delivery":0.001516822267294335,
       "healthcare processes":0.001634123062214868,
       "immediate-release":0.008305093196486528,
       "limited access to treatment by skilled providers":0.002078517999270774,
       "multidisciplinary panel":0.001615330334508834,
       "clinical guidelines":0.0021739752295951474,
       "qms":0.0024067505728765618,
       "quality indicators":0.002233678579302099,
       "us agency for healthcare research and quality (ahrq)":0.001615330334508834,
       "adult adhd quality of life survey":0.0038066131557717912,
       "adult adhd self-report scale":0.0023678427236536624,
       "measure":0.001516822267294335,
       "affective lability scale –short form (als-18) ":0.0067263304576527716,
       "affective reactivity index (ari)":0.0067263304576527716,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":0.0067263304576527716,
       "behavior rating inventory of executive function (brief or emotion control subscale)":0.0067263304576527716,
       "brown add rating scales for children, adolescents and adults (badds)":0.0067263304576527716,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":0.007350444606275889,
       "difﬁculties in emotion regulation scale (ders)":0.008256606778396236,
       "distress tolerance scale":0.006419023505161636,
       "drug holidays":0.005151970565232192,
       "emotion dysregulation scale, short version (eds-short)":0.007350444606275889,
       "emotion regulation checklist (erc)":0.007350444606275889,
       "emotion regulation index for adults and children (erica)":0.007350444606275889,
       "emotion regulation questionnaire (erq)":0.00853251102197851,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":0.00594704778102958,
       "expression and emotion scale for children (eesc)":0.006143119261579363,
       "frustration discomfort scale":0.00594704778102958,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":0.006419023505161635,
       "trials norms availability":0.007350444606275889,
       "adults (11 studies, 2909 participants)":0.004958356186297092,
       "adults (cortese et al., 2018a)":0.004958356186297092,
       "adults treated with viloxazine":0.0052805577199414025,
       "adults unresponsive to mph trial":0.004573895530740467,
       "advancing age":0.0039062396135870177,
       "adverse":0.004667598443948644,
       "clinical response":0.008118808937691008,
       "driving and work performance":0.008035101755700245,
       "emergency room visits":0.00864287601563871,
       "maximum daily dose":0.008742425887180511,
       "discontinuation":0.005661285733713366,
       "follow-up visit":0.013826323499116078,
       "medication response":0.013826323499116078,
       "health care facilities":0.0033801848312041208,
       "adverse outcomes":0.00039342075509090594,
       "prevalence of stimulant nmu":0.009248826718768087,
       "adverse side effects of atomoxetine":0.00186307230543486,
       "monitoring and management":0.005211540996603124,
       "adverse side effects of guanfacine":0.00186307230543486,
       "adzenys xr -odt":0.0010642216220707475,
       "dexedrine spansule":0.0010642216220707475,
       "dyanavel xr":0.0009525786659644758,
       "mydayis":0.0010642216220707475,
       "tips for using amphetamine-based medications":0.0009525786659644758,
       "aerobic activity":0.0018875059699807314,
       "improvement in the core symptoms of adhd":0.0061057432949578015,
       "aerobic exercise":0.0022665522448186586,
       "affective components of executive control":0.00023584531468501184,
       "dopaminergic system":0.0021631774247722418,
       "executive control":0.0025102962316414135,
       "mood regulation":0.0021631774247722418,
       "noradrenergic system":0.0021631774247722418,
       "affordable care act":0.00016835068407689628,
       "african-american students":0.0021763900504515534,
       "viloxazine dose":0.006218664050148047,
       "liver problems":0.010980680436184925,
       "nausea/vomiting":0.010980680436184925,
       "viloxazine (qelbree)":0.031112434693152346,
       "agitation":0.006605669748807349,
       "expert clinicians":0.0006889967890773057,
       "ahrq, medicare and medicaid":0.00016835068407689628,
       "alcohol use disorder: treatment overview":0.0017404696892115833,
       "counseling":8.466887890898967e-05,
       "limit their alcohol consumption":8.265808659693196e-05,
       "low-risk and risky alcohol use":8.466887890898967e-05,
       "opioid use disorder: treatment overview":8.265808659693196e-05,
       "stimulant use disorder: treatment overview":8.265808659693196e-05,
       "stimulants for adhd":0.0017404696892115833,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":0.007249250593181335,
       "all-cause treatment discontinuation":0.007054698274270885,
       "dizziness":0.03353906730209199,
       "increased blood pressure and heart rate":0.0024690510307447105,
       "itching":0.0024104200427601617,
       "monitoring":0.0024690510307447105,
       "rash":0.0024104200427601617,
       "vomiting":0.013005838983241062,
       "motor or vocal tics":0.008125174310743362,
       "nonstimulants for adhd":0.005822781546686223,
       "alpha agonists (clonidine and guanfacine)":0.02009507781078746,
       "liver problems such as hepatitis":0.017347286139560197,
       "american academy of child and adolescent psychiatry adhd resource center":0.015653539664361966,
       "attention deficit disorder association (adda)":0.015653539664361966,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":0.014959448042123093,
       "centers for disease control and prevention (cdc) adhd":0.015653539664361966,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":0.015653539664361966,
       "national institute of mental health (nimh) adhd":0.014959448042123093,
       "the american professional society of adhd and related disorders (apsard)":0.015653539664361966,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":0.014959448042123093,
       "american academy of pediatricians":0.0025658208583340205,
       "american professional society of adhd and related disorders":0.00088558572060024,
       "canadian adhd resource alliance":0.0008742988882410962,
       "world federation of adhd":0.019604767309732762,
       "american psychopathological association":1.2341557623048537e-33,
       "pau l hoch award":1.2341557623048537e-33,
       "state university o f new york":1.9271994020713704e-33,
       "reasonable accommodations":0.00013783775213383286,
       "amp":0.0010724681132885262,
       "attention and impulsivity":0.004958356186297092,
       "cardiac arrest":0.00639585145369392,
       "cerebrovascular disease":0.00639585145369392,
       "daily timing":0.004958356186297092,
       "heart failure":0.00639585145369392,
       "ischemic heart disease":0.00639585145369392,
       "misuse and diversion":0.006675631392095472,
       "prescribing medications for adhd":0.006675631392095472,
       "prescription refill requests":0.006675631392095472,
       "risks of stimulant misuse and diversion":0.006675631392095472,
       "schedule ii controlled substances":0.006517099271229316,
       "short-acting amphetamines":0.004958356186297092,
       "studies regarding nmu of mph or amp":0.00799299112292736,
       "symptom control":0.004958356186297092,
       "tachyarrhythmias":0.00639585145369392,
       "venous thromboembolism":0.00639585145369392,
       "amphetamine formulations":0.003887577071654057,
       "lisdexamfetamine dimesylate (ldx)":0.005025623682300513,
       "amphetamine medication":0.0009149237053848759,
       "amphetamine stimulants":0.004691241294981186,
       "children (7 studies, 1930 participants)":0.005795367596111008,
       "growth suppression":0.012872212636649616,
       "pregnant woman":0.0063626495904240046,
       "youths (9 studies, 2677 participants)":0.004958356186297092,
       "analysis":0.0005671151738330044,
       "discontinuation due to adverse event":0.013575344297127931,
       "lisdexamphetamine":0.013575344297127931,
       "worse anorexia":0.013575344297127931,
       "antacids":0.0045982453168224085,
       "antecedents of behaviour":0.0010437479417110924,
       "reinforcement techniques":0.0010437479417110924,
       "anthony l. rostain":0.0008760192892033317,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":0.0008760192892033317,
       "anticipatory appraisal and valuation":0.0016333792267313946,
       "emotion generation":0.003234957680088984,
       "emotional state":0.005568143311540472,
       "regulation":0.0007851789113179166,
       "antipsychotics":0.004573895530740467,
       "not recommended adhd treatment":0.004573895530740467,
       "dry mouth":0.031710882151290296,
       "anxiety and substance use disorders":0.0011250137191895402,
       "benzodiazepines":0.0051802980746540935,
       "childhood irritability":0.016380987778332346,
       "opioid":0.009243361914905034,
       "any interpretation should keep in mind that the ratings are of relative importance":0.004748365039216752,
       "care coordination":0.017468407469148954,
       "care coordination and the patient experience domains":0.00022290998795701178,
       "follow-up":0.009468971777173789,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":0.004638217853349035,
       "low rating only means that the item is not essential for documenting the basics of quality care":0.00022290998795701178,
       "patient experience":0.000850560161359281,
       "patients and health care systems":0.00022833210107561235,
       "quality diagnosis":0.00448056648875533,
       "quality in these domains may be viewed as less relevant":0.00044777844230261426,
       "results may reflect a systematic bias in our sample of raters":0.00022833210107561235,
       "should include other relevant stakeholders, including patients and health care systems":0.00022833210107561235,
       "systematic bias in our sample of raters":0.00022833210107561235,
       "apsard":0.0004751872870836535,
       "apten sio xr":0.008121030019978503,
       "capsules":0.008121030019978503,
       "daytrana":0.008121030019978503,
       "focalin xr":0.004105449410782471,
       "liquid":0.0042053176816702394,
       "patches":0.004105449410782471,
       "quillivant xr":0.0042053176816702394,
       "ritalin la":0.004105449410782471,
       "arterial disease":0.0030207909412267296,
       "asian federation of adhd":5.5145561362229204e-05,
       "asian resource":0.0007981253036373324,
       "assignments":0.0006577306388639067,
       "association for behavior and cognitive therapies":0.0009727828590786089,
       "behavioral therapist":0.0035233234948138454,
       "caregivers of children age 6 to 12 years":0.0035233234948138454,
       "centers for disease control and prevention (cdc)":0.0035233234948138454,
       "association for child and adolescent mental health":1.436854441826503e-49,
       "atomox etine":0.004482829050798391,
       "atomoxetine levels":0.003019922811643725,
       "atypical antidepressants":0.008245246013632294,
       "blood monitoring":0.003019922811643725,
       "brain cells communication":0.003019922811643725,
       "cardiac malformations":0.00813762310868785,
       "chemical messengers (norepinephrine)":0.003019922811643725,
       "constipation":0.010654462965362857,
       "correct dose":0.0029482090819615684,
       "treatment discontinuation":0.007054698274270885,
       "tricyclic antidepressants (tcas)":0.008245246013632294,
       "atomoxetine treatment for adhd":0.00186307230543486,
       "attention and arousal":0.0002137100840649043,
       "behavioral functioning":0.01626827705791286,
       "chronic condition management":0.01626827705791286,
       "information provision":0.01626827705791286,
       "dizziness and lightheadedness":0.03192400136596025,
       "fatigue":0.034721423994174945,
       "sedation":0.03064059806993515,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":0.005544686930780547,
       "behavioral management techniques that are used for children with adhd":0.0005787547621424107,
       "coexisting conditions that are associated with adhd or mimic its symptoms":0.00013486951711332064,
       "nonadherence to the treatment plan":0.0009127584447932584,
       "repetition of the diagnostic evaluation":0.00013486951711332064,
       "evidence-based statements about adhd":0.01389625227067289,
       "international consensus statement":0.013566210843140764,
       "meta-analyses and very large studies":0.01389625227067289,
       "parents' medication guide":0.013881709972758649,
       "parents' medication guidedysregulation":0.015560426611049318,
       "project steering committee":0.013566210843140764,
       "research and clinical care of adhd":0.013566210843140764,
       "scientific data":0.013566210843140764,
       "attention-deﬁcit/hyperactivity disorder":0.0013765634255221459,
       "impulsive aggression":0.004112432290584474,
       "liver damage":0.006605669748807349,
       "psychotic symptoms":0.006605669748807349,
       "self-harming behavior":0.006605669748807349,
       "unusual changes in behavior":0.006605669748807349,
       "atx or dex":0.004573895530740467,
       "atx treatment":0.004573895530740467,
       "liver disease evaluation":0.004573895530740467,
       "augmentation strategies":0.0005659462743291446,
       "charles bradley":0.0009149237053848759,
       "child psychiatry":0.0008931992603852627,
       "minimal brain dysfunction-related behaviors":0.0009149237053848759,
       "morris et al. and o'neal and robins":0.0009149237053848759,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":0.0014233104070859475,
       "u.s. food and drug administration":0.008420846627750537,
       "world health organization":0.0008931992603852627,
       "authors":0.0008691776431778214,
       "emotional problems":0.003672076103284133,
       "seizures":0.012586768646537513,
       "sleep disorder":0.003672076103284133,
       "availability of treatment":0.0005797115760136204,
       "avoid caffeine":2.491775274607727e-05,
       "evening":2.838594594218986e-05,
       "good sleep habits":0.0010209451068895977,
       "avoid skipped doses":0.0010161286898507614,
       "maladaptive emotions":0.0015830856887334226,
       "bachelor's degree":0.0019488904203164299,
       "dorsal anterior cingulate cortex":0.0009321184153493361,
       "fmri meta-analyses":0.001295510820747277,
       "inferior frontal cortex":0.0024881847314476703,
       "neutral fmri tasks":0.0007497558718817179,
       "supplementary motor area":0.0007497558718817179,
       "typically developing individuals":0.0007497558718817179,
       "ventral anterior cingulate cortex":0.0009321184153493361,
       "become unusually quiet or appear over-focused":0.0075899356328479745,
       "child development":0.0009239103721712604,
       "metacognitive executive function training":0.004583932086475183,
       "pre-kindergarten academic curriculum (stp-pre-k)":0.004583932086475183,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":0.004583932086475183,
       "tools":0.0009239103721712604,
       "behavior modification system":0.0014393663794684717,
       "behavior problems":0.008573181929660875,
       "blood pressure monitoring":0.008414506047395784,
       "chest pain":0.008414506047395784,
       "education on side effects":0.01074906521368128,
       "growth monitoring":0.008414506047395784,
       "heart rate assessment":0.008414506047395784,
       "impulsiveness":0.008414506047395784,
       "long-term use":0.008720180113550672,
       "mood monitoring":0.008414506047395784,
       "mood swings":0.022748617583432718,
       "palpitations":0.008414506047395784,
       "peripheral vasculopathy":0.008619183205167863,
       "raynaud’s phenomenon":0.008619183205167863,
       "severe allergic reactions":0.008619183205167863,
       "severe psychiatric symptoms":0.008414506047395784,
       "side effects information":0.008669761293292652,
       "sudden cardiac death":0.01051478219048939,
       "swelling of the face, lips, tongue, or throat":0.008619183205167863,
       "weight monitoring":0.008414506047395784,
       "blurred vision or other visual changes":0.006221955169515681,
       "development or worsening of motor or vocal tics":0.007589814176170056,
       "elevated blood pressure (hypertension)":0.006074205601001879,
       "especially in children":0.006074205601001879,
       "increased aggression or hostility":0.006074205601001879,
       "increased heart rate (tachycardia)":0.006074205601001879,
       "nervousness":0.006074205601001879,
       "rash or hypersensitivity reactions":0.006221955169515681,
       "skin reactions":0.006221955169515681,
       "trouble falling and staying asleep":0.006074205601001879,
       "visual disturbances":0.006221955169515681,
       "behavioral disinhibition":4.300742947979599e-05,
       "observed behavior":0.0002225624525632372,
       "behavioral expression":0.001588549235073041,
       "behavioral indicators":0.0020999753707943605,
       "subjective emotionality":0.0020999753707943605,
       "high emotional thresholds":0.0014941388283027995,
       "recovery times":0.0010626351454349023,
       "quick return to baseline":0.001585882458935937,
       "behavioral response system":5.4140516001513844e-06,
       "subjective/cognitive response system":5.4140516001513844e-06,
       "child’s behavior":0.0016741667611928637,
       "coping strategies":0.0016741667611928637,
       "negative behaviors":0.0016741667611928637,
       "negative thought patterns":0.002786975393875818,
       "parent -child relationship":0.0016741667611928637,
       "positive behaviors":0.0016741667611928637,
       "problematic behaviors":0.0016741667611928637,
       "finding activities in which the child can be successful (eg, hobbies, sports)":0.0009727828590786089,
       "identifying unintentional reinforcement of negative behaviors":0.0009727828590786089,
       "keeping environmental distractions to a minimum":0.0009727828590786089,
       "limiting choices":0.0009727828590786089,
       "maintaining a daily schedule":0.0009727828590786089,
       "national institute for children's health quality toolkit":0.0009727828590786089,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":0.0009727828590786089,
       "rewarding positive behavior (eg, with a 'token economy')":0.0009727828590786089,
       "setting small, reachable goals":0.0009727828590786089,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":0.0009727828590786089,
       "using charts and checklists to help the child stay 'on task'":0.0009727828590786089,
       "parenting context":0.0015318469869148653,
       "pharmaco logical therapy":0.0021670742443897885,
       "benefits and risks of treatment":0.0005996560529506286,
       "best practices":0.00016835068407689628,
       "best studies":5.5145561362229204e-05,
       "pulse":0.000918842000977107,
       "blood pressure and pulse quarterly":0.005385971083594028,
       "blood tests":0.0052875428687908345,
       "bone fractures":0.002546329837722313,
       "borderline personality disorder":0.0013765634255221459,
       "boundaries between adhd and other disorders":0.0018111741918709536,
       "long-term side effects":0.006564894540417904,
       "broader scope of the review":0.00041882474497077863,
       "bupropion (wellbutrin, zyban)":0.0030914202608784045,
       "caddra":0.0004751872870836535,
       "caffeine levels":0.0052875428687908345,
       "calendar year":0.0009024118802427165,
       "chelation":0.0023426403756651192,
       "primary care practitioner":0.006263868820044724,
       "risks and benefits":0.0023426403756651192,
       "nonmedical users":0.0016571277657110141,
       "cardiac history or cardiac symptoms":7.917337673768434e-05,
       "cardiac review":0.0063249901644550285,
       "cardiologist consultation":7.917337673768434e-05,
       "findings outside of normal limits":7.917337673768434e-05,
       "sudden death or ventricular arrhythmia":0.005857197013610818,
       "cardiovascular health":0.0018875059699807314,
       "clinical response, duration of the effect during the day, and side effects":0.0022059740524496747,
       "electrocardiogram (ecg)":7.917337673768434e-05,
       "low dose stimulant treatment":0.00027009175824456547,
       "short-acting dextroamphetamine-amphetamine":7.917337673768434e-05,
       "child's height":0.008458077112400068,
       "child's weight":0.008458077112400068,
       "regular measurement":0.008458077112400068,
       "qm":0.0006081161549786221,
       "quality care":0.0006328207306346,
       "treatment follow-up":0.0010651223672229165,
       "care management plan":0.0013119894325807906,
       "careful dose titration required":0.004465273511231494,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":0.003776308993278672,
       "child's practitioner":0.01050357132522789,
       "caregiver decision":0.0036492516987609385,
       "catapres":0.0024598084774828037,
       "category":0.000778844582181755,
       "causes":0.0033899931799043176,
       "cbcl-dysregulation profile":0.001310015709502787,
       "emotional dysregulation scores":0.001310015709502787,
       "cbt group and individual therapy programs":0.0009603144798595568,
       "cbt group treatment":0.004763803867386642,
       "orthostatic hypotension":0.00647530883266149,
       "slow heart rate (bradycardia)":0.00647530883266149,
       "cereals":2.491775274607727e-05,
       "certain children":0.0043604027639288796,
       "certain events":0.0003966224913887123,
       "certain foci in the literature may have been missed":0.00041882474497077863,
       "chadd website":0.000576558327209334,
       "coalition to prevent adhd medication misuse":0.000576558327209334,
       "college administrators":0.000576558327209334,
       "collegiate student leaders":0.000576558327209334,
       "cpamm":0.0006434206321480879,
       "information about misuse and diversion":0.0027173866868844946,
       "personnel":0.000576558327209334,
       "pharmaceutical industry":0.000576558327209334,
       "changing the drug":0.001118465285687892,
       "heart symptoms":0.014404297075022552,
       "height":0.007855645357166957,
       "long-term studies (lower risk of later cigarette or illegal substance use)":0.007839372833529612,
       "meal timing":0.0072430846945638295,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":0.003776308993278672,
       "mental health challenges":0.004307963631789164,
       "mirtazapine":0.0072430846945638295,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":0.005212066656544068,
       "mood problem":0.0080467396668065,
       "moodiness":0.010827761591017403,
       "over-focused or repeated movements (tics or habits)":0.003776308993278672,
       "preparation":0.007855645357166957,
       "separate issue":0.0080467396668065,
       "sleep habits":0.0072430846945638295,
       "worsened heart problems":0.004479144083581488,
       "zombie effect":0.003776308993278672,
       "child and adolescent psychiatrist":0.00200637071262357,
       "child psychologist":0.004060659049857135,
       "immediate action":0.006651699789615734,
       "medication holidays":0.002935486887648937,
       "childhood diagnosis of adhd":0.003358904323237188,
       "children in intervention group":0.0041594370370350775,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":0.0075899356328479745,
       "loss of appetite (anorexia)":0.008523360535334548,
       "monitor for changes in behavior and report to the healthcare provider":0.0075899356328479745,
       "monitor your child closely for new or worsening tics":0.0075899356328479745,
       "offer high-calorie snacks such as instant breakfast drinks":0.0075899356328479745,
       "regularly check your child's weight to ensure they are growing normally":0.0075899356328479745,
       "sleep intervention":0.004060659049857135,
       "teacher-reported behavior":0.0041594370370350775,
       "cohort studies":0.0072430846945638295,
       "children and youth with special health care needs":0.001139876594844508,
       "children who have not yet entered elementary school":0.002265307813570522,
       "classroom modifications":0.0025261077894923206,
       "developmental behavioral pediatrician":0.00200637071262357,
       "intentional and unintentional injury":0.0025261077894923206,
       "china adhd alliance":0.0004751872870836535,
       "classroom modifications and accommodations":0.0010813193106842985,
       "combined medication and behavior treatment":0.00011553078757608215,
       "combined treatment":2.63001169356567e-05,
       "lower doses of medication":2.63001169356567e-05,
       "non-adhd symptoms":0.00011553078757608215,
       "provision of tutoring or resource room support":0.0005235494424101173,
       "school-aged children":0.005678414534115964,
       "stressors in family life":0.0003530537203876644,
       "suboptimal response to pharmacotherapy":0.00016052449306873956,
       "normative data":0.002891004455014014,
       "parents and teacher reports":0.002266780449657493,
       "preschool teachers and clinicians":0.003162901589568155,
       "ratings from other individuals":0.0022115150402280473,
       "scales":0.0022801655233054725,
       "secondary school teachers":0.0022115150402280473,
       "self-report":0.009663346990447672,
       "structured behavioural observations":0.002265307813570522,
       "such as":0.0036626618130618216,
       "tools for screening":0.001955713349746423,
       "longer acting than clonidine":0.0024598084774828037,
       "short-acting medication":0.0024598084774828037,
       "tenex":0.0024598084774828037,
       "tic problems":0.0024598084774828037,
       "close monitoring":0.00800358859961222,
       "close monitoring by healthcare provider":0.002943526484853316,
       "persistent adhd":0.0017910606427626024,
       "cognitive components of executive control":0.00023584531468501184,
       "cognitive flexibility":0.0009356919375995451,
       "cognitive strengths and weaknesses":0.002041234629822348,
       "play-based interventions":0.00336209249357515,
       "problems with peers":0.0015621127613191241,
       "psychotherapy interventions":0.014213426766249471,
       "students with disabilities":0.001139876594844508,
       "summer treatment camp":0.0014393663794684717,
       "deficits":0.001967343846341185,
       "guided walks":0.0018875059699807314,
       "increases the effectiveness of":0.004220417658427151,
       "organizational/planning skills":0.0018875059699807314,
       "psychosocial well-being":0.0018875059699807314,
       "yoga":0.0018875059699807314,
       "patient's family":0.0023043011037093713,
       "collateral report":0.0005334530657688134,
       "colleagues":0.0005233486299315903,
       "gpas":0.0017718072918588075,
       "college peers":0.0021182706574569303,
       "common misconceptions":0.002218532790232256,
       "nmu of mph":0.0027801708292330817,
       "nmu population prevalence":0.0026288610407656236,
       "parents with suspected or diagnosed adhd":0.0021763900504515534,
       "peer behavior":0.0021561064868309983,
       "printed handouts":0.0021561064868309983,
       "repetition":0.0021561064868309983,
       "sanctions":0.0021561064868309983,
       "social situations":0.0021763900504515534,
       "us college populations":0.005281309035264061,
       "young adult populations":0.0021561064868309983,
       "enforcement":0.005498821503516336,
       "incoming students":0.0016553901615795814,
       "com-ponents of emotional symptoms":0.000979209960748978,
       "different terms used to describe them":0.000979209960748978,
       "community psychosocial care":0.0009603144798595568,
       "community support":0.0017709522248982217,
       "specific treatment approach":0.005100398471594713,
       "medication adherence":0.0020170930471629187,
       "diagnostic challenges":0.001052393041378107,
       "simplex adhd":0.0010274041908787876,
       "standard information gathering":0.001052393041378107,
       "comprehensive approach to literature on nmu":0.00041882474497077863,
       "concerns being discussed":0.0016114597435426523,
       "extended-release tablets":0.003922723816284268,
       "reduce the need to take multiple doses throughout the day":0.003922723816284268,
       "consistent sleep schedule":2.491775274607727e-05,
       "consult with healthcare provider":0.003191798252660589,
       "consult with the healthcare provider for further advice":0.004090894785526001,
       "contents":0.0008903181607227692,
       "contraindications to drug treatment":0.000661430103029774,
       "cooperating":0.0006865920025356864,
       "ingroup therapy":0.0009603144798595568,
       "integrative treatment program":0.0009603144798595568,
       "parental satisfaction":0.0009603144798595568,
       "core symptoms":0.0036492516987609385,
       "corticocerebellar networks":0.00040534474521091075,
       "criteria":0.0009620377388406175,
       "critical care unit":0.0010724681132885262,
       "current adhd symptoms":0.0032300914798013003,
       "secular private schools":0.0015217475408168472,
       "decongestants":0.00639597552869736,
       "food supplements":0.00800358859961222,
       "hepatitis":0.00800358859961222,
       "low dose medication":0.00800358859961222,
       "medication adjustment":0.009727871872060373,
       "medication with food":0.00800358859961222,
       "executive control and corticocerebellar networks":0.0013174777630507617,
       "frontal and parietal cortical areas":0.000359222763082637,
       "inferior parietal and medial temporal regions":0.00035414452970379637,
       "medial prefrontal and the posterior cingulate cortices":0.00035414452970379637,
       "orbitofrontal cortex":0.00035414452970379637,
       "reward system":0.013833559155006614,
       "thalamus":0.0005679751967778586,
       "ventromedial prefrontal cortex":0.00035414452970379637,
       "denmark, finland, sweden, norway, and iceland":0.003919330906801053,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":0.0008760192892033317,
       "those reporting nmu in a survey of 4,297 us adults":1.436854441826503e-49,
       "detect nmu":0.0007586468409859943,
       "medical/neurological history":0.0011410423697993063,
       "stimulant misuse risk assessment":0.005152137388151155,
       "deﬁcits in response inhibition to frustration":0.0008574453826268703,
       "documented dsm-5 diagnosis of adhd":0.0015605554889171717,
       "diagnostic guidelines":0.0018420443412393548,
       "diagnostic utility for adhd":0.000979209960748978,
       "symptoms commonly occurring in other disorders":0.000979209960748978,
       "dietary restrictions":0.0015798776830515348,
       "disability services":0.001485259393525804,
       "discontinuing medication":0.0019742806478271163,
       "discussions":0.001485259393525804,
       "discussions of transfer of care with new clinician made":0.0015731922420367096,
       "emotional upsets":0.0003966224913887123,
       "motivation":0.0003966224913887123,
       "social payoff":0.0003966224913887123,
       "diurnal variation in symptoms":0.005385971083594028,
       "malingering":0.004145530025270852,
       "pills per prescription":0.01012490863273533,
       "extended-release form":0.004512659573007414,
       "hydration":0.005690480550102766,
       "loss of appetite":0.006085215853915837,
       "medication form adjustment":0.005278064990205206,
       "more irritability or moodiness when taking medication":0.0016842870931710176,
       "slowing of heart rate":0.00945582962378349,
       "snacks":0.004512659573007414,
       "supplemental medications":0.0016842870931710176,
       "timing of medication":0.001561852088238409,
       "dmdd":0.002228592070615406,
       "intensified negative mood":0.002228592070615406,
       "document":0.0005233486299315903,
       "documentation":0.003000674031436369,
       "frontal lobes":0.0002137100840649043,
       "learning and memory":0.0002137100840649043,
       "movement regulation":0.0002137100840649043,
       "novelty processing":0.0002137100840649043,
       "parietal cortex":0.00023592784181101413,
       "reward processing":0.0002137100840649043,
       "signal-to-noise processing":0.0002137100840649043,
       "stress response":0.0002137100840649043,
       "mood symptoms":0.005861090369439939,
       "time":0.008626919912205464,
       "dose reduction":0.007514651979992983,
       "dosing":0.0015224921694042771,
       "driving licenses suspension/revocation":0.013476295208614741,
       "driving performance improvement":0.002708588763494645,
       "gradually increase dose":0.0010161286898507614,
       "monitor mood symptoms":0.0011553149127277167,
       "excessive weight loss":0.0048081189697999635,
       "dsm criteria":0.0011910750329247116,
       "us college-aged women":0.002171494082325934,
       "eating foods high in added sugar":0.0008706656152721615,
       "hyperactivity/impulsivity subtypes":0.0008706656152721615,
       "inattention symptoms and unhealthy eating habits":0.0008706656152721615,
       "monozygotic twins":0.0008706656152721615,
       "unhealthy dietary habits":0.0008706656152721615,
       "stimulant misuse":0.004417526003682431,
       "history of psychosis":0.000780748795319961,
       "prescribed stimulants":0.00453903453792929,
       "size":0.0006346062737189737,
       "effect size findings":0.0008157370505714756,
       "effective self-regulation":0.0005571973298024492,
       "effortful strategy":0.004117162138118651,
       "emotional arousal":0.004117162138118651,
       "high ei":0.0005644321151822187,
       "reappraisal":0.0049826959547692755,
       "self-monitoring":0.0049826959547692755,
       "valuation":0.0005090259458225865,
       "el":0.0005226477191611597,
       "emotionally intense provocation":0.002685906898380374,
       "hyperactive-impulsive adhd presentations":0.0005226477191611597,
       "inadequate self-control and weak behavioral inhibition":0.0017891450265517695,
       "patients with no ei":0.0008903198567370336,
       "rapid changes in emotional states":0.0011028778596194639,
       "self-regulatory processes":0.0005478961896765474,
       "elevated mood":0.005661285733713366,
       "elevation of blood pressure or heart rate":0.0033531599249388483,
       "feeling sad":0.0023809091369598415,
       "healthcare facility utilization":0.0011974414472530077,
       "poison control centers data":0.00021023215310021653,
       "sleep difficulties":0.0010016862451906314,
       "study of 15,629 adults and adolescents":0.00021023215310021653,
       "regulatory processes":0.0007472921436933971,
       "emotional experience":0.002024436423501975,
       "emotional valence":0.0018420443412393548,
       "heterogeneity":0.00236643235591163,
       "neural activation":0.001890117708114955,
       "poorly controlled emotionally driven behavior":0.0009076403091324757,
       "self-regulatory deficits":0.0021649947740192215,
       "self-regulatory deﬁcits":0.0009076403091324757,
       "executive function control of emotional response":0.00481413627626531,
       "extended-release methylphenidate":0.00213412462465082,
       "intermittent explosive disorder":0.0035522329883319733,
       "methylphenidate preparations":0.0018715482150301415,
       "oppositional deﬁant disorder":0.0013765634255221459,
       "emotional functioning":0.0005637872282465727,
       "impaired":0.005291987019583953,
       "emotional instability":0.0013175907659058951,
       "negative emotion":0.0004690937671909919,
       "emotional reactivity":0.0014787276070869152,
       "high emotional impulsivity":0.0006302306083720125,
       "response systems":0.00013750856569589437,
       "future development of adhd criteria":0.000979209960748978,
       "measurement tool/assessment instrument":0.000979209960748978,
       "mistake for emotional symptoms to be specific for adhd":0.000979209960748978,
       "multidimensional nature of emotional symptoms":0.000979209960748978,
       "stephen v. faraone":0.0008760192892033317,
       "evidence-based assertions":0.01396979577674434,
       "findings":0.0013202936686943878,
       "manuscript":0.0008903181607227692,
       "participants":0.0024646875806027964,
       "waiting-list controls":0.0009795022918133258,
       "encourage good sleep habits":0.004090894785526001,
       "eunethydis":0.001910944950349049,
       "euphoria":0.005661285733713366,
       "european network adult adhd":0.0004751872870836535,
       "evaluation":0.0005334530657688134,
       "frozen yogurt":2.491775274607727e-05,
       "instant breakfast drinks":2.491775274607727e-05,
       "limit naps to less than 45 minutes":2.491775274607727e-05,
       "reduce screen time before bed":2.491775274607727e-05,
       "evidenced based fda approved medication":0.004236999327702047,
       "exacerbation":0.005661285733713366,
       "give medication with food to minimize stomach discomfort":0.004090894785526001,
       "irritability or aggression (infrequent)":0.0041904019635595185,
       "monitor headaches and consult with the healthcare provider":0.004090894785526001,
       "monitor irritability and consult with the healthcare provider":0.0041904019635595185,
       "some children do better with the daily dose divided into two doses":0.004090894785526001,
       "start with a low dose and gradually increase":0.004090894785526001,
       "this side effect usually improves over time":0.004090894785526001,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":2.3677940209348045e-06,
       "exclusion criteria":0.0029651819951458493,
       "extended time":0.0006577306388639067,
       "factors leading to favorable outcomes":0.00016835068407689628,
       "fear of exposing nmu or minor unwanted effects":0.00041882474497077863,
       "individuals who experience minor unwanted effects":0.00041882474497077863,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":2.3677940209348045e-06,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":2.3677940209348045e-06,
       "feigned":0.004161902017143241,
       "genu ine":0.004161902017143241,
       "ferritin":0.0008126271335556193,
       "serum":0.0007942055833651181,
       "serum iron":0.0007942055833651181,
       "findings of interest":0.0019522889139009735,
       "misusers":0.002160804391835216,
       "first drug treatment try":0.004465273511231494,
       "fluctuating periods of remission and recurrence":0.0012125595032627039,
       "patient's symptoms":0.005610839537939631,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":9.861186256096122e-36,
       "patients with neither one physician visit nor medication claim in 6 months":9.861186256096122e-36,
       "use of outside provider for adhd diagnosis":9.861186256096122e-36,
       "job/school performance":0.005385971083594028,
       "medication side effects/toxicity or signs of abuse/diversion":0.005385971083594028,
       "potential side effects of atx":0.005516987127138047,
       "relationship issues":0.005385971083594028,
       "sexual dysfunction and dysmenorrhea":0.005516987127138047,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":0.005385971083594028,
       "target symptoms":0.005385971083594028,
       "vital signs":0.0059224631556459,
       "food":0.001118465285687892,
       "foxp1":0.0007984521765791502,
       "synapse formation":0.0007984521765791502,
       "friendships":0.0006865920025356864,
       "functional impairment related to adhd":0.0038251580201325527,
       "functional outcomes":0.0038066131557717912,
       "insights into key details of nmu":0.00041882474497077863,
       "general qol measures for adults":0.0038066131557717912,
       "generic medication preparations":0.0003369907334525088,
       "pharmacies":0.0003369907334525088,
       "united kingdom":0.0010017687668921998,
       "grade point average (gpa)":0.0017328342602891515,
       "greater family cohesion":0.0017709522248982217,
       "group of experts":5.648715130548971e-05,
       "organizations that study and treat adhd":5.648715130548971e-05,
       "severe hypotension":0.0027513748714176095,
       "guanfacine treatment for adhd":0.00186307230543486,
       "individuals who abused":0.0010724681132885262,
       "minor toxicity":0.0010724681132885262,
       "poison control centers":0.0010724681132885262,
       "health effects":0.006739817910965128,
       "icasa":0.0004751872870836535,
       "national health and medical research council (australia)":0.0004751872870836535,
       "ukaan":0.0004751872870836535,
       "heart rate monitoring":0.001818830191437181,
       "high risk for nmu":0.006739817910965128,
       "high risk patients":0.0005207864257352504,
       "high-calorie foods":0.0010919060678331678,
       "high-quality studies":5.5145561362229204e-05,
       "high-risk populations":0.004100926647558038,
       "prisoners":0.0032507699820408156,
       "vulnerability to psychosis":0.004180462680096374,
       "holidays":0.004210479545107475,
       "household public assistance":0.0017709522248982217,
       "huybrechts et al., 2018":0.003919330906801053,
       "hyperactive-impulsive symptoms":0.001736149034180107,
       "id":0.004546718289272877,
       "immediate-release preparations allowed":0.004465273511231494,
       "physical functioning":0.0005637872282465727,
       "school functioning":0.0005637872282465727,
       "popularity":0.0006865920025356864,
       "reciprocity":0.0006865920025356864,
       "rejection/likability":0.0006865920025356864,
       "sharing":0.0006865920025356864,
       "socializing with peers":0.0006865920025356864,
       "turn-taking":0.0006865920025356864,
       "meditation-based therapy":0.0036507063651170612,
       "in insomnia":0.0033531599249388483,
       "inclusion criteria":0.0012362843999496628,
       "medications misuse":0.0019435163048571998,
       "individuals at greatest risk":0.0007586468409859943,
       "study routes of administration":0.0007586468409859943,
       "individuals who die from stimulant overdoses":0.00041882474497077863,
       "information about negative academic or health effects":0.004920548858129236,
       "willingness to use stimulants":0.004920548858129236,
       "patient preference":0.0005797115760136204,
       "insu fflation":0.004473099429341299,
       "smok ing":0.0045768635335727715,
       "stimulant s":0.004473099429341299,
       "us adults":0.0045768635335727715,
       "insurance companies":0.00016835068407689628,
       "large studies":0.0010205422739721429,
       "new scientific findings from the past 20 years":5.5145561362229204e-05,
       "specific search terms":5.5145561362229204e-05,
       "international society of psychiatric geneti cs":1.2341557623048535e-33,
       "lifetime ach ievement award":1.2341557623048535e-33,
       "internet":0.006849228309593172,
       "intolerance":0.00584489379836575,
       "intuniv (guanfacine)":0.005273904466228616,
       "irritability in adhd":0.0008574453826268703,
       "irritability in odd":0.0008574453826268703,
       "vulnerability for emotional disorders (mood and anxiety)":0.0008574453826268703,
       "legal issue":0.005055265713353936,
       "liver function tests":0.001818830191437181,
       "long-acting preparations recommended":0.004465273511231494,
       "long-term outcomes":0.0019742806478271163,
       "low initial doses recommended":0.004465273511231494,
       "neuroenhancement":0.0013347247871591196,
       "mania":0.0012323799606093592,
       "randomized trial":0.0015798776830515348,
       "medial frontal reductions":0.0006460394819553458,
       "medical causes of adhd symptoms":0.00364067527965683,
       "problems":0.008564517027527975,
       "safe storage":0.007779276742217737,
       "medication choice":0.002574500712155411,
       "medication contract":0.004161902017143241,
       "patient commitment":0.004161902017143241,
       "patient values and preferences":0.0036492516987609385,
       "phone calls":0.0009024118802427165,
       "target outcomes":0.0036492516987609385,
       "stimulant therapy dose":0.0008649910229202237,
       "medication trial":0.004465273511231494,
       "naturalistic studies":0.0038066131557717912,
       "quality of life enjoyment and satisfaction questionnaire":0.0038066131557717912,
       "weiss functional impairment rating scale":0.0045876102435865145,
       "neuronal development":0.0007794934841083325,
       "neuronal proliferation":0.0007794934841083325,
       "synapse development":0.0007794934841083325,
       "mental health assessment":0.001818830191437181,
       "standardized mean difference":0.0008157370505714756,
       "pregnancies in denmark":0.0029054023139441086,
       "pregnancies in the united states":0.0029054023139441086,
       "time course for improvement":0.003934825757610996,
       "united states":0.003919330906801053,
       "new onset":0.005661285733713366,
       "motiv ations":0.0019522889139009735,
       "outcomes associated with nmu":0.0019522889139009735,
       "risk factors":0.0030369348221624464,
       "risk reduction methods":0.002048083392919986,
       "mon itoring body mass index":0.001118465285687892,
       "severe mood swings":0.001818830191437181,
       "sweating of the face, lips, tongue, or throat":0.002695348395727814,
       "underlying heart conditions":0.0020685216529983054,
       "national survey on drug use and health (nsduh)":0.0021182706574569303,
       "neurotransmitters":0.006313331016061095,
       "new clinician":0.001485259393525804,
       "us data bases":0.0021182706574569303,
       "pediatricians":0.004803696227437099,
       "performance enhancement":0.004803696227437099,
       "research methods":0.0007586468409859943,
       "stimulant-naïve college students":0.004803696227437099,
       "nmu crisis":0.0010388858281809117,
       "nmu of prescription stimulants is highly prevalent":0.00041882474497077863,
       "wide variations in the definition of nmu":0.00041882474497077863,
       "performance enhancing drugs":0.005178237748781534,
       "performance validity tests":0.005178237748781534,
       "societal pressures to seek high levels of achievement":0.005178237748781534,
       "symptom validity tests":0.005178237748781534,
       "none":7.714053545946456e-41,
       "nonmedical use and diversion":0.0009116973650252053,
       "nonmedical use and diversion of prescription stimulants":0.0001410781225126808,
       "overdose":0.0015224921694042771,
       "therapeutic range":0.0015224921694042771,
       "numbers":0.0005233486299315903,
       "offspring of mothers with a single prior miscarriage":7.714053545946456e-41,
       "organizational structure or systems":0.00016835068407689628,
       "pill counts":0.001728252217213898,
       "symptoms and prescription refill requests":0.002201396853559063,
       "patient perceptions":0.00016835068407689628,
       "patient supply":0.004303508821122068,
       "patient-generated goals discussed":0.0016114597435426523,
       "patients leaving practice":0.001485259393525804,
       "patients seen within a timely fashion":0.0016114597435426523,
       "seen within a timely fashion":0.0016114597435426523,
       "patients with documentation of concerns being discussed":0.0016114597435426523,
       "patients with documented satisfaction assessment":0.0016114597435426523,
       "satisfaction assessment at least annually":0.0016114597435426523,
       "psychosocial treatment":0.001485259393525804,
       "transfer of care":0.001485259393525804,
       "poison control centers and dawn data":0.00041882474497077863,
       "population":0.0002196324983141859,
       "preferential seating":0.0006577306388639067,
       "teacher":0.0006577306388639067,
       "safeguards":0.004700767654119282,
       "prescription for adhd medication":0.004805358308607894,
       "suds":0.004805358308607894,
       "theft":0.003152165018313146,
       "serious health outcomes":0.001345701282668122,
       "trends in nmu":0.0002289753842409367,
       "stimulant treatment history":0.004805358308607894,
       "subsequent substance use, abuse, or dependence":0.004805358308607894,
       "surgical treatment":0.004691241294981186,
       "primary inattentive adhd":0.001736149034180107,
       "psychostimulant medications":0.00010168794090476967,
       "risk of psychosis":0.00010168794090476967,
       "qol benefits":0.0019742806478271163,
       "rating scales with adult norms":0.0032300914798013003,
       "sustained remission":0.0012125595032627039,
       "regional and national databases":0.0004713064298373939,
       "research participants":0.0005233486299315903,
       "signatories":0.0005233486299315903,
       "topic":0.0005233486299315903,
       "residential instability":0.0017709522248982217,
       "risk for adverse events":0.0012370228226019967,
       "risky behaviors":0.001736149034180107,
       "treatment alternatives, benefits and risks have been discussed":0.0013119894325807906,
       "validated measure":0.00047111113486635525,
       "stimulant overdoses before contacting emergency services":0.00041882474497077863,
       "systematic literature review":0.00041882474497077863,
       "study selection":0.0012362843999496628,
       "structural magnetic resonance imaging (mri) data":2.7446689221767523e-05,
       "treatment discontinuity":0.0019742806478271163,
       "taking medication":0.001118465285687892,
       "verbal working memory":0.0036943755095283576
    },
    "page_rank":{
       "adhd":0.06512479180932092,
       "$77.5 to $115.9 billion":0.0002155257245932553,
       "adolescents and young adults with adhd":0.004101145445285683,
       "substantial impairments":0.000505040274533609,
       "traffic accidents":0.000505040274533609,
       "% of patients medicated for adhd ":0.0008625544285513543,
       "prescription refills are coordinated with other prescribers":0.00022459400374490393,
       "transition care coordinated for vacations and other times away":0.00022459400374490393,
       "% patients evaluated with parent vanderbilt rating scales":0.0002800645489387034,
       "% patients meeting dsm criteria for adhd":0.0008659634475983577,
       "% patients treated with psychostimulant medication":0.0008659634475983577,
       "% patients evaluated with teacher vanderbilt rating scales":0.0002800645489387034,
       "% patients on medication with at least 2 follow-up visits a year in record":0.0002800645489387034,
       "% patients seen within 30 days medication initiation":0.0002800645489387034,
       "% patients whose medical record contains documentation of dsm criteria":0.0002800645489387034,
       "confirmation of impairment in 2+ settings":0.0002800645489387034,
       "seen within one month of first prescription":0.00022459400374490393,
       "screening":0.0014703176050075589,
       "% patients stabilized on an adhd medication ":0.00032591116962166585,
       "seen at least once per year":0.00033951734363572736,
       "communication with other health care providers occurs at least annually":0.00022459400374490393,
       "external treatment resources":0.00022459400374490393,
       "prescription monitoring program consulted at least annually":0.00022459400374490393,
       "psychosocial and educational needs have been re-evaluated at least annually":0.00022459400374490393,
       "risks and benefits of stopping treatment discussed at least annually":0.00022459400374490393,
       "substance use evaluated at least annually":0.00022459400374490393,
       "vitals taken at least annually":0.0002822638075862126,
       "% patients with adhd with documentation of impairment":0.00018181769283039467,
       "1.4 million individuals":0.00019182264790864988,
       "amphetamine":0.004464499255748564,
       "intentional, nontherapeutic use":0.0007438744277388743,
       "stimulants":0.015007889889108728,
       "2000 people":0.00020458728626692024,
       "adhd medication":0.008612270930009403,
       "medical literature":0.0008109094636705829,
       "studies":0.0022335088510317814,
       "28 adhd experts":0.00021383215401984983,
       "draft list of 46 qms":0.0007239548708565149,
       "quality measure":0.0017141126977041207,
       "2–4 hours":0.00024802297094132374,
       "adhd impairments":0.0017807535631932411,
       "long acting":0.0016241483593872031,
       "short acting":0.0016241483593872031,
       "4.4% of adults":0.0002155257245932553,
       "40-50 percent of participants met adhd criteria at any given follow-up":0.0002132634864095573,
       "recurrence":0.0007933593701290203,
       "remission":0.0009376520236591456,
       "48 cohorts":0.0002432446164367859,
       "structural grey matter volume reductions":0.0004438746424959974,
       "5 mg orally in the morning on the first day":0.00024068257206333966,
       "cardiovascular history":0.0010431032151393003,
       "5.9%":0.00021435451883920366,
       "thorough evaluation":0.0007511456063214841,
       "adolescence":0.01248388457304458,
       "50":0.00019638358724818826,
       "adult":0.004518244185888796,
       "daily report card":0.0004114904825364695,
       "5mg and 10mg":0.00024045525413210519,
       "concerta":0.0003899551616332657,
       "dose":0.0015387005555150576,
       "long-acting medications":0.0003447764328105009,
       "dexmethylphenidate":0.007805687457688276,
       "79 authors":0.00022679643789397689,
       "authors from 27 countries and 6 continents":0.0003584071616247988,
       "empirically supported statements":0.0012348227236097257,
       "a death in the family":0.00017489391659721736,
       "rutter's indicators of adversity":0.0012948369814978376,
       "a father or brother or sister with epilepsy":0.00017317582334456358,
       "epilepsy":0.0008408201546457415,
       "a frequent complaint among users":0.0002868494546178901,
       "behavioral changes":0.0010234060734084804,
       "cardiovascular effects":0.0011961577001197011,
       "central nervous system effects":0.0015349363671321708,
       "gastrointestinal issues":0.001195822682764569,
       "mental conditions":0.003643922504799104,
       "sleep disturbances":0.0015773003067736013,
       "a person's mother with epilepsy":0.00017317582334456358,
       "abdominal pain":0.0006552972303719056,
       "abnormalities of chromosomes":0.000257234515338737,
       "adhd and many other psychiatric disorders":0.0005732136231638184,
       "high polygenic risk for adhd":0.001185381420567415,
       "polygenic risk":0.0006096793068372812,
       "abstinence is not an absolute precondition to start treatment":0.00025139635238709734,
       "drug treatment":0.010449597012473172,
       "stabilize substance use":0.00025139635238709734,
       "abstract problem solving":0.0004267996966353255,
       "basal ganglia":0.0020720998876621955,
       "focused attention":0.00033937728081908085,
       "inhibitory control":0.0010542909161568197,
       "adhd individuals":0.0026513812941846774,
       "sustained attention":0.0006024092419412816,
       "verbal memory":0.00033937728081908085,
       "working memory":0.0010373034768251259,
       "abuse":0.0006605814631674334,
       "diversion":0.000583582388905955,
       "misuse":0.001722406805212968,
       "nmu":0.0028753677938166368,
       "nmu of stimulants":0.0028802311429054032,
       "abuse liability":0.00014875076003345014,
       "nortriptyline":0.0008489574611894764,
       "tricyclic antidepressant":0.0008489574611894764,
       "abuse of prescription drugs":0.00019182264790864988,
       "alcohol":0.0009051515443270694,
       "atomoxetine":0.00402751431510926,
       "long -acting stimulants":0.0003239047852683613,
       "norepinephrine reuptake inhibitors":0.0004054295615214124,
       "short-acting stimulants":0.0003239047852683613,
       "treatment ending early as the result of adverse events":0.0003239047852683613,
       "abuse, misuse and diversion":0.0005589320686734123,
       "adh d medications":0.00019476839109364762,
       "asthma medications":0.0004191483278716429,
       "multiple prescribers":0.00019476839109364762,
       "prescriptions at multiple pharmacies":0.00019476839109364762,
       "shopping behavior":0.0008833115009911979,
       "academic activity":0.000254245708489563,
       "stimulant use":0.0011285705893635443,
       "weekends":0.00036516393992274847,
       "academic difficulties":0.0002065778311677577,
       "academic dishonesty":0.0001533631096332215,
       "academic function":0.00020256511429182108,
       "academic integrity policies":0.0003093389804765212,
       "alcohol/drug use policies":0.000205881105531826,
       "nmu (non-medical use)":0.0018816030254011902,
       "students who reported nmu":0.00012675120537519562,
       "academic outcomes":0.0015776775551595815,
       "adverse medical outcomes":0.0007922911947466514,
       "amp abuse":0.00019488951800371862,
       "clinically significant effects":0.00024743201984116063,
       "clinician":0.0023008525676314305,
       "co-occurring disorders":0.00019908584702171638,
       "college graduation":0.00024743201984116063,
       "exposures":0.00019488951800371862,
       "family or friends":0.00033226791438684654,
       "disorders":0.000733133460856867,
       "intravenous abusers":0.00019488951800371862,
       "intravenous":0.0002799945971487107,
       "longitudinal study":0.00024743201984116063,
       "nasal abusers":0.00019488951800371862,
       "nmu behavior":0.0007827844359288975,
       "patient education":0.0010110952704599186,
       "poison control calls":0.00024743201984116063,
       "practitioner":0.0006732119744040726,
       "prevention strategies":0.0008750420024281457,
       "rating scales":0.0010439355684142713,
       "risk of dying":0.0007597691292378743,
       "adverse effects":0.0035958907379050626,
       "social interactions":0.0002420513329564727,
       "treatment plan":0.0011100354046121314,
       "academic performance enhancement":0.00029502526668249475,
       "educational attainment":0.0008260218903077014,
       "misuse and diversion of stimulant medications":0.0005037599373814922,
       "non-medical use of prescribed stimulants":0.0006293196313852385,
       "psychotic events":0.0005037599373814922,
       "academic skills":0.00031577108100298065,
       "accommodations":0.0006832091490015339,
       "symptoms":0.0039046207938508125,
       "inattention symptoms":0.0008113522117189362,
       "accidental injuries":0.0004996589251252113,
       "depression":0.0022520835907213366,
       "sleep issues":0.0006656770314038003,
       "substance abuse":0.0030811886425838753,
       "attempted suicide":0.0036044384792741488,
       "mortality":0.0010225630887156154,
       "motor tics":0.001974429943538289,
       "accidental physical injuries":0.00023685339753096724,
       "bullying":0.00023685339753096724,
       "burn injuries":0.00033300594341994496,
       "accidental poisoning":0.00020905866756513702,
       "accidents":0.0002984809390023239,
       "further reduce qol":0.0002984809390023239,
       "americans with disabilities act":0.00029708941655165954,
       "classroom-based programs":0.00021354798527477962,
       "disability":0.00022317551289947128,
       "idea (pl-101-476)":0.00022317551289947128,
       "school-based interventions":0.0006984830906217783,
       "section 504 of the rehabilitation act of 1973":0.00015991238505869246,
       "accommodations for children with adhd":0.00026613035722681557,
       "brand medication":0.0004730112196151261,
       "generic medication":0.0006289069727682815,
       "medications for children with adhd":0.0004730112196151261,
       "accurate diagnosis":0.0001715184736650326,
       "activated emotions":0.000254378249705418,
       "adhd child":0.0008157357138211902,
       "ei (emotional impulsivity)":0.0014199338488815505,
       "activation of mania or hypomania":0.0006552590718213484,
       "viloxazine":0.001387931482410179,
       "active substance use disorder":0.00047197960747713655,
       "adhd patients with co-occurring sud":0.00020757056029563565,
       "cocaine use disorder":0.000260021644974064,
       "dextroamphetamine-amphetamine":0.0005208230139959041,
       "nicotine dependence":0.000260021644974064,
       "opioid dependence":0.00016332343766053812,
       "active substance use disorder (sud)":0.0003702007647847322,
       "tcas":0.0010351041298609202,
       "acupuncture, yoga, and ayurvedic therapies":0.00016605475572860812,
       "adhd symptoms or associated impairments":0.0007449658496455911,
       "acute co-administration of alcohol and stimulants":0.00021844591924802704,
       "health consequences":0.00021844591924802704,
       "acute mania":0.00018517839652694424,
       "psychosis":0.0006548455340393575,
       "stimulant adverse effects":0.0007241010210204126,
       "adderall":0.00038273193406100344,
       "form":0.0003466140250528334,
       "form and doses":0.00018939825015209014,
       "usage":0.0003871412332432405,
       "adderall xr":0.0006547269253973091,
       "bubblegum flavor":0.00021904511784312863,
       "children who have trouble swallowing pills":0.00021904511784312863,
       "evekeo":0.0002781849552498544,
       "morning":0.0006136606620100774,
       "procentra":0.0006136606620100774,
       "adhd symptoms":0.009852743425306058,
       "symptoms throughout the day":0.0002781849552498544,
       "symptoms with just one dose":0.00021904511784312863,
       "vyvanse":0.0006688539649099894,
       "zenzedi":0.00026200836913346125,
       "addiction":0.00018976245757098566,
       "misuse of prescription drugs":0.00032533017967597124,
       "additional meals or snacks":0.00015573273933955822,
       "weight loss":0.0014515440822794965,
       "weight loss in people with adhd":0.0006560765910694087,
       "additional pharmacotherapy":0.0005874281676931678,
       "adhd patients":0.005823566643785876,
       "aggression and emotionaldysregulation":0.0002090703228658837,
       "atomoxetine (atx)":0.0005874281676931678,
       "callous emotional traits":0.0002090703228658837,
       "child emotionality":0.0002090703228658837,
       "emotion dysregulation":0.0030937762394623635,
       "emotional dysregulation symptoms":0.0005165134945560952,
       "odd symptoms":0.0002090703228658837,
       "wraadds (wender-reimherr adult attention deﬁcitdisorder scale)":0.0002090703228658837,
       "additional problems the patient may have":0.0001662358677381419,
       "adhd clinical diagnoses":0.00205288581709928,
       "address this growing public health problem":0.0006058359936334469,
       "consistent nomenclature":0.0002232239209487965,
       "definition of nmu":0.0002232239209487965,
       "epidemic levels":0.0002062070187854575,
       "health care professionals":0.0006553473885082741,
       "patient advocacy groups":0.00015997753421003933,
       "prescription stimulant":0.0010250914315452304,
       "surveys and databases":0.00015997753421003933,
       "genomewide study":6.398089104054257e-05,
       "adhd -iv rating scales":0.00026755154849852133,
       "adhd aetiology":0.00017029909216313043,
       "adhd biological pathways":0.00016247410336361494,
       "adhd children":0.0033656774710384956,
       "adhd controls":0.00018026604883154493,
       "adhd criteria":0.0012741092105613637,
       "adhd and emotional dysregulation":0.00258733341787784,
       "adhd genetic liability":0.00014870065135244166,
       "adhd genetic risk":0.00019678479222101183,
       "adhd guideline ng87":0.00019678479222101183,
       "adhd guidelines":0.00025207591545515964,
       "adhd in females":0.0005058269403494678,
       "adhd in their children":0.00019678479222101183,
       "adhd investigator symptom rating scale (aisrs)":0.00015971785807280522,
       "adhd lifespan course":0.00019678479222101183,
       "adhd medication use":0.00024912161283781656,
       "adhd medications (primarily stimulants)":0.00048070225288615305,
       "adhd presentation":0.00018017523008549826,
       "adhd probands":0.0005061038792837665,
       "adhd prototype":0.00025141460979022503,
       "adhd research":0.0008361961684721071,
       "adhd severity fluctuations":0.00019678479222101183,
       "adhd symptoms (e.g., aggression, hyperactivity)":0.0002637387709634221,
       "adhd symptoms/b ehaviors":0.0004927811202654988,
       "adhd traits":0.0009092009985022787,
       "adhd treatment effectiveness":0.00019678479222101183,
       "adhd outcomes":0.0007470425364248196,
       "adhd treatment response":0.00019678479222101183,
       "adhd-associated iq deficits":0.0003091934794809899,
       "adhd-c":0.0003518663968103443,
       "adhd-like behaviors and their associated impairments":0.00019678479222101183,
       "adhd-like symptoms":0.001271170193821458,
       "adhd-related brain structural differences":0.00021803007792873947,
       "adhd-related hospital admissions":0.00019678479222101183,
       "adherence":0.00047900545926396796,
       "adverse outcomes later in life":0.00016605475572860812,
       "age":0.0009751863768736972,
       "age 25":0.00019638358724818826,
       "age at diagnosis":0.0002176013171076732,
       "age at menopause":0.0006888792199020986,
       "age at onset":0.00019678479222101183,
       "age at onset variation":0.00019678479222101183,
       "age of first birth":0.0006888792199020986,
       "air pollution":0.00019678479222101183,
       "alexander crichton":0.000302035052588685,
       "allergic reactions":0.001137739338820702,
       "allergic rhinitis":0.0002583649586951027,
       "alpha agonists":0.00045036126964736274,
       "alpha-2 adrenergic agonists (clonidine)":0.00020342049073979765,
       "alpha-2 adrenergic agonists (guanfacine)":0.00020342049073979765,
       "amblyopia":0.00019678479222101183,
       "amygdala":0.0005060455980822625,
       "ankylosing spondylitis":0.00017317582334456358,
       "antidepressant":0.0004786013657148077,
       "antisocial behaviour":0.00015282298089649548,
       "antisocial personality disorder (aspd)":0.00017455981781107133,
       "anxiety":0.0013787599776670357,
       "anxiety disorder":0.0013639706475978126,
       "anxiety or depression":0.000257234515338737,
       "anxiety or tics":0.00019166317624005145,
       "appetite suppression":0.00026491110282544683,
       "arbor pharmaceuticals, llc":0.00023730686697848914,
       "arithmetic":0.0001978318425237111,
       "arrested":0.0001614108345546134,
       "artificial food color exclusion":0.0003557266925029619,
       "artificial food dyes":0.00022761541516987458,
       "asd":0.0009430925242488646,
       "asd and adhd":0.0003098856615786152,
       "aspd":0.0001614108345546134,
       "assessment and treatment response":0.00021067447003364818,
       "assets and strengths":0.00016079232756949956,
       "asthma":0.0006472567130204529,
       "asthmatic mothers":0.00015599020278642492,
       "astigmatism":0.00019678479222101183,
       "at all ages":0.0001666971347852982,
       "atomoxetine dosing":0.0007049898117339147,
       "atopic dermatitis":0.0002707141947598543,
       "attention":0.0008976544842992143,
       "attention and cognitive control networks":0.00017970317927681846,
       "attention and somatoform networks":0.00017970317927681846,
       "attention and working memory tasks":0.00025066281230372094,
       "atx":0.001250553659889883,
       "augusto vidal perera":0.0010950781514838537,
       "autism":0.0021333244450870126,
       "autoimmune disease":0.0002118548026743757,
       "autoimmune thyroid disease":0.00017317582334456358,
       "behavior":0.0012427753038820885,
       "behavior management":0.0003153628391269595,
       "behavior management training":0.0002099793419978329,
       "behavior modification":0.0002625163824326658,
       "behavior therapy":0.0020526464902233268,
       "behavior therapy principles":0.00020803805716830103,
       "behavioral and mental health assessment":0.0013295018220948313,
       "behavioral intervention":0.0009293735317486415,
       "behavior monitoring":0.00037060023338328813,
       "behavioral regulation index of the brief-a":0.0006121377859604855,
       "behavioral responses":0.00022358121182930669,
       "behavioral responses and emotional responses":0.00022358121182930669,
       "behavioural interventions":0.0004837259655342521,
       "benefits for adhd":0.00024593728789966364,
       "better understand the nature and causes of emotional symptoms in adhd and whether these should be incorporated into diagnostic criteria":0.00017492542694490606,
       "biologic vulnerability":0.00015680151964770717,
       "biological and psychological causal mechanisms":0.00024401783745030422,
       "biological pathways":0.00022483130893870967,
       "biological test":0.0001662358677381419,
       "bipolar disorder":0.0012174161176429312,
       "black and latin minority youth":0.00019678479222101183,
       "black individuals":0.000303863946771856,
       "black patients with adhd":0.00019678479222101183,
       "blood lead levels":0.0005965159113123224,
       "blood pressure":0.0007051708499926097,
       "body mass index":0.0007797720432182425,
       "boys":0.0003004205742023804,
       "boys and girls":0.0001572899151194349,
       "boys born to women who lost a close relative during pregnancy":0.00025866225592465256,
       "boys with adhd":0.0006434275789365276,
       "brain":0.0004159063177368374,
       "brain areas involved in cognition":0.0001957915271419221,
       "brain differences":0.00016079232756949956,
       "brain functioning":0.00019678479222101183,
       "brain imaging":0.00026771510539926795,
       "brain imaging studies":0.00023574231467267092,
       "brain volumes":0.0001563068916295146,
       "brain-specific neuronal subtypes":0.00019678479222101183,
       "brains of people with adhd":0.0005205514623169465,
       "breastfeeding women":0.00020256511429182108,
       "brief behavioral sleep intervention":0.0002356579315333885,
       "bupropion":0.0018320453213543368,
       "bupropion extended-release":0.0001493374288279736,
       "cannabis abuse or dependence":0.00019493385788639669,
       "cannabis use disorder":0.0007300747989111552,
       "cardiometabolic disease":0.000289975316069055,
       "cardiac events":0.0026518663703353905,
       "cardiovascular monitoring":0.001290306892995854,
       "care":0.0002795665500145854,
       "caregiver":0.0015804095719279126,
       "cause of adhd":0.0001731157909095749,
       "cbt":0.001207860077219831,
       "cbt methods for emotional dysregulation issues":0.00015599020278642492,
       "cbt and dbt program":0.00022009528272061093,
       "cd":0.0003597393849270699,
       "celiac disease":0.0007885720860492192,
       "central nervous system injury":0.00015611740890258648,
       "certain areas":0.00019678479222101183,
       "certain birth defects":0.00014799040180883948,
       "chadd":0.001151134919643905,
       "changing antecedent behavior and reinforcement":0.00023804576673252425,
       "characterization of ei/desr in adhd":0.00023730686697848914,
       "child's developmental stage":0.0002962578193261951,
       "child's health":0.00048767990549995115,
       "childhood adhd":0.00016616533442670705,
       "children and adolescents who do not respond to stimulants":0.00019166317624005145,
       "children and adolescents who have adhd plus other mental health conditions":0.00019166317624005145,
       "children and adolescents with adhd":0.0004678864414952173,
       "children who experienced sexual abuse or physical neglect":0.00026078473998017177,
       "children who grow up in difficult family situations":0.00020545362139575267,
       "children who had a specific type of viral infection (enterovirus)":0.00020545362139575267,
       "children whose mothers were severely obese":0.00026078473998017177,
       "children with adhd and smd":0.00022382415494708927,
       "children with low lead levels":0.00019678479222101183,
       "children without adhd":0.0006434275789365276,
       "cholinesterase inhibitors":0.0001763363434852263,
       "chrna7":0.0007458843407277664,
       "cigarettes smoked per day":0.0006888792199020986,
       "cingulate region":0.0003607771119086498,
       "clinical assessment":0.0001662358677381419,
       "clinical experience":0.00026755154849852133,
       "clinical features":0.00019678479222101183,
       "clinical global impression ratings":0.00015971785807280522,
       "clinical research":0.0005478055289600636,
       "clinician interview":0.00015862785849185762,
       "clonidine":0.0016676956842382174,
       "clonidine extended-release":0.0005505142921058295,
       "close friends":0.00027763699114718017,
       "cnvs":0.00019678479222101183,
       "cnvs in the 1q21.1 region":0.0002192355178786096,
       "cnvs in the 6q26 region":0.0002663879213495957,
       "co-contraindication for stimulant prescription":0.00023770052199668666,
       "cocaine":0.0004024416964666405,
       "cocaine or methamphetamine use":0.0005061038792837665,
       "coexisting condition":0.00038632788971903424,
       "coexisting mental health disorders":0.000792867421938657,
       "cognitive behavior therapy":0.002959710866081274,
       "cognitive errors":0.00024446727530780997,
       "cognitive function":0.0006654003763221544,
       "cognitive training":0.00105862053775646,
       "college completion":0.000567543006122599,
       "combination therapies":0.00020225820417901948,
       "combinations of social disadvantages":0.00017489391659721736,
       "common adverse effects":0.0001526739492749956,
       "community controls":0.0001614108345546134,
       "comorbid anxiety or tics":0.0002386744444483833,
       "comorbid condition":0.0023623418188025783,
       "comorbidities aggravate these outcomes":0.00024802297094132374,
       "complete specificity":0.00022774964272741027,
       "completion of no more than compulsory education":0.00017489391659721736,
       "complex cases":0.000488442935809395,
       "complex psychosocial circumstances":0.00027066748222254194,
       "computer-based training":0.0003517060345311782,
       "condition":0.00038351097074357585,
       "conduct disorder":0.00037946216479739525,
       "conduct disorder (cd)":0.00020524097781103885,
       "conduct problems":0.00038665326205263706,
       "confounders":0.00024613446316189096,
       "conners global index (cgi) emotional lability scale":0.0006653036304592726,
       "adhd index of the conners adult adhd rating scale":0.0004126395295280928,
       "consistent set of causes for the disorder":0.0001662358677381419,
       "consultation":0.0006376898979373955,
       "controls":0.00039833490219026664,
       "core disorder in adhd":0.00021566003643148565,
       "core symptoms of adhd":0.0002637387709634221,
       "coronary artery disease":0.0006888792199020986,
       "cortical surface area":0.00035668663485473627,
       "cortical thickness":0.00022285591329407916,
       "crash risk":0.0001616941466908269,
       "crashes":0.0001548789646951843,
       "criminal offenses":0.00015599020278642492,
       "criminal records":0.00015926656244710113,
       "curative treatments for adhd":0.00015626917383359073,
       "d-amphetamine sulfate":0.0001526739492749956,
       "daily functioning":0.0004014733809185132,
       "daily life":0.00024325082584261066,
       "danish national register longitudinal cohort study":0.00017489391659721736,
       "danish national registers":0.00046207123115132707,
       "danish population":0.00015599020278642492,
       "death by homicide":0.00020092995500482354,
       "death from natural causes":0.0001616941466908269,
       "decision-making":0.0001572899151194349,
       "decrease":0.00016734191256367377,
       "decreased appetite":0.001092153141837617,
       "decreases in appetite":0.0001957915271419221,
       "default-mode network (dmn)":0.0009442706136856842,
       "delayed onset of sleep":0.0001957915271419221,
       "delayed reinforcement":0.00024686520663042786,
       "deliberate self-poisoning":0.0002216626414821723,
       "dementia":0.00019243567949755758,
       "deprivation":0.00025866225592465256,
       "desr":0.0005277921951901927,
       "determine if and how mild or sub-threshold cases of adhd should be diagnosed and treated":0.00017492542694490606,
       "developmental disability–children’s global assessment scale":0.0002984809390023239,
       "developmental history":0.00033766927195434313,
       "dex":0.000708326785393247,
       "dexedrine":0.00023585576455889656,
       "dextro amphetamine":0.0003713619948611794,
       "deﬁcient emotional self-regulation (desr)":0.00016559235443572415,
       "diagnoses":0.002088631905386521,
       "diagnosis of apparent adult-onset adhd":0.00019678479222101183,
       "diagnostic criteria":0.00020960083545654802,
       "diagnostic delays":0.0002176013171076732,
       "diets":0.0003557266925029619,
       "differ between children and adults":0.0002984809390023239,
       "differences between groups of people who are and are not diagnosed with adhd":0.0005205514623169465,
       "difficult life circumstances":0.00015926656244710113,
       "difficulty breathing":0.00022694974928075132,
       "difficulty sustaining attention":0.0002215913047403219,
       "digital health interventions (dhis)":0.0005160938626566187,
       "disability service options":0.00025966648860580895,
       "disinhibited emotionally expressive behavior":0.00018017523008549826,
       "disorder":0.0002745111232634684,
       "disruptive mood dysregulation disorder":0.0005269651264838617,
       "distress":0.00021115725226922134,
       "distress tolerance":0.000851698398543372,
       "dlpfc":0.00025066281230372094,
       "dmn":0.0006224702092254781,
       "doctor":0.00083117735811306,
       "does not seem to listen":0.0002215913047403219,
       "domains":0.0002180232452009759,
       "dopamine":0.000239198160577827,
       "dopamine levels in synapses":0.0002192355178786096,
       "dopamine regulation":0.00027834034915991373,
       "double-blind, placebo-controlled trials":0.0002933713721745627,
       "driver license suspensions":0.00016559235443572415,
       "drug contract or conducting periodic drug screens":0.00025139635238709734,
       "dsm and icd criteria":0.00019678479222101183,
       "dsm-5":0.00032330175916193255,
       "dsm-5 diagnosis":0.00020486887776965856,
       "dsm-5 symptom criteria":0.00021868456455106813,
       "dsm-5’s dmdd":0.0001698470620615559,
       "duration":0.0001763363434852263,
       "duration of treatment":0.0003681212967797017,
       "dusp6":0.0007458843407277666,
       "dysfunctional cognitive beliefs":0.0002984809390023239,
       "dysphoria":0.00044760739273892356,
       "dysregulation":0.0001629870598017563,
       "désiré-magloire bourneville, charles boulanger, georges paul-boncour, and jean philippe":0.00019678479222101183,
       "earnings reduction":0.0002216626414821723,
       "anorexia":0.0013853174419683639,
       "editorial support":0.00023730686697848914,
       "education planning":0.00024136237190480866,
       "educational and occupational failure":0.0002909862222316563,
       "eeg neurofeedback":0.00037580958925724674,
       "efficacy":0.00042014692351747526,
       "efficacy in treating adhd":0.0007385650433245959,
       "ei":0.0013389092440890395,
       "ei and desr":0.0010020290146774099,
       "electrical stimulation":0.00026755154849852133,
       "electrophysiology":0.000180733453390248,
       "elevations in the theta/beta on the electroencephalogram":0.00019678479222101183,
       "elimination diets":0.00039707849675868685,
       "embryogenesis":0.0002192355178786096,
       "emergent health conditions":0.00019678479222101183,
       "emerging problems":0.0001575805183495256,
       "emotion processing":0.0009092009985022787,
       "emotion regulation":0.0033600138074847746,
       "emotional and behavioral trajectories":0.00025141460979022503,
       "emotional control scores":0.00024353353205041063,
       "emotional control subscale":0.00024353353205041063,
       "emotional intensity (ei)":0.0004715164764168395,
       "emotional lability":0.000974233658930267,
       "emotion":0.0010320400243829346,
       "emotional symptoms":0.003264300279740345,
       "employed":0.00017455981781107133,
       "employment reduction":0.0002216626414821723,
       "enigma-adhd working group set of cohort from around the world":0.00023943888917737544,
       "enterovirus patients":0.0002091988373153248,
       "environment":0.00021710856192838014,
       "environmental correlates":0.0002623550921879174,
       "environmental correlates of adhd":0.001042687380467937,
       "environmental factors":0.0009800285907765117,
       "environmental risks":0.00025264212591019083,
       "epidemiologic studies":0.00033260098354113786,
       "essential fatty acid supplementation":0.0006919623277662002,
       "europe":0.00019678479222101183,
       "european network for hyper kinetic disorders (eunethydis)":0.0005091993917081116,
       "euthymic baseline":0.0001629870598017563,
       "evaluate care-giver burden in children":0.0002984809390023239,
       "evaluate family-related qol and activities of daily living in children":0.0002984809390023239,
       "evaluate overall functioning in children":0.0002984809390023239,
       "evidence":0.0005474010827145709,
       "exaggerated delay discounting":0.00017693571557243396,
       "executive dysfunction":0.0005282944680258688,
       "executive function":0.0009576312909233148,
       "executive function control":0.0003294459479596288,
       "executive functioning":0.0002815233601900913,
       "exposure‐response trend":0.0002091988373153248,
       "externalizing behavior problems":0.00030460322817111717,
       "extreme deprivation early in life":0.00025224695506506536,
       "fails to give close attention":0.0002215913047403219,
       "false positive diagnoses":0.0002435570430320155,
       "familial co-aggregation":0.00019195845788005927,
       "familial or genetic factors":0.00019678479222101183,
       "family":0.00040096365469131787,
       "family conflict":0.00024802297094132374,
       "family function":0.00020256511429182108,
       "family history of adhd":0.00028182800774041803,
       "family history of mental health issues":0.00025410088584485883,
       "family problems":0.00015926656244710113,
       "family strain index":0.0002984809390023239,
       "fatty acid concentrations":0.00026755154849852133,
       "fda approval":0.00024208490595456286,
       "fda approved medication":0.00020486887776965856,
       "fda-approved treatment for adhd":0.0002675005248863521,
       "felony":0.0001614108345546134,
       "female":0.0002452811035495696,
       "fidgeting":0.00016640659694271392,
       "fidgets with hands or feet":0.0002215913047403219,
       "financial problems":0.00016559235443572415,
       "financial stability":0.00024802297094132374,
       "fmri neurofeedback":0.0002469254524494353,
       "fmri studies of cognitive control":0.000567543006122599,
       "dietary interventions":0.0005220666036148409,
       "foster care":0.00015926656244710113,
       "foxp1 and foxp2":0.00016938621213197073,
       "foxp2":0.00027555108691306287,
       "franz kramer and hans pollnow":0.0010950781514838537,
       "free fatty acids":0.00035472757573497656,
       "free tools":0.00019678479222101183,
       "frontal region":0.0003607771119086498,
       "functional impairment":0.0003125930668616364,
       "functioning":0.0003243798374509937,
       "funding for manuscript development":0.00023730686697848914,
       "fusiform gyrus":0.0002760994269971925,
       "future patient outcomes":0.0001662358677381419,
       "gastric/duodenal ulcers and gastroesophageal reflux disease":0.00026804521439419745,
       "general behavior":0.00016933718556378887,
       "general population":0.00016663248047750858,
       "general psychopathology and several psychiatric disorders":0.0001612700066944367,
       "generalized emotional under-control":0.00023730686697848914,
       "genes and environment":0.00017492542694490606,
       "genetic and environmental risk factors":0.00025224695506506536,
       "genetic correlation":0.000567543006122599,
       "genetic factors":0.00024367178775469353,
       "genetic influence":0.00034873333407834083,
       "genetic or familial causes":0.0001770185584777901,
       "genetic risk":0.0003532691204648137,
       "genetic variants":0.0010083014353690694,
       "genetics":0.00033716574147396426,
       "genomic loci":0.00019678479222101183,
       "geographic region":0.00024613446316189096,
       "george still":0.00042592822618226753,
       "girls":0.0001715184736650326,
       "girls with adhd":0.00024613446316189096,
       "glaucoma":0.00016492270801238284,
       "glutamatergic neurotransmission":0.00019678479222101183,
       "gonzalo rodriguez-lafora":0.00022294421245316635,
       "grade point sum":0.00015680151964770717,
       "growth issues":0.00044186776140349703,
       "guanfacine":0.0019265109816609658,
       "extended release guanfacine":0.0008580416436892438,
       "gudjonsson et al.":0.00034183289064944203,
       "guidelines":0.0007278746582238638,
       "gwas":0.00019678479222101183,
       "hba1c":0.00019834329296279296,
       "headache":0.0019963801997397715,
       "health-care disparities":0.00019678479222101183,
       "health care provider":0.0012336694001565212,
       "healthcare systems":0.00030463701307610917,
       "heart rate":0.0008839983198370858,
       "heinrich hoffmann":0.000302035052588685,
       "high blood pressure":0.0010432827661226614,
       "high iqs":0.0001715184736650326,
       "high lead levels":0.00019678479222101183,
       "high risk of substance abuse":0.00025139635238709734,
       "high school and collegiate athletes":0.0001616941466908269,
       "high ses":0.00019678479222101183,
       "higher adhd symptom severity and poorer outcomes":0.0001525256641291064,
       "hippocampus":0.0005011765097368414,
       "hippocampus volume":0.00025114636230722014,
       "history of illicit stimulant use":0.00019803169871244501,
       "hong kong database":0.0001591863039948405,
       "hyperactivity":0.0009648665166898003,
       "hyperactivity in children":0.0001776491060247498,
       "hyperkinetic disorder":0.00031638253728741826,
       "hyperthyroidism (overactive thyroid)":0.00020545362139575267,
       "hypospadias":0.0001770185584777901,
       "hypotension":0.0005516046043038995,
       "hypothyroidism (underactive thyroid)":0.00020545362139575267,
       "icd-11":0.0002108667690696945,
       "icd-11 criteria":0.00019678479222101183,
       "ifc":0.00017970317927681846,
       "ifc and insula":0.0001563068916295146,
       "illegally used drugs":0.0002507446943035129,
       "imaging studies":0.00019678479222101183,
       "immediate reinforcement":0.00017693571557243396,
       "immediate rewards":0.00032232428051767265,
       "impaired academic functioning":0.0003084929727259542,
       "impairment":0.0018470857270006763,
       "impairments in quality of life":0.00021115725226922134,
       "improved academic performance":0.00016889823770257595,
       "improved brain function, most prominently in inferior frontal and striatal regions":0.00015680151964770717,
       "improved parent-reported child behavior":0.0002177776259848704,
       "improved relationships with caregivers, teachers, siblings, or peers":0.00016889823770257595,
       "improved rule following":0.00016889823770257595,
       "improved sleep":0.0002356579315333885,
       "improvements":0.0004474699062999757,
       "improvements in living":0.00021115725226922134,
       "impulsive decision-making":0.0002951594533107872,
       "impulsivity":0.0005478541428391367,
       "high inattentive factor":0.0016641562133557655,
       "inattention and hyperactivity":0.0002772593273860319,
       "inattentive type":0.0002091988373153248,
       "adhd inattentive type":0.00026078473998017177,
       "incarceration":0.00015599020278642492,
       "increase the risks of suicidality":0.00024802297094132374,
       "increased rate of rare genetic mutations":0.0003098856615786152,
       "incredible years (iy)":0.0003534439939870054,
       "individual":0.00037794651378176045,
       "infection":0.00025156602623059994,
       "inferior frontal dysfunction":0.00025114636230722014,
       "inflammation":0.00017492542694490606,
       "health professionals, patients and families":0.001316829921718429,
       "inhibition":0.00015599020278642492,
       "initial treatment":0.000649830374749794,
       "injuries":0.000359043833283902,
       "insomnia":0.0021971494839052945,
       "insula":0.00020096768759680702,
       "insulin resistance":0.00017492542694490606,
       "integrative treatment":0.0006651577436475025,
       "integrity of auditory sensory memory and involuntary attention switching":0.00019678479222101183,
       "intellectual disabilities":0.00029101574800935947,
       "intellectual functioning":0.00019678479222101183,
       "intelligence":0.000610658022343936,
       "intelligent individuals":0.0001715184736650326,
       "intensity":0.0001763363434852263,
       "intensity of subjective states and behavior":0.00022358121182930669,
       "intentional exposures":0.0002507446943035129,
       "interdisciplinary collaborations":0.00019678479222101183,
       "international resources":0.00019678479222101183,
       "interventions":0.0008057647080766928,
       "intracranial brain volume":0.00016079232756949956,
       "iq":0.0005901714004817042,
       "iq differences":0.0005954824169464828,
       "iq scores":0.0001978318425237111,
       "iq tests":0.00015926656244710113,
       "irritability":0.0037461562222809728,
       "juvenile detention":0.00019678479222101183,
       "kidney failure":0.00016492270801238284,
       "kidscreen-10":0.0002984809390023239,
       "l-deprenyl":0.0001763363434852263,
       "large family size":0.00017489391659721736,
       "large population studies":0.00028182800774041803,
       "larger delayed ones":0.00018175083542343334,
       "lead burden":0.0001770185584777901,
       "learning disorder":0.0002701145984341558,
       "leaves seat in situations":0.0002215913047403219,
       "licensed clinician":0.0001715184736650326,
       "limbic volume":0.0002760994269971925,
       "lines of communication":0.00014925238044202546,
       "lisdexamfetamine":0.0006895637106599213,
       "long-range fronto-posterior association tracts":0.00025114636230722014,
       "long-term medication use":0.00021803007792873947,
       "low ses":0.00019678479222101183,
       "low social class":0.00017489391659721736,
       "low social class conditions":0.00015926656244710113,
       "lower achievement scores":0.00020524097781103885,
       "lower family income":0.00020545362139575267,
       "lower quality of life":0.00016559235443572415,
       "lung cancer":0.0006888792199020986,
       "major depression":0.0008786204126850646,
       "makes careless mistakes":0.0002215913047403219,
       "male":0.0003338888764646146,
       "male-to-female sex ratio of adhd":0.0008791177572623256,
       "maois":0.0005817520742116844,
       "map1a":0.00019678479222101183,
       "maternal alcohol use during pregnancy":0.00021868456455106813,
       "maternal mental disorder":0.00017489391659721736,
       "maternal pre-existing type 1 diabetes":0.00025529468502737205,
       "maternal prenatal use of acetaminophen":0.00019678479222101183,
       "maternal smoking":0.000782169084132589,
       "maximimum tolerated dose":0.0001563068916295146,
       "measurement tools":0.00017091663699182264,
       "measurement-based care":0.00019678479222101183,
       "measures of neurocognitive functioning":0.00019678479222101183,
       "measures to evaluate qol or functional impairment":0.0002984809390023239,
       "mechanisms of disease onset":0.00019678479222101183,
       "mechanisms/pathophysiology":0.00019678479222101183,
       "medical history":0.00025410088584485883,
       "medical problem":0.00020677440473670515,
       "medication periods":0.0002187324392707759,
       "medication therapy":0.0004023862084293534,
       "medication-free weekends":0.00020256511429182108,
       "mef2c":0.0008105675748984482,
       "melchior adam weikard":0.000302035052588685,
       "memory":0.0001572899151194349,
       "meta-analyses":0.0014707302425751225,
       "metabolic disorders":0.00016492270801238284,
       "methamphetamine":0.0001526739492749956,
       "method of diagnosing adhd":0.00024401783745030422,
       "methods to improve adherence":0.0001614108345546134,
       "methylphenidate treatment":0.0005413225901389639,
       "methylphenidate users":0.0002070973322680596,
       "methylphenidate users ages 46-65":0.0002070973322680596,
       "methylphenidate users with previous alcohol and drug misuse":0.0002070973322680596,
       "methyphenidate prescription":0.0003395873078531756,
       "migraine":0.00023279343146161206,
       "milder adhd":0.00023250631979560666,
       "mindfulness and positive aspects of adhd":0.00019678479222101183,
       "mindfulness meditation":0.0001616084483135011,
       "mindfulness-based treatments":0.0001616084483135011,
       "minimal brain dysfunction":0.0003807449963522238,
       "minor structural and functional brain differences":0.00020284248324915836,
       "misconceptions":0.0009814830689717834,
       "misdemeanors":0.0001614108345546134,
       "mismatch negativity":0.00019678479222101183,
       "misuse and diversion of these medications":0.0002185727889803594,
       "mixed amphetamine salts":0.00028295243614714726,
       "modafinil":0.0006313968904220991,
       "molecular genetic data":0.00021974225130295312,
       "mood":0.0005625483981795715,
       "mood disorder":0.0006188879542770103,
       "mortality rates":0.0002582319341368483,
       "most cases of adhd":0.00019678479222101183,
       "mothers":0.0005610348754666117,
       "mothers who were obese before pregnancy":0.00020545362139575267,
       "mothers with two or more prior miscarriages":0.0002091988373153248,
       "motor vehicle collision":0.0003497831359656794,
       "mtbi":0.0001616941466908269,
       "multidisciplinary efforts":0.00023730686697848914,
       "multiple settings":0.00020013580962127377,
       "narcolepsy":0.00015971785807280522,
       "national health and nutrition examination survey":0.0001770185584777901,
       "national health insurance data":0.0001526387931246614,
       "national institute for health and care excellence (nice)":0.00019678479222101183,
       "national institute of mental health":0.00016942030145403915,
       "nationwide population study":0.0003152773441429022,
       "nausea":0.0013072091947333862,
       "negative parenting":0.00030756904601579496,
       "negative reinforcement":0.00017693571557243396,
       "neglect":0.00020465297635185764,
       "network meta-analyses":0.0003273301176124105,
       "network of researchers with annual meeting":0.00016728903908356363,
       "neurobiological research":0.00019678479222101183,
       "neurobiology":0.00017004868312909066,
       "neurocognitive function":0.0004771825978848034,
       "neurocognitive impairment":0.0002180232452009759,
       "neurodevelopment":0.00022483130893870967,
       "neurodevelopmental condition":0.00015626917383359073,
       "neuroimaging scans":0.0002590220519157004,
       "neuroimaging studies":0.00019678479222101183,
       "neuronal and nicotinic signalling pathways":0.00019678479222101183,
       "neuronal development and migration":0.00027146978623552887,
       "neuropsychological tests":0.0002532175197471618,
       "new directions for diagnosis":0.0009397205881097115,
       "new medications currently in development":0.0002097021177640614,
       "nice guidelines":0.0004985966689584116,
       "nicotine":0.00023640809807439866,
       "nicotinic signalling":0.0002192355178786096,
       "no association with adhd":0.00019678479222101183,
       "no significant effect on adhd":0.00019678479222101183,
       "non-medical treatments":0.00073204304495893,
       "non-responders":0.0010011961722065047,
       "non-stimulant medications":0.0004432305179511279,
       "non-stimulants":0.0018327547742746837,
       "nonstimulant medications":0.000511020421691849,
       "noradrenaline":0.00040384788898521437,
       "normal cognitive fluctuations":0.00019678479222101183,
       "normed scales":0.00019678479222101183,
       "north america":0.00019678479222101183,
       "number of children":0.0006888792199020986,
       "number of sessions":0.0001763363434852263,
       "obesity":0.001286217428175846,
       "occupational functioning":0.00016640659694271392,
       "ocd":0.00096956531364187,
       "odd":0.0011093764627895747,
       "older adolescents and adults":0.00016640659694271392,
       "omni healthcare communications":0.00023730686697848914,
       "onset":0.0006234893842568222,
       "onset prior to the age 12 years cannot be documented":0.00019678479222101183,
       "oppositional defiant disorder":0.0007898369138273384,
       "organisation skills":0.00021358472340394453,
       "other approaches to emotion-regulatory processes disrupted in adhd":0.0001674220238890236,
       "other psychiatric and substance use disorder":0.0001616941466908269,
       "other psychiatric diagnosis":0.0003837009303412754,
       "other stimulant class":0.0001563068916295146,
       "out-of-home care":0.00017489391659721736,
       "outcomes":0.0006637209691576636,
       "outcomes over longer periods of time":0.00021817641751879988,
       "overused medication":0.0006618680538243993,
       "oxidative stress":0.00017492542694490606,
       "paid tools":0.00019678479222101183,
       "parent":0.001331810134942193,
       "parent behavior management training (pbmt)":0.00035344399398700544,
       "parent management training":0.00020677440473670515,
       "parent referral for treatment":0.00023250631979560666,
       "parent training":0.0009413686678931715,
       "parent training in behavior management (ptbm)":0.00016596924063077369,
       "parent-child behavior therapy":0.00043476599623594426,
       "parental criminality":0.00017489391659721736,
       "parental educational attainment":0.00017489391659721736,
       "parental outcomes":0.0001705994995236398,
       "parental relative income poverty":0.00017489391659721736,
       "parental unemployment":0.00017489391659721736,
       "parenting skills":0.00024802297094132374,
       "parents having low educational levels":0.00015926656244710113,
       "pargyline":0.0001763363434852263,
       "parietal region":0.0002760994269971925,
       "paroxetine":0.00015971785807280522,
       "particulate matter":0.00019678479222101183,
       "pathophysiology":0.00016114330717058707,
       "patient":0.00352470011518289,
       "patient’s level of ei":0.00019678479222101183,
       "pbmt":0.0001698470620615559,
       "peer conflicts and social exclusion":0.00024802297094132374,
       "peers":0.0006053143698651435,
       "people":0.0003691182741762074,
       "people all around the world":0.0001715184736650326,
       "people who have read this document and agree with its contents":0.00022679643789397689,
       "performance deficits in psychological processes":0.0002590220519157004,
       "perpetrators of physical dating violence":0.00019678479222101183,
       "person":0.00025224695506506536,
       "personalized approach":0.00019821769958000644,
       "personalized treatments":0.00019678479222101183,
       "pharmacokinetic profiles of long-acting and immediate-release preparations":0.0002366586649693271,
       "pharmacotherapy":0.0007922576454219086,
       "physical conditions":0.00019181566757377853,
       "physical examination":0.0003182037644209701,
       "placebo":0.0003916424946603011,
       "points of intervention that will improve the effectiveness of medical and non-medical treatments and prevent onset of the disorder":0.00024401783745030422,
       "poisoning in children":0.0002216626414821723,
       "police station interrogations":0.00019678479222101183,
       "polr3c":0.00027834034915991373,
       "polygenic cause":0.00019678479222101183,
       "polythetic criteria":0.00022774964272741027,
       "poor judgment":0.00015680151964770717,
       "poor work performance":0.00016559235443572415,
       "positive parenting":0.000180733453390248,
       "positive reinforcement":0.00016596924063077369,
       "posterior corpus callosum":0.0002760994269971925,
       "posterior parieto-temporal attention regions":0.00025114636230722014,
       "poverty":0.00029508216130931866,
       "pre-existing type 1 diabetes":0.00015599020278642492,
       "prediction":0.00019821769958000644,
       "predictive modelling":0.00019678479222101183,
       "predictor of treatment response":0.00024401783745030422,
       "preeclampsia":0.00021154774076383512,
       "pregnancies":0.0012440232677032668,
       "pregnancy and adhd":0.00019678479222101183,
       "pregnant or breastfeeding women":0.00020256511429182108,
       "premature death":0.0011971154690490011,
       "prenatal exposure":0.0003380235461522342,
       "prenatal exposure to maternal smoking":0.0001770185584777901,
       "preschool or daycare":0.00015611740890258648,
       "preschoolers with symptoms of adhd":0.0002625163824326658,
       "prescriber":0.0003458030797116132,
       "prevalence":0.0005979509358951321,
       "prevalence of adhd":0.0003016775427178861,
       "prevalence of adhd among adolescents":0.00019678479222101183,
       "prevalence of adhd in prisons":0.00019678479222101183,
       "prevalence of false confessions":0.00019678479222101183,
       "prevalence of physical dating violence":0.00019678479222101183,
       "priapism":0.0007793515926947288,
       "prior miscarriage":0.0002091988373153248,
       "prisma diagram in supplemental figure 1":0.00022679643789397689,
       "prison inmates":0.00019678479222101183,
       "prkn":0.00019678479222101183,
       "proband":0.00036050625790366253,
       "problem behaviors (e.g., aggression, caregiver-child relations)":0.0002637387709634221,
       "problem solving":0.00035087186780793965,
       "problematic substance use":0.00024167906074789832,
       "problems with connections between the two hemispheres":0.00025114636230722014,
       "professional health care associations":0.0001607384599424687,
       "proteins":0.00016079232756949956,
       "proton pump inhibitors":0.00026804521439419745,
       "provocation":0.00024651017888590297,
       "psoriasis":0.00017317582334456358,
       "comorbid psychiatric conditions":0.000909413380206292,
       "psychoeducation":0.0009801891235155522,
       "psychological tests":0.00015926656244710113,
       "psychological treatment":0.00019803169871244501,
       "psychosocial domains of qol":0.0002984809390023239,
       "psychosocial interventions":0.0005863496565669359,
       "psychosocial, school and emotional functioning":0.0002984809390023239,
       "psychotherapy":0.0007889602607464377,
       "psychotropic co-prescriptions":0.00021115725226922134,
       "ptbm":0.00047243706795243185,
       "ptbm (behavior therapy)":0.000650369198764828,
       "qol domains":0.0002984809390023239,
       "quality of life":0.0006412374093203786,
       "racemic amphetamine sulfate":0.0001526739492749956,
       "racial and ethnic minority populations":0.00016663248047750858,
       "rage":0.0001492862461929096,
       "randomized controlled trials (rcts)":0.00015680151964770717,
       "rare genetic mutations":0.00014799040180883948,
       "rare single gene defects":0.000257234515338737,
       "rct":0.00031778775097499246,
       "rcts of adhd medications":0.00023846104938062479,
       "re-evaluate goals and behavior":0.00017916437374012955,
       "reading":0.0001978318425237111,
       "reading, spelling and arithmetic":0.00015926656244710113,
       "rebound effect":0.000383664366318935,
       "reduce self-esteem and wellbeing":0.00024802297094132374,
       "reducing inattention, hyperactivity, and impulsivity":0.00016102358682621793,
       "referral to a dietician":0.00026755154849852133,
       "regular check-ups":0.001290306892995854,
       "reinforcer":0.00024686520663042786,
       "relationship quality":0.00024802297094132374,
       "reliability and validity":0.00020656057449283755,
       "reliable diagnostic measure for adhd":0.00019678479222101183,
       "research":0.0014387263259765949,
       "resilience":0.000180733453390248,
       "resilience factors":0.00016079232756949956,
       "resources":0.000252267898780011,
       "responders":0.0010011961722065047,
       "response cost":0.00016596924063077369,
       "response to treatment":0.0001662358677381419,
       "response-inhibition":0.0001526387931246614,
       "restlessness":0.00016640659694271392,
       "reward":0.0005235175018508871,
       "right inferior frontal cortex":0.0003292546869996973,
       "potential risks":0.00031682199107308873,
       "risky driving behaviors":0.00029705226278824463,
       "robins and guze criteria":0.00023192344260234852,
       "sagitatal striatum":0.0002760994269971925,
       "scaffolding":0.0005520142596746665,
       "scales for emotion regulation":0.00015926656244710113,
       "schizophrenia":0.0009006430638431344,
       "school":0.00023913200491905697,
       "school interventions":0.0002637387709634221,
       "school performance":0.00015384867497727372,
       "school-based accommodations":0.0002514535821858349,
       "screening measures":0.000685917861855219,
       "selective amplification of certain emotional states":0.00023730686697848914,
       "selective noradrenaline reuptake inhibitors":0.0005505142921058295,
       "self-esteem":0.00024237218161048758,
       "self-injury":0.0001630153749225859,
       "self-perceptions of competence":0.000180733453390248,
       "self-referential thoughts and mind-wandering":0.00017970317927681846,
       "self-referral":0.00023250631979560666,
       "self-regulatory skills":0.0002962729414270874,
       "self-regulatory strategies":0.00023730686697848914,
       "self-report measures":0.00021037564169436264,
       "self-report scale":0.00020486887776965856,
       "self-reported executive function ratings":0.00024782534309145544,
       "serious transport accidents":0.00029148681619572676,
       "serotonin syndrome":0.0005539413440131711,
       "settings":0.00019770189635300256,
       "severe adhd":0.00023250631979560666,
       "severe marital discord":0.0002773864518784353,
       "severe mood dys-regulation (smd)":0.0001698470620615559,
       "sex":0.00024613446316189096,
       "sexual crimes victims":0.0004135640809108556,
       "sexually transmitted infections":0.00024008695299311422,
       "shared components of etiology":0.00022774964272741027,
       "shared mechanisms among disorders":0.00022774964272741027,
       "short- and long-acting formulations of a-2 adrenergic agonists":0.0002933713721745627,
       "simulant":0.0002314149062619182,
       "simulant medications":0.0002314149062619182,
       "single genetic abnormality":0.00025224695506506536,
       "six symptoms of hyperactivity-impulsivity":0.00015882682851366727,
       "six symptoms of inattention":0.00015882682851366727,
       "skills training":0.00035205576798055354,
       "sleep":0.00023063798643450207,
       "sleep efficiency":0.0001957915271419221,
       "sleep onset":0.0001999542536649679,
       "sleep onset delay":0.0002386744444483833,
       "small differences in brain structure and function":0.0001798824566806291,
       "small for gestational age":0.00021154774076383512,
       "small particulate matter levels":0.00019678479222101183,
       "small to moderate difficulties":0.00030513445675054763,
       "small-to-moderate reductions in mismatch negativity amplitude":0.00015462839780025587,
       "smaller brain areas":0.00020096768759680702,
       "smaller brain volumes":0.00019678479222101183,
       "cigarette smoking":0.0004406921532273298,
       "smoking initiation":0.0006888792199020986,
       "social acceptance":0.000180733453390248,
       "social anxiety disorder":0.0002296962824356435,
       "social cognitive programs":0.0001698470620615559,
       "social function":0.00020256511429182108,
       "social functioning":0.00028416096837939755,
       "social skills":0.0003549126980727888,
       "social skills training":0.0004624458748245534,
       "socially and clinically important outcomes":0.00021576178554250398,
       "society for developmental and behavioral pediatrics":0.00016673696468289684,
       "socioeconomic cost":0.00018026604883154493,
       "ses (socioeconomic status)":0.0002641461481446024,
       "solriamfetol":0.000984574424022721,
       "somatic co-prescriptions":0.00021115725226922134,
       "somatic disorders that co-occur with adhd":0.0002097021177640614,
       "sorcs3":0.0008105675748984482,
       "sorcs3, ptprf, and mef2c":0.00019678479222101183,
       "specialist":0.0002916550389825721,
       "speech disorders":0.0003966158829845613,
       "spelling":0.0001978318425237111,
       "splenium of the corpus callosum":0.0005954824169464828,
       "spouses":0.0005336024427844304,
       "ssri/snri":0.0004250757259614127,
       "standard diagnostic criteria":0.00020935088395947874,
       "standard therapies":0.00027763699114718017,
       "stigma":0.0016812914445857548,
       "adhd stigma":0.0005265991017221641,
       "stimulant":0.0015805415893944516,
       "stimulant medication":0.004773375403954683,
       "stimulant therapy":0.0009596196139905399,
       "stimulant-refractory":0.0001563068916295146,
       "stimulants are the first line of drug treatment for adhd":0.00019803169871244501,
       "stress":0.00020545362139575267,
       "stress-related strains on cognition":0.00019678479222101183,
       "stressed events during childhood":0.00015926656244710113,
       "subcortical regions":0.0001937413654697976,
       "subjective well-being":0.0006888792199020986,
       "subsequent substance use":0.00015680151964770717,
       "substance misuse":0.00019803169871244501,
       "substance use":0.0004956519187751176,
       "sud":0.00015599020278642492,
       "suicide related events":0.000491726226526246,
       "support groups":0.0002795665500145854,
       "sustained release bupropion":0.0001493374288279736,
       "sweden":0.00019678479222101183,
       "swedish national registers":0.00043464012325679987,
       "swedish population-based study":0.00024008695299311422,
       "swedish registry study":0.0001591863039948405,
       "symptom change":0.00032126360205270523,
       "symptom checklists":0.00018217187526438757,
       "symptom expression":0.00016079232756949956,
       "symptom severity":0.00015599020278642492,
       "synapse formation and plasticity":0.00043018088467658145,
       "synaptic development":0.00019678479222101183,
       "taiwan health insurance research database":0.00024008695299311422,
       "taiwanese study":0.00024008695299311422,
       "taiwanese youths":0.00024613446316189096,
       "tca (nortriptyline)":0.0004250757259614127,
       "tdcs":0.0008499742220148189,
       "teacher-assessed social skills":0.00016933718556378887,
       "teachers of children with adhd":0.0002055804267756693,
       "techniques":0.00023804576673252425,
       "teenage pregnancy":0.0003188621409001133,
       "teenage pregnancy and sexually transmitted diseases":0.00024802297094132374,
       "temper outbursts":0.00028850734663788573,
       "temporal pole":0.0002760994269971925,
       "temporal region":0.0003607771119086498,
       "temporo-parieto-occipital regions":0.0002760994269971925,
       "test scores":0.0002187324392707759,
       "testicular dysfunction":0.00016492270801238284,
       "tetrahydrocannabinol (marijuana)":0.00024593728789966364,
       "therapeutic approaches":0.00023653235460587767,
       "therapies":0.00023730686697848914,
       "therapy":0.0011760843071633217,
       "those seeking treatment":0.00016663248047750858,
       "those with epilepsy":0.00017317582334456358,
       "thyroid problems in mothers during pregnancy":0.00020545362139575267,
       "time management":0.0003082650474789763,
       "time off medication":0.00019681192626760631,
       "time-out":0.00016596924063077369,
       "tms":0.00037580958925724674,
       "tns":0.0005160938626566187,
       "token economy":0.00016596924063077369,
       "tolerability":0.0005202995539370866,
       "total sleep time":0.0001957915271419221,
       "toxic substances":0.00014799040180883948,
       "tracking and remote measurement technologies":0.00021067447003364818,
       "trans-diagnostic phenomena":0.00022774964272741027,
       "transport accidents":0.0005955218692634506,
       "trauma":0.00046156430606826473,
       "trauma-related emergency room admission":0.0003395873078531756,
       "traumatic brain injuries":0.0006928568703198381,
       "traumatic brain injury early in life":0.00025224695506506536,
       "treating adhd and preventing adverse outcomes":0.0001548789646951843,
       "treatment efficacy":0.00021601912657035562,
       "drug treatment initiation":0.0017626861585209764,
       "treatment of coexisting conditions":0.0006544191411776438,
       "treatment planning":0.00016386842688361457,
       "treatment targets":0.00022774964272741027,
       "trial":0.0002795665500145854,
       "trigeminal nerve stimulation":0.0005523341773468326,
       "trigeminal nerve stimulation (tns)":0.0002675005248863521,
       "twins":0.00020465297635185764,
       "type 1 diabetes mellitus (t1dm)":0.00031034384079471497,
       "type 2 diabetes":0.0009550628076786282,
       "typically developing peers":0.0004414185500045362,
       "ulcerative colitis":0.00017317582334456358,
       "unemployment":0.0003322435646657456,
       "unintended injuries":0.0007134483833146465,
       "unmedicated adults":0.00019195845788005927,
       "upper secondary school":0.00015680151964770717,
       "urbanization level":0.00024613446316189096,
       "us":0.00019678479222101183,
       "us population":0.000303863946771856,
       "use of cannabis is not necessarily a contraindication to prescribing stimulant medication":0.00019803169871244501,
       "validated measure of symptom change":0.0001614108345546134,
       "validity of adhd as a mental disorder":0.00023192344260234852,
       "valproate":0.00031643048940836104,
       "vehicular crashes":0.0001616941466908269,
       "ventromedial orbito-frontal cortical thickness":0.0002760994269971925,
       "viloxazine er":0.00014993836915712104,
       "viloxazine extended-release":0.00035846062283306887,
       "violent crimes":0.0003418328906494421,
       "violent crimes against youth":0.00019678479222101183,
       "viral pneumonia":0.00016492270801238284,
       "visual attention":0.0009092009985022785,
       "weak support systems":0.00020092465713213463,
       "weight":0.0004038820894387449,
       "well-trained professionals":0.0001662358677381419,
       "wender-reimherr adult attention deficit disorder scale":0.0005190528561205916,
       "wes study":0.00019678479222101183,
       "white blood cell disorders":0.00016492270801238284,
       "white matter":0.00024708009243165434,
       "white matter integrity":0.0001563068916295146,
       "white-majority countries":0.00019678479222101183,
       "work functioning":0.00024802297094132374,
       "work performance":0.0002013075604071932,
       "working memory impairments":0.0002401968778268487,
       "world":0.0003373624930086639,
       "worse social adjustment":0.00016559235443572415,
       "year of first adhd diagnosis":0.0001662358677381419,
       "years of schooling":0.000567543006122599,
       "youth aged 14-20":0.00019678479222101183,
       "youth with adhd":0.00110802147701022,
       "α2 agonists":0.00035846062283306887,
       "emotional factors":0.0002641461481446024,
       "intellectual factors":0.0002641461481446024,
       "mood stabilizing medication":0.00029755119142603394,
       "negative health behaviours":0.0002641461481446024,
       "oocyte leading to pregnancy":0.0002641461481446024,
       "psychosocial impairment":0.0002641461481446024,
       "resilience in those susceptible to adhd":0.0006046482373570036,
       "sero tonergic medication":0.00019078473768077762,
       "sero tonergic reuptake inhibitor":0.00019078473768077762,
       "serotonin activity":0.00022995200585209283,
       "serotonin-norepinephrine reuptake inhibitors (snri)":0.0002643254630439403,
       "social factors":0.0002641461481446024,
       "selective serotonin reuptake inhibitor (ssri)":0.0004243765898477649,
       "adhd and its mental and somatic comorbidities":0.00015973711104947695,
       "classroom":0.00018228854466995,
       "covert smile":0.00023074283537119725,
       "desr (delayed emotional return)":0.000254378249705418,
       "emotional experience and behavior dyssynchrony":0.00018228854466995,
       "emotionally evocative situations":0.00036665052684158684,
       "explosive giggle":0.00018228854466995,
       "provoke- ing stimuli":0.00018228854466995,
       "rapid emotional responses":0.00018228854466995,
       "height gains":0.0003092776734923429,
       "age at which adhd criteria were met":0.00018205860557587658,
       "children with high iq":0.0005977475730604338,
       "rates of learning disorders":0.00018205860557587658,
       "rates of psychiatric disorders":0.00018205860557587658,
       "rates of stimulant treatment":0.00018205860557587658,
       "rates of substance abuse":0.00018205860557587658,
       "nitric oxide":0.00019509466790962565,
       "nitrogen dioxide levels":0.00019509466790962565,
       "particulate matter levels":0.0003651936983831449,
       "sulphur dioxide levels":0.00019509466790962565,
       "genetic architecture of adhd":0.00016746927254511935,
       "affective reactivity":0.000209450021150107,
       "education":0.00044474647327346966,
       "expression of emotions":0.000209450021150107,
       "family life":0.000209450021150107,
       "financial":0.000209450021150107,
       "legal":0.000209450021150107,
       "predicting emotional symptoms":0.000209450021150107,
       "social relations":0.000209450021150107,
       "adhd europe":0.00017752865225965876,
       "health professionals and researchers":0.0011385524465088712,
       "adhd evidence project":0.0002237980351662458,
       "international consensus statement on adhd":0.0014152722385556626,
       "adhd experts":0.0004640005099759551,
       "brainstorming session":0.00021768536016177834,
       "existing guidelines":0.00021768536016177834,
       "literature review":0.000276473112607936,
       "qms (quality measures)":0.0006250399664975402,
       "qms for adhd in youth":0.000276473112607936,
       "survey":0.00021768536016177834,
       "adhd follow-up care visit":0.00017457933621816947,
       "visit":0.00043891424849445835,
       "adhd guidelines group of the association of medical scientific societies in germany":0.0005447090452960574,
       "adhd network of european college of neuropsychopharmacology":0.0005447090452960574,
       "adhd section of the world psychiatric association":0.0005447090452960574,
       "australian adhd professionals association":0.0005447090452960574,
       "chinese society of child and adolescent psychiatry":0.0005447090452960574,
       "federation of adhd":0.0006067778384104814,
       "israeli society of adhd":0.0005447090452960574,
       "large medical database called pubmed":0.0012389514869020975,
       "latin american league of adhd":0.0005447090452960574,
       "neurodevelopmental disorders across lifespan section of european psychiatric association":0.0006989041449895889,
       "pubmed":0.0006067778384104814,
       "saudi adhd society":0.0005447090452960574,
       "adhd in adults":0.00031013237228011095,
       "adhd in big groups of people":0.00020799804064330996,
       "adhd in offspring":0.0004683194881366576,
       "fetal growth restriction":0.0002209316230801525,
       "maternal hyperthyroidism during pregnancy":0.0002209316230801525,
       "maternal hypothyroidism during pregnancy":0.0002209316230801525,
       "maternal preeclampsia":0.0004126272283785224,
       "obesity in mothers":0.0002209316230801525,
       "adhd in older adults":0.00017942306843327018,
       "mild cognitive impairment and dementia":0.00017942306843327018,
       "adhd malingering":0.0001533631096332215,
       "danish study":0.00015046429825016697,
       "reproductive-aged women":0.00018773727882946383,
       "risk of a motor vehicle collision":0.0004942572498756129,
       "short-term effects":0.00016779241405954343,
       "adhd medication metabolism affect":0.00020356786895261511,
       "mph":0.0018353662717982906,
       "comorbid anxiety":0.0002674169258724447,
       "duration of action":0.0007086554459787874,
       "duration of response":0.00023031210035600176,
       "intervention":0.0002414017853906987,
       "level of function":0.0002734271165773386,
       "methylin®":0.0002881212946573652,
       "methylphenidate-based medications":0.0002881212946573652,
       "mood dysregulation":0.00023031210035600176,
       "nonstimulants":0.0006392859362220409,
       "pharmacokinetics":0.00023031210035600176,
       "pharmacotherapies":0.0001525655023093848,
       "second-line nonstimulants":0.0005334719029303197,
       "short-acting methylphenidate":0.0002881212946573652,
       "specifically learning disorders and low iq":0.00019180049594058385,
       "stakeholders":0.0001517978452970518,
       "supplements":0.0005042655875906851,
       "treatment alternatives":0.0002499779225546704,
       "working memory training":0.00030737738648416624,
       "ɑ2 agonists":0.00023031210035600176,
       "prof. faraone":0.00017072966411193585,
       "completed suicide":0.0003345276637695641,
       "crime rates":0.00020553592823313222,
       "criminality":0.0002452047515173739,
       "diversion could be fatal when diverted to a person who is medically at risk":0.00019704143068724437,
       "diversion of medications is a felony":0.00019704143068724437,
       "gateway to non-oral use of illicit drugs":0.0002501239744642546,
       "injecting":0.00046841431240785637,
       "intranasally":0.00019704143068724437,
       "legal consequences of diverting medication":0.00019704143068724437,
       "medical consequences of diverting medication":0.00019704143068724437,
       "men with adhd":0.0003345276637695641,
       "diversion or nmu":0.00030705858365280455,
       "non-oral nmu":0.0002501239744642546,
       "non-oral routes":0.00019704143068724437,
       "oral administration":0.00019704143068724437,
       "repeated suicide attempts":0.0005202361587381846,
       "suicide deaths":0.0003345276637695641,
       "swedish national registers study":0.00015824109771457565,
       "teenagers with adhd":0.00025636097936332044,
       "youth with adhd and other psychiatric diagnoses":0.0005079926757748955,
       "adhd patients with ed but without smd":0.000238597724690825,
       "coping skills for managing anger":0.0006872455851514431,
       "adhd pharmacotherapy":0.0008822845534246732,
       "adolescents with adhd":0.0003731742362487132,
       "driver's license":0.000189945500510073,
       "females with adhd -i or controls":0.00026491954993139335,
       "individuals (age 6 to 24 years) with adhd":0.00024263688185343642,
       "motor vehicle crashes":0.0008822845534246732,
       "natural causes":0.000189945500510073,
       "st imulant medications":0.00026491954993139335,
       "two-year mortality risk from all-causes":0.000189945500510073,
       "unnatural causes such as suicide, accidental poisoning or injury":0.000189945500510073,
       "employment":0.00018686307267963675,
       "employment status jobs":0.00018686307267963675,
       "prescription stimulant misuse":0.00018686307267963675,
       "adhd prs":0.00019174448742834908,
       "irritability traits":0.00019174448742834908,
       "adhd quality of life":0.0001837944059224817,
       "primerthe columbia impairment scale":0.0001837944059224817,
       "adhd rating scales":0.00024090549071541264,
       "cultural context":0.0001543830298949279,
       "culture":0.0001543830298949279,
       "adhd severity":0.0002729501221247413,
       "intelligence quotient":0.00021699608367046108,
       "adhd symptom checklists":0.00034025899391746474,
       "barkley deficits in executive function scale":0.00024188134790031446,
       "improvement in psychosocial functioning":0.00024188134790031446,
       "adhd symptom control extension":0.0002012103722029915,
       "adult adhd symptoms":0.0002937382698966404,
       "aggression":0.0006595727973868523,
       "alpha-2-adrenergic agonists":0.0004930535666364685,
       "amphetamine derivatives":0.00028131670853694514,
       "becoming unnaturally quiet":0.0001455711085877573,
       "broad-spectrum micronutrient supplements":0.00024448043934349685,
       "cbt alone":0.0001903080455119191,
       "child behavior checklist":0.00020105628426723358,
       "clinical prescriber with training in adhd diagnosis and management":0.00015532012760345775,
       "clinical subgroups":0.00015346555362324608,
       "combined treatment with medication and cbt":0.0002212545419440703,
       "dietary approach to stop hypertension":0.00024448043934349685,
       "dietary interventions for adhd":0.00015589912242858987,
       "digital interventions":0.000164706621710444,
       "digital therapies":0.00015045108523278203,
       "direct skills training":0.0007101817872787746,
       "disruptive behavior disorders":0.0007969316164370274,
       "drug treatment resistant patients":0.00015166083161358309,
       "effect":0.00033374735547943827,
       "exclusion of food colour additives and preservatives":0.00024448043934349685,
       "exercise":0.001275717374211178,
       "extended-release preparations":0.00023044864968794842,
       "good sleep practice":0.00018592663687130832,
       "hallucinogens":0.00023305558013866912,
       "healthy diets":0.0005294216121577249,
       "heroin":0.00023305558013866912,
       "homicidality":0.00014617995064487182,
       "imipramine":0.0001455711085877573,
       "immediate-release stimulants":0.00023044864968794842,
       "inhalants":0.00023305558013866912,
       "jornay":0.00023044864968794842,
       "marijuana":0.0002745298203266711,
       "medication alone":0.00046037722992152554,
       "medication or psychosocial interventions":0.0001859785662586843,
       "mediterranean diet":0.00024448043934349685,
       "melatonin":0.00038370662046877417,
       "mirtazapine (remeron)":0.0001455711085877573,
       "negative mood symptoms":0.00025531125662284714,
       "nutrition":0.00020507238900030115,
       "omega-3 fatty acid supplementation":0.0009515747299632001,
       "pain relievers":0.00023305558013866912,
       "parent behavior management program":0.00020105628426723358,
       "parent-rated emotional lability symptoms":0.0001545178818011025,
       "parent-rated oppositional symptoms":0.0001545178818011025,
       "participants and their significant others":0.00015589912242858987,
       "poor dental hygiene":0.00013997862158351883,
       "prognosis":0.0004041147226236976,
       "remission of aggressive behavior":0.00025531125662284714,
       "restricting synthetic food colors":0.0001545178818011025,
       "ssri and stimulant combination":0.00018290607249038022,
       "ssri antidepressants":0.00015346555362324608,
       "stimulant-refractory adhd":0.0005294216121577248,
       "tca":0.00014373880431906504,
       "teacher-rated emotional lability symptoms":0.0001545178818011025,
       "teacher-rated oppositional symptoms":0.0001545178818011025,
       "tranquilizers/sedatives":0.00023305558013866912,
       "treatment selection":0.0001859785662586843,
       "treatment success":0.0002424189136812013,
       "venlafaxine":0.00036116264154341783,
       "youth adhd symptoms":0.0002270994999145366,
       "adhd trea tment":0.00015588493001835542,
       "administration of stimulants in conjunction with alcohol use":0.00033739047191430247,
       "cardiotoxicity":0.00021844591924802704,
       "ecg":0.00015660825284597872,
       "lower all-cause mortality":0.00016779241405954343,
       "males with adhd":0.00016779241405954343,
       "patients medicated for adhd":0.0014866223466489558,
       "plasma levels":0.00015660825284597872,
       "polysubstance use":0.0002007778450670346,
       "qtc prolongation":0.00015660825284597872,
       "tachycardia":0.00015660825284597872,
       "tca treatment":0.00021844591924802704,
       "unnatural causes of mortality":0.00016779241405954343,
       "adhd treatment first line":0.00015592969899536944,
       "impulsive cognition":0.0002119460336268925,
       "learning problems":0.000166597955274959,
       "poorly regulated emotions":0.0002119460336268925,
       "adhd treatment plan":0.00017636024488499604,
       "behaviors that we now associate with adhd":0.00020458728626692024,
       "cam therapies":0.0005761036783233494,
       "chelation therapy":0.00045220071943960515,
       "consensus statement":0.0002542943160808161,
       "large effect":0.00020458728626692024,
       "medium effect":0.00020458728626692024,
       "megavitamins":0.000490447582725788,
       "reviews":0.00020458728626692024,
       "small effect":0.00020458728626692024,
       "smaller studies":0.0003029203419724314,
       "strong effects":0.00020458728626692024,
       "treatment studies":0.00037228544631645773,
       "vitamins":0.0004522007194396051,
       "adhd types":0.00018626832707015946,
       "adhd-like symptoms in children":0.0002277246352032994,
       "adhd-related cost study":0.00036293474066484167,
       "adhd-related costs":0.0006809574053587186,
       "seven european studies":0.00036293474066484167,
       "annual national costs":0.00036293474066484167,
       "€1 billion":0.00036293474066484167,
       "adhd-specific problems in daily life":0.0001837944059224817,
       "adjunctive psychotherapy":0.0002506009683384598,
       "suboptimal response":0.0005518854216551969,
       "adjust the timing of the dose":0.00028767324290680124,
       "excessive tiredness":0.0013924598750950418,
       "stomachaches, nausea":0.0006697880125606168,
       "adjusted odds ratio":0.00015602775459030643,
       "cardiovascular disease diagnosis":0.0004553094328713661,
       "drowsiness":0.0014161850890507244,
       "trouble sleeping":0.0006311533431265998,
       "adjusting the dose or timing may help":0.00020296190867220973,
       "adjustment":0.000105705698123473,
       "administer the stimulant with meals to lessen its impact on appetite":0.00014996967023197437,
       "helping the noncompliant child":0.00020583934157680501,
       "homework organization":0.00020583934157680501,
       "incredible years parenting program":0.00020583934157680501,
       "new forest parenting program":0.00024880259286713766,
       "nmu of amp":0.0003856826920845935,
       "parent-child interaction therapy":0.00020583934157680501,
       "positive parenting program (triple p)":0.00020583934157680501,
       "self-monitoring skills":0.00020583934157680501,
       "study skills":0.00020583934157680501,
       "teacher ratings":0.0008410151774022629,
       "young adults who do not attend college":0.0003856826920845935,
       "intuniv":0.0003539401029747459,
       "kapvay":0.0003539401029747459,
       "qelbree":0.0003201797644670006,
       "adult adhd quality measures initiative (aaqmi)":0.0002737157471805465,
       "ahrq":0.00037510691594538724,
       "candidate qms":0.00027146971427486423,
       "clinical and research experts":0.00027146971427486423,
       "delivery of quality health care to adults with adhd":0.0002737157471805465,
       "development of qms":0.00027146971427486423,
       "existing guidelines for adult adhd":0.00027146971427486423,
       "expert opinion":0.00016239096720504261,
       "extended-release":0.00019078785279126674,
       "healthcare delivery":0.00016239096720504261,
       "healthcare processes":0.0002708677829122848,
       "immediate-release":0.00019078785279126674,
       "limited access to treatment by skilled providers":0.00026406571367182835,
       "multidisciplinary panel":0.00027146971427486423,
       "clinical guidelines":0.0005160761969832907,
       "qms":0.0010674359241979472,
       "quality indicators":0.000257141312068083,
       "us agency for healthcare research and quality (ahrq)":0.00027146971427486423,
       "adult adhd quality of life survey":0.0001837944059224817,
       "adult adhd self-report scale":0.00024368325880574495,
       "measure":0.00016239096720504261,
       "affective lability scale –short form (als-18) ":0.0004232750631995113,
       "affective reactivity index (ari)":0.0004232750631995113,
       "barkley deﬁcits in executive functioning scale — children and adolescents (bdefs-ca)":0.0004232750631995113,
       "behavior rating inventory of executive function (brief or emotion control subscale)":0.0004232750631995113,
       "brown add rating scales for children, adolescents and adults (badds)":0.0004232750631995113,
       "child behavior checklist –dysregulation proﬁle (cbcl-dp)":0.0005682711041957961,
       "difﬁculties in emotion regulation scale (ders)":0.0007285881314447228,
       "distress tolerance scale":0.00042170639586739154,
       "drug holidays":0.00014609908258523635,
       "emotion dysregulation scale, short version (eds-short)":0.0005682711041957961,
       "emotion regulation checklist (erc)":0.0005682711041957961,
       "emotion regulation index for adults and children (erica)":0.0005682711041957961,
       "emotion regulation questionnaire (erq)":0.0008136356377448028,
       "emotional lability t-scores on conners rating scales –revised (crs-r)":0.000301252452568603,
       "expression and emotion scale for children (eesc)":0.0003355651189598529,
       "frustration discomfort scale":0.000301252452568603,
       "strengths and difﬁculties questionnaire – dysregulation proﬁle (sdq-dp)":0.00042170639586739154,
       "trials norms availability":0.0005682711041957961,
       "adults (11 studies, 2909 participants)":0.00014298531821569185,
       "adults (cortese et al., 2018a)":0.00014298531821569185,
       "adults treated with viloxazine":0.000179725966378708,
       "adults unresponsive to mph trial":0.00021751741968502612,
       "advancing age":0.00028869010909049085,
       "adverse":0.0001532879023332944,
       "clinical response":0.0004223774945349821,
       "driving and work performance":0.0002676224294353447,
       "emergency room visits":0.0006539078915332984,
       "maximum daily dose":0.0003629267263484745,
       "discontinuation":0.00020905866756513702,
       "follow-up visit":0.0009843405060616986,
       "medication response":0.0009843405060616986,
       "health care facilities":0.000599749425797628,
       "adverse outcomes":0.0003075896924485403,
       "prevalence of stimulant nmu":0.0008924723847064759,
       "adverse side effects of atomoxetine":0.00020703465630017887,
       "monitoring and management":0.0008070353916349922,
       "adverse side effects of guanfacine":0.00020703465630017887,
       "adzenys xr -odt":0.0004074338126046991,
       "dexedrine spansule":0.0004074338126046991,
       "dyanavel xr":0.00025319779690592876,
       "mydayis":0.0004074338126046991,
       "tips for using amphetamine-based medications":0.00025319779690592876,
       "aerobic activity":0.0001987097860409897,
       "improvement in the core symptoms of adhd":0.0008739051149609346,
       "aerobic exercise":0.0002494240553123504,
       "affective components of executive control":0.0002801924727553662,
       "dopaminergic system":0.0010978686071804454,
       "executive control":0.0012378111076398871,
       "mood regulation":0.0010978686071804454,
       "noradrenergic system":0.0010978686071804454,
       "affordable care act":0.00017525700387642165,
       "african-american students":0.00015286422137427406,
       "viloxazine dose":0.00018784681732069184,
       "liver problems":0.0006039094801444406,
       "nausea/vomiting":0.0006039094801444406,
       "viloxazine (qelbree)":0.0008973544111782576,
       "agitation":0.00018968135747585252,
       "expert clinicians":0.00022177217345967776,
       "ahrq, medicare and medicaid":0.00017525700387642165,
       "alcohol use disorder: treatment overview":0.0006682833177047765,
       "counseling":0.00026638014511118683,
       "limit their alcohol consumption":0.0001909030441832107,
       "low-risk and risky alcohol use":0.00026638014511118683,
       "opioid use disorder: treatment overview":0.0001909030441832107,
       "stimulant use disorder: treatment overview":0.0001909030441832107,
       "stimulants for adhd":0.0006682833177047765,
       "all age groups (youths 21 studies with 3812 participants, adults 11 studies with 3377 participants)":0.00017976952976055905,
       "all-cause treatment discontinuation":0.00017948554641181391,
       "dizziness":0.0015773400139023168,
       "increased blood pressure and heart rate":0.0002167084177778956,
       "itching":0.00017074220836974337,
       "monitoring":0.0002167084177778956,
       "rash":0.00017074220836974337,
       "vomiting":0.0004671539635678675,
       "motor or vocal tics":0.00019245059004500538,
       "nonstimulants for adhd":0.00018889501461431105,
       "alpha agonists (clonidine and guanfacine)":0.0003389527022505711,
       "liver problems such as hepatitis":0.00026034689485560753,
       "american academy of child and adolescent psychiatry adhd resource center":0.00046203767678987473,
       "attention deficit disorder association (adda)":0.00046203767678987473,
       "barkley r. taking charge of adhd, third edition: the complete, authoritative guide for parents":0.000358698796171143,
       "centers for disease control and prevention (cdc) adhd":0.00046203767678987473,
       "children and adults with attention-deficit/ hyperactivity disorder (chadd)":0.00046203767678987473,
       "national institute of mental health (nimh) adhd":0.000358698796171143,
       "the american professional society of adhd and related disorders (apsard)":0.00046203767678987473,
       "wilens te, hammerness pg. straight talk about psychiatric medications for kids, 4th edition":0.000358698796171143,
       "american academy of pediatricians":0.00019691348489760365,
       "american professional society of adhd and related disorders":0.0003884207764383228,
       "canadian adhd resource alliance":0.0003169276353290345,
       "world federation of adhd":0.0011550562030789955,
       "american psychopathological association":0.00036293474066484167,
       "pau l hoch award":0.00036293474066484167,
       "state university o f new york":0.0006809574053587186,
       "reasonable accommodations":0.00018546556182029607,
       "amp":0.00016695278418666655,
       "attention and impulsivity":0.00014298531821569185,
       "cardiac arrest":0.00017930358881066297,
       "cerebrovascular disease":0.00017930358881066297,
       "daily timing":0.00014298531821569185,
       "heart failure":0.00017930358881066297,
       "ischemic heart disease":0.00017930358881066297,
       "misuse and diversion":0.0002435042550252005,
       "prescribing medications for adhd":0.0002435042550252005,
       "prescription refill requests":0.0002435042550252005,
       "risks of stimulant misuse and diversion":0.0002435042550252005,
       "schedule ii controlled substances":0.00019182264790864988,
       "short-acting amphetamines":0.00014298531821569185,
       "studies regarding nmu of mph or amp":0.0005119243959818564,
       "symptom control":0.00014298531821569185,
       "tachyarrhythmias":0.00017930358881066297,
       "venous thromboembolism":0.00017930358881066297,
       "amphetamine formulations":0.00019473469879820619,
       "lisdexamfetamine dimesylate (ldx)":0.00029771748332643093,
       "amphetamine medication":0.00024254790181204338,
       "amphetamine stimulants":0.00015444120076287568,
       "children (7 studies, 1930 participants)":0.00018347314557000025,
       "growth suppression":0.0003928636334022679,
       "pregnant woman":0.00039174588756194596,
       "youths (9 studies, 2677 participants)":0.00014298531821569185,
       "analysis":0.000183063947020501,
       "discontinuation due to adverse event":0.00044054606313220426,
       "lisdexamphetamine":0.00044054606313220426,
       "worse anorexia":0.00044054606313220426,
       "antacids":0.00014273834227238578,
       "antecedents of behaviour":0.00019337946283554602,
       "reinforcement techniques":0.00019337946283554602,
       "anthony l. rostain":0.0001984492349598245,
       "departments of psychiatry and pediatrics, university of pennsylvania perelman school of medicine, philadelphia, pa":0.0001984492349598245,
       "anticipatory appraisal and valuation":0.0003046890295815158,
       "emotion generation":0.0010270783728511543,
       "emotional state":0.0009471062300115539,
       "regulation":0.00030984553799182627,
       "antipsychotics":0.00021751741968502612,
       "not recommended adhd treatment":0.00021751741968502612,
       "dry mouth":0.0009868314792223704,
       "anxiety and substance use disorders":0.00016702827486199195,
       "benzodiazepines":0.0002178148299290073,
       "childhood irritability":0.00018664370034035256,
       "opioid":0.000260967563946268,
       "any interpretation should keep in mind that the ratings are of relative importance":0.0008822288237282901,
       "care coordination":0.0008331690052617419,
       "care coordination and the patient experience domains":0.00017179709110495866,
       "follow-up":0.000491355491468428,
       "future efforts should include other relevant stakeholders, including patients and health care systems, who may be more likely to emphasize the care coordination and the patient experience domains":0.0008280314002037012,
       "low rating only means that the item is not essential for documenting the basics of quality care":0.00017179709110495866,
       "patient experience":0.00046860659176000053,
       "patients and health care systems":0.0002397866820761838,
       "quality diagnosis":0.000511794985361774,
       "quality in these domains may be viewed as less relevant":0.0002181496479069828,
       "results may reflect a systematic bias in our sample of raters":0.0002397866820761838,
       "should include other relevant stakeholders, including patients and health care systems":0.0002397866820761838,
       "systematic bias in our sample of raters":0.0002397866820761838,
       "apsard":0.00017752865225965876,
       "apten sio xr":0.0005057969053123151,
       "capsules":0.0005057969053123151,
       "daytrana":0.0005057969053123151,
       "focalin xr":0.00025009867242679917,
       "liquid":0.00030129509490142887,
       "patches":0.00025009867242679917,
       "quillivant xr":0.00030129509490142887,
       "ritalin la":0.00025009867242679917,
       "arterial disease":0.00015602775459030643,
       "asian federation of adhd":0.00015604398078633146,
       "asian resource":0.0001697957319720471,
       "assignments":0.00020203453383728948,
       "association for behavior and cognitive therapies":0.00023975091999210585,
       "behavioral therapist":0.000887827791463187,
       "caregivers of children age 6 to 12 years":0.000887827791463187,
       "centers for disease control and prevention (cdc)":0.000887827791463187,
       "association for child and adolescent mental health":6.398089104054257e-05,
       "atomox etine":0.0001592551330381839,
       "atomoxetine levels":0.0002001398480346696,
       "atypical antidepressants":0.00026970097114694416,
       "blood monitoring":0.0002001398480346696,
       "brain cells communication":0.0002001398480346696,
       "cardiac malformations":0.0002676298329102792,
       "chemical messengers (norepinephrine)":0.0002001398480346696,
       "constipation":0.0003963606267469528,
       "correct dose":0.0001434944350060003,
       "treatment discontinuation":0.00017948554641181391,
       "tricyclic antidepressants (tcas)":0.00026970097114694416,
       "atomoxetine treatment for adhd":0.00020703465630017887,
       "attention and arousal":0.00023539732204175913,
       "behavioral functioning":0.00032794976393512275,
       "chronic condition management":0.00032794976393512275,
       "information provision":0.00032794976393512275,
       "dizziness and lightheadedness":0.0007676519116270892,
       "fatigue":0.0008386511175479719,
       "sedation":0.0007295947904719952,
       "attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis":0.0006424041995185684,
       "behavioral management techniques that are used for children with adhd":0.0001801393674895844,
       "coexisting conditions that are associated with adhd or mimic its symptoms":0.00021719197333748666,
       "nonadherence to the treatment plan":0.0001719767782381921,
       "repetition of the diagnostic evaluation":0.00021719197333748666,
       "evidence-based statements about adhd":0.0002300298319763451,
       "international consensus statement":0.00016483411707244867,
       "meta-analyses and very large studies":0.0002300298319763451,
       "parents' medication guide":0.00016037967011954963,
       "parents' medication guidedysregulation":0.00018748525241724134,
       "project steering committee":0.00016483411707244867,
       "research and clinical care of adhd":0.00016483411707244867,
       "scientific data":0.00016483411707244867,
       "attention-deﬁcit/hyperactivity disorder":0.00016163869937791872,
       "impulsive aggression":0.000493228635251545,
       "liver damage":0.00018968135747585252,
       "psychotic symptoms":0.00018968135747585252,
       "self-harming behavior":0.00018968135747585252,
       "unusual changes in behavior":0.00018968135747585252,
       "atx or dex":0.00021751741968502612,
       "atx treatment":0.00021751741968502612,
       "liver disease evaluation":0.00021751741968502612,
       "augmentation strategies":0.00016629221258821836,
       "charles bradley":0.00024254790181204338,
       "child psychiatry":0.0001737709458814551,
       "minimal brain dysfunction-related behaviors":0.00024254790181204338,
       "morris et al. and o'neal and robins":0.00024254790181204338,
       "research showing that the diagnosis predicts treatment response, clinical course, and family history of the disorder":0.00022808606081432055,
       "u.s. food and drug administration":0.0003037158911161957,
       "world health organization":0.0001737709458814551,
       "authors":0.0001688304469528456,
       "emotional problems":0.00017797808057211194,
       "seizures":0.00036883878550550544,
       "sleep disorder":0.00017797808057211194,
       "availability of treatment":0.0002320833596225104,
       "avoid caffeine":0.00023496536603435778,
       "evening":0.000827271253433833,
       "good sleep habits":0.0009220518442268736,
       "avoid skipped doses":0.00014869222527513404,
       "maladaptive emotions":0.00043859329508402897,
       "bachelor's degree":0.0003131816806663137,
       "dorsal anterior cingulate cortex":0.0003696319165418852,
       "fmri meta-analyses":0.00019532170359038892,
       "inferior frontal cortex":0.0006597780396524441,
       "neutral fmri tasks":0.0001525886639555875,
       "supplementary motor area":0.0001525886639555875,
       "typically developing individuals":0.0001525886639555875,
       "ventral anterior cingulate cortex":0.0003696319165418851,
       "become unusually quiet or appear over-focused":0.00014996967023197437,
       "child development":0.00018477017900915538,
       "metacognitive executive function training":0.00044338034582317977,
       "pre-kindergarten academic curriculum (stp-pre-k)":0.00044338034582317977,
       "social-emotional and self-regulation training program (stp-pre-k enhanced)":0.00044338034582317977,
       "tools":0.00018477017900915538,
       "behavior modification system":0.00025027475003505813,
       "behavior problems":0.00023947923043817583,
       "blood pressure monitoring":0.00027797671555023905,
       "chest pain":0.00027797671555023905,
       "education on side effects":0.0003533965997690496,
       "growth monitoring":0.00027797671555023905,
       "heart rate assessment":0.00027797671555023905,
       "impulsiveness":0.00027797671555023905,
       "long-term use":0.00031498239221400325,
       "mood monitoring":0.00027797671555023905,
       "mood swings":0.0007371822450860034,
       "palpitations":0.00027797671555023905,
       "peripheral vasculopathy":0.0003162709910201579,
       "raynaud’s phenomenon":0.0003162709910201579,
       "severe allergic reactions":0.0003162709910201579,
       "severe psychiatric symptoms":0.00027797671555023905,
       "side effects information":0.0003154252598685958,
       "sudden cardiac death":0.00041932550811146703,
       "swelling of the face, lips, tongue, or throat":0.0003162709910201579,
       "weight monitoring":0.00027797671555023905,
       "blurred vision or other visual changes":0.00029107922200883696,
       "development or worsening of motor or vocal tics":0.00029005600885851946,
       "elevated blood pressure (hypertension)":0.00025586908860040483,
       "especially in children":0.00025586908860040483,
       "increased aggression or hostility":0.00025586908860040483,
       "increased heart rate (tachycardia)":0.00025586908860040483,
       "nervousness":0.00025586908860040483,
       "rash or hypersensitivity reactions":0.00029107922200883696,
       "skin reactions":0.00029107922200883696,
       "trouble falling and staying asleep":0.00025586908860040483,
       "visual disturbances":0.00029107922200883696,
       "behavioral disinhibition":0.00019076862882482296,
       "observed behavior":0.0005854167160167846,
       "behavioral expression":0.00045684011742092555,
       "behavioral indicators":0.0005280624869979478,
       "subjective emotionality":0.0005280624869979478,
       "high emotional thresholds":0.00031325546076491675,
       "recovery times":0.00025824251879727304,
       "quick return to baseline":0.00038607511986323966,
       "behavioral response system":0.0002354949817154358,
       "subjective/cognitive response system":0.0002354949817154358,
       "child’s behavior":0.00016116317152782864,
       "coping strategies":0.00016116317152782864,
       "negative behaviors":0.00016116317152782864,
       "negative thought patterns":0.00020610042076121756,
       "parent -child relationship":0.00016116317152782864,
       "positive behaviors":0.00016116317152782864,
       "problematic behaviors":0.00016116317152782864,
       "finding activities in which the child can be successful (eg, hobbies, sports)":0.00023975091999210585,
       "identifying unintentional reinforcement of negative behaviors":0.00023975091999210585,
       "keeping environmental distractions to a minimum":0.00023975091999210585,
       "limiting choices":0.00023975091999210585,
       "maintaining a daily schedule":0.00023975091999210585,
       "national institute for children's health quality toolkit":0.00023975091999210585,
       "providing specific and logical places for the child to keep their schoolwork, toys, and clothes":0.00023975091999210585,
       "rewarding positive behavior (eg, with a 'token economy')":0.00023975091999210585,
       "setting small, reachable goals":0.00023975091999210585,
       "using calm discipline (eg, time out, distraction, removing the child from the situation)":0.00023975091999210585,
       "using charts and checklists to help the child stay 'on task'":0.00023975091999210585,
       "parenting context":0.00015751933968010163,
       "pharmaco logical therapy":0.00015062171862069033,
       "benefits and risks of treatment":0.00019441804131592865,
       "best practices":0.00017525700387642165,
       "best studies":0.00015604398078633146,
       "pulse":0.00018088238420578624,
       "blood pressure and pulse quarterly":0.00023263463571790134,
       "blood tests":0.00014641409480128004,
       "bone fractures":0.00014995091129463108,
       "borderline personality disorder":0.00016163869937791872,
       "boundaries between adhd and other disorders":0.00016648676985977438,
       "long-term side effects":0.00026613035722681557,
       "broader scope of the review":0.00024303873391366256,
       "bupropion (wellbutrin, zyban)":0.0001789183528421307,
       "caddra":0.00017752865225965876,
       "caffeine levels":0.00014641409480128004,
       "calendar year":0.00017457933621816947,
       "chelation":0.00014570494975157353,
       "primary care practitioner":0.0003387255840118249,
       "risks and benefits":0.00014570494975157353,
       "nonmedical users":0.0001545103382827643,
       "cardiac history or cardiac symptoms":0.00024068257206333966,
       "cardiac review":0.00027014330809553414,
       "cardiologist consultation":0.00024068257206333966,
       "findings outside of normal limits":0.00024068257206333966,
       "sudden death or ventricular arrhythmia":0.00019551239010271397,
       "cardiovascular health":0.0001987097860409897,
       "clinical response, duration of the effect during the day, and side effects":0.0001753240332410201,
       "electrocardiogram (ecg)":0.00024068257206333966,
       "low dose stimulant treatment":0.00018940946135729907,
       "short-acting dextroamphetamine-amphetamine":0.00024068257206333966,
       "child's height":0.00040173913045581994,
       "child's weight":0.00040173913045581994,
       "regular measurement":0.00040173913045581994,
       "qm":0.0003061346285009943,
       "quality care":0.0003596293091031978,
       "treatment follow-up":0.00043114742087826784,
       "care management plan":0.0001719540088732367,
       "careful dose titration required":0.00015592969899536944,
       "careful monitoring of medication, safe storage, education around stimulant misuse, along with the use of extended release stimulants":0.00015928179150118729,
       "child's practitioner":0.0006782722347301324,
       "caregiver decision":0.00019705088373584166,
       "catapres":0.00013831198584553006,
       "category":0.00018388578515779794,
       "causes":0.00014264240100206723,
       "cbcl-dysregulation profile":0.0001901569951071556,
       "emotional dysregulation scores":0.0001901569951071556,
       "cbt group and individual therapy programs":0.000238597724690825,
       "cbt group treatment":0.00014270133486694674,
       "orthostatic hypotension":0.00029600838425825456,
       "slow heart rate (bradycardia)":0.00029600838425825456,
       "cereals":0.00023496536603435778,
       "certain children":0.0002404178324065438,
       "certain events":0.00022644028126149075,
       "certain foci in the literature may have been missed":0.00024303873391366256,
       "chadd website":0.00019316263026647638,
       "coalition to prevent adhd medication misuse":0.00019316263026647638,
       "college administrators":0.00019316263026647638,
       "collegiate student leaders":0.00019316263026647638,
       "cpamm":0.0006095328325456365,
       "information about misuse and diversion":0.00028994798254447556,
       "personnel":0.00019316263026647638,
       "pharmaceutical industry":0.00019316263026647638,
       "changing the drug":0.0002172618638955409,
       "heart symptoms":0.00043151721151473023,
       "height":0.00019255790937190766,
       "long-term studies (lower risk of later cigarette or illegal substance use)":0.000202434525518448,
       "meal timing":0.00014854174329764406,
       "medical history (heart problems, dizziness, irregular heartbeats, shortness of breath, or chest pain)":0.00015928179150118729,
       "mental health challenges":0.00015404244872200938,
       "mirtazapine":0.00014854174329764406,
       "misuse of stimulants (selling, giving away, taking higher than recommended doses, using with substances of misuse)":0.00019967517596295058,
       "mood problem":0.0002444637873789356,
       "moodiness":0.0002639010699681719,
       "over-focused or repeated movements (tics or habits)":0.00015928179150118729,
       "preparation":0.00019255790937190766,
       "separate issue":0.0002444637873789356,
       "sleep habits":0.00014854174329764406,
       "worsened heart problems":0.00020504538614530117,
       "zombie effect":0.00015928179150118729,
       "child and adolescent psychiatrist":0.0001503805323056557,
       "child psychologist":0.00015608213114574765,
       "immediate action":0.0002722146410906687,
       "medication holidays":0.00023048983400773823,
       "childhood diagnosis of adhd":0.00015683993641270018,
       "children in intervention group":0.00021776149582612087,
       "discuss with the healthcare provider about adjusting or switching medications if tics become problematic":0.00014996967023197437,
       "loss of appetite (anorexia)":0.0001910601552176032,
       "monitor for changes in behavior and report to the healthcare provider":0.00014996967023197437,
       "monitor your child closely for new or worsening tics":0.00014996967023197437,
       "offer high-calorie snacks such as instant breakfast drinks":0.00014996967023197437,
       "regularly check your child's weight to ensure they are growing normally":0.00014996967023197437,
       "sleep intervention":0.00015608213114574765,
       "teacher-reported behavior":0.00021776149582612087,
       "cohort studies":0.00014854174329764406,
       "children and youth with special health care needs":0.00018945605591331162,
       "children who have not yet entered elementary school":0.00024708533162903985,
       "classroom modifications":0.00025336870852234807,
       "developmental behavioral pediatrician":0.0001503805323056557,
       "intentional and unintentional injury":0.00025336870852234807,
       "china adhd alliance":0.00017752865225965876,
       "classroom modifications and accommodations":0.0009172709635350766,
       "combined medication and behavior treatment":0.0002004335082592474,
       "combined treatment":0.00023535823208433053,
       "lower doses of medication":0.00023535823208433053,
       "non-adhd symptoms":0.0002004335082592474,
       "provision of tutoring or resource room support":0.00018458203970561236,
       "school-aged children":0.0003949121126723057,
       "stressors in family life":0.00020079844199774122,
       "suboptimal response to pharmacotherapy":0.00019108540798562875,
       "normative data":0.000290864927736643,
       "parents and teacher reports":0.00024731710345059194,
       "preschool teachers and clinicians":0.00023497555320652915,
       "ratings from other individuals":0.00019459980104699704,
       "scales":0.00024402313362294922,
       "secondary school teachers":0.00019459980104699704,
       "self-report":0.0003334808076373887,
       "structured behavioural observations":0.00024708533162903985,
       "such as":0.00023397130756384955,
       "tools for screening":0.00015276566688770897,
       "longer acting than clonidine":0.00013831198584553006,
       "short-acting medication":0.00013831198584553006,
       "tenex":0.00013831198584553006,
       "tic problems":0.00013831198584553006,
       "close monitoring":0.0003473476181175729,
       "close monitoring by healthcare provider":0.00018792803358913066,
       "persistent adhd":0.00020387377255380294,
       "cognitive components of executive control":0.0002801924727553662,
       "cognitive flexibility":0.0004127699148893623,
       "cognitive strengths and weaknesses":0.00020750183875925624,
       "play-based interventions":0.00029299566436616993,
       "problems with peers":0.0001651011682254665,
       "psychotherapy interventions":0.00015809140684564278,
       "students with disabilities":0.00018945605591331162,
       "summer treatment camp":0.00025027475003505813,
       "deficits":0.00024851723664312997,
       "guided walks":0.0001987097860409897,
       "increases the effectiveness of":0.0002373367522978718,
       "organizational/planning skills":0.0001987097860409897,
       "psychosocial well-being":0.0001987097860409897,
       "yoga":0.0001987097860409897,
       "patient's family":0.00020889606459076668,
       "collateral report":0.00021513828516704235,
       "colleagues":0.00020820996765209216,
       "gpas":0.00036903028563630027,
       "college peers":0.00015467348254671296,
       "common misconceptions":0.0002891994319082939,
       "nmu of mph":0.0002442270021597386,
       "nmu population prevalence":0.00044233441026879887,
       "parents with suspected or diagnosed adhd":0.00015286422137427406,
       "peer behavior":0.0002353950936338199,
       "printed handouts":0.0002353950936338199,
       "repetition":0.0002353950936338199,
       "sanctions":0.0002353950936338199,
       "social situations":0.00015286422137427406,
       "us college populations":0.00027637048194223933,
       "young adult populations":0.0002353950936338199,
       "enforcement":0.0001475270095195666,
       "incoming students":0.0001585854521495565,
       "com-ponents of emotional symptoms":0.0002026055340887682,
       "different terms used to describe them":0.0002026055340887682,
       "community psychosocial care":0.000238597724690825,
       "community support":0.0001801868355996384,
       "specific treatment approach":0.0002364223902526942,
       "medication adherence":0.0002056637191050709,
       "diagnostic challenges":0.0002536624399503111,
       "simplex adhd":0.00018163534004764827,
       "standard information gathering":0.0002536624399503111,
       "comprehensive approach to literature on nmu":0.00024303873391366256,
       "concerns being discussed":0.00023373928679069848,
       "extended-release tablets":0.00024045525413210519,
       "reduce the need to take multiple doses throughout the day":0.00024045525413210519,
       "consistent sleep schedule":0.00023496536603435778,
       "consult with healthcare provider":0.00018482431385578976,
       "consult with the healthcare provider for further advice":0.00020296190867220973,
       "contents":0.0002356619215899802,
       "contraindications to drug treatment":0.00017546499812461387,
       "cooperating":0.00021286924841291613,
       "ingroup therapy":0.000238597724690825,
       "integrative treatment program":0.000238597724690825,
       "parental satisfaction":0.000238597724690825,
       "core symptoms":0.00019705088373584166,
       "corticocerebellar networks":0.00017492630352537164,
       "criteria":0.00017129490156341009,
       "critical care unit":0.00016695278418666655,
       "current adhd symptoms":0.0001859785662586843,
       "secular private schools":0.00016269386875781758,
       "decongestants":0.0001457605913146854,
       "food supplements":0.0003473476181175729,
       "hepatitis":0.0003473476181175729,
       "low dose medication":0.0003473476181175729,
       "medication adjustment":0.0006352749032086458,
       "medication with food":0.0003473476181175729,
       "executive control and corticocerebellar networks":0.0001771121916578782,
       "frontal and parietal cortical areas":0.00018491275560634534,
       "inferior parietal and medial temporal regions":0.00022822869034194138,
       "medial prefrontal and the posterior cingulate cortices":0.00022822869034194138,
       "orbitofrontal cortex":0.00022822869034194138,
       "reward system":0.00024618326952261795,
       "thalamus":0.00038120122451722947,
       "ventromedial prefrontal cortex":0.00022822869034194138,
       "denmark, finland, sweden, norway, and iceland":0.00019160981305141537,
       "departments of psychiatry, neuroscience and physiology, suny upstate medical university, syracuse, ny":0.0001984492349598245,
       "those reporting nmu in a survey of 4,297 us adults":6.398089104054257e-05,
       "detect nmu":0.00019560315110155835,
       "medical/neurological history":0.00016855543395984018,
       "stimulant misuse risk assessment":0.00019894005366816804,
       "deﬁcits in response inhibition to frustration":0.0001933512349391812,
       "documented dsm-5 diagnosis of adhd":0.0001669167584854763,
       "diagnostic guidelines":0.0001648733785652601,
       "diagnostic utility for adhd":0.0002026055340887682,
       "symptoms commonly occurring in other disorders":0.0002026055340887682,
       "dietary restrictions":0.00019801058790433154,
       "disability services":0.00019515345292646694,
       "discontinuing medication":0.00017942306843327018,
       "discussions":0.00019515345292646694,
       "discussions of transfer of care with new clinician made":0.0001676199443837569,
       "emotional upsets":0.00022644028126149075,
       "motivation":0.00022644028126149075,
       "social payoff":0.00022644028126149075,
       "diurnal variation in symptoms":0.00023263463571790134,
       "malingering":0.0003347245509636521,
       "pills per prescription":0.00029887202609533785,
       "extended-release form":0.0001409167701390815,
       "hydration":0.0002183335559136795,
       "loss of appetite":0.0002528764804451435,
       "medication form adjustment":0.0003056451412475,
       "more irritability or moodiness when taking medication":0.00030831987875836673,
       "slowing of heart rate":0.0004378972666103094,
       "snacks":0.0001409167701390815,
       "supplemental medications":0.00030831987875836673,
       "timing of medication":0.00026392033416456956,
       "dmdd":0.00017399323148244768,
       "intensified negative mood":0.00017399323148244768,
       "document":0.00020820996765209216,
       "documentation":0.00015388869666998367,
       "frontal lobes":0.00023539732204175913,
       "learning and memory":0.00023539732204175913,
       "movement regulation":0.00023539732204175913,
       "novelty processing":0.00023539732204175913,
       "parietal cortex":0.00028548481725547257,
       "reward processing":0.00023539732204175913,
       "signal-to-noise processing":0.00023539732204175913,
       "stress response":0.00023539732204175913,
       "mood symptoms":0.0003279500809468939,
       "time":0.0002744734149884029,
       "dose reduction":0.00026986343299859343,
       "dosing":0.00014875076003345014,
       "driving licenses suspension/revocation":0.0001762553195370193,
       "driving performance improvement":0.0001657090192221901,
       "gradually increase dose":0.00014869222527513404,
       "monitor mood symptoms":0.0001951406461151092,
       "excessive weight loss":0.00019745754642248864,
       "dsm criteria":0.00018181769283039467,
       "us college-aged women":0.00014639666662287894,
       "eating foods high in added sugar":0.00034325342026916844,
       "hyperactivity/impulsivity subtypes":0.00034325342026916844,
       "inattention symptoms and unhealthy eating habits":0.00034325342026916844,
       "monozygotic twins":0.00034325342026916844,
       "unhealthy dietary habits":0.00034325342026916844,
       "stimulant misuse":0.00015438178269671038,
       "history of psychosis":0.00020594825940090846,
       "prescribed stimulants":0.00031044338081849196,
       "size":0.000176356417075848,
       "effect size findings":0.00019197235335615784,
       "effective self-regulation":0.00017235661174398856,
       "effortful strategy":0.0004904349609568574,
       "emotional arousal":0.0004904349609568574,
       "high ei":0.0002957339037156703,
       "reappraisal":0.0005393584409473088,
       "self-monitoring":0.0005393584409473088,
       "valuation":0.0002943167562531542,
       "el":0.00020578135876187602,
       "emotionally intense provocation":0.00015438084589796807,
       "hyperactive-impulsive adhd presentations":0.00020578135876187602,
       "inadequate self-control and weak behavioral inhibition":0.00016356482531610457,
       "patients with no ei":0.00017440794525759538,
       "rapid changes in emotional states":0.0001669570606352882,
       "self-regulatory processes":0.00017300302288104203,
       "elevated mood":0.00020905866756513702,
       "elevation of blood pressure or heart rate":0.00014049015806471136,
       "feeling sad":0.00015061178903722253,
       "healthcare facility utilization":0.000160709185031985,
       "poison control centers data":0.00019906476479569383,
       "sleep difficulties":0.00014969077247217527,
       "study of 15,629 adults and adolescents":0.00019906476479569383,
       "regulatory processes":0.00025623473888026853,
       "emotional experience":0.0003470044976678324,
       "emotional valence":0.0001648733785652601,
       "heterogeneity":0.00029842022407775964,
       "neural activation":0.00022393032109026858,
       "poorly controlled emotionally driven behavior":0.00019564982209857408,
       "self-regulatory deficits":0.00015775124974058208,
       "self-regulatory deﬁcits":0.00019564982209857408,
       "executive function control of emotional response":0.00019062745280522313,
       "extended-release methylphenidate":0.00015936464103509637,
       "intermittent explosive disorder":0.00019777078795857445,
       "methylphenidate preparations":0.00015800526235731075,
       "oppositional deﬁant disorder":0.00016163869937791872,
       "emotional functioning":0.0001817352624772262,
       "impaired":0.0004962902519892909,
       "emotional instability":0.00016744812370943348,
       "negative emotion":0.00018118273696581886,
       "emotional reactivity":0.00016114348505976572,
       "high emotional impulsivity":0.00017487809831615112,
       "response systems":0.00018260296657694196,
       "future development of adhd criteria":0.0002026055340887682,
       "measurement tool/assessment instrument":0.0002026055340887682,
       "mistake for emotional symptoms to be specific for adhd":0.0002026055340887682,
       "multidimensional nature of emotional symptoms":0.0002026055340887682,
       "stephen v. faraone":0.0001984492349598245,
       "evidence-based assertions":0.00021800371352455688,
       "findings":0.00022054263219317737,
       "manuscript":0.0002356619215899802,
       "participants":0.0003147388077013603,
       "waiting-list controls":0.0002215313196051201,
       "encourage good sleep habits":0.00020296190867220973,
       "eunethydis":0.0002179220367214221,
       "euphoria":0.00020905866756513702,
       "european network adult adhd":0.00017752865225965876,
       "evaluation":0.00021513828516704235,
       "frozen yogurt":0.00023496536603435778,
       "instant breakfast drinks":0.00023496536603435778,
       "limit naps to less than 45 minutes":0.00023496536603435778,
       "reduce screen time before bed":0.00023496536603435778,
       "evidenced based fda approved medication":0.00016530283068358456,
       "exacerbation":0.00020905866756513702,
       "give medication with food to minimize stomach discomfort":0.00020296190867220973,
       "irritability or aggression (infrequent)":0.00024440289119682376,
       "monitor headaches and consult with the healthcare provider":0.00020296190867220973,
       "monitor irritability and consult with the healthcare provider":0.00024440289119682376,
       "some children do better with the daily dose divided into two doses":0.00020296190867220973,
       "start with a low dose and gradually increase":0.00020296190867220973,
       "this side effect usually improves over time":0.00020296190867220973,
       "excluded meta-analyses that did not assess publication bias, except for prevalence":0.00018280835633217299,
       "exclusion criteria":0.00019263955213759206,
       "extended time":0.00020203453383728948,
       "factors leading to favorable outcomes":0.00017525700387642165,
       "fear of exposing nmu or minor unwanted effects":0.00024303873391366256,
       "individuals who experience minor unwanted effects":0.00024303873391366256,
       "search criteria: adhd [all fields] and (meta- analysis [title] or meta-analysis [title] or meta-analytic [title] or systematic review [title])":0.00018280835633217299,
       "search criteria: adhd [tiab] and (nationwide [tiab] or national [tiab] or register [tiab] or registry [tiab]) not review [publication type] not meta-analysis [publication type]":0.00018280835633217299,
       "feigned":0.00018624348307918483,
       "genu ine":0.00018624348307918483,
       "ferritin":0.0002717988454533969,
       "serum":0.0001887014961228053,
       "serum iron":0.0001887014961228053,
       "findings of interest":0.00020977600686926322,
       "misusers":0.0004419860399736754,
       "first drug treatment try":0.00015592969899536944,
       "fluctuating periods of remission and recurrence":0.0001589483714766918,
       "patient's symptoms":0.00027898719251992553,
       "follow-up rating scales completed by parent or teacher soon after medication initiation":0.00042653927360361706,
       "patients with neither one physician visit nor medication claim in 6 months":0.00042653927360361706,
       "use of outside provider for adhd diagnosis":0.00042653927360361706,
       "job/school performance":0.00023263463571790134,
       "medication side effects/toxicity or signs of abuse/diversion":0.00023263463571790134,
       "potential side effects of atx":0.0002801557850270113,
       "relationship issues":0.00023263463571790134,
       "sexual dysfunction and dysmenorrhea":0.0002801557850270113,
       "sustained resting tachycardia, arrhythmia or systolic bp of greater than the 95th%":0.00023263463571790134,
       "target symptoms":0.00023263463571790134,
       "vital signs":0.00036692207559908287,
       "food":0.0002172618638955409,
       "foxp1":0.00023746807253625048,
       "synapse formation":0.00023746807253625048,
       "friendships":0.00021286924841291613,
       "functional impairment related to adhd":0.00016773147255563336,
       "functional outcomes":0.0001837944059224817,
       "insights into key details of nmu":0.00024303873391366256,
       "general qol measures for adults":0.0001837944059224817,
       "generic medication preparations":0.0001885983781145856,
       "pharmacies":0.0001885983781145856,
       "united kingdom":0.00017146382331462192,
       "grade point average (gpa)":0.00015870032148792892,
       "greater family cohesion":0.0001801868355996384,
       "group of experts":0.00021775441312513026,
       "organizations that study and treat adhd":0.00021775441312513026,
       "severe hypotension":0.00013834296388576847,
       "guanfacine treatment for adhd":0.00020703465630017887,
       "individuals who abused":0.00016695278418666655,
       "minor toxicity":0.00016695278418666655,
       "poison control centers":0.00016695278418666655,
       "health effects":0.00019324786067563706,
       "icasa":0.00017752865225965876,
       "national health and medical research council (australia)":0.00017752865225965876,
       "ukaan":0.00017752865225965876,
       "heart rate monitoring":0.0001484887579199863,
       "high risk for nmu":0.00019324786067563706,
       "high risk patients":0.00012357802360065415,
       "high-calorie foods":0.00015573273933955822,
       "high-quality studies":0.00015604398078633146,
       "high-risk populations":0.000278874399862998,
       "prisoners":0.00016622115498403681,
       "vulnerability to psychosis":0.0003563586689265334,
       "holidays":0.00015738629232121492,
       "household public assistance":0.0001801868355996384,
       "huybrechts et al., 2018":0.00019160981305141537,
       "hyperactive-impulsive symptoms":0.00018626832707015946,
       "id":0.00014815313390513054,
       "immediate-release preparations allowed":0.00015592969899536944,
       "physical functioning":0.0001817352624772262,
       "school functioning":0.0001817352624772262,
       "popularity":0.00021286924841291613,
       "reciprocity":0.00021286924841291613,
       "rejection/likability":0.00021286924841291613,
       "sharing":0.00021286924841291613,
       "socializing with peers":0.00021286924841291613,
       "turn-taking":0.00021286924841291613,
       "meditation-based therapy":0.0001544789164609148,
       "in insomnia":0.00014049015806471136,
       "inclusion criteria":0.00015297072885335047,
       "medications misuse":0.00015917499690066848,
       "individuals at greatest risk":0.00019560315110155835,
       "study routes of administration":0.00019560315110155835,
       "individuals who die from stimulant overdoses":0.00024303873391366256,
       "information about negative academic or health effects":0.00021709246428697963,
       "willingness to use stimulants":0.00021709246428697963,
       "patient preference":0.0002320833596225104,
       "insu fflation":0.00026774845830578975,
       "smok ing":0.00032608429445630827,
       "stimulant s":0.00026774845830578975,
       "us adults":0.00032608429445630827,
       "insurance companies":0.00017525700387642165,
       "large studies":0.00036625421857815205,
       "new scientific findings from the past 20 years":0.00015604398078633146,
       "specific search terms":0.00015604398078633146,
       "international society of psychiatric geneti cs":0.00036293474066484167,
       "lifetime ach ievement award":0.00036293474066484167,
       "internet":0.00015078098709325662,
       "intolerance":0.00014293449540416506,
       "intuniv (guanfacine)":0.000181192985368563,
       "irritability in adhd":0.0001933512349391812,
       "irritability in odd":0.0001933512349391812,
       "vulnerability for emotional disorders (mood and anxiety)":0.0001933512349391812,
       "legal issue":0.0001533631096332215,
       "liver function tests":0.0001484887579199863,
       "long-acting preparations recommended":0.00015592969899536944,
       "long-term outcomes":0.00017942306843327018,
       "low initial doses recommended":0.00015592969899536944,
       "neuroenhancement":0.00020036023805853034,
       "mania":0.0001552362254305772,
       "randomized trial":0.00019801058790433154,
       "medial frontal reductions":0.0001867395058639531,
       "medical causes of adhd symptoms":0.00016096356174602957,
       "problems":0.0001917839656351425,
       "safe storage":0.0001488584321407337,
       "medication choice":0.00015422086513568783,
       "medication contract":0.00018624348307918483,
       "patient commitment":0.00018624348307918483,
       "patient values and preferences":0.00019705088373584166,
       "phone calls":0.00017457933621816947,
       "target outcomes":0.00019705088373584166,
       "stimulant therapy dose":0.00017636024488499604,
       "medication trial":0.00015592969899536944,
       "naturalistic studies":0.0001837944059224817,
       "quality of life enjoyment and satisfaction questionnaire":0.0001837944059224817,
       "weiss functional impairment rating scale":0.0002187923968569944,
       "neuronal development":0.0001701457658216347,
       "neuronal proliferation":0.0001701457658216347,
       "synapse development":0.0001701457658216347,
       "mental health assessment":0.0001484887579199863,
       "standardized mean difference":0.00019197235335615784,
       "pregnancies in denmark":0.00017983572670586778,
       "pregnancies in the united states":0.00017983572670586778,
       "time course for improvement":0.00019555893297304458,
       "united states":0.00019160981305141537,
       "new onset":0.00020905866756513702,
       "motiv ations":0.00020977600686926322,
       "outcomes associated with nmu":0.00020977600686926322,
       "risk factors":0.00030468911426450435,
       "risk reduction methods":0.00033021487248794307,
       "mon itoring body mass index":0.0002172618638955409,
       "severe mood swings":0.0001484887579199863,
       "sweating of the face, lips, tongue, or throat":0.00018561358108134689,
       "underlying heart conditions":0.00018798191319637373,
       "national survey on drug use and health (nsduh)":0.00015467348254671296,
       "neurotransmitters":0.0002299215208617359,
       "new clinician":0.00019515345292646694,
       "us data bases":0.00015467348254671296,
       "pediatricians":0.00015562357092977147,
       "performance enhancement":0.00015562357092977147,
       "research methods":0.00019560315110155835,
       "stimulant-naïve college students":0.00015562357092977147,
       "nmu crisis":0.0001617344583306839,
       "nmu of prescription stimulants is highly prevalent":0.00024303873391366256,
       "wide variations in the definition of nmu":0.00024303873391366256,
       "performance enhancing drugs":0.0002139346773439435,
       "performance validity tests":0.0002139346773439435,
       "societal pressures to seek high levels of achievement":0.0002139346773439435,
       "symptom validity tests":0.0002139346773439435,
       "none":0.00042653927360361706,
       "nonmedical use and diversion":0.00015620690450325624,
       "nonmedical use and diversion of prescription stimulants":0.0001687531978842932,
       "overdose":0.00014875076003345014,
       "therapeutic range":0.00014875076003345014,
       "numbers":0.00020820996765209216,
       "offspring of mothers with a single prior miscarriage":0.00042653927360361706,
       "organizational structure or systems":0.00017525700387642165,
       "pill counts":0.00015775700905270543,
       "symptoms and prescription refill requests":0.00015271545833552146,
       "patient perceptions":0.00017525700387642165,
       "patient supply":0.00015790632006978727,
       "patient-generated goals discussed":0.00023373928679069848,
       "patients leaving practice":0.00019515345292646694,
       "patients seen within a timely fashion":0.00023373928679069848,
       "seen within a timely fashion":0.00023373928679069848,
       "patients with documentation of concerns being discussed":0.00023373928679069848,
       "patients with documented satisfaction assessment":0.00023373928679069848,
       "satisfaction assessment at least annually":0.00023373928679069848,
       "psychosocial treatment":0.00019515345292646694,
       "transfer of care":0.00019515345292646694,
       "poison control centers and dawn data":0.00024303873391366256,
       "population":0.00011819206768779318,
       "preferential seating":0.00020203453383728948,
       "teacher":0.00020203453383728948,
       "safeguards":0.0001560409128186369,
       "prescription for adhd medication":0.00021543691111407134,
       "suds":0.00021543691111407134,
       "theft":0.00014615024794031536,
       "serious health outcomes":0.0001626551746185454,
       "trends in nmu":0.00018336307979176158,
       "stimulant treatment history":0.00021543691111407134,
       "subsequent substance use, abuse, or dependence":0.00021543691111407134,
       "surgical treatment":0.00015444120076287568,
       "primary inattentive adhd":0.00018626832707015946,
       "psychostimulant medications":0.00021681559292152427,
       "risk of psychosis":0.00021681559292152427,
       "qol benefits":0.00017942306843327018,
       "rating scales with adult norms":0.0001859785662586843,
       "sustained remission":0.0001589483714766918,
       "regional and national databases":0.00019321938453016567,
       "research participants":0.00020820996765209216,
       "signatories":0.00020820996765209216,
       "topic":0.00020820996765209216,
       "residential instability":0.0001801868355996384,
       "risk for adverse events":0.0001653680531275783,
       "risky behaviors":0.00018626832707015946,
       "treatment alternatives, benefits and risks have been discussed":0.0001719540088732367,
       "validated measure":0.00016938293999768563,
       "stimulant overdoses before contacting emergency services":0.00024303873391366256,
       "systematic literature review":0.00024303873391366256,
       "study selection":0.00015297072885335047,
       "structural magnetic resonance imaging (mri) data":0.0002432446164367859,
       "treatment discontinuity":0.00017942306843327018,
       "taking medication":0.0002172618638955409,
       "verbal working memory":0.00015904601719803112
    }
 }